<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>What came of it? Status changes</title>
  <id>https://staging.whatcameofit.com/changes.xml</id>
  <link rel="self" href="https://staging.whatcameofit.com/changes.xml"/>
  <link href="https://staging.whatcameofit.com/"/>
  <updated>2026-11-19T00:00:00Z</updated>
  <entry>
    <title>&quot;Rush&quot; regimen for anaphylaxis</title>
    <id>https://staging.whatcameofit.com/rush-regimen--anaphylaxis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rush-regimen--anaphylaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>&quot;Rush&quot; regimen for egg hypersensitivity</title>
    <id>https://staging.whatcameofit.com/rush-regimen--egg-hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rush-regimen--egg-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>&quot;Rush&quot; regimen for milk hypersensitivity</title>
    <id>https://staging.whatcameofit.com/rush-regimen--milk-hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rush-regimen--milk-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>&quot;Synchronised&quot; arm (intervention) for malaria</title>
    <id>https://staging.whatcameofit.com/synchronised-arm-intervention--malaria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/synchronised-arm-intervention--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>&quot;Trained Eye&quot; (Angiography-Guided) LM PCI for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/trained-eye-angiography-guided-lm-pci--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/trained-eye-angiography-guided-lm-pci--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/2r-6r-hydroxynorketamine-0-25-to-2-0-mg-kg-placebo--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/2r-6r-hydroxynorketamine-0-25-to-2-0-mg-kg-placebo--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/2r-6r-hydroxynorketamine-0-25-to-2-0-mg-kg-placebo--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/2r-6r-hydroxynorketamine-0-25-to-2-0-mg-kg-placebo--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytoma</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib + Temozolomide for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib + Temozolomide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib-temozolomide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib for astrocytoma</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[11C]AZ1419 3391 + Palacaparib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/11c-az1419-3391-palacaparib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>[68Ga]Ga-OncoACP3 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/68ga-ga-oncoacp3--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/68ga-ga-oncoacp3--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>[F-18]Flornaptitril for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/f-18-flornaptitril--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/f-18-flornaptitril--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>0.25% RCI001 Ophthalmic Solution for dry eye syndromes</title>
    <id>https://staging.whatcameofit.com/0-25-rci001-ophthalmic-solution--dry-eye-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/0-25-rci001-ophthalmic-solution--dry-eye-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>0.75% Phentolamine Ophthalmic Solution for vitamin a deficiency</title>
    <id>https://staging.whatcameofit.com/0-75-phentolamine-ophthalmic-solution--vitamin-a-deficiency#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/0-75-phentolamine-ophthalmic-solution--vitamin-a-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>1 mg QD to 15 mg QD PF-06649751 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/1-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/1-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/1-mg-qd-to-7-mg-qd-pf-06649751-if-de-escalated-in-parent-study--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/1-mg-qd-to-7-mg-qd-pf-06649751-if-de-escalated-in-parent-study--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>1 Stent for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/1-stent--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/1-stent--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>1.5 x 10^6 UC-MSC + CM for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/1-5-x-10-6-uc-msc-cm--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/1-5-x-10-6-uc-msc-cm--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>10 GE Xenokidney for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/10-ge-xenokidney--kidney-failure-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/10-ge-xenokidney--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>100 mg for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/100-mg--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/100-mg--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>120 milligrams of ENERGI-F705 Tablets for parkinson disease</title>
    <id>https://staging.whatcameofit.com/120-milligrams-of-energi-f705-tablets--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/120-milligrams-of-energi-f705-tablets--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>130 mCi NYMO32 + 200 mCi NYMO32 + 30 mCi NYMO32 + 50 mCi NYMO32 + 80 mCi NYMO32 for neoplasms</title>
    <id>https://staging.whatcameofit.com/130-mci-nymo32-200-mci-nymo32-30-mci-nymo32-50-mci-nymo32-80-mci-nymo32--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/130-mci-nymo32-200-mci-nymo32-30-mci-nymo32-50-mci-nymo32-80-mci-nymo32--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson disease</title>
    <id>https://staging.whatcameofit.com/15-mg-qd-de-escalated-to-7-mg-qd-pf-06649751-in-parent-study-remain-at-7-mg-qd--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/15-mg-qd-de-escalated-to-7-mg-qd-pf-06649751-in-parent-study-remain-at-7-mg-qd--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>15 mg QD PF-06649751 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/15-mg-qd-pf-06649751--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/15-mg-qd-pf-06649751--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>16-hour PP for acute lung injury</title>
    <id>https://staging.whatcameofit.com/16-hour-pp--acute-lung-injury#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/16-hour-pp--acute-lung-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>186RNL for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/186rnl--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/186rnl--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>2 Stents for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/2-stents--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/2-stents--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>3 mg QD to 15 mg QD PF-06649751 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/3-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/3-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/3-mg-qd-to-7-mg-qd-pf-06649751-de-escalated-in-parent-study--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/3-mg-qd-to-7-mg-qd-pf-06649751-de-escalated-in-parent-study--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>30mg PRAX-628 for epilepsy, generalized</title>
    <id>https://staging.whatcameofit.com/30mg-prax-628--epilepsy-generalized#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/30mg-prax-628--epilepsy-generalized"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>30mg PRAX-628 for seizures</title>
    <id>https://staging.whatcameofit.com/30mg-prax-628--seizures#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/30mg-prax-628--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>4 in 1 block for lacerations</title>
    <id>https://staging.whatcameofit.com/4-in-1-block--lacerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/4-in-1-block--lacerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>4,4&apos;,4&apos;&apos;-(4-PROPYL-(1H)-PYRAZOLE-1,3,5-TRIYL)TRISPHENOL for leptospirosis</title>
    <id>https://staging.whatcameofit.com/4-4-4-4-propyl-1h-pyrazole-1-3-5-triyl-trisphenol--leptospirosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/4-4-4-4-propyl-1h-pyrazole-1-3-5-triyl-trisphenol--leptospirosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>40 Hz sound stimulation for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/40-hz-sound-stimulation--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/40-hz-sound-stimulation--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>40 Hz Synchronous Audio-Visual Stimulation for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/40-hz-synchronous-audio-visual-stimulation--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/40-hz-synchronous-audio-visual-stimulation--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>4CMenB vaccine for gonorrhea</title>
    <id>https://staging.whatcameofit.com/4cmenb-vaccine--gonorrhea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/4cmenb-vaccine--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>4D-110 for choroideremia</title>
    <id>https://staging.whatcameofit.com/4d-110--choroideremia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/4d-110--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>5 x 10^6 UC-MSC + CM for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/5-x-10-6-uc-msc-cm--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/5-x-10-6-uc-msc-cm--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/5-fu-leucovorin-oxaliplatin-docetaxel--adenocarcinoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/5-fu-leucovorin-oxaliplatin-docetaxel--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>50 mg qhs for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/50-mg-qhs--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/50-mg-qhs--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>60 milligrams of ENERGI-F705 Tablets for parkinson disease</title>
    <id>https://staging.whatcameofit.com/60-milligrams-of-energi-f705-tablets--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/60-milligrams-of-energi-f705-tablets--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/61cu-nodaga-lm3-comparator--neuroendocrine-tumors#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/61cu-nodaga-lm3-comparator--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>68-Gallium DOTATATE for neuroectodermal tumors, primitive</title>
    <id>https://staging.whatcameofit.com/68-gallium-dotatate--neuroectodermal-tumors-primitive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/68-gallium-dotatate--neuroectodermal-tumors-primitive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>68-Gallium DOTATATE for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/68-gallium-dotatate--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/68-gallium-dotatate--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>7 mg QD to 15 mg QD PF-06649751 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/7-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/7-mg-qd-to-15-mg-qd-pf-06649751--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/7-mg-qd-to-7-mg-qd-pf-06649751-de-escalated-in-parent-study--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/7-mg-qd-to-7-mg-qd-pf-06649751-de-escalated-in-parent-study--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>8% arginine + Zinc toothpaste for dentin sensitivity</title>
    <id>https://staging.whatcameofit.com/8-arginine-zinc-toothpaste--dentin-sensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/8-arginine-zinc-toothpaste--dentin-sensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) for penile neoplasms</title>
    <id>https://staging.whatcameofit.com/9-valent-human-papillomavirus-types-6-11-16-18-31-33-45-52-and-58-recombinant-vaccine-hansenula-polymorpha--penile-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/9-valent-human-papillomavirus-types-6-11-16-18-31-33-45-52-and-58-recombinant-vaccine-hansenula-polymorpha--penile-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>9vHPV Vaccine for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/9vhpv-vaccine--papillomavirus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/9vhpv-vaccine--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>A &quot;simple medical strategy&quot; consisting of silver diamine fluoride (SDF) for dental caries</title>
    <id>https://staging.whatcameofit.com/a-simple-medical-strategy-consisting-of-silver-diamine-fluoride-sdf--dental-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/a-simple-medical-strategy-consisting-of-silver-diamine-fluoride-sdf--dental-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>A &quot;simple medical strategy&quot; consisting of silver diamine fluoride (SDF) for tooth loss</title>
    <id>https://staging.whatcameofit.com/a-simple-medical-strategy-consisting-of-silver-diamine-fluoride-sdf--tooth-loss#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/a-simple-medical-strategy-consisting-of-silver-diamine-fluoride-sdf--tooth-loss"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>a wake prone positioning for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/a-wake-prone-positioning--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/a-wake-prone-positioning--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>a wake prone positioning for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/a-wake-prone-positioning--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/a-wake-prone-positioning--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AADvac1 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/aadvac1--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aadvac1--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AADvac1 for pick disease of the brain</title>
    <id>https://staging.whatcameofit.com/aadvac1--pick-disease-of-the-brain#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aadvac1--pick-disease-of-the-brain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aav-gad for parkinson disease</title>
    <id>https://staging.whatcameofit.com/aav-gad--parkinson-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/aav-gad--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AAV-mediated REP1 gene replacement for choroideremia</title>
    <id>https://staging.whatcameofit.com/aav-mediated-rep1-gene-replacement--choroideremia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aav-mediated-rep1-gene-replacement--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AAV2-hRPE65v2,voretigene neparvovec-rzyl for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/aav2-hrpe65v2-voretigene-neparvovec-rzyl--leber-congenital-amaurosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aav2-hrpe65v2-voretigene-neparvovec-rzyl--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/aav2-hrpe65v2-voretigene-neparvovec-rzyl--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aav2-hrpe65v2-voretigene-neparvovec-rzyl--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AAV2/8-HLP-FVIII-V3 for hemophilia a</title>
    <id>https://staging.whatcameofit.com/aav2-8-hlp-fviii-v3--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/aav2-8-hlp-fviii-v3--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AAV9-Follistatin gene therapy + VEGF Plasmid for sarcopenia</title>
    <id>https://staging.whatcameofit.com/aav9-follistatin-gene-therapy-vegf-plasmid--sarcopenia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/aav9-follistatin-gene-therapy-vegf-plasmid--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AAV9-Follistatin gene therapy for sarcopenia</title>
    <id>https://staging.whatcameofit.com/aav9-follistatin-gene-therapy--sarcopenia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/aav9-follistatin-gene-therapy--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AB-1001 Gene Therapy for huntington disease</title>
    <id>https://staging.whatcameofit.com/ab-1001-gene-therapy--huntington-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ab-1001-gene-therapy--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AB-1005 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/ab-1005--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ab-1005--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AB-8939 for gata2 deficiency</title>
    <id>https://staging.whatcameofit.com/ab-8939--gata2-deficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ab-8939--gata2-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Abatacept for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/abatacept--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/abatacept--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Abatacept for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/abatacept--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/abatacept--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Abbott Laboratories Infinity™ implantable deep brain stimulation system for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/abbott-laboratories-infinity-implantable-deep-brain-stimulation-system--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/abbott-laboratories-infinity-implantable-deep-brain-stimulation-system--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ABBV-706 + ATEZOLIZUMAB + Alveltamig for neoplasms</title>
    <id>https://staging.whatcameofit.com/abbv-706-atezolizumab-alveltamig--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/abbv-706-atezolizumab-alveltamig--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Abemaciclib + Irinotecan + Temozolomide for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/abemaciclib-irinotecan-temozolomide--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/abemaciclib-irinotecan-temozolomide--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Abemaciclib + Irinotecan + Temozolomide for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/abemaciclib-irinotecan-temozolomide--sarcoma-ewing#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/abemaciclib-irinotecan-temozolomide--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Abemaciclib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/abemaciclib--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/abemaciclib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Abemaciclib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/abemaciclib--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/abemaciclib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ABIRATERONE ACETATE + Prednisone for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/abiraterone-acetate-prednisone--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/abiraterone-acetate-prednisone--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>abiraterone acetate with prednisone + Tinengotinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/abiraterone-acetate-with-prednisone-tinengotinib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/abiraterone-acetate-with-prednisone-tinengotinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ablative-prostate-boost-androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Abrocitinib for eczema</title>
    <id>https://staging.whatcameofit.com/abrocitinib--eczema#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/abrocitinib--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>abrysvo + Beyfortus for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/abrysvo-beyfortus--respiratory-syncytial-virus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/abrysvo-beyfortus--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>abrysvo for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/abrysvo--respiratory-syncytial-virus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/abrysvo--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ABS-201 SC Multiple Doses + Placebo SC Injection for alopecia</title>
    <id>https://staging.whatcameofit.com/abs-201-sc-multiple-doses-placebo-sc-injection--alopecia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/abs-201-sc-multiple-doses-placebo-sc-injection--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AC-101 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/ac-101--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ac-101--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Academic Competency Enhancement (ACE) classroom for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/academic-competency-enhancement-ace-classroom--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/academic-competency-enhancement-ace-classroom--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Accelerated Hypofractionated Radiation Therapy for glioblastoma</title>
    <id>https://staging.whatcameofit.com/accelerated-hypofractionated-radiation-therapy--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/accelerated-hypofractionated-radiation-therapy--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Accelerated protocol of home Transcranial direct current stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/accelerated-protocol-of-home-transcranial-direct-current-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/accelerated-protocol-of-home-transcranial-direct-current-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Accelerated theta-burst stimulation treatment for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/accelerated-theta-burst-stimulation-treatment--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/accelerated-theta-burst-stimulation-treatment--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Accelerated theta-burst stimulation treatment for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/accelerated-theta-burst-stimulation-treatment--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/accelerated-theta-burst-stimulation-treatment--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acceptance and Commitment Therapy + Ketamine for alcoholism</title>
    <id>https://staging.whatcameofit.com/acceptance-and-commitment-therapy-ketamine--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acceptance-and-commitment-therapy-ketamine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acceptance-Based Behavior Therapy (ABBT) for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/acceptance-based-behavior-therapy-abbt--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/acceptance-based-behavior-therapy-abbt--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ACDN-01 for cone-rod dystrophies</title>
    <id>https://staging.whatcameofit.com/acdn-01--cone-rod-dystrophies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/acdn-01--cone-rod-dystrophies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ACDN-01 for stargardt disease</title>
    <id>https://staging.whatcameofit.com/acdn-01--stargardt-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/acdn-01--stargardt-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Aceclidine for myopia</title>
    <id>https://staging.whatcameofit.com/aceclidine--myopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aceclidine--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aceclidine for presbyopia</title>
    <id>https://staging.whatcameofit.com/aceclidine--presbyopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aceclidine--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aceclidine+Brimonidine combination ophthalmic solution for myopia</title>
    <id>https://staging.whatcameofit.com/aceclidine-brimonidine-combination-ophthalmic-solution--myopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aceclidine-brimonidine-combination-ophthalmic-solution--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aceclidine+Brimonidine combination ophthalmic solution for presbyopia</title>
    <id>https://staging.whatcameofit.com/aceclidine-brimonidine-combination-ophthalmic-solution--presbyopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aceclidine-brimonidine-combination-ophthalmic-solution--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Acetaminophen (or equivalent) + Dexamethasone (or equivalent) + Histamine H1 Receptor Antagonist + Histamine H2 Receptor Antagonist + MK-2010 + Steroid mouthwash (dexamethasone or equivalent) + Sacituzumab tirumotecan + Epinephrine for neoplasms</title>
    <id>https://staging.whatcameofit.com/acetaminophen-or-equivalent-dexamethasone-or-equivalent-histamine-h1-receptor-antagonist-histamine-h2-receptor-antagonist-mk-2010-steroid-mouthwash-dexamethasone-or-equivalent-sacituzumab-tirumotecan-epinephrine--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/acetaminophen-or-equivalent-dexamethasone-or-equivalent-histamine-h1-receptor-antagonist-histamine-h2-receptor-antagonist-mk-2010-steroid-mouthwash-dexamethasone-or-equivalent-sacituzumab-tirumotecan-epinephrine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Acetylcysteinamide for dementia</title>
    <id>https://staging.whatcameofit.com/acetylcysteinamide--dementia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/acetylcysteinamide--dementia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Acetylcysteine for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/acetylcysteine--st-elevation-myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acetylcysteine--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acoziborole for trypanosomiasis</title>
    <id>https://staging.whatcameofit.com/acoziborole--trypanosomiasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/acoziborole--trypanosomiasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Acoziborole for trypanosomiasis, african</title>
    <id>https://staging.whatcameofit.com/acoziborole--trypanosomiasis-african#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/acoziborole--trypanosomiasis-african"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ACP-204 for hallucinations</title>
    <id>https://staging.whatcameofit.com/acp-204--hallucinations#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/acp-204--hallucinations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/actinium-225ac-zadavotide-guraxetan-azd2265-fpi-2265--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/actinium-225ac-zadavotide-guraxetan-azd2265-fpi-2265--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/actinium-ac-225-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/actinium-ac-225-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Activa PC+S Neurostimulator for parkinson disease</title>
    <id>https://staging.whatcameofit.com/activa-pc-s-neurostimulator--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/activa-pc-s-neurostimulator--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Activa Tremor Control Sys (DBS Implant) for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/activa-tremor-control-sys-dbs-implant--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/activa-tremor-control-sys-dbs-implant--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Activa Tremor Control Sys (DBS Implant) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/activa-tremor-control-sys-dbs-implant--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/activa-tremor-control-sys-dbs-implant--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active - Conventional tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-conventional-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-conventional-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active - HD tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-hd-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-hd-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>active FMT for axial spondyloarthritis</title>
    <id>https://staging.whatcameofit.com/active-fmt--axial-spondyloarthritis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/active-fmt--axial-spondyloarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Active Oral Hygiene Regimen for periodontitis</title>
    <id>https://staging.whatcameofit.com/active-oral-hygiene-regimen--periodontitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-oral-hygiene-regimen--periodontitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>active rTMS treatment for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/active-rtms-treatment--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-rtms-treatment--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>active rTMS treatment for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-rtms-treatment--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-rtms-treatment--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>active tDCS + mindfulness meditation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-tdcs-mindfulness-meditation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs-mindfulness-meditation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>active tDCS stimulating left DLPFC for depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-tdcs-stimulating-left-dlpfc--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs-stimulating-left-dlpfc--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active tDCS with Sternberg task for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active tDCS with Sternberg task for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active tDCS with Sternberg task for neuralgia</title>
    <id>https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--neuralgia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-tdcs-with-sternberg-task--neuralgia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active transcranial direct current stimulation for depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-transcranial-direct-current-stimulation--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-transcranial-direct-current-stimulation--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active Whole-Body Hyperthermia (Active WBH) for hyperthermia</title>
    <id>https://staging.whatcameofit.com/active-whole-body-hyperthermia-active-wbh--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-whole-body-hyperthermia-active-wbh--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active Whole-Body Hyperthermia (Active WBH) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/active-whole-body-hyperthermia-active-wbh--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-whole-body-hyperthermia-active-wbh--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Active, self-directed electrical stimulation of the median nerve for tics</title>
    <id>https://staging.whatcameofit.com/active-self-directed-electrical-stimulation-of-the-median-nerve--tics#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/active-self-directed-electrical-stimulation-of-the-median-nerve--tics"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acupuncture - Group 1 for xerostomia</title>
    <id>https://staging.whatcameofit.com/acupuncture-group-1--xerostomia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/acupuncture-group-1--xerostomia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>acupuncture (strong reaction acupoints) + SSRIs for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture-strong-reaction-acupoints-ssris--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture-strong-reaction-acupoints-ssris--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>acupuncture (weak reaction acupoints) + SSRIs for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture-weak-reaction-acupoints-ssris--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture-weak-reaction-acupoints-ssris--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>acupuncture + placebo for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture-placebo--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture-placebo--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acupuncture + Questionnaires for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/acupuncture-questionnaires--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/acupuncture-questionnaires--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>acupuncture + SSRIs for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture-ssris--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture-ssris--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>acupuncture and moxibustion for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture-and-moxibustion--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture-and-moxibustion--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Acupuncture for agnosia</title>
    <id>https://staging.whatcameofit.com/acupuncture--agnosia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/acupuncture--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Acupuncture for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/acupuncture--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/acupuncture--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AD-303A for alopecia</title>
    <id>https://staging.whatcameofit.com/ad-303a--alopecia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ad-303a--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AD04 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ad04--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ad04--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/ad26-zebov-mva-bn-filo--hemorrhagic-fever-ebola#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ad26-zebov-mva-bn-filo--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AD5-NCOV for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ad5-ncov--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ad5-ncov--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Adalimumab for alopecia</title>
    <id>https://staging.whatcameofit.com/adalimumab--alopecia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adalimumab--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adalimumab-800CW + Fluorescence Imaging for inflammatory bowel diseases</title>
    <id>https://staging.whatcameofit.com/adalimumab-800cw-fluorescence-imaging--inflammatory-bowel-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/adalimumab-800cw-fluorescence-imaging--inflammatory-bowel-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-closed-loop-dbs-intermittent-open-loop-dbs-open-loop-dbs--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-closed-loop-dbs-intermittent-open-loop-dbs-open-loop-dbs--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-closed-loop-dbs-open-loop-dbs--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-closed-loop-dbs-open-loop-dbs--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-dbs-activa-pc-s-neurostimulator-continuous-dbs-activa-pc-s-neurostimulator--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-dbs-activa-pc-s-neurostimulator-continuous-dbs-activa-pc-s-neurostimulator--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>adaptive DBS (aDBS) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-dbs-adbs--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-dbs-adbs--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>adaptive DBS delivered through AlphaDBS IPG System for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-dbs-delivered-through-alphadbs-ipg-system--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/adaptive-dbs-delivered-through-alphadbs-ipg-system--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Adaptive DBS for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-dbs--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-dbs--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>adaptive deep brain stimulation + conventional deep brain stimulation for dyskinesias</title>
    <id>https://staging.whatcameofit.com/adaptive-deep-brain-stimulation-conventional-deep-brain-stimulation--dyskinesias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-deep-brain-stimulation-conventional-deep-brain-stimulation--dyskinesias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>adaptive deep brain stimulation + conventional deep brain stimulation for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adaptive-deep-brain-stimulation-conventional-deep-brain-stimulation--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-deep-brain-stimulation-conventional-deep-brain-stimulation--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adaptive Hypofractionated Radiotherapy for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adaptive Hypofractionated Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adaptive-hypofractionated-radiotherapy--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>aDBS-Extended (Medtronic Percept™) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/adbs-extended-medtronic-percept--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adbs-extended-medtronic-percept--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adductor canal block for anterior cruciate ligament injuries</title>
    <id>https://staging.whatcameofit.com/adductor-canal-block--anterior-cruciate-ligament-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adductor-canal-block--anterior-cruciate-ligament-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adductor canal block with IPACK for lacerations</title>
    <id>https://staging.whatcameofit.com/adductor-canal-block-with-ipack--lacerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adductor-canal-block-with-ipack--lacerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adebelimab Combined with Apatinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/adebelimab-combined-with-apatinib--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adebelimab-combined-with-apatinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/adebrelimab-combined-with-albumin-paclitaxel--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adebrelimab-combined-with-albumin-paclitaxel--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Adebrelimab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/adebrelimab--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/adebrelimab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + Nogapendekin Alfa Inbakicept + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/adher2dc-vaccine-pathway-her2-4b5-assay-nogapendekin-alfa-inbakicept-pembrolizumab-lenvatinib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/adher2dc-vaccine-pathway-her2-4b5-assay-nogapendekin-alfa-inbakicept-pembrolizumab-lenvatinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/adher2dc-vaccine-pathway-her2-4b5-assay-pembrolizumab-lenvatinib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/adher2dc-vaccine-pathway-her2-4b5-assay-pembrolizumab-lenvatinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/administer-leqemi-10-mg-kg-every-two-weeks--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/administer-leqemi-10-mg-kg-every-two-weeks--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>AdMSC for microstomia</title>
    <id>https://staging.whatcameofit.com/admsc--microstomia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/admsc--microstomia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AdMSC for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/admsc--scleroderma-systemic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/admsc--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aducanumab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/aducanumab--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aducanumab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aducanumab for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/aducanumab--cognitive-dysfunction#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/aducanumab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>ADVM-022 for choroidal neovascularization</title>
    <id>https://staging.whatcameofit.com/advm-022--choroidal-neovascularization#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/advm-022--choroidal-neovascularization"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ADVM-022 for wet macular degeneration</title>
    <id>https://staging.whatcameofit.com/advm-022--wet-macular-degeneration#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/advm-022--wet-macular-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aerobic exercise intervention for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/aerobic-exercise-intervention--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aerobic-exercise-intervention--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Agbs for obesity</title>
    <id>https://staging.whatcameofit.com/agbs--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/agbs--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Agilik + standard care for cerebral palsy</title>
    <id>https://staging.whatcameofit.com/agilik-standard-care--cerebral-palsy#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/agilik-standard-care--cerebral-palsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Agilik for cerebral palsy</title>
    <id>https://staging.whatcameofit.com/agilik--cerebral-palsy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/agilik--cerebral-palsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Agilik for spinal dysraphism</title>
    <id>https://staging.whatcameofit.com/agilik--spinal-dysraphism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/agilik--spinal-dysraphism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AI-Guided Multimodal Rehabilitation Program for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/ai-guided-multimodal-rehabilitation-program--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ai-guided-multimodal-rehabilitation-program--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aia for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/aia--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aia--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Air cleaner for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/air-cleaner--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/air-cleaner--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>AK105 and anlotinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/ak105-and-anlotinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ak105-and-anlotinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Albipagrastim alf for febrile neutropenia</title>
    <id>https://staging.whatcameofit.com/albipagrastim-alf--febrile-neutropenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/albipagrastim-alf--febrile-neutropenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Alcohol beverage for ketosis</title>
    <id>https://staging.whatcameofit.com/alcohol-beverage--ketosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alcohol-beverage--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytoma</title>
    <id>https://staging.whatcameofit.com/aldara-imiquimod-5-idh1r132h-vac-vorasidenib-hemicitric-acid-hemihydrate--astrocytoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aldara-imiquimod-5-idh1r132h-vac-vorasidenib-hemicitric-acid-hemihydrate--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytoma</title>
    <id>https://staging.whatcameofit.com/aldara-imiquimod-5-idh1r132h-vac--astrocytoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aldara-imiquimod-5-idh1r132h-vac--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE + Melphalan for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/alemtuzumab-cyclophosphamide-fludarabine-melphalan--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alemtuzumab-cyclophosphamide-fludarabine-melphalan--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ALEMTUZUMAB + Cyclophosphamide + FLUDARABINE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/alemtuzumab-cyclophosphamide-fludarabine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alemtuzumab-cyclophosphamide-fludarabine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Alginos Oral Suspension for esophagitis</title>
    <id>https://staging.whatcameofit.com/alginos-oral-suspension--esophagitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alginos-oral-suspension--esophagitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ALK-inhibitor or RET-inhibitor + BNT116 for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/alk-inhibitor-or-ret-inhibitor-bnt116--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/alk-inhibitor-or-ret-inhibitor-bnt116--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Allay Lamp for migraine disorders</title>
    <id>https://staging.whatcameofit.com/allay-lamp--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/allay-lamp--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Allogeneic genetically modified gamma-delta T cells for glioblastoma</title>
    <id>https://staging.whatcameofit.com/allogeneic-genetically-modified-gamma-delta-t-cells--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/allogeneic-genetically-modified-gamma-delta-t-cells--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/allogeneic-hematopoietic-stem-cell-transplantation-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/allogeneic-hematopoietic-stem-cell-transplantation-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>allogeneic hematopoietic stem cell transplantation + Pharmacological Study + CLOFARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/allogeneic-hematopoietic-stem-cell-transplantation-pharmacological-study-clofarabine-melphalan-sirolimus-tacrolimus--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/allogeneic-hematopoietic-stem-cell-transplantation-pharmacological-study-clofarabine-melphalan-sirolimus-tacrolimus--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Alpelisib for lymphangioma, cystic</title>
    <id>https://staging.whatcameofit.com/alpelisib--lymphangioma-cystic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alpelisib--lymphangioma-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Alpelisib for lymphatic abnormalities</title>
    <id>https://staging.whatcameofit.com/alpelisib--lymphatic-abnormalities#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alpelisib--lymphatic-abnormalities"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Alpha-galactosylceramide for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/alpha-galactosylceramide--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/alpha-galactosylceramide--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ambroxol for parkinson disease</title>
    <id>https://staging.whatcameofit.com/ambroxol--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ambroxol--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ambroxol hydrochloride for lewy body disease</title>
    <id>https://staging.whatcameofit.com/ambroxol-hydrochloride--lewy-body-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ambroxol-hydrochloride--lewy-body-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AMDC-USR (iltamiocel) for urinary incontinence, stress</title>
    <id>https://staging.whatcameofit.com/amdc-usr-iltamiocel--urinary-incontinence-stress#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amdc-usr-iltamiocel--urinary-incontinence-stress"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm D for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-d--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-d--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm D for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-d--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-d--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm F for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-f--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-f--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm F for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-f--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-f--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm H for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-h--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-h--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm H for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-h--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-h--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm J for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-j--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-j--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm J for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-j--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-j--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm L for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-l--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-l--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Adjuvant Dose Arm L for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-l--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-adjuvant-dose-arm-l--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Antigen High Dose Arm A for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-antigen-high-dose-arm-a--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-antigen-high-dose-arm-a--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Antigen High Dose Arm A for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-antigen-high-dose-arm-a--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-antigen-high-dose-arm-a--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Antigen Low Dose Arm B for chickenpox</title>
    <id>https://staging.whatcameofit.com/amezosvatein-antigen-low-dose-arm-b--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-antigen-low-dose-arm-b--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amezosvatein Antigen Low Dose Arm B for herpes zoster</title>
    <id>https://staging.whatcameofit.com/amezosvatein-antigen-low-dose-arm-b--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amezosvatein-antigen-low-dose-arm-b--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/aminohippurate-sodium-inj-20-canagliflozin--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aminohippurate-sodium-inj-20-canagliflozin--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/aminolevulinic-acid-20-topical-solution-with-blue-light-dose-10-j-cm2--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aminolevulinic-acid-20-topical-solution-with-blue-light-dose-10-j-cm2--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/aminolevulinic-acid-20-topical-solution-with-blue-light-dose-20-j-cm2--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aminolevulinic-acid-20-topical-solution-with-blue-light-dose-20-j-cm2--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amiodarone for heart arrest</title>
    <id>https://staging.whatcameofit.com/amiodarone--heart-arrest#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amiodarone--heart-arrest"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Amlitelimab for eczema</title>
    <id>https://staging.whatcameofit.com/amlitelimab--eczema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/amlitelimab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Amoxicillin for treponemal infections</title>
    <id>https://staging.whatcameofit.com/amoxicillin--treponemal-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amoxicillin--treponemal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Amrecibart for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/amrecibart--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amrecibart--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Amrecibart for thrombosis</title>
    <id>https://staging.whatcameofit.com/amrecibart--thrombosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amrecibart--thrombosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Amrecibart for venous thromboembolism</title>
    <id>https://staging.whatcameofit.com/amrecibart--venous-thromboembolism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/amrecibart--venous-thromboembolism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>AMXI-5001:Dose Escalation Phase I + AMXI-5001:Dose Expansion Phase II for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/amxi-5001-dose-escalation-phase-i-amxi-5001-dose-expansion-phase-ii--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/amxi-5001-dose-escalation-phase-i-amxi-5001-dose-expansion-phase-ii--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Amygdala neurofeedback for borderline personality disorder</title>
    <id>https://staging.whatcameofit.com/amygdala-neurofeedback--borderline-personality-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/amygdala-neurofeedback--borderline-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Anaprazole + Rabeprazole placebo for esophagitis, peptic</title>
    <id>https://staging.whatcameofit.com/anaprazole-rabeprazole-placebo--esophagitis-peptic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/anaprazole-rabeprazole-placebo--esophagitis-peptic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Anastrozole placebo + Letrozole placebo + CAMIZESTRANT for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/anastrozole-placebo-letrozole-placebo-camizestrant--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/anastrozole-placebo-letrozole-placebo-camizestrant--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ANB-010, dose 1 for hemophilia a</title>
    <id>https://staging.whatcameofit.com/anb-010-dose-1--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anb-010-dose-1--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ANB-010, dose 2 for hemophilia a</title>
    <id>https://staging.whatcameofit.com/anb-010-dose-2--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anb-010-dose-2--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ANB-010, dose 3 for hemophilia a</title>
    <id>https://staging.whatcameofit.com/anb-010-dose-3--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anb-010-dose-3--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-higher-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-androgen-receptor-pathway-inhibitors-arpis-intermediate-nodal-dose-escalation-sbrt-based-prostate-radiotherapy-no-boost-ultrahypofractionated-whole-pelvis-radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Apalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-apalutamide--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-apalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy (ADT) + Placebo for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-placebo--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-placebo--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Androgen deprivation therapy (ADT) + SRT + REZVILUTAMIDE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-srt-rezvilutamide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-adt-srt-rezvilutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy + Apalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy-apalutamide--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy-apalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Deprivation Therapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-deprivation-therapy--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/androgen-deprivation-therapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Androgen Receptor Signal Inhibitor (ARSI) + Luteinizing Hormone-Releasing Hormone (LHRH) analog + DOCETAXEL for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/androgen-receptor-signal-inhibitor-arsi-luteinizing-hormone-releasing-hormone-lhrh-analog-docetaxel--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/androgen-receptor-signal-inhibitor-arsi-luteinizing-hormone-releasing-hormone-lhrh-analog-docetaxel--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistant</title>
    <id>https://staging.whatcameofit.com/androgen-receptor-signaling-inhibitor-arsi-vir-5500-docetaxel--prostatic-neoplasms-castration-resistant#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/androgen-receptor-signaling-inhibitor-arsi-vir-5500-docetaxel--prostatic-neoplasms-castration-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistant</title>
    <id>https://staging.whatcameofit.com/androgen-receptor-signaling-inhibitor-arsi-vir-5500--prostatic-neoplasms-castration-resistant#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/androgen-receptor-signaling-inhibitor-arsi-vir-5500--prostatic-neoplasms-castration-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>aNPC for intervertebral disc degeneration</title>
    <id>https://staging.whatcameofit.com/anpc--intervertebral-disc-degeneration#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anpc--intervertebral-disc-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ansuvimab for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/ansuvimab--hemorrhagic-fever-ebola#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ansuvimab--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/anti-thymocyte-globulin-gm-csf-total-body-irradiation-alemtuzumab-rituximab-human-immunoglobulin-g-cyclophosphamide-thiotepa-mesna--lung-diseases-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/anti-thymocyte-globulin-gm-csf-total-body-irradiation-alemtuzumab-rituximab-human-immunoglobulin-g-cyclophosphamide-thiotepa-mesna--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/anti-thymocyte-globulin-gm-csf-total-body-irradiation-alemtuzumab-rituximab-human-immunoglobulin-g-cyclophosphamide-thiotepa-mesna--scleroderma-diffuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/anti-thymocyte-globulin-gm-csf-total-body-irradiation-alemtuzumab-rituximab-human-immunoglobulin-g-cyclophosphamide-thiotepa-mesna--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>anti-CD19 CAR-T cells for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/anti-cd19-car-t-cells--scleroderma-systemic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/anti-cd19-car-t-cells--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>anti-HER3 antibody conjugated to topoisomerase I inhibitor + BNT116 for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/anti-her3-antibody-conjugated-to-topoisomerase-i-inhibitor-bnt116--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anti-her3-antibody-conjugated-to-topoisomerase-i-inhibitor-bnt116--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Anti-PD-1 monoclonal antibody + LCB84 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Anti-PD-1 monoclonal antibody + LCB84 for glioblastoma</title>
    <id>https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/anti-pd-1-monoclonal-antibody-lcb84--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>anti-PD1 agent therapy - 1 year for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/anti-pd1-agent-therapy-1-year--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/anti-pd1-agent-therapy-1-year--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>anti-PD1 agent therapy - 2 years for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/anti-pd1-agent-therapy-2-years--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/anti-pd1-agent-therapy-2-years--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Antithrombin iii human for antithrombin iii deficiency</title>
    <id>https://staging.whatcameofit.com/antithrombin-iii-human--antithrombin-iii-deficiency#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/antithrombin-iii-human--antithrombin-iii-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>AP306 100 mg TID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-100-mg-tid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-100-mg-tid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AP306 125 mg BID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-125-mg-bid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-125-mg-bid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AP306 125 mg TID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-125-mg-tid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-125-mg-tid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AP306 150 mg BID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-150-mg-bid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-150-mg-bid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AP306 75 mg BID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-75-mg-bid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-75-mg-bid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AP306 75 mg TID for hyperphosphatemia</title>
    <id>https://staging.whatcameofit.com/ap306-75-mg-tid--hyperphosphatemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ap306-75-mg-tid--hyperphosphatemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Apalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/apalutamide--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/apatinib-camrelizumab-sox-preoperative-radiotherapy--adenocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/apatinib-camrelizumab-sox-preoperative-radiotherapy--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Apecotrep for glomerulosclerosis, focal segmental</title>
    <id>https://staging.whatcameofit.com/apecotrep--glomerulosclerosis-focal-segmental#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apecotrep--glomerulosclerosis-focal-segmental"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>APG-157 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/apg-157--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/apg-157--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Apitegromab for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/apitegromab--muscular-atrophy#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apitegromab--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Apitegromab for spinal muscular atrophies of childhood</title>
    <id>https://staging.whatcameofit.com/apitegromab--spinal-muscular-atrophies-of-childhood#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apitegromab--spinal-muscular-atrophies-of-childhood"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Apixaban for heart failure</title>
    <id>https://staging.whatcameofit.com/apixaban--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apixaban--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Apixaban for thrombosis</title>
    <id>https://staging.whatcameofit.com/apixaban--thrombosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/apixaban--thrombosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>apomorphine infusion for dyskinesias</title>
    <id>https://staging.whatcameofit.com/apomorphine-infusion--dyskinesias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/apomorphine-infusion--dyskinesias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>apomorphine infusion for parkinson disease</title>
    <id>https://staging.whatcameofit.com/apomorphine-infusion--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/apomorphine-infusion--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>App AURORA (Digital Therapy) + conventional treatment for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/app-aurora-digital-therapy-conventional-treatment--generalized-anxiety-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/app-aurora-digital-therapy-conventional-treatment--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Apps for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/apps--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/apps--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Apremilast for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/apremilast--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/apremilast--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Apremilast for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/apremilast--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/apremilast--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AR101 for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/ar101--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ar101--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>AR101 powder provided in capsules &amp; sachets for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/ar101-powder-provided-in-capsules-sachets--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ar101-powder-provided-in-capsules-sachets--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>arabinoxylan for obesity</title>
    <id>https://staging.whatcameofit.com/arabinoxylan--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/arabinoxylan--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Arbaclofen for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/arbaclofen--autism-spectrum-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/arbaclofen--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ARBs in combination of SGLT2i for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/arbs-in-combination-of-sglt2i--diabetes-mellitus#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/arbs-in-combination-of-sglt2i--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ARBs in combination of SGLT2i for proteinuria</title>
    <id>https://staging.whatcameofit.com/arbs-in-combination-of-sglt2i--proteinuria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/arbs-in-combination-of-sglt2i--proteinuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ARC-BSI Lumbar system for paraplegia</title>
    <id>https://staging.whatcameofit.com/arc-bsi-lumbar-system--paraplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/arc-bsi-lumbar-system--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/archive-sample-retrieval-biospecimen-collection-ph-low-insertion-peptide-exatecan-conjugate-cbx-12-radiologic-imaging-procedure--rhabdomyosarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/archive-sample-retrieval-biospecimen-collection-ph-low-insertion-peptide-exatecan-conjugate-cbx-12-radiologic-imaging-procedure--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/archive-sample-retrieval-biospecimen-collection-ph-low-insertion-peptide-exatecan-conjugate-cbx-12-radiologic-imaging-procedure--sarcoma-ewing#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/archive-sample-retrieval-biospecimen-collection-ph-low-insertion-peptide-exatecan-conjugate-cbx-12-radiologic-imaging-procedure--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aripiprazole + IEM (Ingestible Event Marker) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/aripiprazole-iem-ingestible-event-marker--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aripiprazole-iem-ingestible-event-marker--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aripiprazole + IEM (Ingestible Event Marker) for schizophrenia</title>
    <id>https://staging.whatcameofit.com/aripiprazole-iem-ingestible-event-marker--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aripiprazole-iem-ingestible-event-marker--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aripiprazole for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/aripiprazole--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aripiprazole--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aripiprazole for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/aripiprazole--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aripiprazole--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aripiprazole for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/aripiprazole--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aripiprazole--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aripiprazole for schizophrenia</title>
    <id>https://staging.whatcameofit.com/aripiprazole--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aripiprazole--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Arm 1: treatment with Shockwave Reducer for angina pectoris</title>
    <id>https://staging.whatcameofit.com/arm-1-treatment-with-shockwave-reducer--angina-pectoris#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/arm-1-treatment-with-shockwave-reducer--angina-pectoris"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Arm 2A: TRACT/MONO mTOR for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/arm-2a-tract-mono-mtor--kidney-failure-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/arm-2a-tract-mono-mtor--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Arm 2B: TRACT/MONO CNI for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/arm-2b-tract-mono-cni--kidney-failure-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/arm-2b-tract-mono-cni--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aroxxen for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/aroxxen--coronary-artery-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aroxxen--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Art and physical activity program. for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/art-and-physical-activity-program--anxiety-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/art-and-physical-activity-program--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ART6043 + Olaparib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/art6043-olaparib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/art6043-olaparib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ART6043 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/art6043--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/art6043--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Artemether + Lumefantrine + TAFENOQUINE for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/artemether-lumefantrine-tafenoquine--malaria-vivax#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/artemether-lumefantrine-tafenoquine--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Artemether + Lumefantrine for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/artemether-lumefantrine--malaria-vivax#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/artemether-lumefantrine--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>artemether-lumefantrine + Mosquirixs for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/artemether-lumefantrine-mosquirixs--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/artemether-lumefantrine-mosquirixs--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>artemether-lumefantrine for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/artemether-lumefantrine--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/artemether-lumefantrine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Artesunate for cytomegalovirus infections</title>
    <id>https://staging.whatcameofit.com/artesunate--cytomegalovirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/artesunate--cytomegalovirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Arthroscopic partial menisectomy + Postoperative rehabilitative physical therapy for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/arthroscopic-partial-menisectomy-postoperative-rehabilitative-physical-therapy--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/arthroscopic-partial-menisectomy-postoperative-rehabilitative-physical-therapy--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ascorbic Acid for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/ascorbic-acid--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ascorbic-acid--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>aSMDC for fecal incontinence</title>
    <id>https://staging.whatcameofit.com/asmdc--fecal-incontinence#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/asmdc--fecal-incontinence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/asp2998-carboplatin-enfortumab-vedotin-pembrolizumab--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/asp2998-carboplatin-enfortumab-vedotin-pembrolizumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ASP2998 for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/asp2998--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/asp2998--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ASP3082 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/asp3082--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/asp3082--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/asparaginase-erwinia-chrysanthemi-recombinant-rywn-g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/asparaginase-erwinia-chrysanthemi-recombinant-rywn-g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn + G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/asparaginase-erwinia-chrysanthemi-recombinant-rywn-g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/asparaginase-erwinia-chrysanthemi-recombinant-rywn-g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aspirin for pre-eclampsia</title>
    <id>https://staging.whatcameofit.com/aspirin--pre-eclampsia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aspirin--pre-eclampsia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aspirin for premature birth</title>
    <id>https://staging.whatcameofit.com/aspirin--premature-birth#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/aspirin--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Aspirin for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/aspirin--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aspirin--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aspirin for purpura, thrombotic thrombocytopenic</title>
    <id>https://staging.whatcameofit.com/aspirin--purpura-thrombotic-thrombocytopenic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aspirin--purpura-thrombotic-thrombocytopenic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ASTX727 for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/astx727--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/astx727--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATEZOLIZUMAB + Divarasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/atezolizumab-divarasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/atezolizumab-divarasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ATEZOLIZUMAB + Doxorubicin hydrochloride for sarcoma</title>
    <id>https://staging.whatcameofit.com/atezolizumab-doxorubicin-hydrochloride--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab-doxorubicin-hydrochloride--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/atezolizumab-vincristine-irinotecan-temozolomide--rhabdomyosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/atezolizumab-vincristine-irinotecan-temozolomide--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for carcinoma, neuroendocrine</title>
    <id>https://staging.whatcameofit.com/atezolizumab--carcinoma-neuroendocrine#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--carcinoma-neuroendocrine"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/atezolizumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for fatty liver</title>
    <id>https://staging.whatcameofit.com/atezolizumab--fatty-liver#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--fatty-liver"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/atezolizumab--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/atezolizumab--neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Atezolizumab for sarcoma</title>
    <id>https://staging.whatcameofit.com/atezolizumab--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atezolizumab--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATG + CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System + Prednisone/Methylprenisolone + Total Body Irradiation + RITUXIMAB + CLOFARABINE + Melphalan + PALIFERMIN for crohn disease</title>
    <id>https://staging.whatcameofit.com/atg-clinimacs-tcr-α-β-reagent-kit-and-clinimacs-cd19-system-prednisone-methylprenisolone-total-body-irradiation-rituximab-clofarabine-melphalan-palifermin--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/atg-clinimacs-tcr-α-β-reagent-kit-and-clinimacs-cd19-system-prednisone-methylprenisolone-total-body-irradiation-rituximab-clofarabine-melphalan-palifermin--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ATI-045 for eczema</title>
    <id>https://staging.whatcameofit.com/ati-045--eczema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ati-045--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atibuclimab for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/atibuclimab--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atibuclimab--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atibuclimab for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/atibuclimab--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atibuclimab--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aticaprant for anhedonia</title>
    <id>https://staging.whatcameofit.com/aticaprant--anhedonia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/aticaprant--anhedonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/atir101-t-cell-depleted-hsct-from-a-related-haploidentical-donor--graft-vs-host-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/atir101-t-cell-depleted-hsct-from-a-related-haploidentical-donor--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/atir101-t-cell-depleted-hsct-from-a-related-haploidentical-donor--myelodysplastic-syndromes#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/atir101-t-cell-depleted-hsct-from-a-related-haploidentical-donor--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>ATLAS 2030 exoskeleton for cerebral palsy</title>
    <id>https://staging.whatcameofit.com/atlas-2030-exoskeleton--cerebral-palsy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/atlas-2030-exoskeleton--cerebral-palsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ATO + Ascorbic acid for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/ato-ascorbic-acid--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ato-ascorbic-acid--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Atorvastatin + Aspirin for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/atorvastatin-aspirin--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/atorvastatin-aspirin--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Atorvastatin calcium trihydrate for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/atorvastatin-calcium-trihydrate--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atorvastatin-calcium-trihydrate--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atorvastatin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/atorvastatin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atorvastatin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atorvastatin for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/atorvastatin--myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/atorvastatin--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Atorvastatin for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/atorvastatin--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/atorvastatin--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Atovaquone-Proguanil for asymptomatic infections</title>
    <id>https://staging.whatcameofit.com/atovaquone-proguanil--asymptomatic-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atovaquone-proguanil--asymptomatic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atovaquone-Proguanil for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/atovaquone-proguanil--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atovaquone-proguanil--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATR-258 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/atr-258--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atr-258--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATR-258 for obesity</title>
    <id>https://staging.whatcameofit.com/atr-258--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atr-258--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Atrasentan for proteinuria</title>
    <id>https://staging.whatcameofit.com/atrasentan--proteinuria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/atrasentan--proteinuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Atropine sulfate for myopia</title>
    <id>https://staging.whatcameofit.com/atropine-sulfate--myopia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atropine-sulfate--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ATTN201 Focused Ultrasound to the CMN for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/attn201-focused-ultrasound-to-the-cmn--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/attn201-focused-ultrasound-to-the-cmn--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ATTN201 Focused Ultrasound to the CMN for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/attn201-focused-ultrasound-to-the-cmn--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/attn201-focused-ultrasound-to-the-cmn--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ATTO-1310 for pruritus</title>
    <id>https://staging.whatcameofit.com/atto-1310--pruritus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/atto-1310--pruritus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Atuzaginstat for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/atuzaginstat--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/atuzaginstat--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Audiovisual stimulation VR system for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/audiovisual-stimulation-vr-system--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/audiovisual-stimulation-vr-system--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Audiovisual stimulation VR system for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/audiovisual-stimulation-vr-system--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/audiovisual-stimulation-vr-system--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/aumolertinib-combined-with-phased-chemotherapy-pemetrexed-and-carboplatin--adenocarcinoma-of-lung#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aumolertinib-combined-with-phased-chemotherapy-pemetrexed-and-carboplatin--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AUR103 Calcium for neoplasms</title>
    <id>https://staging.whatcameofit.com/aur103-calcium--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/aur103-calcium--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Auricular Acupuncture for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/auricular-acupuncture--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/auricular-acupuncture--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autoinjector + EVOLOCUMAB for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/autoinjector-evolocumab--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autoinjector-evolocumab--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autoinjector + EVOLOCUMAB for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/autoinjector-evolocumab--hypercholesterolemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autoinjector-evolocumab--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autoinjector + EVOLOCUMAB for hyperlipoproteinemias</title>
    <id>https://staging.whatcameofit.com/autoinjector-evolocumab--hyperlipoproteinemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autoinjector-evolocumab--hyperlipoproteinemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autoinjector + Maridebart Cafraglutide for obesity</title>
    <id>https://staging.whatcameofit.com/autoinjector-maridebart-cafraglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/autoinjector-maridebart-cafraglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--glioblastoma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--gliosarcoma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendroglioma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--oligodendroglioma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration-nivolumab--oligodendroglioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastoma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--glioblastoma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--gliosarcoma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendroglioma</title>
    <id>https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--oligodendroglioma#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/autologous-dendritic-cells-pulsed-with-tumor-lysate-antigen-vaccine-laboratory-biomarker-analysis-quality-of-life-assessment-questionnaire-administration--oligodendroglioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>autologous dopaminergic cell implantation for parkinson disease</title>
    <id>https://staging.whatcameofit.com/autologous-dopaminergic-cell-implantation--parkinson-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/autologous-dopaminergic-cell-implantation--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Autologous genetically modified gamma-delta T cells for glioblastoma</title>
    <id>https://staging.whatcameofit.com/autologous-genetically-modified-gamma-delta-t-cells--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/autologous-genetically-modified-gamma-delta-t-cells--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Autologous hALK.CAR T cells for neuroblastoma</title>
    <id>https://staging.whatcameofit.com/autologous-halk-car-t-cells--neuroblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/autologous-halk-car-t-cells--neuroblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Autologous hematopoietic stem cell transplantation + BCMA CAR-T + GPRC5D/CD3 BiTEs for bites and stings</title>
    <id>https://staging.whatcameofit.com/autologous-hematopoietic-stem-cell-transplantation-bcma-car-t-gprc5d-cd3-bites--bites-and-stings#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/autologous-hematopoietic-stem-cell-transplantation-bcma-car-t-gprc5d-cd3-bites--bites-and-stings"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Autologous iPSC-derived RPE for macular degeneration</title>
    <id>https://staging.whatcameofit.com/autologous-ipsc-derived-rpe--macular-degeneration#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-ipsc-derived-rpe--macular-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autologous midbrain dopamine neurons for parkinson disease</title>
    <id>https://staging.whatcameofit.com/autologous-midbrain-dopamine-neurons--parkinson-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/autologous-midbrain-dopamine-neurons--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>autologous NK cell plus GD2 antibody for neuroblastoma</title>
    <id>https://staging.whatcameofit.com/autologous-nk-cell-plus-gd2-antibody--neuroblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-nk-cell-plus-gd2-antibody--neuroblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for hematologic diseases</title>
    <id>https://staging.whatcameofit.com/autologous-testicular-tissue-transplantation-of-prepubertal-frozen-testicular-tissue--hematologic-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-testicular-tissue-transplantation-of-prepubertal-frozen-testicular-tissue--hematologic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Autologous testicular tissue transplantation of prepubertal frozen testicular tissue for neoplasms</title>
    <id>https://staging.whatcameofit.com/autologous-testicular-tissue-transplantation-of-prepubertal-frozen-testicular-tissue--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-testicular-tissue-transplantation-of-prepubertal-frozen-testicular-tissue--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>autologous transplantation of cryopreserved testicular tissue for azoospermia</title>
    <id>https://staging.whatcameofit.com/autologous-transplantation-of-cryopreserved-testicular-tissue--azoospermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-transplantation-of-cryopreserved-testicular-tissue--azoospermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>autologous transplantation of cryopreserved testicular tissue for oligospermia</title>
    <id>https://staging.whatcameofit.com/autologous-transplantation-of-cryopreserved-testicular-tissue--oligospermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/autologous-transplantation-of-cryopreserved-testicular-tissue--oligospermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Avacopan for vasculitis</title>
    <id>https://staging.whatcameofit.com/avacopan--vasculitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/avacopan--vasculitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/avb-001-dose-escalation-phase-avb-001-dose-expansion-phase--fallopian-tube-neoplasms#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/avb-001-dose-escalation-phase-avb-001-dose-expansion-phase--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/avb-001-dose-escalation-phase-avb-001-dose-expansion-phase--neoplasm-metastasis#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/avb-001-dose-escalation-phase-avb-001-dose-expansion-phase--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Avelumab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/avelumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/avelumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Avelumab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/avelumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/avelumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Avelumab for glioma</title>
    <id>https://staging.whatcameofit.com/avelumab--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/avelumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Avexitide for glucose metabolism disorders</title>
    <id>https://staging.whatcameofit.com/avexitide--glucose-metabolism-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/avexitide--glucose-metabolism-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Avexitide for hypoglycemia</title>
    <id>https://staging.whatcameofit.com/avexitide--hypoglycemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/avexitide--hypoglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Aviptadil for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/aviptadil--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aviptadil--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aviptadil for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/aviptadil--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/aviptadil--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Awake prone positioning for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/awake-prone-positioning--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/awake-prone-positioning--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Awake prone positioning for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/awake-prone-positioning--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/awake-prone-positioning--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Awake timed prone and repositioning for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/awake-timed-prone-and-repositioning--coronavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/awake-timed-prone-and-repositioning--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Axelopran + pembrolizumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/axelopran-pembrolizumab--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/axelopran-pembrolizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Axelopran + pembrolizumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/axelopran-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/axelopran-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Axitinib + AVELUMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/axitinib-avelumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/axitinib-avelumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine + Ascorbic Acid for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azacitidine-ascorbic-acid--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine-ascorbic-acid--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine + Ascorbic Acid for myeloproliferative disorders</title>
    <id>https://staging.whatcameofit.com/azacitidine-ascorbic-acid--myeloproliferative-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine-ascorbic-acid--myeloproliferative-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine + ENASIDENIB MESYLATE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azacitidine-enasidenib-mesylate--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine-enasidenib-mesylate--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine + Venetoclax + Mobinitinib for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azacitidine-venetoclax-mobinitinib--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azacitidine-venetoclax-mobinitinib--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine for anemia</title>
    <id>https://staging.whatcameofit.com/azacitidine--anemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azacitidine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azacitidine for thrombocytopenia</title>
    <id>https://staging.whatcameofit.com/azacitidine--thrombocytopenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azacitidine--thrombocytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AZD0120 for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/azd0120--scleroderma-systemic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd0120--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD3632 + Posaconazole for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azd3632-posaconazole--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd3632-posaconazole--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD3632 for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/azd3632--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd3632--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD6234 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/azd6234--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/azd6234--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AZD6234 for obesity</title>
    <id>https://staging.whatcameofit.com/azd6234--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/azd6234--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/azd6750-rilvegostomig--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd6750-rilvegostomig--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD6750 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/azd6750--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd6750--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD7760 for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/azd7760--kidney-failure-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd7760--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD7760 for sepsis</title>
    <id>https://staging.whatcameofit.com/azd7760--sepsis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd7760--sepsis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD7760 for staphylococcal infections</title>
    <id>https://staging.whatcameofit.com/azd7760--staphylococcal-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd7760--staphylococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD7798 for crohn disease</title>
    <id>https://staging.whatcameofit.com/azd7798--crohn-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azd7798--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>AZD8205 and AZD2936 (Rilvegostomig) for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/azd8205-and-azd2936-rilvegostomig--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd8205-and-azd2936-rilvegostomig--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD8205 and AZD5305 (saruparib) + AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/azd8205-and-azd5305-saruparib-azd8205-and-azd5305-saruparib-and-azd2936-rilvegostomig--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd8205-and-azd5305-saruparib-azd8205-and-azd5305-saruparib-and-azd2936-rilvegostomig--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>AZD8205 in combination with AZD9574 + AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/azd8205-in-combination-with-azd9574-azd8205-in-combination-with-azd9574-plus-rilvegostomig-azd2936--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/azd8205-in-combination-with-azd9574-azd8205-in-combination-with-azd9574-plus-rilvegostomig-azd2936--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Azenosertib for uterine neoplasms</title>
    <id>https://staging.whatcameofit.com/azenosertib--uterine-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azenosertib--uterine-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azithromycin + Hydroxychloroquine for neoplasms</title>
    <id>https://staging.whatcameofit.com/azithromycin-hydroxychloroquine--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/azithromycin-hydroxychloroquine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/azithromycin-250-mg-x3-week-3-tablets-week-hydroxychloroquine-prednisone--lung-diseases-interstitial#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/azithromycin-250-mg-x3-week-3-tablets-week-hydroxychloroquine-prednisone--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Azithromycin for respiration disorders</title>
    <id>https://staging.whatcameofit.com/azithromycin--respiration-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/azithromycin--respiration-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Azithromycin for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/azithromycin--respiratory-insufficiency#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/azithromycin--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>B1962 for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/b1962--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/b1962--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bacillus calmette-guerin live antigen, unspecified substrain for tuberculosis</title>
    <id>https://staging.whatcameofit.com/bacillus-calmette-guerin-live-antigen-unspecified-substrain--tuberculosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bacillus-calmette-guerin-live-antigen-unspecified-substrain--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Back Exosuit for musculoskeletal pain</title>
    <id>https://staging.whatcameofit.com/back-exosuit--musculoskeletal-pain#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/back-exosuit--musculoskeletal-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Back Exosuit for occupational injuries</title>
    <id>https://staging.whatcameofit.com/back-exosuit--occupational-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/back-exosuit--occupational-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Baclofen for alcoholism</title>
    <id>https://staging.whatcameofit.com/baclofen--alcoholism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/baclofen--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Baclofen for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/baclofen--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/baclofen--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Baclofen for liver diseases, alcoholic</title>
    <id>https://staging.whatcameofit.com/baclofen--liver-diseases-alcoholic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/baclofen--liver-diseases-alcoholic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Baclofen for psychomotor agitation</title>
    <id>https://staging.whatcameofit.com/baclofen--psychomotor-agitation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/baclofen--psychomotor-agitation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/balstilimab-evofosfamide-zalifrelimab--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/balstilimab-evofosfamide-zalifrelimab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/balstilimab-evofosfamide-zalifrelimab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/balstilimab-evofosfamide-zalifrelimab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Baricitinib for alopecia</title>
    <id>https://staging.whatcameofit.com/baricitinib--alopecia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/baricitinib--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Baricitinib for alopecia areata</title>
    <id>https://staging.whatcameofit.com/baricitinib--alopecia-areata#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/baricitinib--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Barley beta-glucan(3.0g) for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/barley-beta-glucan-3-0g--hyperlipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/barley-beta-glucan-3-0g--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Barley beta-glucan(3.0g) for overweight</title>
    <id>https://staging.whatcameofit.com/barley-beta-glucan-3-0g--overweight#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/barley-beta-glucan-3-0g--overweight"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseases</title>
    <id>https://staging.whatcameofit.com/base-edited-hematopoietic-stem-and-progenitor-cells-alemtuzumab-busulfan-filgrastim-palifermin-plerixafor--x-linked-combined-immunodeficiency-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/base-edited-hematopoietic-stem-and-progenitor-cells-alemtuzumab-busulfan-filgrastim-palifermin-plerixafor--x-linked-combined-immunodeficiency-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BBB opening for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/bbb-opening--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bbb-opening--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BBI-001 for hemochromatosis</title>
    <id>https://staging.whatcameofit.com/bbi-001--hemochromatosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bbi-001--hemochromatosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BC006 for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/bc006--idiopathic-pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bc006--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i</title>
    <id>https://staging.whatcameofit.com/beam-301-single-dose-of-beam-301-administered-by-iv--glycogen-storage-disease-type-i#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/beam-301-single-dose-of-beam-301-administered-by-iv--glycogen-storage-disease-type-i"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Becotatug for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/becotatug--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/becotatug--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Becotatug Vedotin for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/becotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/becotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bedaquiline for tuberculosis, multidrug-resistant</title>
    <id>https://staging.whatcameofit.com/bedaquiline--tuberculosis-multidrug-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bedaquiline--tuberculosis-multidrug-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Behavioral Activation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/behavioral-activation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/behavioral-activation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Behavioural Activation (BA) Therapy for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/behavioural-activation-ba-therapy--bipolar-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/behavioural-activation-ba-therapy--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Behavioural Activation (BA) Therapy for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/behavioural-activation-ba-therapy--depressive-disorder-treatment-resistant#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/behavioural-activation-ba-therapy--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Behavioural Activation (BA) Therapy for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/behavioural-activation-ba-therapy--major-depressive-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/behavioural-activation-ba-therapy--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Belantamab mafodotin for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/belantamab-mafodotin--kidney-failure-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/belantamab-mafodotin--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Belimumab for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/belimumab--lung-diseases-interstitial#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/belimumab--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Belimumab for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/belimumab--scleroderma-diffuse#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/belimumab--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Belimumab+SOC for antiphospholipid syndrome</title>
    <id>https://staging.whatcameofit.com/belimumab-soc--antiphospholipid-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/belimumab-soc--antiphospholipid-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Belumosudil 200 mg QD for pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/belumosudil-200-mg-qd--pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/belumosudil-200-mg-qd--pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Benralizumab for hypereosinophilic syndrome</title>
    <id>https://staging.whatcameofit.com/benralizumab--hypereosinophilic-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/benralizumab--hypereosinophilic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Benralizumab for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/benralizumab--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/benralizumab--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Benserazide Only Product for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/benserazide-only-product--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/benserazide-only-product--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Benserazide Only Product for beta-thalassemia</title>
    <id>https://staging.whatcameofit.com/benserazide-only-product--beta-thalassemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/benserazide-only-product--beta-thalassemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Benznidazole for chagas disease</title>
    <id>https://staging.whatcameofit.com/benznidazole--chagas-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/benznidazole--chagas-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Benzocaine Gel applied to the cervix + Hydroxyzine Hydrochloride for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/benzocaine-gel-applied-to-the-cervix-hydroxyzine-hydrochloride--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/benzocaine-gel-applied-to-the-cervix-hydroxyzine-hydrochloride--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bepirovirsen for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/bepirovirsen--renal-insufficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bepirovirsen--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Berberine ursodeoxycholate for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/berberine-ursodeoxycholate--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/berberine-ursodeoxycholate--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Berberine ursodeoxycholate for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/berberine-ursodeoxycholate--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/berberine-ursodeoxycholate--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Beremagene geperpavec for epidermolysis bullosa dystrophica</title>
    <id>https://staging.whatcameofit.com/beremagene-geperpavec--epidermolysis-bullosa-dystrophica#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/beremagene-geperpavec--epidermolysis-bullosa-dystrophica"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Berobenatide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/berobenatide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/berobenatide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Berobenatide for dyspnea</title>
    <id>https://staging.whatcameofit.com/berobenatide--dyspnea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/berobenatide--dyspnea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Berobenatide for obesity</title>
    <id>https://staging.whatcameofit.com/berobenatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/berobenatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Berobenatide for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/berobenatide--osteoarthritis-knee#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/berobenatide--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bersiporocin for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/bersiporocin--idiopathic-pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bersiporocin--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Berzosertib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/berzosertib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/berzosertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Beta glucan for insulin resistance</title>
    <id>https://staging.whatcameofit.com/beta-glucan--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/beta-glucan--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet. for obesity</title>
    <id>https://staging.whatcameofit.com/beta-glucan-addition-to-a-restricted-calorie-of-meal-replacements-and-carbohydrate-diet--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/beta-glucan-addition-to-a-restricted-calorie-of-meal-replacements-and-carbohydrate-diet--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bevacizumab + atezolizumab for fatty liver</title>
    <id>https://staging.whatcameofit.com/bevacizumab-atezolizumab--fatty-liver#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-atezolizumab--fatty-liver"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BEVACIZUMAB + Divarasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/bevacizumab-divarasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-divarasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Bevacizumab + nivolumab + relatlimab for neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab-nivolumab-relatlimab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-nivolumab-relatlimab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bevacizumab + nivolumab + rucaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab-nivolumab-rucaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-nivolumab-rucaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bevacizumab + nivolumab for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab-nivolumab--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-nivolumab--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab-pembrolizumab-izalontamab-brengitecan--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-pembrolizumab-izalontamab-brengitecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab-pembrolizumab-izalontamab-brengitecan--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab-pembrolizumab-izalontamab-brengitecan--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bevacizumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/bevacizumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevacizumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bevonescein (ALM 488) Infusion for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/bevonescein-alm-488-infusion--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bevonescein-alm-488-infusion--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bexicaserin for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/bexicaserin--epilepsies-myoclonic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bexicaserin--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bexicaserin for neurodevelopmental disorders</title>
    <id>https://staging.whatcameofit.com/bexicaserin--neurodevelopmental-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bexicaserin--neurodevelopmental-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bexicaserin for seizures</title>
    <id>https://staging.whatcameofit.com/bexicaserin--seizures#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bexicaserin--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bexmarilimab for neoplasms</title>
    <id>https://staging.whatcameofit.com/bexmarilimab--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bexmarilimab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Beyfortus for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/beyfortus--respiratory-syncytial-virus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/beyfortus--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bezlotoxumab for clostridium infections</title>
    <id>https://staging.whatcameofit.com/bezlotoxumab--clostridium-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezlotoxumab--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bezlotoxumab for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/bezlotoxumab--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezlotoxumab--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bezlotoxumab for crohn disease</title>
    <id>https://staging.whatcameofit.com/bezlotoxumab--crohn-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezlotoxumab--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bezuclastinib for immune complex diseases</title>
    <id>https://staging.whatcameofit.com/bezuclastinib--immune-complex-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezuclastinib--immune-complex-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bezuclastinib for myeloproliferative disorders</title>
    <id>https://staging.whatcameofit.com/bezuclastinib--myeloproliferative-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezuclastinib--myeloproliferative-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bezuclastinib for soft tissue neoplasms</title>
    <id>https://staging.whatcameofit.com/bezuclastinib--soft-tissue-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bezuclastinib--soft-tissue-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BHB810 for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/bhb810--adenocarcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bhb810--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BI 1820237 + Placebo for BI 1820237 + Placebo for BI 456906 + Survodutide for obesity</title>
    <id>https://staging.whatcameofit.com/bi-1820237-placebo-for-bi-1820237-placebo-for-bi-456906-survodutide--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bi-1820237-placebo-for-bi-1820237-placebo-for-bi-456906-survodutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BI 1820237 for obesity</title>
    <id>https://staging.whatcameofit.com/bi-1820237--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bi-1820237--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BI 3034701 for obesity</title>
    <id>https://staging.whatcameofit.com/bi-3034701--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bi-3034701--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>bi-4SCAR GD2/CD70 T cells for neoplasms</title>
    <id>https://staging.whatcameofit.com/bi-4scar-gd2-cd70-t-cells--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bi-4scar-gd2-cd70-t-cells--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BIIB112 for choroideremia</title>
    <id>https://staging.whatcameofit.com/biib112--choroideremia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/biib112--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>BIIB122 225 mg for parkinson disease</title>
    <id>https://staging.whatcameofit.com/biib122-225-mg--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biib122-225-mg--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BIIB122 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/biib122--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biib122--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bilateral implantation of DBS system to Habeluna for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/bilateral-implantation-of-dbs-system-to-habeluna--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bilateral-implantation-of-dbs-system-to-habeluna--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bimagrumab for obesity</title>
    <id>https://staging.whatcameofit.com/bimagrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bimagrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bimatoprost ophthalmic solution 0.01% YSBP for glaucoma, open-angle</title>
    <id>https://staging.whatcameofit.com/bimatoprost-ophthalmic-solution-0-01-ysbp--glaucoma-open-angle#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bimatoprost-ophthalmic-solution-0-01-ysbp--glaucoma-open-angle"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Bimekizumab for psoriasis</title>
    <id>https://staging.whatcameofit.com/bimekizumab--psoriasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bimekizumab--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bioajusta X Orthodontic treatment for malocclusion</title>
    <id>https://staging.whatcameofit.com/bioajusta-x-orthodontic-treatment--malocclusion#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bioajusta-x-orthodontic-treatment--malocclusion"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/biopsy-biospecimen-collection-efineptakin-alfa-pembrolizumab--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-biospecimen-collection-efineptakin-alfa-pembrolizumab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/biopsy-biospecimen-collection-efineptakin-alfa-pembrolizumab--gliosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-biospecimen-collection-efineptakin-alfa-pembrolizumab--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy + Cystoscopy + Bone Scan + Digital Rectal Examination + MRI-Guided Transurethral Ultrasound Ablation + Multiparametric Magnetic Resonance Imaging + PSMA PET Scan + Questionnaire Administration for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-cystoscopy-bone-scan-digital-rectal-examination-mri-guided-transurethral-ultrasound-ablation-multiparametric-magnetic-resonance-imaging-psma-pet-scan-questionnaire-administration--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/biopsy-cystoscopy-bone-scan-digital-rectal-examination-mri-guided-transurethral-ultrasound-ablation-multiparametric-magnetic-resonance-imaging-psma-pet-scan-questionnaire-administration--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/biopsy-histotripsy-durvalumab--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/biopsy-histotripsy-durvalumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Biopsy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/biopsy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/biopsy--osteosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillary</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--adenocarcinoma-papillary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--adenocarcinoma-papillary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamous</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--carcinoma-basosquamous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--carcinoma-basosquamous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cell</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--carcinoma-signet-ring-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--carcinoma-signet-ring-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinoma</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--eccrine-porocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--eccrine-porocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammary</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--paget-disease-extramammary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-positron-emission-mammography-talimogene-laherparepvec-nivolumab--paget-disease-extramammary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for glioma</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-multigated-acquisition-scan-radiologic-examination-osimertinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for glioma</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-radiologic-examination-crizotinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for glioma</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-laboratory-biomarker-analysis-radiologic-examination-pertuzumab-trastuzumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-multigated-acquisition-scan-radiologic-imaging-procedure-pidnarulex-trastuzumab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/biopsy-procedure-biospecimen-collection-echocardiography-test-multigated-acquisition-scan-radiologic-imaging-procedure-pidnarulex-trastuzumab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal neovascularization</title>
    <id>https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--corneal-neovascularization#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--corneal-neovascularization"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal opacity</title>
    <id>https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--corneal-opacity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--corneal-opacity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for limbal stem cell deficiency</title>
    <id>https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--limbal-stem-cell-deficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/biopsy-to-collect-limbal-epithelial-stem-cells-that-will-be-cultivated-into-a-graft-calec-transplant-cultivation-of-limbal-epithelial-cells-into-a-graft--limbal-stem-cell-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Bone Marrow Aspiration + Olaparib for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-bone-marrow-aspiration-olaparib--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-bone-marrow-aspiration-olaparib--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Computed Tomography + Gallium Ga 68 Gozetotide + Positron Emission Tomography + Questionnaire Administration + Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-computed-tomography-gallium-ga-68-gozetotide-positron-emission-tomography-questionnaire-administration-single-photon-emission-computed-tomography-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-computed-tomography-gallium-ga-68-gozetotide-positron-emission-tomography-questionnaire-administration-single-photon-emission-computed-tomography-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Diagnostic Imaging Testing + Excisional Biopsy + Minimally Invasive Surgery + Pelvic Lymphadenectomy + Questionnaire Administration + Sentinel Lymph Node Mapping + Indocyanine Green for carcinosarcoma</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-diagnostic-imaging-testing-excisional-biopsy-minimally-invasive-surgery-pelvic-lymphadenectomy-questionnaire-administration-sentinel-lymph-node-mapping-indocyanine-green--carcinosarcoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-diagnostic-imaging-testing-excisional-biopsy-minimally-invasive-surgery-pelvic-lymphadenectomy-questionnaire-administration-sentinel-lymph-node-mapping-indocyanine-green--carcinosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-mammography-questionnaire-administration-random-periareolar-fine-needle-aspiration-tamoxifen-omega-3-acid-ethyl-esters--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-mammography-questionnaire-administration-random-periareolar-fine-needle-aspiration-tamoxifen-omega-3-acid-ethyl-esters--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-mammography-questionnaire-administration-random-periareolar-fine-needle-aspiration-tamoxifen--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-mammography-questionnaire-administration-random-periareolar-fine-needle-aspiration-tamoxifen--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for autoimmune diseases</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-nasal-swab-survey-administration-remdesivir--autoimmune-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-nasal-swab-survey-administration-remdesivir--autoimmune-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/biospecimen-collection-nasal-swab-survey-administration-remdesivir--respiratory-syncytial-virus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/biospecimen-collection-nasal-swab-survey-administration-remdesivir--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BiOSS LIM C for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/bioss-lim-c--coronary-artery-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bioss-lim-c--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>BiOSS LIM C for coronary stenosis</title>
    <id>https://staging.whatcameofit.com/bioss-lim-c--coronary-stenosis#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bioss-lim-c--coronary-stenosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester) for obesity</title>
    <id>https://staging.whatcameofit.com/bis-octanoyl-r-1-3-butanediol-c8-ketone-di-ester--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bis-octanoyl-r-1-3-butanediol-c8-ketone-di-ester--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BiVACOR TAH System for heart failure</title>
    <id>https://staging.whatcameofit.com/bivacor-tah-system--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bivacor-tah-system--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bladder Transplantation for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/bladder-transplantation--renal-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bladder-transplantation--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BLINATUMOMAB + Venetoclax for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/blinatumomab-venetoclax--neoplasm-residual#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/blinatumomab-venetoclax--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Blinatumomab for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/blinatumomab--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/blinatumomab--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Blmz for tuberculosis, multidrug-resistant</title>
    <id>https://staging.whatcameofit.com/blmz--tuberculosis-multidrug-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blmz--tuberculosis-multidrug-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Blood and adrenaline for cholera</title>
    <id>https://staging.whatcameofit.com/blood-and-adrenaline--cholera#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/blood-and-adrenaline--cholera"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Blood and adrenaline for severe acute malnutrition</title>
    <id>https://staging.whatcameofit.com/blood-and-adrenaline--severe-acute-malnutrition#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/blood-and-adrenaline--severe-acute-malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Blood and adrenaline for shock, septic</title>
    <id>https://staging.whatcameofit.com/blood-and-adrenaline--shock-septic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/blood-and-adrenaline--shock-septic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Blood Brain Barrier (BBB) Disruption for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/blood-brain-barrier-bbb-disruption--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blood-brain-barrier-bbb-disruption--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician&apos;s Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitive</title>
    <id>https://staging.whatcameofit.com/blood-sample-cerebrospinal-fluid-csf-sample-chemotherapy-drug-cancer-physician-s-choice-non-investigational-surgical-resection-radiotherapy-rt-tumor-tissue-sample-temozolomide--neuroectodermal-tumors-primitive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/blood-sample-cerebrospinal-fluid-csf-sample-chemotherapy-drug-cancer-physician-s-choice-non-investigational-surgical-resection-radiotherapy-rt-tumor-tissue-sample-temozolomide--neuroectodermal-tumors-primitive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician&apos;s Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for pyloric stenosis, hypertrophic</title>
    <id>https://staging.whatcameofit.com/blood-sample-cerebrospinal-fluid-csf-sample-chemotherapy-drug-cancer-physician-s-choice-non-investigational-surgical-resection-radiotherapy-rt-tumor-tissue-sample-temozolomide--pyloric-stenosis-hypertrophic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/blood-sample-cerebrospinal-fluid-csf-sample-chemotherapy-drug-cancer-physician-s-choice-non-investigational-surgical-resection-radiotherapy-rt-tumor-tissue-sample-temozolomide--pyloric-stenosis-hypertrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Blood sampling for microRNA testing for migraine disorders</title>
    <id>https://staging.whatcameofit.com/blood-sampling-for-microrna-testing--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blood-sampling-for-microrna-testing--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Blood Specimen Collection + Photographs of Rash + Questionnaires + Stool Specimen collection + Doxycycline for acneiform eruptions</title>
    <id>https://staging.whatcameofit.com/blood-specimen-collection-photographs-of-rash-questionnaires-stool-specimen-collection-doxycycline--acneiform-eruptions#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blood-specimen-collection-photographs-of-rash-questionnaires-stool-specimen-collection-doxycycline--acneiform-eruptions"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Blood Specimen Collection + Photographs of Rash + Questionnaires + Stool Specimen collection + Isotretinoin for acneiform eruptions</title>
    <id>https://staging.whatcameofit.com/blood-specimen-collection-photographs-of-rash-questionnaires-stool-specimen-collection-isotretinoin--acneiform-eruptions#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blood-specimen-collection-photographs-of-rash-questionnaires-stool-specimen-collection-isotretinoin--acneiform-eruptions"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Blue-depleted evening light condition for mental disorders</title>
    <id>https://staging.whatcameofit.com/blue-depleted-evening-light-condition--mental-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/blue-depleted-evening-light-condition--mental-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/bms-986470-famotidine-pantoprazole--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bms-986470-famotidine-pantoprazole--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BMS-986470 + Placebo for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/bms-986470-placebo--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bms-986470-placebo--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BMS-986470 for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/bms-986470--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bms-986470--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BMX-001 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/bmx-001--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bmx-001--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BMX-001 for stomatitis</title>
    <id>https://staging.whatcameofit.com/bmx-001--stomatitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bmx-001--stomatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + BNT316 for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-bnt316--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-bnt316--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + CEMIPLIMAB + Carboplatin + Paclitaxel for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-cemiplimab-carboplatin-paclitaxel--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-cemiplimab-carboplatin-paclitaxel--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + CEMIPLIMAB for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-cemiplimab--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-cemiplimab--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + DOCETAXEL for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-docetaxel--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-docetaxel--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + OSIMERTINIB for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-osimertinib--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-osimertinib--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + Pumitamig for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-pumitamig--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-pumitamig--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 + Tambotatug Pelitecan for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116-tambotatug-pelitecan--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116-tambotatug-pelitecan--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT116 for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt116--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt116--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT326 + ITRACONAZOLE for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt326-itraconazole--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt326-itraconazole--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT326 + Paroxetine for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt326-paroxetine--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt326-paroxetine--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT326 + Pumitamig for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt326-pumitamig--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt326-pumitamig--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT326 for arthrogryposis</title>
    <id>https://staging.whatcameofit.com/bnt326--arthrogryposis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt326--arthrogryposis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/bnt329-ca19-9-targeting-monoclonal-antibody--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt329-ca19-9-targeting-monoclonal-antibody--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BNT329 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/bnt329--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bnt329--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Bocunebart for migraine disorders</title>
    <id>https://staging.whatcameofit.com/bocunebart--migraine-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bocunebart--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Body Composition + Blood Draw + CGM/CKM + gradCPT + Ketogenic Diet + Ketone/Glucose Monitoring + NIH Toolbox + PHQ-9 + Resting-state fMRI + SKID + Sleep Monitoring + Task-fMRI + WHO-5 for ketosis</title>
    <id>https://staging.whatcameofit.com/body-composition-blood-draw-cgm-ckm-gradcpt-ketogenic-diet-ketone-glucose-monitoring-nih-toolbox-phq-9-resting-state-fmri-skid-sleep-monitoring-task-fmri-who-5--ketosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/body-composition-blood-draw-cgm-ckm-gradcpt-ketogenic-diet-ketone-glucose-monitoring-nih-toolbox-phq-9-resting-state-fmri-skid-sleep-monitoring-task-fmri-who-5--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bodycad Unicompartmental Knee System (BUKS) + Unicompartmental Knee Arthroplasty Surgery for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/bodycad-unicompartmental-knee-system-buks-unicompartmental-knee-arthroplasty-surgery--osteoarthritis-knee#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bodycad-unicompartmental-knee-system-buks-unicompartmental-knee-arthroplasty-surgery--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Bone marrow aspirate matrix for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/bone-marrow-aspirate-matrix--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bone-marrow-aspirate-matrix--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bone marrow cell-based therapy &amp; single-drug immunosuppression. + Deceased donor hand transplantation for amputation, traumatic</title>
    <id>https://staging.whatcameofit.com/bone-marrow-cell-based-therapy-single-drug-immunosuppression-deceased-donor-hand-transplantation--amputation-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bone-marrow-cell-based-therapy-single-drug-immunosuppression-deceased-donor-hand-transplantation--amputation-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bone marrow cell-based therapy &amp; single-drug immunosuppression. + Deceased donor hand transplantation for hand injuries</title>
    <id>https://staging.whatcameofit.com/bone-marrow-cell-based-therapy-single-drug-immunosuppression-deceased-donor-hand-transplantation--hand-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bone-marrow-cell-based-therapy-single-drug-immunosuppression-deceased-donor-hand-transplantation--hand-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Botulinum toxin type a for alopecia</title>
    <id>https://staging.whatcameofit.com/botulinum-toxin-type-a--alopecia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/botulinum-toxin-type-a--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Botulinum toxin type a for urinary bladder, overactive</title>
    <id>https://staging.whatcameofit.com/botulinum-toxin-type-a--urinary-bladder-overactive#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/botulinum-toxin-type-a--urinary-bladder-overactive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Botulinum toxin type a for urinary incontinence</title>
    <id>https://staging.whatcameofit.com/botulinum-toxin-type-a--urinary-incontinence#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/botulinum-toxin-type-a--urinary-incontinence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>BPA prophylaxis + Factor (FVIII or FIX) prophylaxis + FITUSIRAN for hemophilia a</title>
    <id>https://staging.whatcameofit.com/bpa-prophylaxis-factor-fviii-or-fix-prophylaxis-fitusiran--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/bpa-prophylaxis-factor-fviii-or-fix-prophylaxis-fitusiran--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>BPaLMZ Regimen for latent tuberculosis</title>
    <id>https://staging.whatcameofit.com/bpalmz-regimen--latent-tuberculosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bpalmz-regimen--latent-tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BPL-003 for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/bpl-003--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/bpl-003--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BR005-036C for migraine disorders</title>
    <id>https://staging.whatcameofit.com/br005-036c--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/br005-036c--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/brachytherapy-external-beam-radiotherapy-ebrt-nimotuzumab-cisplatin--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brachytherapy-external-beam-radiotherapy-ebrt-nimotuzumab-cisplatin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/brachytherapy-external-beam-radiotherapy-ebrt-placebo-for-nimotuzumab-cisplatin--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brachytherapy-external-beam-radiotherapy-ebrt-placebo-for-nimotuzumab-cisplatin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brachytherapy for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/brachytherapy--osteosarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brachytherapy--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/brain-surgery-retifanlimab-ragifilimab--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brain-surgery-retifanlimab-ragifilimab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/brain-surgery-srs-retifanlimab-ragifilimab--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brain-surgery-srs-retifanlimab-ragifilimab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BrainGate Neural Interface System for aphasia</title>
    <id>https://staging.whatcameofit.com/braingate-neural-interface-system--aphasia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/braingate-neural-interface-system--aphasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BrainGate Neural Interface System for aphasia, broca</title>
    <id>https://staging.whatcameofit.com/braingate-neural-interface-system--aphasia-broca#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/braingate-neural-interface-system--aphasia-broca"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BrainGate Neural Interface System for dysarthria</title>
    <id>https://staging.whatcameofit.com/braingate-neural-interface-system--dysarthria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/braingate-neural-interface-system--dysarthria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>BrainGate Neural Interface System for locked-in syndrome</title>
    <id>https://staging.whatcameofit.com/braingate-neural-interface-system--locked-in-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/braingate-neural-interface-system--locked-in-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bread with added beta-glucans for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/bread-with-added-beta-glucans--dyslipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bread-with-added-beta-glucans--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bread with added beta-glucans for hyperglycemia</title>
    <id>https://staging.whatcameofit.com/bread-with-added-beta-glucans--hyperglycemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bread-with-added-beta-glucans--hyperglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bread with added beta-glucans for hypertension</title>
    <id>https://staging.whatcameofit.com/bread-with-added-beta-glucans--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bread-with-added-beta-glucans--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bread with added beta-glucans for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/bread-with-added-beta-glucans--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bread-with-added-beta-glucans--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bread with added beta-glucans for obesity, abdominal</title>
    <id>https://staging.whatcameofit.com/bread-with-added-beta-glucans--obesity-abdominal#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bread-with-added-beta-glucans--obesity-abdominal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Breast Radiotherapy for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/breast-radiotherapy--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/breast-radiotherapy--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brenipatide for alcoholism</title>
    <id>https://staging.whatcameofit.com/brenipatide--alcoholism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brenipatide--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brenipatide for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/brenipatide--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brenipatide--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brentuximab vedotin for hematologic diseases</title>
    <id>https://staging.whatcameofit.com/brentuximab-vedotin--hematologic-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brentuximab-vedotin--hematologic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brief Cognitive Behavioral Conjoint Therapy (bCBCT) + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/brief-cognitive-behavioral-conjoint-therapy-bcbct-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brief-cognitive-behavioral-conjoint-therapy-bcbct-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brief cognitive task-based intervention for abortion, spontaneous</title>
    <id>https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--abortion-spontaneous#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--abortion-spontaneous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brief cognitive task-based intervention for pregnancy, ectopic</title>
    <id>https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--pregnancy-ectopic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--pregnancy-ectopic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brief cognitive task-based intervention for psychological trauma</title>
    <id>https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--psychological-trauma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--psychological-trauma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brief cognitive task-based intervention for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/brief-cognitive-task-based-intervention--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Brief Negotiation Interview + Naltrexone + Gabapentin for alcoholism</title>
    <id>https://staging.whatcameofit.com/brief-negotiation-interview-naltrexone-gabapentin--alcoholism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brief-negotiation-interview-naltrexone-gabapentin--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brief Negotiation Interview for alcoholism</title>
    <id>https://staging.whatcameofit.com/brief-negotiation-interview--alcoholism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brief-negotiation-interview--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo for presbyopia</title>
    <id>https://staging.whatcameofit.com/brimochol-pf-eye-drops-carbachol-pf-eye-drops-brimonidine-eye-drops-placebo--presbyopia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brimochol-pf-eye-drops-carbachol-pf-eye-drops-brimonidine-eye-drops-placebo--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brimonidine for myopia</title>
    <id>https://staging.whatcameofit.com/brimonidine--myopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brimonidine--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brimonidine for presbyopia</title>
    <id>https://staging.whatcameofit.com/brimonidine--presbyopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brimonidine--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brinretigene Vesgedparvovec for eye abnormalities</title>
    <id>https://staging.whatcameofit.com/brinretigene-vesgedparvovec--eye-abnormalities#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/brinretigene-vesgedparvovec--eye-abnormalities"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Brinretigene Vesgedparvovec for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/brinretigene-vesgedparvovec--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/brinretigene-vesgedparvovec--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Brinretigene Vesgedparvovec for retinal degeneration</title>
    <id>https://staging.whatcameofit.com/brinretigene-vesgedparvovec--retinal-degeneration#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/brinretigene-vesgedparvovec--retinal-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Brivaracetam for epilepsy, absence</title>
    <id>https://staging.whatcameofit.com/brivaracetam--epilepsy-absence#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/brivaracetam--epilepsy-absence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Brivekimig for crohn disease</title>
    <id>https://staging.whatcameofit.com/brivekimig--crohn-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brivekimig--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brivekimig for glomerulosclerosis, focal segmental</title>
    <id>https://staging.whatcameofit.com/brivekimig--glomerulosclerosis-focal-segmental#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brivekimig--glomerulosclerosis-focal-segmental"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Brivekimig for nephrosis, lipoid</title>
    <id>https://staging.whatcameofit.com/brivekimig--nephrosis-lipoid#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/brivekimig--nephrosis-lipoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>BS01 for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/bs01--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/bs01--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Buntanetap tartrate for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/buntanetap-tartrate--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/buntanetap-tartrate--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Buntanetap tartrate for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/buntanetap-tartrate--cognitive-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/buntanetap-tartrate--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Buprenorphine hydrochloride for agnosia</title>
    <id>https://staging.whatcameofit.com/buprenorphine-hydrochloride--agnosia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/buprenorphine-hydrochloride--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Bupropion + Escitalopram + Venlafaxine + SERTRALINE for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--bipolar-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Bupropion + Escitalopram + Venlafaxine + SERTRALINE for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--major-depressive-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Bupropion + Escitalopram + Venlafaxine + SERTRALINE for schizophrenia</title>
    <id>https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--schizophrenia#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/bupropion-escitalopram-venlafaxine-sertraline--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Burning Pain + Myofascial Pain + Neuralgia Pain + Orofacial Bone Pain + Persistent Pain for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/burning-pain-myofascial-pain-neuralgia-pain-orofacial-bone-pain-persistent-pain--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/burning-pain-myofascial-pain-neuralgia-pain-orofacial-bone-pain-persistent-pain--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Bv+r-chp for pyloric stenosis, hypertrophic</title>
    <id>https://staging.whatcameofit.com/bv-r-chp--pyloric-stenosis-hypertrophic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/bv-r-chp--pyloric-stenosis-hypertrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cabamiquine for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/cabamiquine--malaria-falciparum#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cabamiquine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cabotegravir for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/cabotegravir--substance-related-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cabotegravir--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cabozantinib + BEVACIZUMAB + ATEZOLIZUMAB + EMACTUZUMAB + RUCAPARIB + SIMLUKAFUSP ALFA + ALECTINIB for neoplasms</title>
    <id>https://staging.whatcameofit.com/cabozantinib-bevacizumab-atezolizumab-emactuzumab-rucaparib-simlukafusp-alfa-alectinib--neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cabozantinib-bevacizumab-atezolizumab-emactuzumab-rucaparib-simlukafusp-alfa-alectinib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cabozantinib + NIVOLUMAB + IPILIMUMAB for neoplasms</title>
    <id>https://staging.whatcameofit.com/cabozantinib-nivolumab-ipilimumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cabozantinib-nivolumab-ipilimumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cabozantinib + NIVOLUMAB for carcinoid tumor</title>
    <id>https://staging.whatcameofit.com/cabozantinib-nivolumab--carcinoid-tumor#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cabozantinib-nivolumab--carcinoid-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cabozantinib for carcinoid tumor</title>
    <id>https://staging.whatcameofit.com/cabozantinib--carcinoid-tumor#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cabozantinib--carcinoid-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cabozantinib for neoplasms</title>
    <id>https://staging.whatcameofit.com/cabozantinib--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cabozantinib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cadonilimab + lenvatinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cadonilimab-lenvatinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cadonilimab-lenvatinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cadonilimab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cadonilimab--uterine-cervical-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cadonilimab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cagrilintide and Semaglutide + Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/cagrilintide-and-semaglutide-placebo--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cagrilintide-and-semaglutide-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cagrilintide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/cagrilintide--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cagrilintide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cagrilintide for obesity</title>
    <id>https://staging.whatcameofit.com/cagrilintide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cagrilintide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cagrilintide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/cagrilintide--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cagrilintide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CagriSema (Cagrilintide B + semaglutide I) + Low Energy Diet for obesity</title>
    <id>https://staging.whatcameofit.com/cagrisema-cagrilintide-b-semaglutide-i-low-energy-diet--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cagrisema-cagrilintide-b-semaglutide-i-low-energy-diet--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CagriSema (Cagrilintide B + semaglutide I) for obesity</title>
    <id>https://staging.whatcameofit.com/cagrisema-cagrilintide-b-semaglutide-i--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cagrisema-cagrilintide-b-semaglutide-i--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CagriSema for hypertension</title>
    <id>https://staging.whatcameofit.com/cagrisema--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cagrisema--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CagriSema for obesity</title>
    <id>https://staging.whatcameofit.com/cagrisema--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cagrisema--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cal-Mag Butyrate for cognition disorders</title>
    <id>https://staging.whatcameofit.com/cal-mag-butyrate--cognition-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cal-mag-butyrate--cognition-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CAL101 for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/cal101--idiopathic-pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cal101--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Calf Plantar flexion + Dietary nitrate for peripheral arterial disease</title>
    <id>https://staging.whatcameofit.com/calf-plantar-flexion-dietary-nitrate--peripheral-arterial-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/calf-plantar-flexion-dietary-nitrate--peripheral-arterial-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Calorie restricted diet and exercise intervention for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/calorie-restricted-diet-and-exercise-intervention--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/calorie-restricted-diet-and-exercise-intervention--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Calorie restriction via total food replacement for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/calorie-restriction-via-total-food-replacement--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/calorie-restriction-via-total-food-replacement--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Calorie restriction via total food replacement for obesity, morbid</title>
    <id>https://staging.whatcameofit.com/calorie-restriction-via-total-food-replacement--obesity-morbid#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/calorie-restriction-via-total-food-replacement--obesity-morbid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>camrelizumab； famitinib malate for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/camrelizumab-famitinib-malate--uterine-cervical-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/camrelizumab-famitinib-malate--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Canakinumab for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/canakinumab--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/canakinumab--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Canakinumab for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/canakinumab--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/canakinumab--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol + Dronabinol for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/cannabidiol-dronabinol--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cannabidiol-dronabinol--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for drug resistant epilepsy</title>
    <id>https://staging.whatcameofit.com/cannabidiol--drug-resistant-epilepsy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--drug-resistant-epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/cannabidiol--epilepsies-myoclonic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for epilepsy, absence</title>
    <id>https://staging.whatcameofit.com/cannabidiol--epilepsy-absence#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--epilepsy-absence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for lennox gastaut syndrome</title>
    <id>https://staging.whatcameofit.com/cannabidiol--lennox-gastaut-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--lennox-gastaut-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for liver cirrhosis</title>
    <id>https://staging.whatcameofit.com/cannabidiol--liver-cirrhosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--liver-cirrhosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for marijuana abuse</title>
    <id>https://staging.whatcameofit.com/cannabidiol--marijuana-abuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--marijuana-abuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/cannabidiol--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for seizures</title>
    <id>https://staging.whatcameofit.com/cannabidiol--seizures#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for spasms, infantile</title>
    <id>https://staging.whatcameofit.com/cannabidiol--spasms-infantile#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--spasms-infantile"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CAPA-IVM + In-House CAPA-IVM Pre-Maturation Medium + Minimal-Stimulation OS-IVF for infertility, female</title>
    <id>https://staging.whatcameofit.com/capa-ivm-in-house-capa-ivm-pre-maturation-medium-minimal-stimulation-os-ivf--infertility-female#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/capa-ivm-in-house-capa-ivm-pre-maturation-medium-minimal-stimulation-os-ivf--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Capa-ivm for infertility</title>
    <id>https://staging.whatcameofit.com/capa-ivm--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/capa-ivm--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CAPA-IVM System + ICSI, Blastocyst Culture, PGT-A, Embryo Vitrification/Accumulation, and Single Euploid Embryo Transfer + Serial Unstimulated Transvaginal Oocyte Retrieval for infertility</title>
    <id>https://staging.whatcameofit.com/capa-ivm-system-icsi-blastocyst-culture-pgt-a-embryo-vitrification-accumulation-and-single-euploid-embryo-transfer-serial-unstimulated-transvaginal-oocyte-retrieval--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/capa-ivm-system-icsi-blastocyst-culture-pgt-a-embryo-vitrification-accumulation-and-single-euploid-embryo-transfer-serial-unstimulated-transvaginal-oocyte-retrieval--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Capecitabine + pembrolizumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/capecitabine-pembrolizumab--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/capecitabine-pembrolizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Capecitabine for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/capecitabine--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/capecitabine--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Capecitabine for neoplasms</title>
    <id>https://staging.whatcameofit.com/capecitabine--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/capecitabine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>capecitabine or 5-FU + Intensity Modulated Radiation Therapy (IMRT) + DOSTARLIMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/capecitabine-or-5-fu-intensity-modulated-radiation-therapy-imrt-dostarlimab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/capecitabine-or-5-fu-intensity-modulated-radiation-therapy-imrt-dostarlimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerations</title>
    <id>https://staging.whatcameofit.com/capeox-bevacizumab-pd-1-inhibitors-sbrt--spinocerebellar-degenerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/capeox-bevacizumab-pd-1-inhibitors-sbrt--spinocerebellar-degenerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Capivasertib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/capivasertib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/capivasertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Capivasertib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/capivasertib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/capivasertib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Capivasertib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/capivasertib--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/capivasertib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Capivasertib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/capivasertib--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/capivasertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Capivasertib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/capivasertib--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/capivasertib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CAR-T cells targeting CD19 for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/car-t-cells-targeting-cd19--scleroderma-systemic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/car-t-cells-targeting-cd19--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet + Naproxen 500 Mg + Opioids for back injuries</title>
    <id>https://staging.whatcameofit.com/carbidopa-levodopa-25-mg-100-mg-oral-tablet-naproxen-500-mg-opioids--back-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carbidopa-levodopa-25-mg-100-mg-oral-tablet-naproxen-500-mg-opioids--back-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet + Naproxen 500 Mg + Opioids for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/carbidopa-levodopa-25-mg-100-mg-oral-tablet-naproxen-500-mg-opioids--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carbidopa-levodopa-25-mg-100-mg-oral-tablet-naproxen-500-mg-opioids--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carbon ion irradiation for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/carbon-ion-irradiation--carcinoma-adenoid-cystic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carbon-ion-irradiation--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB + Paclitaxel for glioma</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB + Paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB + Paclitaxel for sarcoma</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib-paclitaxel--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB for glioma</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + ELRAGLUSIB for sarcoma</title>
    <id>https://staging.whatcameofit.com/carboplatin-elraglusib--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-elraglusib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/carboplatin-nab-paclitaxel-cetuximab-cisplatin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-nab-paclitaxel-cetuximab-cisplatin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/carboplatin-nab-paclitaxel--uterine-cervical-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/carboplatin-nab-paclitaxel--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/carboplatin-pembrolizumab-cisplatin-sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/carboplatin-pembrolizumab-cisplatin-sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/carboplatin-pembrolizumab-cisplatin-sigvotatug-vedotin--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/carboplatin-pembrolizumab-cisplatin-sigvotatug-vedotin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/carboplatin-pembrolizumab-paclitaxel--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin-pembrolizumab-paclitaxel--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/carboplatin-pembrolizumab-sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/carboplatin-pembrolizumab-sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/carboplatin-pembrolizumab-sigvotatug-vedotin--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/carboplatin-pembrolizumab-sigvotatug-vedotin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/carboplatin--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin for vulvar neoplasms</title>
    <id>https://staging.whatcameofit.com/carboplatin--vulvar-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/carboplatin--vulvar-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin-Paclitaxel for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/carboplatin-paclitaxel--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/carboplatin-paclitaxel--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Carboplatin-Paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/carboplatin-paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/carboplatin-paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cardio-Oncology Referral for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cardio-oncology-referral--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cardio-oncology-referral--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cardiovalve TR valve replacement System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/cardiovalve-tr-valve-replacement-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cardiovalve-tr-valve-replacement-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/cardiovascular-polypill-valsartan-atorvastatin-aspirin-colchicine-0-5-mg--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cardiovascular-polypill-valsartan-atorvastatin-aspirin-colchicine-0-5-mg--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine-placebo 0.5 mg for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/cardiovascular-polypill-valsartan-atorvastatin-aspirin-colchicine-placebo-0-5-mg--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cardiovascular-polypill-valsartan-atorvastatin-aspirin-colchicine-placebo-0-5-mg--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cardiovascular Polypill for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/cardiovascular-polypill--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cardiovascular-polypill--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Carvedilol for heart failure</title>
    <id>https://staging.whatcameofit.com/carvedilol--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/carvedilol--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Caspofungin for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/caspofungin--lung-diseases-interstitial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/caspofungin--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Caspofungin for respiratory aspiration</title>
    <id>https://staging.whatcameofit.com/caspofungin--respiratory-aspiration#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/caspofungin--respiratory-aspiration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CBCT + Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/cbct-therapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cbct-therapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cca for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cca--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cca--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cementless Oxford Unicompartmental Knee Arthroplasty for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/cementless-oxford-unicompartmental-knee-arthroplasty--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cementless-oxford-unicompartmental-knee-arthroplasty--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cemiplimab-fianlimab-fixed-dose-combination-fdc-cemiplimab-ubletamig--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cemiplimab-fianlimab-fixed-dose-combination-fdc-cemiplimab-ubletamig--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/cemiplimab-fianlimab-fixed-dose-combination-fdc-cemiplimab-ubletamig--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cemiplimab-fianlimab-fixed-dose-combination-fdc-cemiplimab-ubletamig--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/cemiplimab-gemcitabine-motixafortide-nab-paclitaxel--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cemiplimab-gemcitabine-motixafortide-nab-paclitaxel--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cemiplimab for penile neoplasms</title>
    <id>https://staging.whatcameofit.com/cemiplimab--penile-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cemiplimab--penile-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cenicriviroc for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/cenicriviroc--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cenicriviroc--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cenicriviroc for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/cenicriviroc--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cenicriviroc--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cenobamate (syrup) for 2 to &lt; 18 year olds + Cenobamate (tablet) for 12 to &lt; 18 year olds for epilepsies, partial</title>
    <id>https://staging.whatcameofit.com/cenobamate-syrup-for-2-to-18-year-olds-cenobamate-tablet-for-12-to-18-year-olds--epilepsies-partial#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cenobamate-syrup-for-2-to-18-year-olds-cenobamate-tablet-for-12-to-18-year-olds--epilepsies-partial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cenvacibart for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/cenvacibart--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cenvacibart--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cenvacibart for thrombosis</title>
    <id>https://staging.whatcameofit.com/cenvacibart--thrombosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cenvacibart--thrombosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cenvacibart for venous thromboembolism</title>
    <id>https://staging.whatcameofit.com/cenvacibart--venous-thromboembolism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cenvacibart--venous-thromboembolism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ceralasertib + Olaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/ceralasertib-olaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ceralasertib-olaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cervical Lymphatic Microsurgery for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/cervical-lymphatic-microsurgery--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cervical-lymphatic-microsurgery--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/cervical-lymphaticovenous-and-lymph-node-to-vein-anastomosis--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cervical-lymphaticovenous-and-lymph-node-to-vein-anastomosis--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>cfMSC therapy for diabetes for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/cfmsc-therapy-for-diabetes--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cfmsc-therapy-for-diabetes--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>cfMSC therapy for diabetes for insulin resistance</title>
    <id>https://staging.whatcameofit.com/cfmsc-therapy-for-diabetes--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cfmsc-therapy-for-diabetes--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Chemically induced pluripotent stem cells biological Artificial Liver for liver failure</title>
    <id>https://staging.whatcameofit.com/chemically-induced-pluripotent-stem-cells-biological-artificial-liver--liver-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/chemically-induced-pluripotent-stem-cells-biological-artificial-liver--liver-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/chemotherapy-preferably-with-a-single-chemotherapeutic-agent-combined-with-capecitabine-including-capecitabine-monotherapy-when-the-preferred-drug-identified-is-capecitabine-alone--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-preferably-with-a-single-chemotherapeutic-agent-combined-with-capecitabine-including-capecitabine-monotherapy-when-the-preferred-drug-identified-is-capecitabine-alone--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/chemotherapy-famitinib-l-malate-camrelizumab--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-famitinib-l-malate-camrelizumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/chemotherapy-hypofractionated-external-beam-radiation-image-guided-brachytherapy--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-hypofractionated-external-beam-radiation-image-guided-brachytherapy--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Chemotherapy + MAPK inhibitors + ARSENIC TRIOXIDE for neuroblastoma</title>
    <id>https://staging.whatcameofit.com/chemotherapy-mapk-inhibitors-arsenic-trioxide--neuroblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-mapk-inhibitors-arsenic-trioxide--neuroblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Chemotherapy TIP for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/chemotherapy-tip--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-tip--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Chemotherapy TIP for penile neoplasms</title>
    <id>https://staging.whatcameofit.com/chemotherapy-tip--penile-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/chemotherapy-tip--penile-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Chlorhexidine for erectile dysfunction</title>
    <id>https://staging.whatcameofit.com/chlorhexidine--erectile-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/chlorhexidine--erectile-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Chlorhexidine for infections</title>
    <id>https://staging.whatcameofit.com/chlorhexidine--infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/chlorhexidine--infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ChoironeX GalKO Porcine Thymokidney for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/choironex-galko-porcine-thymokidney--kidney-failure-chronic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/choironex-galko-porcine-thymokidney--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cholecalciferol for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/cholecalciferol--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cholecalciferol--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cholecalciferol for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cholecalciferol--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cholecalciferol--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cholecalciferol for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/cholecalciferol--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cholecalciferol--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cholecalciferol for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/cholecalciferol--vitamin-d-deficiency#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cholecalciferol--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Chronic speech BCI for locked-in syndrome</title>
    <id>https://staging.whatcameofit.com/chronic-speech-bci--locked-in-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/chronic-speech-bci--locked-in-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Chronic speech BCI for speech disorders</title>
    <id>https://staging.whatcameofit.com/chronic-speech-bci--speech-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/chronic-speech-bci--speech-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>chronobiological augmentation for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/chronobiological-augmentation--bipolar-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/chronobiological-augmentation--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>chronobiological augmentation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/chronobiological-augmentation--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/chronobiological-augmentation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ci + ends for obesity</title>
    <id>https://staging.whatcameofit.com/ci-ends--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ci-ends--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CI + No ENDS for obesity</title>
    <id>https://staging.whatcameofit.com/ci-no-ends--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ci-no-ends--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CI-581a for alcoholism</title>
    <id>https://staging.whatcameofit.com/ci-581a--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ci-581a--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CI/BNST stimulation + ITP Stimulation + No stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ci-bnst-stimulation-itp-stimulation-no-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ci-bnst-stimulation-itp-stimulation-no-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CI/BNST stimulation + No stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ci-bnst-stimulation-no-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ci-bnst-stimulation-no-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CI/BNST stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ci-bnst-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ci-bnst-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CID-103 for purpura</title>
    <id>https://staging.whatcameofit.com/cid-103--purpura#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cid-103--purpura"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CIL001 (Paliroden) for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/cil001-paliroden--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cil001-paliroden--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cilastatin for acute kidney injury</title>
    <id>https://staging.whatcameofit.com/cilastatin--acute-kidney-injury#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cilastatin--acute-kidney-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cilastatin sodium for acute kidney injury</title>
    <id>https://staging.whatcameofit.com/cilastatin-sodium--acute-kidney-injury#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cilastatin-sodium--acute-kidney-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CIPROFLOXACIN + Ceftazidime for febrile neutropenia</title>
    <id>https://staging.whatcameofit.com/ciprofloxacin-ceftazidime--febrile-neutropenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ciprofloxacin-ceftazidime--febrile-neutropenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/circulating-tumor-dna-ctdna-testing-datopotamab-deruxtecan--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/circulating-tumor-dna-ctdna-testing-datopotamab-deruxtecan--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/circulating-tumor-dna-test-ctdna-test-dose-de-escalation-to-contralateral-neck-dose-de-escalation-to-gross-disease-dose-de-escalation-to-gross-disease-to-contralateral-neck--papillomavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/circulating-tumor-dna-test-ctdna-test-dose-de-escalation-to-contralateral-neck-dose-de-escalation-to-gross-disease-dose-de-escalation-to-gross-disease-to-contralateral-neck--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/circulating-tumor-dna-test-ctdna-test-dose-de-escalation-to-contralateral-neck-dose-de-escalation-to-gross-disease-dose-de-escalation-to-gross-disease-to-contralateral-neck--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/circulating-tumor-dna-test-ctdna-test-dose-de-escalation-to-contralateral-neck-dose-de-escalation-to-gross-disease-dose-de-escalation-to-gross-disease-to-contralateral-neck--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cisplatin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/cisplatin--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cisplatin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/cisplatin-pemetrexed-or-carboplatin-pemetrexed-oral-restorative-microbiota-therapy-rmt-capsules-durvalumab--adenocarcinoma-of-lung#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cisplatin-pemetrexed-or-carboplatin-pemetrexed-oral-restorative-microbiota-therapy-rmt-capsules-durvalumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/cisplatin-pemetrexed-or-carboplatin-pemetrexed-placebo-durvalumab--adenocarcinoma-of-lung#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cisplatin-pemetrexed-or-carboplatin-pemetrexed-placebo-durvalumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Citicoline eye drops 2% for glaucoma, open-angle</title>
    <id>https://staging.whatcameofit.com/citicoline-eye-drops-2--glaucoma-open-angle#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/citicoline-eye-drops-2--glaucoma-open-angle"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Classical wound irrigation (control) for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/classical-wound-irrigation-control--wounds-and-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/classical-wound-irrigation-control--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clazakizumab for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/clazakizumab--atherosclerosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clazakizumab--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clazakizumab for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/clazakizumab--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clazakizumab--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clazakizumab for hypertension</title>
    <id>https://staging.whatcameofit.com/clazakizumab--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clazakizumab--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clazakizumab for obesity</title>
    <id>https://staging.whatcameofit.com/clazakizumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clazakizumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clazakizumab for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/clazakizumab--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clazakizumab--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clemastine for eye pain</title>
    <id>https://staging.whatcameofit.com/clemastine--eye-pain#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clemastine--eye-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clinical assessment + salivary collections of amylase and cortisol + Stress elicitation experiment + Structural and Functional MRI for borderline personality disorder</title>
    <id>https://staging.whatcameofit.com/clinical-assessment-salivary-collections-of-amylase-and-cortisol-stress-elicitation-experiment-structural-and-functional-mri--borderline-personality-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clinical-assessment-salivary-collections-of-amylase-and-cortisol-stress-elicitation-experiment-structural-and-functional-mri--borderline-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clinical decision support tool for hemangioma</title>
    <id>https://staging.whatcameofit.com/clinical-decision-support-tool--hemangioma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/clinical-decision-support-tool--hemangioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Clinical decision support tool for keratosis, seborrheic</title>
    <id>https://staging.whatcameofit.com/clinical-decision-support-tool--keratosis-seborrheic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/clinical-decision-support-tool--keratosis-seborrheic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Clinical decision support tool for nevus, pigmented</title>
    <id>https://staging.whatcameofit.com/clinical-decision-support-tool--nevus-pigmented#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/clinical-decision-support-tool--nevus-pigmented"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CliniMACS + G-CSF + HPC,A Infusion + RITUXIMAB + BLINATUMOMAB + Cyclophosphamide + THIOTEPA + LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN + Mesna + FLUDARABINE + Melphalan + Sirolimus + Tacrolimus for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/clinimacs-g-csf-hpc-a-infusion-rituximab-blinatumomab-cyclophosphamide-thiotepa-lapine-t-lymphocyte-immune-globulin-mesna-fludarabine-melphalan-sirolimus-tacrolimus--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clinimacs-g-csf-hpc-a-infusion-rituximab-blinatumomab-cyclophosphamide-thiotepa-lapine-t-lymphocyte-immune-globulin-mesna-fludarabine-melphalan-sirolimus-tacrolimus--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CliniMacs TCR alpha-beta-Biotin system for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/clinimacs-tcr-alpha-beta-biotin-system--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clinimacs-tcr-alpha-beta-biotin-system--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Clofutriben for acth syndrome, ectopic</title>
    <id>https://staging.whatcameofit.com/clofutriben--acth-syndrome-ectopic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clofutriben--acth-syndrome-ectopic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clofutriben for cushing syndrome</title>
    <id>https://staging.whatcameofit.com/clofutriben--cushing-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clofutriben--cushing-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clofutriben for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/clofutriben--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/clofutriben--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Clomiphene Citrate 25mg for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/clomiphene-citrate-25mg--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clomiphene-citrate-25mg--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>clonal fetal MSCs for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/clonal-fetal-mscs--pulmonary-disease-chronic-obstructive#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clonal-fetal-mscs--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Clopidogrel for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/clopidogrel--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clopidogrel--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Clopidogrel for angina, stable</title>
    <id>https://staging.whatcameofit.com/clopidogrel--angina-stable#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clopidogrel--angina-stable"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Clopidogrel for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/clopidogrel--myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/clopidogrel--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson disease</title>
    <id>https://staging.whatcameofit.com/closed-loop-stimulation-gpi-alone-stn-gpi-stn-alone--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/closed-loop-stimulation-gpi-alone-stn-gpi-stn-alone--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Clotting factor concentrates (CFC) or bypassing agents (BPA) + EMICIZUMAB + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a</title>
    <id>https://staging.whatcameofit.com/clotting-factor-concentrates-cfc-or-bypassing-agents-bpa-emicizumab-fitusiran-antithrombin-iii-human--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/clotting-factor-concentrates-cfc-or-bypassing-agents-bpa-emicizumab-fitusiran-antithrombin-iii-human--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Clotting factor concentrates (CFC) or bypassing agents (BPA) + FITUSIRAN + ANTITHROMBIN III HUMAN for hemophilia a</title>
    <id>https://staging.whatcameofit.com/clotting-factor-concentrates-cfc-or-bypassing-agents-bpa-fitusiran-antithrombin-iii-human--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/clotting-factor-concentrates-cfc-or-bypassing-agents-bpa-fitusiran-antithrombin-iii-human--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Clozapine for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/clozapine--bipolar-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/clozapine--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Clozapine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/clozapine--major-depressive-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/clozapine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Clozapine for schizophrenia</title>
    <id>https://staging.whatcameofit.com/clozapine--schizophrenia#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/clozapine--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>CM326 dose 1 + CM326 dose 2 for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/cm326-dose-1-cm326-dose-2--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cm326-dose-1-cm326-dose-2--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CMP-002 for nervous system diseases</title>
    <id>https://staging.whatcameofit.com/cmp-002--nervous-system-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cmp-002--nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>coadministration for rabies</title>
    <id>https://staging.whatcameofit.com/coadministration--rabies#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/coadministration--rabies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Coartem® Baby for malaria</title>
    <id>https://staging.whatcameofit.com/coartem-baby--malaria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coartem-baby--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia (WBH) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia-wbh--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia-wbh--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia for hyperthermia</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt-whole-body-hyperthermia--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy (CBT) for hyperthermia</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy (CBT) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-cbt--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Behavioral Therapy + Psilocybin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-behavioral-therapy-psilocybin--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cognitive-behavioral-therapy-psilocybin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cognitive Processing Therapy for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/cognitive-processing-therapy--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cognitive-processing-therapy--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cognitive task + Left DLPFC tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-task-left-dlpfc-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-task-left-dlpfc-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive task + Right DLPFC tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/cognitive-task-right-dlpfc-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cognitive-task-right-dlpfc-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cognitive Training + Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/cognitive-training-personalized-neuroprotective-strategies-vitamin-b12-folinic-acid-omega-3-nac--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cognitive-training-personalized-neuroprotective-strategies-vitamin-b12-folinic-acid-omega-3-nac--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cognitive Training for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/cognitive-training--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cognitive-training--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine 0.5 mg + Usual Care Group for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/colchicine-0-5-mg-usual-care-group--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine-0-5-mg-usual-care-group--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine 0.5 mg for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/colchicine-0-5-mg--atherosclerosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/colchicine-0-5-mg--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Colchicine 0.5 mg for coronary disease</title>
    <id>https://staging.whatcameofit.com/colchicine-0-5-mg--coronary-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine-0-5-mg--coronary-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine 0.5 mg for heart diseases</title>
    <id>https://staging.whatcameofit.com/colchicine-0-5-mg--heart-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine-0-5-mg--heart-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine 0.5 mg for pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/colchicine-0-5-mg--pulmonary-fibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine-0-5-mg--pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/colchicine--acute-coronary-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/colchicine--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/colchicine--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for coronary disease</title>
    <id>https://staging.whatcameofit.com/colchicine--coronary-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine--coronary-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for heart failure</title>
    <id>https://staging.whatcameofit.com/colchicine--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/colchicine--myocardial-infarction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/colchicine--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine for myocarditis</title>
    <id>https://staging.whatcameofit.com/colchicine--myocarditis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine--myocarditis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Colchicine-placebo 0.5 mg + Usual Care Group for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/colchicine-placebo-0-5-mg-usual-care-group--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/colchicine-placebo-0-5-mg-usual-care-group--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/combination-5-azacytidine-and-nivolumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/combination-5-azacytidine-and-nivolumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/combination-metyrosine-derivative-low-dose-methoxsalen-phenytoin-and-sirolimus-mps--sarcoma-ewing#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/combination-metyrosine-derivative-low-dose-methoxsalen-phenytoin-and-sirolimus-mps--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for encopresis</title>
    <id>https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--encopresis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--encopresis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for fecal incontinence</title>
    <id>https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--fecal-incontinence#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--fecal-incontinence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--neurogenic-bowel#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/combination-of-neostigmine-and-glycopyrrolate-i-box-by-dynatronics--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Combined antioxidant therapy for myocardial reperfusion injury</title>
    <id>https://staging.whatcameofit.com/combined-antioxidant-therapy--myocardial-reperfusion-injury#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/combined-antioxidant-therapy--myocardial-reperfusion-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Combined antioxidant therapy for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/combined-antioxidant-therapy--st-elevation-myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/combined-antioxidant-therapy--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Combined Kidney and Bladder Transplantation for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/combined-kidney-and-bladder-transplantation--renal-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/combined-kidney-and-bladder-transplantation--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Combined LAI Treatment: Cabenuva and Sublocade for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/combined-lai-treatment-cabenuva-and-sublocade--opioid-related-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/combined-lai-treatment-cabenuva-and-sublocade--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Combined metabolic activators for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/combined-metabolic-activators--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/combined-metabolic-activators--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Communication Bridge™ for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/communication-bridge--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/communication-bridge--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Communication Bridge™ for aphasia, primary progressive</title>
    <id>https://staging.whatcameofit.com/communication-bridge--aphasia-primary-progressive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/communication-bridge--aphasia-primary-progressive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Community Treatment for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/community-treatment--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/community-treatment--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Comprehensive weight loss + Enhanced lifestyle changes + Naltrexone-Bupropion + Phentermine-Topiramate for obesity</title>
    <id>https://staging.whatcameofit.com/comprehensive-weight-loss-enhanced-lifestyle-changes-naltrexone-bupropion-phentermine-topiramate--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/comprehensive-weight-loss-enhanced-lifestyle-changes-naltrexone-bupropion-phentermine-topiramate--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Comprehensive weight loss + Enhanced lifestyle changes + Semaglutide + Tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/comprehensive-weight-loss-enhanced-lifestyle-changes-semaglutide-tirzepatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/comprehensive-weight-loss-enhanced-lifestyle-changes-semaglutide-tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Concomitant Renal and Urinary Bladder Allograft Transplantation for bladder exstrophy</title>
    <id>https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--bladder-exstrophy#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--bladder-exstrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Concomitant Renal and Urinary Bladder Allograft Transplantation for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--renal-insufficiency-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Concomitant Renal and Urinary Bladder Allograft Transplantation for urinary bladder neck obstruction</title>
    <id>https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--urinary-bladder-neck-obstruction#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/concomitant-renal-and-urinary-bladder-allograft-transplantation--urinary-bladder-neck-obstruction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/concurrent-chemotherapy-definitive-hypofractionated-intensity-modulated-radiation-theraphy--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/concurrent-chemotherapy-definitive-hypofractionated-intensity-modulated-radiation-theraphy--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Contingency management for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/contingency-management--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/contingency-management--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/continous-glucose-monitor-cgm-low-calorie-diet-personalized-exercise-program--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/continous-glucose-monitor-cgm-low-calorie-diet-personalized-exercise-program--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for obesity</title>
    <id>https://staging.whatcameofit.com/continous-glucose-monitor-cgm-low-calorie-diet-personalized-exercise-program--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/continous-glucose-monitor-cgm-low-calorie-diet-personalized-exercise-program--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Continuous sciatic PNB for lacerations</title>
    <id>https://staging.whatcameofit.com/continuous-sciatic-pnb--lacerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/continuous-sciatic-pnb--lacerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Continuous, hyperfractionated, accelerated radiotherapy(CHART) for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/continuous-hyperfractionated-accelerated-radiotherapy-chart--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/continuous-hyperfractionated-accelerated-radiotherapy-chart--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Control for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/control--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/control--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Control for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/control--dyslipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/control--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Control for hypertension</title>
    <id>https://staging.whatcameofit.com/control--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/control--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Control for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/control--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/control--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Control for respiration disorders</title>
    <id>https://staging.whatcameofit.com/control--respiration-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/control--respiration-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplastic</title>
    <id>https://staging.whatcameofit.com/conventional-surgery-intensity-modulated-radiation-therapy-quality-of-life-assessment-trametinib-pembrolizumab-dabrafenib--thyroid-carcinoma-anaplastic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/conventional-surgery-intensity-modulated-radiation-therapy-quality-of-life-assessment-trametinib-pembrolizumab-dabrafenib--thyroid-carcinoma-anaplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CoolSculpting® System for lipid metabolism disorders</title>
    <id>https://staging.whatcameofit.com/coolsculpting-system--lipid-metabolism-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coolsculpting-system--lipid-metabolism-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/core-biopsy-questionnaire-administration-afimoxifene--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/core-biopsy-questionnaire-administration-afimoxifene--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Coronary Sinus Reducer for angina pectoris</title>
    <id>https://staging.whatcameofit.com/coronary-sinus-reducer--angina-pectoris#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coronary-sinus-reducer--angina-pectoris"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Coronary Sinus Reducer for angina, stable</title>
    <id>https://staging.whatcameofit.com/coronary-sinus-reducer--angina-stable#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coronary-sinus-reducer--angina-stable"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Coronary Sinus Reducer for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/coronary-sinus-reducer--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coronary-sinus-reducer--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Coronary Sinus Reducer for microvascular angina</title>
    <id>https://staging.whatcameofit.com/coronary-sinus-reducer--microvascular-angina#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/coronary-sinus-reducer--microvascular-angina"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Corticosteroids + Ruxolitinib for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/corticosteroids-ruxolitinib--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/corticosteroids-ruxolitinib--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Counseling + Biospecimen Collection + Interview + Survey Administration + Psilocybin for depressive disorder</title>
    <id>https://staging.whatcameofit.com/counseling-biospecimen-collection-interview-survey-administration-psilocybin--depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/counseling-biospecimen-collection-interview-survey-administration-psilocybin--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Counseling + Phone calls + Self-monitoring tools + Text Messages for obesity</title>
    <id>https://staging.whatcameofit.com/counseling-phone-calls-self-monitoring-tools-text-messages--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/counseling-phone-calls-self-monitoring-tools-text-messages--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Counseling + Questionnaire Administration + Psilocybin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/counseling-questionnaire-administration-psilocybin--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/counseling-questionnaire-administration-psilocybin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Counseling + Quitting using Medication for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/counseling-quitting-using-medication--substance-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/counseling-quitting-using-medication--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Counseling + Switching to E-Cigarette for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/counseling-switching-to-e-cigarette--substance-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/counseling-switching-to-e-cigarette--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/covid-19-convalescent-plasma--lung-diseases-interstitial#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/covid-19-convalescent-plasma--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>COVID-19 vaccine for rabies</title>
    <id>https://staging.whatcameofit.com/covid-19-vaccine--rabies#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/covid-19-vaccine--rabies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>cow&apos;s milk for food hypersensitivity</title>
    <id>https://staging.whatcameofit.com/cow-s-milk--food-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cow-s-milk--food-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CP-383 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/cp-383--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cp-383--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CP-383 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/cp-383--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cp-383--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CPAP + Dexamethasone for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/cpap-dexamethasone--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cpap-dexamethasone--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cpap for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/cpap--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cpap--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CR-002 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cr-002--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cr-002--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CR-002 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/cr-002--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cr-002--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CR-002 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/cr-002--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cr-002--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/cready-cognitive-remediation-of-executive-and-adaptive-deficits-in-youth--anemia-sickle-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cready-cognitive-remediation-of-executive-and-adaptive-deficits-in-youth--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/cready-cognitive-remediation-of-executive-and-adaptive-deficits-in-youth--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cready-cognitive-remediation-of-executive-and-adaptive-deficits-in-youth--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Crisaborole 2% topical ointment for vitiligo</title>
    <id>https://staging.whatcameofit.com/crisaborole-2-topical-ointment--vitiligo#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/crisaborole-2-topical-ointment--vitiligo"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Crisugabalin for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/crisugabalin--generalized-anxiety-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/crisugabalin--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Crizanlizumab for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/crizanlizumab--anemia-sickle-cell#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/crizanlizumab--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/cryoablation-tqb2868-injection-catequentinib--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cryoablation-tqb2868-injection-catequentinib--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>cryolipolysis and aerobic exercise for obesity, abdominal</title>
    <id>https://staging.whatcameofit.com/cryolipolysis-and-aerobic-exercise--obesity-abdominal#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cryolipolysis-and-aerobic-exercise--obesity-abdominal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cryolipolysis device for obesity</title>
    <id>https://staging.whatcameofit.com/cryolipolysis-device--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cryolipolysis-device--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cryolipolysis for obesity</title>
    <id>https://staging.whatcameofit.com/cryolipolysis--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cryolipolysis--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CSL222 (AAV5-hFIXco-Padua) for hemophilia b</title>
    <id>https://staging.whatcameofit.com/csl222-aav5-hfixco-padua--hemophilia-b#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/csl222-aav5-hfixco-padua--hemophilia-b"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) for hemophilia b</title>
    <id>https://staging.whatcameofit.com/csl222-adeno-associated-viral-vector-serotype-5-aav5-hfixco-padua--hemophilia-b#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/csl222-adeno-associated-viral-vector-serotype-5-aav5-hfixco-padua--hemophilia-b"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CTO0308 for myopia</title>
    <id>https://staging.whatcameofit.com/cto0308--myopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cto0308--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CTX-471 + Tovecimig for glioblastoma</title>
    <id>https://staging.whatcameofit.com/ctx-471-tovecimig--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ctx-471-tovecimig--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CTX310 for homozygous familial hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/ctx310--homozygous-familial-hypercholesterolemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ctx310--homozygous-familial-hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CTX310 for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/ctx310--hypercholesterolemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ctx310--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CTX310 for hyperlipoproteinemia type v</title>
    <id>https://staging.whatcameofit.com/ctx310--hyperlipoproteinemia-type-v#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ctx310--hyperlipoproteinemia-type-v"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>CUE1 for parkinson disease</title>
    <id>https://staging.whatcameofit.com/cue1--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cue1--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CUE1 non-invasive device for corticobasal degeneration</title>
    <id>https://staging.whatcameofit.com/cue1-non-invasive-device--corticobasal-degeneration#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cue1-non-invasive-device--corticobasal-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CUE1 non-invasive device for dystonia</title>
    <id>https://staging.whatcameofit.com/cue1-non-invasive-device--dystonia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cue1-non-invasive-device--dystonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CUE1 non-invasive device for multiple system atrophy</title>
    <id>https://staging.whatcameofit.com/cue1-non-invasive-device--multiple-system-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cue1-non-invasive-device--multiple-system-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CUE1 non-invasive device for parkinson disease</title>
    <id>https://staging.whatcameofit.com/cue1-non-invasive-device--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cue1-non-invasive-device--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for obesity</title>
    <id>https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program-culturally-tailored-dpp-enhanced-with-socioeconomic-supports--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program-culturally-tailored-dpp-enhanced-with-socioeconomic-supports--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for prediabetic state</title>
    <id>https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program-culturally-tailored-dpp-enhanced-with-socioeconomic-supports--prediabetic-state#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program-culturally-tailored-dpp-enhanced-with-socioeconomic-supports--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Culturally Tailored Diabetes Prevention Program for obesity</title>
    <id>https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Culturally Tailored Diabetes Prevention Program for prediabetic state</title>
    <id>https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program--prediabetic-state#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/culturally-tailored-diabetes-prevention-program--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cultured limbal stem cells Transplantation for limbal stem cell deficiency</title>
    <id>https://staging.whatcameofit.com/cultured-limbal-stem-cells-transplantation--limbal-stem-cell-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cultured-limbal-stem-cells-transplantation--limbal-stem-cell-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Curcumin and Fluoxetine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/curcumin-and-fluoxetine--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/curcumin-and-fluoxetine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Curcumin for gastritis, atrophic</title>
    <id>https://staging.whatcameofit.com/curcumin--gastritis-atrophic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/curcumin--gastritis-atrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Curcumin for laryngostenosis</title>
    <id>https://staging.whatcameofit.com/curcumin--laryngostenosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/curcumin--laryngostenosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Curcumin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/curcumin--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/curcumin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>CVI-VZV-001 for chickenpox</title>
    <id>https://staging.whatcameofit.com/cvi-vzv-001--chickenpox#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cvi-vzv-001--chickenpox"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CVI-VZV-001 for herpes zoster</title>
    <id>https://staging.whatcameofit.com/cvi-vzv-001--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cvi-vzv-001--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CVN424 150 mg for parkinson disease</title>
    <id>https://staging.whatcameofit.com/cvn424-150-mg--parkinson-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cvn424-150-mg--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>CVN424 75 mg for parkinson disease</title>
    <id>https://staging.whatcameofit.com/cvn424-75-mg--parkinson-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cvn424-75-mg--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cyanocobalamin for vitamin b 12 deficiency</title>
    <id>https://staging.whatcameofit.com/cyanocobalamin--vitamin-b-12-deficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyanocobalamin--vitamin-b-12-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyclobenzaprine hydrochloride for stress disorders, traumatic, acute</title>
    <id>https://staging.whatcameofit.com/cyclobenzaprine-hydrochloride--stress-disorders-traumatic-acute#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyclobenzaprine-hydrochloride--stress-disorders-traumatic-acute"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyclophosphamide + FLUDARABINE + Prulacabtagene Leucel for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/cyclophosphamide-fludarabine-prulacabtagene-leucel--scleroderma-systemic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cyclophosphamide-fludarabine-prulacabtagene-leucel--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cyclophosphamide + VINORELBINE for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/cyclophosphamide-vinorelbine--rhabdomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyclophosphamide-vinorelbine--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyclophosphamide for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/cyclophosphamide--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyclophosphamide--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyclophosphamide for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/cyclophosphamide--graft-vs-host-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/cyclophosphamide--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Cyclophosphamide for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/cyclophosphamide--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/cyclophosphamide--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Cyclosporine for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/cyclosporine--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyclosporine--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyclosporine for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/cyclosporine--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyclosporine--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CYP Cocktail + ZIPALERTINIB for carcinoma</title>
    <id>https://staging.whatcameofit.com/cyp-cocktail-zipalertinib--carcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyp-cocktail-zipalertinib--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CYP Cocktail + ZIPALERTINIB for lung diseases</title>
    <id>https://staging.whatcameofit.com/cyp-cocktail-zipalertinib--lung-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyp-cocktail-zipalertinib--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyproheptadine for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/cyproheptadine--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyproheptadine--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cyproheptadine for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/cyproheptadine--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cyproheptadine--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CYTARABINE + Azacitidine + Venetoclax for pyloric stenosis, hypertrophic</title>
    <id>https://staging.whatcameofit.com/cytarabine-azacitidine-venetoclax--pyloric-stenosis-hypertrophic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytarabine-azacitidine-venetoclax--pyloric-stenosis-hypertrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>CYTARABINE + Cladribine + Azacitidine + Venetoclax for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/cytarabine-cladribine-azacitidine-venetoclax--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytarabine-cladribine-azacitidine-venetoclax--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytokine support + EB-PT-CAR-NK-D + EB-PT-CAR-NK-S + Lymphodepleting chemotherapy for neoplasms</title>
    <id>https://staging.whatcameofit.com/cytokine-support-eb-pt-car-nk-d-eb-pt-car-nk-s-lymphodepleting-chemotherapy--neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/cytokine-support-eb-pt-car-nk-d-eb-pt-car-nk-s-lymphodepleting-chemotherapy--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-adavosertib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-afatinib-afatinib-dimaleate--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-binimetinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-capivasertib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-copanlisib-hydrochloride-copanlisib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-crizotinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-dasatinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-defactinib-defactinib-hydrochloride--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-fexagratinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-gsk-2636771--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ipatasertib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab-relatlimab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-nivolumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-palbociclib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-sapanisertib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-taselisib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib-dabrafenib-mesylate-dabrafenib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trametinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-trastuzumab-trastuzumab-emtansine--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for glioma</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/cytology-specimen-collection-procedure-laboratory-biomarker-analysis-ulixertinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>D Vitamin for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/d-vitamin--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/d-vitamin--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>D-Cycloserine (DCS) for combat disorders</title>
    <id>https://staging.whatcameofit.com/d-cycloserine-dcs--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/d-cycloserine-dcs--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>D-Cycloserine (DCS) for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/d-cycloserine-dcs--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/d-cycloserine-dcs--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dabrafenib and trametinib (combination) for ameloblastoma</title>
    <id>https://staging.whatcameofit.com/dabrafenib-and-trametinib-combination--ameloblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dabrafenib-and-trametinib-combination--ameloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dabrafenib, trametinib, nivolumab for glioma</title>
    <id>https://staging.whatcameofit.com/dabrafenib-trametinib-nivolumab--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dabrafenib-trametinib-nivolumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>dabrafenib/trametinib for thyroid carcinoma, anaplastic</title>
    <id>https://staging.whatcameofit.com/dabrafenib-trametinib--thyroid-carcinoma-anaplastic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dabrafenib-trametinib--thyroid-carcinoma-anaplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dacarbazine for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/dacarbazine--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dacarbazine--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/dalpicilib-combined-with-cetuximab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dalpicilib-combined-with-cetuximab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Danicopan for hemoglobinuria, paroxysmal</title>
    <id>https://staging.whatcameofit.com/danicopan--hemoglobinuria-paroxysmal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/danicopan--hemoglobinuria-paroxysmal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Danuglipron for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/danuglipron--diabetes-mellitus#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/danuglipron--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Danuglipron for obesity</title>
    <id>https://staging.whatcameofit.com/danuglipron--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/danuglipron--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Daoib for dementia</title>
    <id>https://staging.whatcameofit.com/daoib--dementia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/daoib--dementia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin + Elecoglipron for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dapagliflozin-elecoglipron--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin-elecoglipron--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin + Empagliflozin for heart failure, systolic</title>
    <id>https://staging.whatcameofit.com/dapagliflozin-empagliflozin--heart-failure-systolic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin-empagliflozin--heart-failure-systolic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/dapagliflozin--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/dapagliflozin--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin for heart failure</title>
    <id>https://staging.whatcameofit.com/dapagliflozin--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin for obesity</title>
    <id>https://staging.whatcameofit.com/dapagliflozin--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin plus Glucophage (MET ER) for obesity</title>
    <id>https://staging.whatcameofit.com/dapagliflozin-plus-glucophage-met-er--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin-plus-glucophage-met-er--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin propanediol for heart failure, systolic</title>
    <id>https://staging.whatcameofit.com/dapagliflozin-propanediol--heart-failure-systolic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin-propanediol--heart-failure-systolic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dapagliflozin propanediol for iron deficiencies</title>
    <id>https://staging.whatcameofit.com/dapagliflozin-propanediol--iron-deficiencies#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dapagliflozin-propanediol--iron-deficiencies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for diphtheria</title>
    <id>https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for haemophilus infections</title>
    <id>https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--haemophilus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--haemophilus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine) for tetanus</title>
    <id>https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL®: DTaP for diphtheria</title>
    <id>https://staging.whatcameofit.com/daptacel-dtap--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-dtap--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL®: DTaP for tetanus</title>
    <id>https://staging.whatcameofit.com/daptacel-dtap--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-dtap--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for diphtheria</title>
    <id>https://staging.whatcameofit.com/daptacel-dtap-ipol-and-acthib--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-dtap-ipol-and-acthib--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DAPTACEL®. (DTaP), IPOL®., and ActHIB®. for tetanus</title>
    <id>https://staging.whatcameofit.com/daptacel-dtap-ipol-and-acthib--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daptacel-dtap-ipol-and-acthib--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Daraxonrasib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/daraxonrasib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/daraxonrasib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Daraxonrasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/daraxonrasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/daraxonrasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Darbepoetin alfa + canakinumab for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/darbepoetin-alfa-canakinumab--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/darbepoetin-alfa-canakinumab--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Daridorexant for alcoholism</title>
    <id>https://staging.whatcameofit.com/daridorexant--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/daridorexant--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Darolutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/darolutamide--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/darolutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Datopotamab Deruxtecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/datopotamab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/datopotamab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>DB-2304 + Placebo + Prednisone for lupus erythematosus, cutaneous</title>
    <id>https://staging.whatcameofit.com/db-2304-placebo-prednisone--lupus-erythematosus-cutaneous#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/db-2304-placebo-prednisone--lupus-erythematosus-cutaneous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>DB-2304 + Placebo for lupus erythematosus, cutaneous</title>
    <id>https://staging.whatcameofit.com/db-2304-placebo--lupus-erythematosus-cutaneous#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/db-2304-placebo--lupus-erythematosus-cutaneous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>DBFC with 150g of Alpha-gal Knock Out (KO) pork + DBFC with 150g of Wild Type (WT) pork for food hypersensitivity</title>
    <id>https://staging.whatcameofit.com/dbfc-with-150g-of-alpha-gal-knock-out-ko-pork-dbfc-with-150g-of-wild-type-wt-pork--food-hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dbfc-with-150g-of-alpha-gal-knock-out-ko-pork-dbfc-with-150g-of-wild-type-wt-pork--food-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>DBS + No Stimulation (Sham) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/dbs-no-stimulation-sham--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dbs-no-stimulation-sham--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dbs for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/dbs--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dbs--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dbs for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/dbs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dbs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DBS of the NAc for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/dbs-of-the-nac--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dbs-of-the-nac--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DBS system for obsessive-compulsive disorder</title>
    <id>https://staging.whatcameofit.com/dbs-system--obsessive-compulsive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dbs-system--obsessive-compulsive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DC-LVA treatment plus usual care for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/dc-lva-treatment-plus-usual-care--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dc-lva-treatment-plus-usual-care--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DCD Heart Transplantation Using NRP for heart failure</title>
    <id>https://staging.whatcameofit.com/dcd-heart-transplantation-using-nrp--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dcd-heart-transplantation-using-nrp--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deceased donor uterus transplantation + Tacrolimus for infertility, female</title>
    <id>https://staging.whatcameofit.com/deceased-donor-uterus-transplantation-tacrolimus--infertility-female#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/deceased-donor-uterus-transplantation-tacrolimus--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Decidual Stromal Cells for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/decidual-stromal-cells--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/decidual-stromal-cells--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Decitabine + ARSENIC TRIOXIDE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/decitabine-arsenic-trioxide--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/decitabine-arsenic-trioxide--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Decitabine + QUIZARTINIB + Venetoclax for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/decitabine-quizartinib-venetoclax--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/decitabine-quizartinib-venetoclax--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Deep Brain Simulator for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/deep-brain-simulator--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-simulator--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation (DBS) for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-dbs--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-dbs--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for anorexia nervosa</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--anorexia-nervosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--anorexia-nervosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for autistic disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--autistic-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--autistic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for gambling</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--gambling#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--gambling"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for obsessive-compulsive disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--obsessive-compulsive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--obsessive-compulsive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for schizophrenia</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation Model 3387 Model 3389 for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-model-3387-model-3389--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-model-3387-model-3389--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation Model 3387 Model 3389 for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-model-3387-model-3389--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-model-3387-model-3389--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>deep brain stimulation with short &amp; long pulse width for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>deep brain stimulation with short &amp; long pulse width for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>deep brain stimulation with short &amp; long pulse width for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-with-short-long-pulse-width--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation, DBS for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-dbs--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-dbs--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation, implanted for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-implanted--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-implanted--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep brain stimulation(Active) + Deep brain stimulation(Sham) for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-active-deep-brain-stimulation-sham--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-active-deep-brain-stimulation-sham--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep brain stimulation(Active) + Deep brain stimulation(Sham) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-active-deep-brain-stimulation-sham--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-active-deep-brain-stimulation-sham--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation(DBS) + Esketamine for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation-dbs-esketamine--depressive-disorder-treatment-resistant#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation-dbs-esketamine--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymph-node-to-venous-bypass-dclnv-bp--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymph-node-to-venous-bypass-dclnv-bp--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep cervical lymphatic-venous anastomosis for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphatic-venous-anastomosis--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphatic-venous-anastomosis--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep cervical lymphatic-venous anastomosis, LVA for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphatic-venous-anastomosis-lva--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphatic-venous-anastomosis-lva--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--lewy-body-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--lewy-body-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphaticovenous-anastomosis-dlva--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphatlc-venous-anastomosis-surgery--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphatlc-venous-anastomosis-surgery--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Deep cervical lymphovenous anastomosis (LVA) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-lva--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-lva--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-routine-treatment--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-routine-treatment--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Deep Cervical Lymphovenous Anastomosis + Routine Treatment for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-routine-treatment--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-cervical-lymphovenous-anastomosis-routine-treatment--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Definitive radiotherapy for dermatofibrosarcoma</title>
    <id>https://staging.whatcameofit.com/definitive-radiotherapy--dermatofibrosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/definitive-radiotherapy--dermatofibrosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Definitive radiotherapy for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/definitive-radiotherapy--histiocytoma-malignant-fibrous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/definitive-radiotherapy--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Definitive radiotherapy for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/definitive-radiotherapy--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/definitive-radiotherapy--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Definitive radiotherapy for liposarcoma</title>
    <id>https://staging.whatcameofit.com/definitive-radiotherapy--liposarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/definitive-radiotherapy--liposarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Definitive radiotherapy for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/definitive-radiotherapy--sarcoma-synovial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/definitive-radiotherapy--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>delayed APM group recruit participants with symptoms lasting for more than 6 months for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/delayed-apm-group-recruit-participants-with-symptoms-lasting-for-more-than-6-months--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/delayed-apm-group-recruit-participants-with-symptoms-lasting-for-more-than-6-months--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasms</title>
    <id>https://staging.whatcameofit.com/dendritic-cell-vaccine-therapy-fludeoxyglucose-f-18-laboratory-biomarker-analysis-ny-eso-1-reactive-tcr-retroviral-vector-transduced-autologous-pbl-positron-emission-tomography-fludarabine-phosphate-cyclophosphamide-aldesleukin--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dendritic-cell-vaccine-therapy-fludeoxyglucose-f-18-laboratory-biomarker-analysis-ny-eso-1-reactive-tcr-retroviral-vector-transduced-autologous-pbl-positron-emission-tomography-fludarabine-phosphate-cyclophosphamide-aldesleukin--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Depemokimab for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/depemokimab--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/depemokimab--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Depression Cognitive Training + tDCS (active stimulation) for neurobehavioral manifestations</title>
    <id>https://staging.whatcameofit.com/depression-cognitive-training-tdcs-active-stimulation--neurobehavioral-manifestations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/depression-cognitive-training-tdcs-active-stimulation--neurobehavioral-manifestations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Depression Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations</title>
    <id>https://staging.whatcameofit.com/depression-cognitive-training-tdcs-sham-stimulation--neurobehavioral-manifestations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/depression-cognitive-training-tdcs-sham-stimulation--neurobehavioral-manifestations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Desiccated Porcine Thyroid Extract Tablets for hypothyroidism</title>
    <id>https://staging.whatcameofit.com/desiccated-porcine-thyroid-extract-tablets--hypothyroidism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/desiccated-porcine-thyroid-extract-tablets--hypothyroidism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Deucravacitinib for psoriasis</title>
    <id>https://staging.whatcameofit.com/deucravacitinib--psoriasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/deucravacitinib--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Deucravacitinib for vitiligo</title>
    <id>https://staging.whatcameofit.com/deucravacitinib--vitiligo#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/deucravacitinib--vitiligo"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Deuruxolitinib for alopecia areata</title>
    <id>https://staging.whatcameofit.com/deuruxolitinib--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/deuruxolitinib--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Device-only fitting for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/device-only-fitting--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/device-only-fitting--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Device-only fitting for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/device-only-fitting--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/device-only-fitting--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Device: Directional Deep Brain Stimulation for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/device-directional-deep-brain-stimulation--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/device-directional-deep-brain-stimulation--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Device: Directional Deep Brain Stimulation for epilepsy</title>
    <id>https://staging.whatcameofit.com/device-directional-deep-brain-stimulation--epilepsy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/device-directional-deep-brain-stimulation--epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/dexamethasone-prednisolone-farletuzumab-ecteribulin-prednisone--adenocarcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-prednisolone-farletuzumab-ecteribulin-prednisone--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/dexamethasone-prednisolone-farletuzumab-ecteribulin-prednisone--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-prednisolone-farletuzumab-ecteribulin-prednisone--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dexamethasone for bronchopulmonary dysplasia</title>
    <id>https://staging.whatcameofit.com/dexamethasone--bronchopulmonary-dysplasia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone--bronchopulmonary-dysplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone for premature birth</title>
    <id>https://staging.whatcameofit.com/dexamethasone--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/dexamethasone--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone Sodium Phosphate for pulpitis</title>
    <id>https://staging.whatcameofit.com/dexamethasone-sodium-phosphate--pulpitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-sodium-phosphate--pulpitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone. Dart for bronchopulmonary dysplasia</title>
    <id>https://staging.whatcameofit.com/dexamethasone-dart--bronchopulmonary-dysplasia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-dart--bronchopulmonary-dysplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone. Dart for premature birth</title>
    <id>https://staging.whatcameofit.com/dexamethasone-dart--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-dart--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dexamethasone/Dexamethasone acetate + Fludrocortisone/ Fludrocortisone acetate + Rescue Medications + Opevesostat for neoplasms</title>
    <id>https://staging.whatcameofit.com/dexamethasone-dexamethasone-acetate-fludrocortisone-fludrocortisone-acetate-rescue-medications-opevesostat--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexamethasone-dexamethasone-acetate-fludrocortisone-fludrocortisone-acetate-rescue-medications-opevesostat--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-insulin-human--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-insulin-human--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for premature birth</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-insulin-human--premature-birth#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-insulin-human--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-sliding-scale-insulin--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-sliding-scale-insulin--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for premature birth</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-sliding-scale-insulin--premature-birth#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-sliding-scale-insulin--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-up-titration-of-home-insulin--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-up-titration-of-home-insulin--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for premature birth</title>
    <id>https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-up-titration-of-home-insulin--premature-birth#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexcom-g6-professional-continuous-glucose-monitor-up-titration-of-home-insulin--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexmedetomidine hydrochloride for dysautonomia, familial</title>
    <id>https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--dysautonomia-familial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--dysautonomia-familial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexmedetomidine hydrochloride for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dexmedetomidine hydrochloride for stress disorders, traumatic, acute</title>
    <id>https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--stress-disorders-traumatic-acute#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexmedetomidine-hydrochloride--stress-disorders-traumatic-acute"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zoster</title>
    <id>https://staging.whatcameofit.com/dexmedetomidine-nasal-spray-group-long-duration-high-voltage-pulse-rf-therapy-group--herpes-zoster#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dexmedetomidine-nasal-spray-group-long-duration-high-voltage-pulse-rf-therapy-group--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dextromethorphan and Bupropion Sustained-Release Tablets for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/dextromethorphan-and-bupropion-sustained-release-tablets--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dextromethorphan-and-bupropion-sustained-release-tablets--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Diacerein for epidermolysis bullosa simplex</title>
    <id>https://staging.whatcameofit.com/diacerein--epidermolysis-bullosa-simplex#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/diacerein--epidermolysis-bullosa-simplex"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>DIAG723 for pulmonary arterial hypertension</title>
    <id>https://staging.whatcameofit.com/diag723--pulmonary-arterial-hypertension#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/diag723--pulmonary-arterial-hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>DIAG723 for telangiectasia, hereditary hemorrhagic</title>
    <id>https://staging.whatcameofit.com/diag723--telangiectasia-hereditary-hemorrhagic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/diag723--telangiectasia-hereditary-hemorrhagic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Diamorphine hydrochloride anhydrous for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/diamorphine-hydrochloride-anhydrous--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diamorphine-hydrochloride-anhydrous--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diane-35 + N-METHYL-N-ETHYLTRYPTAMINE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/diane-35-n-methyl-n-ethyltryptamine--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/diane-35-n-methyl-n-ethyltryptamine--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dibotatug for lymphoma, extranodal nk-t-cell</title>
    <id>https://staging.whatcameofit.com/dibotatug--lymphoma-extranodal-nk-t-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dibotatug--lymphoma-extranodal-nk-t-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Diclofenac Sodium for pulpitis</title>
    <id>https://staging.whatcameofit.com/diclofenac-sodium--pulpitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diclofenac-sodium--pulpitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet + Exercise + Meditation for parkinson disease</title>
    <id>https://staging.whatcameofit.com/diet-exercise-meditation--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/diet-exercise-meditation--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Diet Management + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/diet-management-sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-management-sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet-as-Usual (DAU) + LCHF Ketogenic Diet for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet-as-Usual (DAU) + LCHF Ketogenic Diet for ketosis</title>
    <id>https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--ketosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet-as-Usual (DAU) + LCHF Ketogenic Diet for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet-as-Usual (DAU) + LCHF Ketogenic Diet for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diet-as-Usual (DAU) + LCHF Ketogenic Diet for schizophrenia</title>
    <id>https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diet-as-usual-dau-lchf-ketogenic-diet--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dietary vitamin D for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/dietary-vitamin-d--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dietary-vitamin-d--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dietary vitamin D for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/dietary-vitamin-d--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dietary-vitamin-d--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Digital Intelligent Tongue-Pressure Biofeedback Resistance Training for deglutition disorders</title>
    <id>https://staging.whatcameofit.com/digital-intelligent-tongue-pressure-biofeedback-resistance-training--deglutition-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/digital-intelligent-tongue-pressure-biofeedback-resistance-training--deglutition-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Digital Intervention + Metformin for prediabetic state</title>
    <id>https://staging.whatcameofit.com/digital-intervention-metformin--prediabetic-state#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/digital-intervention-metformin--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>digital prosthetic interface technology for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/digital-prosthetic-interface-technology--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/digital-prosthetic-interface-technology--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Digoxin for neoplastic cells, circulating</title>
    <id>https://staging.whatcameofit.com/digoxin--neoplastic-cells-circulating#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/digoxin--neoplastic-cells-circulating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dihydroartemisinin + Piperaquine tetraphosphate + TAFENOQUINE for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-tetraphosphate-tafenoquine--malaria-vivax#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-tetraphosphate-tafenoquine--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dihydroartemisinin + Piperaquine tetraphosphate for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-tetraphosphate--malaria-vivax#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-tetraphosphate--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dihydroartemisinin-Piperaquine (DP) for malaria</title>
    <id>https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-dp--malaria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dihydroartemisinin-piperaquine-dp--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dimethyltryptamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/dimethyltryptamine--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dimethyltryptamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for diphtheria</title>
    <id>https://staging.whatcameofit.com/diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine-adsorbed-dtap-vaccine-bk1301--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine-adsorbed-dtap-vaccine-bk1301--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301) for tetanus</title>
    <id>https://staging.whatcameofit.com/diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine-adsorbed-dtap-vaccine-bk1301--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine-adsorbed-dtap-vaccine-bk1301--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for diphtheria</title>
    <id>https://staging.whatcameofit.com/diphtheria-tetanus-and-acellular-pertussis-three-components-combined-vaccine-adsorbed--diphtheria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/diphtheria-tetanus-and-acellular-pertussis-three-components-combined-vaccine-adsorbed--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed for tetanus</title>
    <id>https://staging.whatcameofit.com/diphtheria-tetanus-and-acellular-pertussis-three-components-combined-vaccine-adsorbed--tetanus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/diphtheria-tetanus-and-acellular-pertussis-three-components-combined-vaccine-adsorbed--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Direct intravenous injection of ivlv-X1 lentiviral vector for x-linked combined immunodeficiency diseases</title>
    <id>https://staging.whatcameofit.com/direct-intravenous-injection-of-ivlv-x1-lentiviral-vector--x-linked-combined-immunodeficiency-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/direct-intravenous-injection-of-ivlv-x1-lentiviral-vector--x-linked-combined-immunodeficiency-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Direct oral anticoagulant for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/direct-oral-anticoagulant--acute-coronary-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/direct-oral-anticoagulant--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Direct oral anticoagulant for embolism</title>
    <id>https://staging.whatcameofit.com/direct-oral-anticoagulant--embolism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/direct-oral-anticoagulant--embolism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Direct oral anticoagulant for heart failure</title>
    <id>https://staging.whatcameofit.com/direct-oral-anticoagulant--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/direct-oral-anticoagulant--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Direct oral anticoagulant for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/direct-oral-anticoagulant--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/direct-oral-anticoagulant--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Disitamab + ENVAFOLIMAB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/disitamab-envafolimab--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/disitamab-envafolimab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Disitamab for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/disitamab--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/disitamab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Divalproex sodium for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/divalproex-sodium--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/divalproex-sodium--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Divalproex sodium for mania</title>
    <id>https://staging.whatcameofit.com/divalproex-sodium--mania#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/divalproex-sodium--mania"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Divarasib + Cetuximab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/divarasib-cetuximab--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/divarasib-cetuximab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Divarasib + ERLOTINIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/divarasib-erlotinib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/divarasib-erlotinib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Divarasib + Inavolisib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/divarasib-inavolisib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/divarasib-inavolisib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Divarasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/divarasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/divarasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>dMD-002 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/dmd-002--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dmd-002--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DMR Procedure (Fractyl) for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dmr-procedure-fractyl--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dmr-procedure-fractyl--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DMR Procedure for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dmr-procedure--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dmr-procedure--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/docetaxel-hydroxychloroquine-gemcitabine--osteosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/docetaxel-hydroxychloroquine-gemcitabine--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Dolutegravir + Isoniazid + RIFAPENTINE for latent tuberculosis</title>
    <id>https://staging.whatcameofit.com/dolutegravir-isoniazid-rifapentine--latent-tuberculosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dolutegravir-isoniazid-rifapentine--latent-tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/donanemab-2-pyrazinecarboxamide-n-3-4ar-7as-2-amino-6-5-fluoro-2-pyrimidinyl-4a-5-6-7-tetrahydropyrrolo-3-4-d-1-3-thiazin-7a-4h-yl-4-fluorophenyl-5-methoxy--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donanemab-2-pyrazinecarboxamide-n-3-4ar-7as-2-amino-6-5-fluoro-2-pyrimidinyl-4a-5-6-7-tetrahydropyrrolo-3-4-d-1-3-thiazin-7a-4h-yl-4-fluorophenyl-5-methoxy--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab + Dexamethasone for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/donanemab-dexamethasone--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/donanemab-dexamethasone--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab + Nivegacetor for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/donanemab-nivegacetor--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donanemab-nivegacetor--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/donanemab--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/donanemab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/donanemab--cognitive-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/donanemab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Donanemab for down syndrome</title>
    <id>https://staging.whatcameofit.com/donanemab--down-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/donanemab--down-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Donanemab for lewy body disease</title>
    <id>https://staging.whatcameofit.com/donanemab--lewy-body-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donanemab--lewy-body-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donor Fecal Microbiota Transplantation for irritable bowel syndrome</title>
    <id>https://staging.whatcameofit.com/donor-fecal-microbiota-transplantation--irritable-bowel-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donor-fecal-microbiota-transplantation--irritable-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donor Leukocyte Infusion (DLI) + INTERFERON GAMMA-1B for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/donor-leukocyte-infusion-dli-interferon-gamma-1b--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donor-leukocyte-infusion-dli-interferon-gamma-1b--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donor mobilized PBSC infusion + G-CSF + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/donor-mobilized-pbsc-infusion-g-csf-rituximab-cyclophosphamide-mp-fludarabine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donor-mobilized-pbsc-infusion-g-csf-rituximab-cyclophosphamide-mp-fludarabine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Donor mobilized PBSC infusion + G-CSF + Total Body Irradiation (TBI) (Plan 1) + RITUXIMAB + Cyclophosphamide + MP + FLUDARABINE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/donor-mobilized-pbsc-infusion-g-csf-total-body-irradiation-tbi-plan-1-rituximab-cyclophosphamide-mp-fludarabine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/donor-mobilized-pbsc-infusion-g-csf-total-body-irradiation-tbi-plan-1-rituximab-cyclophosphamide-mp-fludarabine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dornase alfa for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/dornase-alfa--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dornase-alfa--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dornase alfa for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/dornase-alfa--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dornase-alfa--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dose-escalated radiation therapy for glioblastoma</title>
    <id>https://staging.whatcameofit.com/dose-escalated-radiation-therapy--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dose-escalated-radiation-therapy--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastoma</title>
    <id>https://staging.whatcameofit.com/dose-intensified-accelerated-photon-beam-radiation-therapy--glioblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dose-intensified-accelerated-photon-beam-radiation-therapy--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dose-intensified Photon Beam Radiation Therapy for glioblastoma</title>
    <id>https://staging.whatcameofit.com/dose-intensified-photon-beam-radiation-therapy--glioblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dose-intensified-photon-beam-radiation-therapy--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dostarlimab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/dostarlimab--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dostarlimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dostarlimab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/dostarlimab--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dostarlimab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/dostarlimab-gxly-50-mg-1-ml-intravenous-solution-jemperli--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dostarlimab-gxly-50-mg-1-ml-intravenous-solution-jemperli--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/double-active-active-portable-transcranial-stimulation-ptes-and-active-internet-based-behavioral-therapy-ibt--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/double-active-active-portable-transcranial-stimulation-ptes-and-active-internet-based-behavioral-therapy-ibt--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Doublet Chemotherapy, Dose-reduced (75%) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/doublet-chemotherapy-dose-reduced-75--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/doublet-chemotherapy-dose-reduced-75--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Doxorubicin hydrochloride + ELRAGLUSIB for glioma</title>
    <id>https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Doxorubicin hydrochloride + ELRAGLUSIB for sarcoma</title>
    <id>https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/doxorubicin-hydrochloride-elraglusib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Doxycycline for lymphatic abnormalities</title>
    <id>https://staging.whatcameofit.com/doxycycline--lymphatic-abnormalities#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/doxycycline--lymphatic-abnormalities"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Doxycycline for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/doxycycline--osteoarthritis#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/doxycycline--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>DR10624 Injection for hypertriglyceridemia</title>
    <id>https://staging.whatcameofit.com/dr10624-injection--hypertriglyceridemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dr10624-injection--hypertriglyceridemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DR10624 Injection for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/dr10624-injection--non-alcoholic-fatty-liver-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dr10624-injection--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DR10624 Injection for pancreatitis</title>
    <id>https://staging.whatcameofit.com/dr10624-injection--pancreatitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dr10624-injection--pancreatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dronabinol for marijuana abuse</title>
    <id>https://staging.whatcameofit.com/dronabinol--marijuana-abuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dronabinol--marijuana-abuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Droxidopa for acute kidney injury</title>
    <id>https://staging.whatcameofit.com/droxidopa--acute-kidney-injury#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/droxidopa--acute-kidney-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/dry-powder-inhaler-inhaled-mosliciguat--lung-diseases-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dry-powder-inhaler-inhaled-mosliciguat--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>DSP-1083 implantation for parkinson disease</title>
    <id>https://staging.whatcameofit.com/dsp-1083-implantation--parkinson-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/dsp-1083-implantation--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>DT-168 for fuchs&apos; endothelial dystrophy</title>
    <id>https://staging.whatcameofit.com/dt-168--fuchs-endothelial-dystrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/dt-168--fuchs-endothelial-dystrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>DTaP (Diphtheria &amp; Tetanus Toxoids &amp; Acellular Pertussis Adsorbed) for diphtheria</title>
    <id>https://staging.whatcameofit.com/dtap-diphtheria-tetanus-toxoids-acellular-pertussis-adsorbed--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-diphtheria-tetanus-toxoids-acellular-pertussis-adsorbed--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTaP (Diphtheria &amp; Tetanus Toxoids &amp; Acellular Pertussis Adsorbed) for tetanus</title>
    <id>https://staging.whatcameofit.com/dtap-diphtheria-tetanus-toxoids-acellular-pertussis-adsorbed--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-diphtheria-tetanus-toxoids-acellular-pertussis-adsorbed--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTaP-IPV and ActHIB® for diphtheria</title>
    <id>https://staging.whatcameofit.com/dtap-ipv-and-acthib--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-ipv-and-acthib--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTaP-IPV and ActHIB® for tetanus</title>
    <id>https://staging.whatcameofit.com/dtap-ipv-and-acthib--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-ipv-and-acthib--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTaP-IPV combined vaccine for diphtheria</title>
    <id>https://staging.whatcameofit.com/dtap-ipv-combined-vaccine--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-ipv-combined-vaccine--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTaP-IPV combined vaccine for tetanus</title>
    <id>https://staging.whatcameofit.com/dtap-ipv-combined-vaccine--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtap-ipv-combined-vaccine--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DTT106 for erectile dysfunction</title>
    <id>https://staging.whatcameofit.com/dtt106--erectile-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dtt106--erectile-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dulaglutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/dulaglutide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dulaglutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Duloxetine for musculoskeletal pain</title>
    <id>https://staging.whatcameofit.com/duloxetine--musculoskeletal-pain#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/duloxetine--musculoskeletal-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dupilumab for dermatitis</title>
    <id>https://staging.whatcameofit.com/dupilumab--dermatitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dupilumab--dermatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Dupilumab for eczema</title>
    <id>https://staging.whatcameofit.com/dupilumab--eczema#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dupilumab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/durvalumab-datopotamab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/durvalumab-datopotamab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Durvalumab + Gem/Cis for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/durvalumab-gem-cis--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/durvalumab-gem-cis--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Durvalumab + oleclumab for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/durvalumab-oleclumab--hemangiosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/durvalumab-oleclumab--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Durvalumab + oleclumab for liposarcoma</title>
    <id>https://staging.whatcameofit.com/durvalumab-oleclumab--liposarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/durvalumab-oleclumab--liposarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Durvalumab + oleclumab for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/durvalumab-oleclumab--osteosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/durvalumab-oleclumab--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Durvalumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/durvalumab--neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/durvalumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Duvakitug for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/duvakitug--colitis-ulcerative#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/duvakitug--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>dynamic contrast enhanced MRI + geniculate artery embolization for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/dynamic-contrast-enhanced-mri-geniculate-artery-embolization--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/dynamic-contrast-enhanced-mri-geniculate-artery-embolization--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>DynamiCare Health for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/dynamicare-health--opioid-related-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/dynamicare-health--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>E-Cigarette 7.2 mg nicotine for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/e-cigarette-7-2-mg-nicotine--tobacco-use-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/e-cigarette-7-2-mg-nicotine--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EA-230 90mg/kg/hour for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/ea-230-90mg-kg-hour--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ea-230-90mg-kg-hour--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Early arthroscopic partial menisectomy group for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/early-arthroscopic-partial-menisectomy-group--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/early-arthroscopic-partial-menisectomy-group--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EB-1020 (Centanafadine) high dose for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/eb-1020-centanafadine-high-dose--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eb-1020-centanafadine-high-dose--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>EB-1020 (Centanafadine) low dose for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/eb-1020-centanafadine-low-dose--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eb-1020-centanafadine-low-dose--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ECC0509 + ECC4703 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/ecc0509-ecc4703--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ecc0509-ecc4703--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ECC0509 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/ecc0509--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ecc0509--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ECC4703 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/ecc4703--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ecc4703--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--sarcoma-ewing#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--sarcoma-synovial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-biospecimen-collection-computed-tomography-multigated-acquisition-scan-zanzalintinib--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--anemia-sickle-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for arrhythmias, cardiac</title>
    <id>https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--arrhythmias-cardiac#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--arrhythmias-cardiac"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for cardiomyopathies</title>
    <id>https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--cardiomyopathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--cardiomyopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for iron overload</title>
    <id>https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--iron-overload#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-electrocardiogram-ecg-deferiprone-deferoxamine-deferasirox--iron-overload"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Echocardiography Test + Doxorubicin hydrochloride for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/echocardiography-test-doxorubicin-hydrochloride--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/echocardiography-test-doxorubicin-hydrochloride--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ecig 24 mg nicotine for schizophrenia</title>
    <id>https://staging.whatcameofit.com/ecig-24-mg-nicotine--schizophrenia#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ecig-24-mg-nicotine--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ecnoglutide for obesity</title>
    <id>https://staging.whatcameofit.com/ecnoglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ecnoglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ecnoglutide for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/ecnoglutide--osteoarthritis-knee#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ecnoglutide--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>EDG-15400 25 mg for heart failure</title>
    <id>https://staging.whatcameofit.com/edg-15400-25-mg--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/edg-15400-25-mg--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>EDG-15400 50 mg for heart failure</title>
    <id>https://staging.whatcameofit.com/edg-15400-50-mg--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/edg-15400-50-mg--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>EDIT-301 for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/edit-301--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/edit-301--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Educational and Media Intervention for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/educational-and-media-intervention--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/educational-and-media-intervention--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>edupression.com® for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/edupression-com--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/edupression-com--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>edupression.com® for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/edupression-com--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/edupression-com--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Edwards EVOQUE System for heart failure</title>
    <id>https://staging.whatcameofit.com/edwards-evoque-system--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/edwards-evoque-system--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Edwards EVOQUE System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/edwards-evoque-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/edwards-evoque-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/edwards-ewj-202-transcatheter-tricuspid-valve-replacement-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/edwards-ewj-202-transcatheter-tricuspid-valve-replacement-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EEG-based personalized TMS for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/eeg-based-personalized-tms--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/eeg-based-personalized-tms--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>efanesoctocog alfa (BIVV001) for hemophilia a</title>
    <id>https://staging.whatcameofit.com/efanesoctocog-alfa-bivv001--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/efanesoctocog-alfa-bivv001--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Efgartigimod alfa for immunoglobulin g4-related disease</title>
    <id>https://staging.whatcameofit.com/efgartigimod-alfa--immunoglobulin-g4-related-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/efgartigimod-alfa--immunoglobulin-g4-related-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Efineptakin alfa for opportunistic infections</title>
    <id>https://staging.whatcameofit.com/efineptakin-alfa--opportunistic-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/efineptakin-alfa--opportunistic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Eflornithine for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/eflornithine--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/eflornithine--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Efruxifermin for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/efruxifermin--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/efruxifermin--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Efzimfotase Alfa for hypophosphatasia</title>
    <id>https://staging.whatcameofit.com/efzimfotase-alfa--hypophosphatasia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/efzimfotase-alfa--hypophosphatasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>EG-MCV4 for meningococcal infections</title>
    <id>https://staging.whatcameofit.com/eg-mcv4--meningococcal-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/eg-mcv4--meningococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>EGCG and Quinine Sulfate Vaginal Suppository for atypical squamous cells of the cervix</title>
    <id>https://staging.whatcameofit.com/egcg-and-quinine-sulfate-vaginal-suppository--atypical-squamous-cells-of-the-cervix#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/egcg-and-quinine-sulfate-vaginal-suppository--atypical-squamous-cells-of-the-cervix"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/egcg-and-quinine-sulfate-vaginal-suppository--papillomavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/egcg-and-quinine-sulfate-vaginal-suppository--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EGEN-5784 (genetically engineered porcine liver) + metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx) for acute-on-chronic liver failure</title>
    <id>https://staging.whatcameofit.com/egen-5784-genetically-engineered-porcine-liver-metra-extracorporeal-liver-cross-circulation-elc-system-organox--acute-on-chronic-liver-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/egen-5784-genetically-engineered-porcine-liver-metra-extracorporeal-liver-cross-circulation-elc-system-organox--acute-on-chronic-liver-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>EIT-Group for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/eit-group--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/eit-group--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Elasomeran for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/elasomeran--renal-insufficiency-chronic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/elasomeran--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Elecoglipron for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/elecoglipron--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/elecoglipron--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Elecoglipron for obesity</title>
    <id>https://staging.whatcameofit.com/elecoglipron--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/elecoglipron--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Electroacupuncture for depressive disorder</title>
    <id>https://staging.whatcameofit.com/electroacupuncture--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/electroacupuncture--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Electroacupuncture for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/electroacupuncture--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/electroacupuncture--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Electronic Cigarette and behavioural change support. for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/electronic-cigarette-and-behavioural-change-support--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/electronic-cigarette-and-behavioural-change-support--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>electronic cigarette for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/electronic-cigarette--tobacco-use-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/electronic-cigarette--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Electronic Cigarettes (EC) for obesity</title>
    <id>https://staging.whatcameofit.com/electronic-cigarettes-ec--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/electronic-cigarettes-ec--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ELI-002 2P for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/eli-002-2p--cholangiocarcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eli-002-2p--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ELI-002 2P for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/eli-002-2p--neoplasm-residual#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eli-002-2p--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Eliminating RT to the elective neck for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/eliminating-rt-to-the-elective-neck--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/eliminating-rt-to-the-elective-neck--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elironrasib + Daraxonrasib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/elironrasib-daraxonrasib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/elironrasib-daraxonrasib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Elironrasib + Daraxonrasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/elironrasib-daraxonrasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/elironrasib-daraxonrasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Elironrasib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/elironrasib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/elironrasib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Elironrasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/elironrasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/elironrasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Elismetrep for migraine disorders</title>
    <id>https://staging.whatcameofit.com/elismetrep--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/elismetrep--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide + Macupatide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/eloralintide-macupatide--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/eloralintide-macupatide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide + Macupatide for obesity</title>
    <id>https://staging.whatcameofit.com/eloralintide-macupatide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/eloralintide-macupatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide + Tirzepatide for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/eloralintide-tirzepatide--metabolic-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eloralintide-tirzepatide--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide + Tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/eloralintide-tirzepatide--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eloralintide-tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>eloralintide and tirzepatide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/eloralintide-and-tirzepatide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eloralintide-and-tirzepatide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>eloralintide and tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/eloralintide-and-tirzepatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eloralintide-and-tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/eloralintide--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/eloralintide--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Eloralintide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/eloralintide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eloralintide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/eloralintide--metabolic-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eloralintide--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Eloralintide for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/eloralintide--osteoarthritis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eloralintide--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + Gemcitabine Hydrochloride for glioma</title>
    <id>https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + Gemcitabine Hydrochloride for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + Gemcitabine Hydrochloride for sarcoma</title>
    <id>https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-gemcitabine-hydrochloride--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for glioma</title>
    <id>https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for sarcoma</title>
    <id>https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib-nab-paclitaxel-gemcitabine-hydrochloride--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elraglusib for glioma</title>
    <id>https://staging.whatcameofit.com/elraglusib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elraglusib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/elraglusib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elraglusib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/elraglusib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elraglusib for sarcoma</title>
    <id>https://staging.whatcameofit.com/elraglusib--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elraglusib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Elritercept for anemia</title>
    <id>https://staging.whatcameofit.com/elritercept--anemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/elritercept--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Elritercept for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/elritercept--myelodysplastic-syndromes#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/elritercept--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Elunetirom for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/elunetirom--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/elunetirom--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>embolization therapy for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/embolization-therapy--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/embolization-therapy--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Embosphere Microspheres for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/embosphere-microspheres--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/embosphere-microspheres--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Embozene MicroSpheres for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/embozene-microspheres--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/embozene-microspheres--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Embozene™ Microspheres + Transcatheter arterial embolization for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/embozene-microspheres-transcatheter-arterial-embolization--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/embozene-microspheres-transcatheter-arterial-embolization--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Emestedastat for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/emestedastat--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/emestedastat--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Emono for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/emono--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/emono--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for cardiomyopathy, hypertrophic</title>
    <id>https://staging.whatcameofit.com/empagliflozin--cardiomyopathy-hypertrophic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--cardiomyopathy-hypertrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/empagliflozin--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/empagliflozin--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for heart defects, congenital</title>
    <id>https://staging.whatcameofit.com/empagliflozin--heart-defects-congenital#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--heart-defects-congenital"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for heart failure, diastolic</title>
    <id>https://staging.whatcameofit.com/empagliflozin--heart-failure-diastolic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--heart-failure-diastolic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for ketosis</title>
    <id>https://staging.whatcameofit.com/empagliflozin--ketosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/empagliflozin--kidney-failure-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/empagliflozin--non-alcoholic-fatty-liver-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for obesity</title>
    <id>https://staging.whatcameofit.com/empagliflozin--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/empagliflozin--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for ventricular dysfunction, right</title>
    <id>https://staging.whatcameofit.com/empagliflozin--ventricular-dysfunction-right#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--ventricular-dysfunction-right"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Emraclidine for schizophrenia</title>
    <id>https://staging.whatcameofit.com/emraclidine--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/emraclidine--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ENABLE Cornerstone for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/enable-cornerstone--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enable-cornerstone--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enavogliflozin for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/enavogliflozin--tricuspid-valve-insufficiency#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enavogliflozin--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Endd (njoy) for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/endd-njoy--tobacco-use-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/endd-njoy--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Endocalyx Pro for hypertension</title>
    <id>https://staging.whatcameofit.com/endocalyx-pro--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/endocalyx-pro--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>endoscopic repair of myelomeningocele before 26 SA for meningomyelocele</title>
    <id>https://staging.whatcameofit.com/endoscopic-repair-of-myelomeningocele-before-26-sa--meningomyelocele#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/endoscopic-repair-of-myelomeningocele-before-26-sa--meningomyelocele"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ENDS (Vaporizer/e-cig) and smoking cessation counseling for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ENDS (Vaporizer/e-cig) and smoking cessation counseling for lung diseases</title>
    <id>https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--lung-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ENDS (Vaporizer/e-cig) and smoking cessation counseling for respiration disorders</title>
    <id>https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--respiration-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ends-vaporizer-e-cig-and-smoking-cessation-counseling--respiration-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ends + ni for obesity</title>
    <id>https://staging.whatcameofit.com/ends-ni--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ends-ni--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Enfortumab vedotin + pembrolizumab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/enfortumab-vedotin-pembrolizumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enfortumab-vedotin-pembrolizumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide Chloride for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/enlicitide-chloride--hypercholesterolemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/enlicitide-chloride--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide Decanoate for arteriosclerosis</title>
    <id>https://staging.whatcameofit.com/enlicitide-decanoate--arteriosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enlicitide-decanoate--arteriosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide Decanoate for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/enlicitide-decanoate--hypercholesterolemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enlicitide-decanoate--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide Decanoate for hyperlipoproteinemia type ii</title>
    <id>https://staging.whatcameofit.com/enlicitide-decanoate--hyperlipoproteinemia-type-ii#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enlicitide-decanoate--hyperlipoproteinemia-type-ii"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/enlicitide--hypercholesterolemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enlicitide--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enlicitide for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/enlicitide--hyperlipidemias#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/enlicitide--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Enlonstobart for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/enlonstobart--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enlonstobart--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Enoblituzumab for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/enoblituzumab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enoblituzumab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Enoxaparin (Clexane) + Vaginal Micronized Progesterone (Progesterone Besins) for abortion, habitual</title>
    <id>https://staging.whatcameofit.com/enoxaparin-clexane-vaginal-micronized-progesterone-progesterone-besins--abortion-habitual#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/enoxaparin-clexane-vaginal-micronized-progesterone-progesterone-besins--abortion-habitual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Enzalutamide + Mevrometostat for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/enzalutamide-mevrometostat--adenocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/enzalutamide-mevrometostat--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Enzalutamide + Mevrometostat for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/enzalutamide-mevrometostat--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/enzalutamide-mevrometostat--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Enzalutamide + PEMBROLIZUMAB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/enzalutamide-pembrolizumab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enzalutamide-pembrolizumab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Enzalutamide + Tinengotinib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/enzalutamide-tinengotinib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/enzalutamide-tinengotinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Enzalutamide for neoplasms</title>
    <id>https://staging.whatcameofit.com/enzalutamide--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enzalutamide--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Enzalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/enzalutamide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/enzalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program. for paraplegia</title>
    <id>https://staging.whatcameofit.com/epidural-electrical-stimulation-ees-using-an-implanted-paddle-lead-and-pulse-generator-combined-with-a-12-month-intensive-rehabilitation-program--paraplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-electrical-stimulation-ees-using-an-implanted-paddle-lead-and-pulse-generator-combined-with-a-12-month-intensive-rehabilitation-program--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Epidural spinal cord stimulation for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--neurogenic-bowel#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Epidural spinal cord stimulation for paraplegia</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--paraplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Epidural spinal cord stimulation for primary dysautonomias</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--primary-dysautonomias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--primary-dysautonomias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Epidural spinal cord stimulation for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-cord-stimulation--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Epidural Spinal Cord Stimulation System for primary dysautonomias</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-cord-stimulation-system--primary-dysautonomias#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-cord-stimulation-system--primary-dysautonomias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Epidural Spinal Stimulation (ESS) + Upper extremity rehabilitation for quadriplegia</title>
    <id>https://staging.whatcameofit.com/epidural-spinal-stimulation-ess-upper-extremity-rehabilitation--quadriplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/epidural-spinal-stimulation-ess-upper-extremity-rehabilitation--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Eptinezumab for migraine disorders</title>
    <id>https://staging.whatcameofit.com/eptinezumab--migraine-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/eptinezumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>EQW plus DAPA for obesity</title>
    <id>https://staging.whatcameofit.com/eqw-plus-dapa--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/eqw-plus-dapa--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ER-100 epigenetic therapy for glaucoma, open-angle</title>
    <id>https://staging.whatcameofit.com/er-100-epigenetic-therapy--glaucoma-open-angle#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/er-100-epigenetic-therapy--glaucoma-open-angle"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ER-100 epigenetic therapy for retinal diseases</title>
    <id>https://staging.whatcameofit.com/er-100-epigenetic-therapy--retinal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/er-100-epigenetic-therapy--retinal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ERAS-601 for chordoma</title>
    <id>https://staging.whatcameofit.com/eras-601--chordoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eras-601--chordoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/erdafitinib-carboplatin-cetrelimab-cisplatin--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/erdafitinib-carboplatin-cetrelimab-cisplatin--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Erdafitinib + cetrelimab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/erdafitinib-cetrelimab--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/erdafitinib-cetrelimab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Erenumab + calcitonin gene-related peptide for migraine disorders</title>
    <id>https://staging.whatcameofit.com/erenumab-calcitonin-gene-related-peptide--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/erenumab-calcitonin-gene-related-peptide--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Erenumab 70 mg + GALCANEZUMAB + ATOGEPANT + EPTINEZUMAB for migraine disorders</title>
    <id>https://staging.whatcameofit.com/erenumab-70-mg-galcanezumab-atogepant-eptinezumab--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/erenumab-70-mg-galcanezumab-atogepant-eptinezumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Erenumab for epilepsy</title>
    <id>https://staging.whatcameofit.com/erenumab--epilepsy#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/erenumab--epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Erenumab for migraine disorders</title>
    <id>https://staging.whatcameofit.com/erenumab--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/erenumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Erenumab matching placebo + ERENUMAB for migraine disorders</title>
    <id>https://staging.whatcameofit.com/erenumab-matching-placebo-erenumab--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/erenumab-matching-placebo-erenumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disorders</title>
    <id>https://staging.whatcameofit.com/erenumab-aooe-140-mg-ml-aimovig--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/erenumab-aooe-140-mg-ml-aimovig--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ervebo® booster for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/ervebo-booster--hemorrhagic-fever-ebola#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ervebo-booster--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Escitalopram + Esketamine + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/escitalopram-esketamine-venlafaxine-duloxetine-sertraline--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/escitalopram-esketamine-venlafaxine-duloxetine-sertraline--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Escitalopram oxalate for aphasia</title>
    <id>https://staging.whatcameofit.com/escitalopram-oxalate--aphasia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/escitalopram-oxalate--aphasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Escitalopram oxalate for lethargy</title>
    <id>https://staging.whatcameofit.com/escitalopram-oxalate--lethargy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/escitalopram-oxalate--lethargy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--bipolar-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for schizophrenia</title>
    <id>https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--schizophrenia#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/esketamine-esketamine-hydrochloride-ketamine-hydrochloride--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Esketamine for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/esketamine--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/esketamine--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Esketamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/esketamine--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/esketamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/esketamine-treatment-as-usual-esk-virtual-reality-based-mindfulness-intervention--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/esketamine-treatment-as-usual-esk-virtual-reality-based-mindfulness-intervention--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/esketamine-treatment-as-usual-esk-virtual-reality-based-mindfulness-intervention--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/esketamine-treatment-as-usual-esk-virtual-reality-based-mindfulness-intervention--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Esomeprazole for autistic disorder</title>
    <id>https://staging.whatcameofit.com/esomeprazole--autistic-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/esomeprazole--autistic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Essential Amino Acid Supplementation for femoral fractures</title>
    <id>https://staging.whatcameofit.com/essential-amino-acid-supplementation--femoral-fractures#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/essential-amino-acid-supplementation--femoral-fractures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Essential Amino Acid Supplementation for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/essential-amino-acid-supplementation--muscular-atrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/essential-amino-acid-supplementation--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Essential Pro Paclitaxel Drug-Eluting Balloon for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/essential-pro-paclitaxel-drug-eluting-balloon--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/essential-pro-paclitaxel-drug-eluting-balloon--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Estradiol for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/estradiol--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/estradiol--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Etanercept for acquired hyperostosis syndrome</title>
    <id>https://staging.whatcameofit.com/etanercept--acquired-hyperostosis-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/etanercept--acquired-hyperostosis-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Etanercept for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/etanercept--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/etanercept--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ethiodized Oil-based emulsion for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/ethiodized-oil-based-emulsion--osteoarthritis-knee#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ethiodized-oil-based-emulsion--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Etofenprox-treated lesu for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/etofenprox-treated-lesu--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/etofenprox-treated-lesu--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ETX-19477 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/etx-19477--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/etx-19477--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ETX-19477 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/etx-19477--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/etx-19477--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ETX101 for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/etx101--epilepsies-myoclonic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/etx101--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Evenamide 15 mg bid for schizophrenia, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/evenamide-15-mg-bid--schizophrenia-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evenamide-15-mg-bid--schizophrenia-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Evolocumab for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/evolocumab--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evolocumab--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Evolocumab for coronary disease</title>
    <id>https://staging.whatcameofit.com/evolocumab--coronary-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evolocumab--coronary-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Evolocumab for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/evolocumab--hypercholesterolemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evolocumab--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Evolocumab for non-st elevated myocardial infarction</title>
    <id>https://staging.whatcameofit.com/evolocumab--non-st-elevated-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evolocumab--non-st-elevated-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Evolocumab for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/evolocumab--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/evolocumab--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney + Kidney Transplantation with Standard Care for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-kidney-kidney-transplantation-with-standard-care--kidney-failure-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-kidney-kidney-transplantation-with-standard-care--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for fatty liver</title>
    <id>https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--fatty-liver#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--fatty-liver"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver cirrhosis</title>
    <id>https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--liver-cirrhosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--liver-cirrhosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failure</title>
    <id>https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--liver-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ex-vivo-crispr-cas9-gene-editing-of-donor-liver--liver-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ex vivo perfusion of six-gene-edited porcine liver + Multi-drug immunosuppressive therapy for liver failure</title>
    <id>https://staging.whatcameofit.com/ex-vivo-perfusion-of-six-gene-edited-porcine-liver-multi-drug-immunosuppressive-therapy--liver-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ex-vivo-perfusion-of-six-gene-edited-porcine-liver-multi-drug-immunosuppressive-therapy--liver-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ex-cipn for peripheral nervous system diseases</title>
    <id>https://staging.whatcameofit.com/ex-cipn--peripheral-nervous-system-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ex-cipn--peripheral-nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ExAblate 4000 Type 2.1 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/exablate-4000-type-2-1--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exablate-4000-type-2-1--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/exablate-model-4000-type-2-aducanumab-lecanemab--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/exablate-model-4000-type-2-aducanumab-lecanemab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/exablate-model-4000-type-2-aducanumab-lecanemab--cognitive-dysfunction#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/exablate-model-4000-type-2-aducanumab-lecanemab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Exagamglogene autotemcel for beta-thalassemia</title>
    <id>https://staging.whatcameofit.com/exagamglogene-autotemcel--beta-thalassemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/exagamglogene-autotemcel--beta-thalassemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Exenatide for obesity</title>
    <id>https://staging.whatcameofit.com/exenatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/exenatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Exenatide for parkinson disease</title>
    <id>https://staging.whatcameofit.com/exenatide--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exenatide--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exercise + Control for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/exercise-control--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise-control--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/exercise--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/exercise--dyslipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise for hypertension</title>
    <id>https://staging.whatcameofit.com/exercise--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/exercise--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise for respiration disorders</title>
    <id>https://staging.whatcameofit.com/exercise--respiration-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/exercise--respiration-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exercise Intervention for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/exercise-intervention--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exercise-intervention--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exercise Therapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/exercise-therapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exercise-therapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exerenibart for beta-thalassemia</title>
    <id>https://staging.whatcameofit.com/exerenibart--beta-thalassemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exerenibart--beta-thalassemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exogenous ketone ester for drug resistant epilepsy</title>
    <id>https://staging.whatcameofit.com/exogenous-ketone-ester--drug-resistant-epilepsy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exogenous-ketone-ester--drug-resistant-epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exogenous ketone ester for status epilepticus</title>
    <id>https://staging.whatcameofit.com/exogenous-ketone-ester--status-epilepticus#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/exogenous-ketone-ester--status-epilepticus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Experimental for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/experimental--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/experimental--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Experimental regimen for depressive disorder</title>
    <id>https://staging.whatcameofit.com/experimental-regimen--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/experimental-regimen--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Experimental. for dental caries</title>
    <id>https://staging.whatcameofit.com/experimental--dental-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/experimental--dental-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Exploratory test group for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/exploratory-test-group--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/exploratory-test-group--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Exploratory test group for hypertension</title>
    <id>https://staging.whatcameofit.com/exploratory-test-group--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/exploratory-test-group--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-pembrolizumab-temozolomide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-pembrolizumab-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-pembrolizumab-temozolomide--gliosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-pembrolizumab-temozolomide--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-therapeutic-conventional-surgery-pembrolizumab-temozolomide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-therapeutic-conventional-surgery-pembrolizumab-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-therapeutic-conventional-surgery-pembrolizumab-temozolomide--gliosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/external-beam-radiation-therapy-laboratory-biomarker-analysis-radiation-therapy-therapeutic-conventional-surgery-pembrolizumab-temozolomide--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Eyecyte-RPE™ for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/eyecyte-rpe--geographic-atrophy#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/eyecyte-rpe--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ezetimibe or ezetimibe-statin combination therapy for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/ezetimibe-or-ezetimibe-statin-combination-therapy--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ezetimibe-or-ezetimibe-statin-combination-therapy--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ezetimibe or ezetimibe-statin combination therapy for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/ezetimibe-or-ezetimibe-statin-combination-therapy--dyslipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ezetimibe-or-ezetimibe-statin-combination-therapy--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Facilitate tDCS + CR for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/facilitate-tdcs-cr--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/facilitate-tdcs-cr--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Facilitate tDCS + CR for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/facilitate-tdcs-cr--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/facilitate-tdcs-cr--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Facilitate tDCS + CR for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/facilitate-tdcs-cr--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/facilitate-tdcs-cr--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Factory-treated lesu for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/factory-treated-lesu--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/factory-treated-lesu--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Faecal bacteriotherapy (FBT) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/faecal-bacteriotherapy-fbt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/faecal-bacteriotherapy-fbt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Faecal microbiota transplantation for gastrointestinal hemorrhage</title>
    <id>https://staging.whatcameofit.com/faecal-microbiota-transplantation--gastrointestinal-hemorrhage#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/faecal-microbiota-transplantation--gastrointestinal-hemorrhage"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Faecal microbiota transplantation for hepatitis, alcoholic</title>
    <id>https://staging.whatcameofit.com/faecal-microbiota-transplantation--hepatitis-alcoholic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/faecal-microbiota-transplantation--hepatitis-alcoholic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Faecal microbiota transplantation for liver cirrhosis</title>
    <id>https://staging.whatcameofit.com/faecal-microbiota-transplantation--liver-cirrhosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/faecal-microbiota-transplantation--liver-cirrhosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Famotidine + Celecoxib for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/famotidine-celecoxib--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/famotidine-celecoxib--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Famotidine + Celecoxib for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/famotidine-celecoxib--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/famotidine-celecoxib--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Famotidine and 4% topical cromolyn sodium for burns</title>
    <id>https://staging.whatcameofit.com/famotidine-and-4-topical-cromolyn-sodium--burns#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/famotidine-and-4-topical-cromolyn-sodium--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Famotidine and 4% topical cromolyn sodium for pruritus</title>
    <id>https://staging.whatcameofit.com/famotidine-and-4-topical-cromolyn-sodium--pruritus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/famotidine-and-4-topical-cromolyn-sodium--pruritus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>FAPi-46 GA-68 for carcinoma, signet ring cell</title>
    <id>https://staging.whatcameofit.com/fapi-46-ga-68--carcinoma-signet-ring-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fapi-46-ga-68--carcinoma-signet-ring-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>FAPi-46 GA-68 for pleural diseases</title>
    <id>https://staging.whatcameofit.com/fapi-46-ga-68--pleural-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fapi-46-ga-68--pleural-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>FAPi-46 GA-68 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/fapi-46-ga-68--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fapi-46-ga-68--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Farletuzumab ecteribulin for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/farletuzumab-ecteribulin--adenocarcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/farletuzumab-ecteribulin--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Farletuzumab ecteribulin for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/farletuzumab-ecteribulin--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/farletuzumab-ecteribulin--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fasedienol for phobia, social</title>
    <id>https://staging.whatcameofit.com/fasedienol--phobia-social#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fasedienol--phobia-social"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fasudil for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/fasudil--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fasudil--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fasudil hydrochloride combined with immunotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/fasudil-hydrochloride-combined-with-immunotherapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fasudil-hydrochloride-combined-with-immunotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Favipiravir for respiration disorders</title>
    <id>https://staging.whatcameofit.com/favipiravir--respiration-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/favipiravir--respiration-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fecal Microbial Transplantation for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbial-transplantation--clostridium-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fecal-microbial-transplantation--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fecal Microbial Transplantation for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/fecal-microbial-transplantation--colitis-ulcerative#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fecal-microbial-transplantation--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fecal microbiota for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal microbiota for colitis</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota--colitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota--colitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal microbiota for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota--peanut-hypersensitivity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplant (FMT) + Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt-vancomycin-nitazoxanide--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt-vancomycin-nitazoxanide--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplant (FMT) for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplant (FMT) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplant-fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal microbiota transplant (Promicrobioma) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplant-promicrobioma--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplant-promicrobioma--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplant for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplant--clostridium-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplant--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplantation (FMT) + ISOTONIC SODIUM CHLORIDE SOLUTION for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantation-fmt-isotonic-sodium-chloride-solution--clostridium-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantation-fmt-isotonic-sodium-chloride-solution--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplantation (FMT) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantation-fmt--clostridium-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantation-fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplantation for inflammatory bowel diseases</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantation--inflammatory-bowel-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantation--inflammatory-bowel-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fecal Microbiota Transplantation for irritable bowel syndrome</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantation--irritable-bowel-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantation--irritable-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>fecal microbiota transplantation from healthy lean donors for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantation-from-healthy-lean-donors--metabolic-syndrome#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantation-from-healthy-lean-donors--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Fecal microbiota transplantion (FMT) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-microbiota-transplantion-fmt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-microbiota-transplantion-fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal Transplant for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-transplant--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-transplant--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fecal Virome Transplantation for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fecal-virome-transplantation--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fecal-virome-transplantation--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FEMJA transplatation for limbal stem cell deficiency</title>
    <id>https://staging.whatcameofit.com/femja-transplatation--limbal-stem-cell-deficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/femja-transplatation--limbal-stem-cell-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fenofibrate for liver cirrhosis, biliary</title>
    <id>https://staging.whatcameofit.com/fenofibrate--liver-cirrhosis-biliary#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fenofibrate--liver-cirrhosis-biliary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fenofibrate in Combination With Ursodeoxycholic Acid for liver cirrhosis, biliary</title>
    <id>https://staging.whatcameofit.com/fenofibrate-in-combination-with-ursodeoxycholic-acid--liver-cirrhosis-biliary#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fenofibrate-in-combination-with-ursodeoxycholic-acid--liver-cirrhosis-biliary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ferric derisomaltose for heart failure</title>
    <id>https://staging.whatcameofit.com/ferric-derisomaltose--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ferric-derisomaltose--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>fetal MSCs combined with 4SCAR T cells for autoimmune diseases</title>
    <id>https://staging.whatcameofit.com/fetal-mscs-combined-with-4scar-t-cells--autoimmune-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetal-mscs-combined-with-4scar-t-cells--autoimmune-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopic repair of spina bifida for arnold-chiari malformation</title>
    <id>https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--arnold-chiari-malformation#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--arnold-chiari-malformation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopic repair of spina bifida for fetal diseases</title>
    <id>https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--fetal-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--fetal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopic repair of spina bifida for hydrocephalus</title>
    <id>https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--hydrocephalus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--hydrocephalus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopic repair of spina bifida for meningomyelocele</title>
    <id>https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--meningomyelocele#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--meningomyelocele"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopic repair of spina bifida for spina bifida cystica</title>
    <id>https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--spina-bifida-cystica#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopic-repair-of-spina-bifida--spina-bifida-cystica"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopy for arnold-chiari malformation</title>
    <id>https://staging.whatcameofit.com/fetoscopy--arnold-chiari-malformation#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopy--arnold-chiari-malformation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopy for gastroschisis</title>
    <id>https://staging.whatcameofit.com/fetoscopy--gastroschisis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopy--gastroschisis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopy for meningomyelocele</title>
    <id>https://staging.whatcameofit.com/fetoscopy--meningomyelocele#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fetoscopy--meningomyelocele"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fetoscopy for spina bifida cystica</title>
    <id>https://staging.whatcameofit.com/fetoscopy--spina-bifida-cystica#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fetoscopy--spina-bifida-cystica"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fetoscopy for spinal dysraphism</title>
    <id>https://staging.whatcameofit.com/fetoscopy--spinal-dysraphism#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fetoscopy--spinal-dysraphism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fidanacogene Elaparvovec for hemophilia a</title>
    <id>https://staging.whatcameofit.com/fidanacogene-elaparvovec--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fidanacogene-elaparvovec--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fidaxomicin for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fidaxomicin--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fidaxomicin--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/filgrastim-peg-filgrastim-liposomal-irinotecan-proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide-vinorelbine-temozolomide--rhabdomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/filgrastim-peg-filgrastim-liposomal-irinotecan-proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide-vinorelbine-temozolomide--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/filgrastim-peg-filgrastim-liposomal-irinotecan-proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide-vinorelbine--rhabdomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/filgrastim-peg-filgrastim-liposomal-irinotecan-proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide-vinorelbine--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Finerenone for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/finerenone--atrial-fibrillation#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/finerenone--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fisetin for intermittent claudication</title>
    <id>https://staging.whatcameofit.com/fisetin--intermittent-claudication#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fisetin--intermittent-claudication"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fitusiran for hemophilia a</title>
    <id>https://staging.whatcameofit.com/fitusiran--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fitusiran--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fitusiran for hemophilia b</title>
    <id>https://staging.whatcameofit.com/fitusiran--hemophilia-b#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fitusiran--hemophilia-b"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fixed-Dose Combination Strategy for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/fixed-dose-combination-strategy--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fixed-dose-combination-strategy--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fixed-Dose Combination Strategy for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/fixed-dose-combination-strategy--dyslipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fixed-dose-combination-strategy--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fixed-Dose Combination Strategy for hypertension</title>
    <id>https://staging.whatcameofit.com/fixed-dose-combination-strategy--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fixed-dose-combination-strategy--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Flecainide for heart arrest</title>
    <id>https://staging.whatcameofit.com/flecainide--heart-arrest#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/flecainide--heart-arrest"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Flecainide for mitral valve prolapse</title>
    <id>https://staging.whatcameofit.com/flecainide--mitral-valve-prolapse#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/flecainide--mitral-valve-prolapse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Flibanserin for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/flibanserin--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/flibanserin--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FLORTAUCIPIR F-18 for neurodegenerative diseases</title>
    <id>https://staging.whatcameofit.com/flortaucipir-f-18--neurodegenerative-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/flortaucipir-f-18--neurodegenerative-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluconazole for crohn disease</title>
    <id>https://staging.whatcameofit.com/fluconazole--crohn-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fluconazole--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Flucytosine (5FC) + Liposomal Amphotericin B (LAmB) for mycoses</title>
    <id>https://staging.whatcameofit.com/flucytosine-5fc-liposomal-amphotericin-b-lamb--mycoses#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/flucytosine-5fc-liposomal-amphotericin-b-lamb--mycoses"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Flucytosine (5FC) for mycoses</title>
    <id>https://staging.whatcameofit.com/flucytosine-5fc--mycoses#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/flucytosine-5fc--mycoses"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FLUDEOXYGLUCOSE F-18 + PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/fludeoxyglucose-f-18-piflufolastat-f-18-gozetotide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fludeoxyglucose-f-18-piflufolastat-f-18-gozetotide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluorescence Imaging for inflammatory bowel diseases</title>
    <id>https://staging.whatcameofit.com/fluorescence-imaging--inflammatory-bowel-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluorescence-imaging--inflammatory-bowel-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/fluoroethoxybenzovesamicol-f-18--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluoroethoxybenzovesamicol-f-18--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>FLUOROETHOXYBENZOVESAMICOL F-18 for down syndrome</title>
    <id>https://staging.whatcameofit.com/fluoroethoxybenzovesamicol-f-18--down-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluoroethoxybenzovesamicol-f-18--down-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluoxetine + Dextromethorphan for body dysmorphic disorders</title>
    <id>https://staging.whatcameofit.com/fluoxetine-dextromethorphan--body-dysmorphic-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluoxetine-dextromethorphan--body-dysmorphic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluoxetine + Dextromethorphan for obsessive-compulsive disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine-dextromethorphan--obsessive-compulsive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluoxetine-dextromethorphan--obsessive-compulsive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluoxetine + Imipramine for dysthymic disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine-imipramine--dysthymic-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fluoxetine-imipramine--dysthymic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fluoxetine + Imipramine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine-imipramine--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fluoxetine-imipramine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fluoxetine for alcoholism</title>
    <id>https://staging.whatcameofit.com/fluoxetine--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fluoxetine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fluoxetine for depressive disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine--depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fluoxetine--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fluoxetine for down syndrome</title>
    <id>https://staging.whatcameofit.com/fluoxetine--down-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/fluoxetine--down-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fluoxetine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fluoxetine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fluoxetine for obsessive-compulsive disorder</title>
    <id>https://staging.whatcameofit.com/fluoxetine--obsessive-compulsive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fluoxetine--obsessive-compulsive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fluvoxamine for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/fluvoxamine--coronavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fluvoxamine--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fluzoparib with Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/fluzoparib-with-temozolomide--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fluzoparib-with-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FMC-376 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/fmc-376--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fmc-376--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FMT (Fecal Microbiota Transplantation) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fmt-fecal-microbiota-transplantation--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fmt-fecal-microbiota-transplantation--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FMT capsule for irritable bowel syndrome</title>
    <id>https://staging.whatcameofit.com/fmt-capsule--irritable-bowel-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fmt-capsule--irritable-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FMT capsule for neoplasms</title>
    <id>https://staging.whatcameofit.com/fmt-capsule--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fmt-capsule--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fmt for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fmt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FMT-c Lactobacillus for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fmt-c-lactobacillus--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fmt-c-lactobacillus--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FMXIN002 double dose + FMXIN002 double dose + NAC + FMXIN002 single dose + FMXIN002 single dose + NAC + Epinephrine for anaphylaxis</title>
    <id>https://staging.whatcameofit.com/fmxin002-double-dose-fmxin002-double-dose-nac-fmxin002-single-dose-fmxin002-single-dose-nac-epinephrine--anaphylaxis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fmxin002-double-dose-fmxin002-double-dose-nac-fmxin002-single-dose-fmxin002-single-dose-nac-epinephrine--anaphylaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical) for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/focal-hifu-treatment-using-focal-one-edap-tms-or-tulsa-pro-profound-medical--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/focal-hifu-treatment-using-focal-one-edap-tms-or-tulsa-pro-profound-medical--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Focal One high intensity focused ultrasound device for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/focal-one-high-intensity-focused-ultrasound-device--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/focal-one-high-intensity-focused-ultrasound-device--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Focused Transcranial Ultrasound for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/focused-transcranial-ultrasound--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/focused-transcranial-ultrasound--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Focused Transcranial Ultrasound for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/focused-transcranial-ultrasound--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/focused-transcranial-ultrasound--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Focused Transcranial Ultrasound for parkinson disease</title>
    <id>https://staging.whatcameofit.com/focused-transcranial-ultrasound--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/focused-transcranial-ultrasound--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FOLFIRI + FOLFOX6/FOLFOX7 + S241656 + PANITUMUMAB + Cetuximab for histiocytosis</title>
    <id>https://staging.whatcameofit.com/folfiri-folfox6-folfox7-s241656-panitumumab-cetuximab--histiocytosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/folfiri-folfox6-folfox7-s241656-panitumumab-cetuximab--histiocytosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Folfoxiri for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/folfoxiri--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/folfoxiri--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Folfoxiri for neoplastic cells, circulating</title>
    <id>https://staging.whatcameofit.com/folfoxiri--neoplastic-cells-circulating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/folfoxiri--neoplastic-cells-circulating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Food allergy desensitization / Oral Immunotherapy for egg hypersensitivity</title>
    <id>https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--egg-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--egg-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Food allergy desensitization / Oral Immunotherapy for milk hypersensitivity</title>
    <id>https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--milk-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--milk-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Food allergy desensitization / Oral Immunotherapy for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/food-allergy-desensitization-oral-immunotherapy--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Food Security Screening &amp; Referral Program for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/food-security-screening-referral-program--cardiovascular-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/food-security-screening-referral-program--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Food Security Screening &amp; Referral Program for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/food-security-screening-referral-program--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/food-security-screening-referral-program--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Food Security Screening &amp; Referral Program for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/food-security-screening-referral-program--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/food-security-screening-referral-program--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Food-based diet for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/food-based-diet--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/food-based-diet--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Food-based diet for obesity</title>
    <id>https://staging.whatcameofit.com/food-based-diet--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/food-based-diet--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Formula diet for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/formula-diet--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/formula-diet--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Formula diet for obesity</title>
    <id>https://staging.whatcameofit.com/formula-diet--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/formula-diet--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Formulation A + Formulation B6 for obesity</title>
    <id>https://staging.whatcameofit.com/formulation-a-formulation-b6--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/formulation-a-formulation-b6--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Formulation B for pneumococcal infections</title>
    <id>https://staging.whatcameofit.com/formulation-b--pneumococcal-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/formulation-b--pneumococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Formulation C for pneumococcal infections</title>
    <id>https://staging.whatcameofit.com/formulation-c--pneumococcal-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/formulation-c--pneumococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Formulation D for pneumococcal infections</title>
    <id>https://staging.whatcameofit.com/formulation-d--pneumococcal-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/formulation-d--pneumococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fosravuconazole + benznidazole for chagas disease</title>
    <id>https://staging.whatcameofit.com/fosravuconazole-benznidazole--chagas-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fosravuconazole-benznidazole--chagas-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fresh FMT for clostridium infections</title>
    <id>https://staging.whatcameofit.com/fresh-fmt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fresh-fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Freshly reconstituted MDCF-2 ingredients for malnutrition</title>
    <id>https://staging.whatcameofit.com/freshly-reconstituted-mdcf-2-ingredients--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/freshly-reconstituted-mdcf-2-ingredients--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Frexalimab for glomerulosclerosis, focal segmental</title>
    <id>https://staging.whatcameofit.com/frexalimab--glomerulosclerosis-focal-segmental#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/frexalimab--glomerulosclerosis-focal-segmental"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Frexalimab for nephrosis, lipoid</title>
    <id>https://staging.whatcameofit.com/frexalimab--nephrosis-lipoid#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/frexalimab--nephrosis-lipoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Frozen-and-Thawed FMT for clostridium infections</title>
    <id>https://staging.whatcameofit.com/frozen-and-thawed-fmt--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/frozen-and-thawed-fmt--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Fucosylated MSC for Osteoporosis for spinal fractures</title>
    <id>https://staging.whatcameofit.com/fucosylated-msc-for-osteoporosis--spinal-fractures#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fucosylated-msc-for-osteoporosis--spinal-fractures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Full Dose Midomafetamine HCl for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/full-dose-midomafetamine-hcl--stress-disorders-post-traumatic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/full-dose-midomafetamine-hcl--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-anastrozole-abemaciclib-letrozole-metformin-tersolisib-palbociclib-exemestane-ribociclib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Fulvestrant + CDK4/6i + Capivasertib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/fulvestrant-cdk4-6i-capivasertib--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-cdk4-6i-capivasertib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + Exemestane for neoplasms</title>
    <id>https://staging.whatcameofit.com/fulvestrant-exemestane--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-exemestane--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + Tersolisib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/fulvestrant-tersolisib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-tersolisib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/fulvestrant-tersolisib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-tersolisib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/fulvestrant-tersolisib--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-tersolisib--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>FULVESTRANT + Tersolisib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/fulvestrant-tersolisib--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/fulvestrant-tersolisib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Furosemide for musculoskeletal pain</title>
    <id>https://staging.whatcameofit.com/furosemide--musculoskeletal-pain#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/furosemide--musculoskeletal-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-mitoxantrone-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-mitoxantrone-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-mitoxantrone-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-mitoxantrone-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + Decitabine + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-stem-cell-transplant-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-stem-cell-transplant-cytarabine-dexrazoxane-etoposide-decitabine-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>G-CSF + ITMHA + Stem Cell Transplant + CYTARABINE + Dexrazoxane + ETOPOSIDE + SORAFENIB + Mitoxantrone + ASPARAGINASE ERWINIA CHRYSANTHEMI + Azacitidine + FLUDARABINE + IDARUBICIN + Daunorubicin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/g-csf-itmha-stem-cell-transplant-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/g-csf-itmha-stem-cell-transplant-cytarabine-dexrazoxane-etoposide-sorafenib-mitoxantrone-asparaginase-erwinia-chrysanthemi-azacitidine-fludarabine-idarubicin-daunorubicin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Galcanezumab + erenumab + fremanezumab for migraine disorders</title>
    <id>https://staging.whatcameofit.com/galcanezumab-erenumab-fremanezumab--migraine-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/galcanezumab-erenumab-fremanezumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>GALCANEZUMAB + Ubrogepant for migraine disorders</title>
    <id>https://staging.whatcameofit.com/galcanezumab-ubrogepant--migraine-disorders#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/galcanezumab-ubrogepant--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Galcanezumab for migraine disorders</title>
    <id>https://staging.whatcameofit.com/galcanezumab--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/galcanezumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GALLIUM GA-68 GOZETOTIDE for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/gallium-ga-68-gozetotide--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gallium-ga-68-gozetotide--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GALLIUM GA-68 GOZETOTIDE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/gallium-ga-68-gozetotide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gallium-ga-68-gozetotide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GALUNISERTIB + Enzalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/galunisertib-enzalutamide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/galunisertib-enzalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Gam-COVID-Vac for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/gam-covid-vac--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gam-covid-vac--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GammaSense Stimulation device for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/gammasense-stimulation-device--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gammasense-stimulation-device--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Garetosmab for myositis ossificans</title>
    <id>https://staging.whatcameofit.com/garetosmab--myositis-ossificans#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/garetosmab--myositis-ossificans"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GC101 for muscular atrophy, spinal</title>
    <id>https://staging.whatcameofit.com/gc101--muscular-atrophy-spinal#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gc101--muscular-atrophy-spinal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GCP intratumoral catheter for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/gcp-intratumoral-catheter--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gcp-intratumoral-catheter--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/gecacitinib-zg005-bevacizumab--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gecacitinib-zg005-bevacizumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Gel-Bead embolization for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/gel-bead-embolization--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gel-bead-embolization--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Gemcitabine + ERLOTINIB + NAB-PACLITAXEL for neoplasms, basal cell</title>
    <id>https://staging.whatcameofit.com/gemcitabine-erlotinib-nab-paclitaxel--neoplasms-basal-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gemcitabine-erlotinib-nab-paclitaxel--neoplasms-basal-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Gemcitabine Hydrochloride for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gemcitabine-hydrochloride--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gemcitabine-hydrochloride--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>genicular artery embolisation for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolisation--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolisation--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>genicular artery embolisation for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolisation--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolisation--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Genicular artery embolization (GAE) for arterial occlusive diseases</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolization-gae--arterial-occlusive-diseases#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolization-gae--arterial-occlusive-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Genicular artery embolization (GAE) for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolization-gae--osteoarthritis-knee#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolization-gae--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Genicular Artery Embolization + Lipiodol for musculoskeletal pain</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolization-lipiodol--musculoskeletal-pain#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolization-lipiodol--musculoskeletal-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Genicular Artery Embolization + Lipiodol for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolization-lipiodol--osteoarthritis-knee#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolization-lipiodol--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>genicular artery embolization for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/genicular-artery-embolization--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/genicular-artery-embolization--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Genicular Nerve Block with bupivacaine and preservative free dexamethasone for anterior cruciate ligament injuries</title>
    <id>https://staging.whatcameofit.com/genicular-nerve-block-with-bupivacaine-and-preservative-free-dexamethasone--anterior-cruciate-ligament-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/genicular-nerve-block-with-bupivacaine-and-preservative-free-dexamethasone--anterior-cruciate-ligament-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>geniculate artery embolization for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/geniculate-artery-embolization--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/geniculate-artery-embolization--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI) for musculoskeletal pain</title>
    <id>https://staging.whatcameofit.com/geniculate-artery-embolization-with-intra-articular-corticosteroid-injection-gae-with-iaci--musculoskeletal-pain#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/geniculate-artery-embolization-with-intra-articular-corticosteroid-injection-gae-with-iaci--musculoskeletal-pain"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI) for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/geniculate-artery-embolization-with-intra-articular-corticosteroid-injection-gae-with-iaci--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/geniculate-artery-embolization-with-intra-articular-corticosteroid-injection-gae-with-iaci--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Gentamicin for ichthyosis</title>
    <id>https://staging.whatcameofit.com/gentamicin--ichthyosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gentamicin--ichthyosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GENUS device (Active Settings) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/genus-device-active-settings--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/genus-device-active-settings--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GENUS device (Active Settings) for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/genus-device-active-settings--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/genus-device-active-settings--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Gepotidacin for gonorrhea</title>
    <id>https://staging.whatcameofit.com/gepotidacin--gonorrhea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/gepotidacin--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GGTA1 KO Thymokidney for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/ggta1-ko-thymokidney--kidney-failure-chronic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ggta1-ko-thymokidney--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GI-102 + BEVACIZUMAB + Paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-bevacizumab-paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-bevacizumab-paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + BEVACIZUMAB + Paclitaxel for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-bevacizumab-paclitaxel--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-bevacizumab-paclitaxel--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + Doxorubicin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-doxorubicin--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-doxorubicin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + Doxorubicin for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-doxorubicin--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-doxorubicin--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + Eribulin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-eribulin--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-eribulin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + Eribulin for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-eribulin--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-eribulin--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + PEMBROLIZUMAB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-pembrolizumab--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-pembrolizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + PEMBROLIZUMAB for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-pembrolizumab--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-pembrolizumab--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + TRASTUZUMAB DERUXTECAN for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-trastuzumab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-trastuzumab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 + TRASTUZUMAB DERUXTECAN for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-trastuzumab-deruxtecan--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-trastuzumab-deruxtecan--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 subcutaneous (SC) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-102-subcutaneous-sc--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-subcutaneous-sc--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-102 subcutaneous (SC) for sarcoma</title>
    <id>https://staging.whatcameofit.com/gi-102-subcutaneous-sc--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-102-subcutaneous-sc--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-108 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/gi-108--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-108--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GI-108 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/gi-108--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gi-108--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ginkgo for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/ginkgo--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ginkgo--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Givinostat for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/givinostat--primary-myelofibrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/givinostat--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Givinostat for thrombocythemia, essential</title>
    <id>https://staging.whatcameofit.com/givinostat--thrombocythemia-essential#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/givinostat--thrombocythemia-essential"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Glucagon-like peptide 1 receptor agonist for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/glucagon-like-peptide-1-receptor-agonist--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/glucagon-like-peptide-1-receptor-agonist--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Glyceryl Trinitrate Only Product in Oromucosal Dose Form for autonomic dysreflexia</title>
    <id>https://staging.whatcameofit.com/glyceryl-trinitrate-only-product-in-oromucosal-dose-form--autonomic-dysreflexia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/glyceryl-trinitrate-only-product-in-oromucosal-dose-form--autonomic-dysreflexia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GNA followed by GAE for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/gna-followed-by-gae--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gna-followed-by-gae--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GnRH agonist and Letrozole + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/gnrh-agonist-and-letrozole-megestrol-medroxyprogesterone--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gnrh-agonist-and-letrozole-megestrol-medroxyprogesterone--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GnRH antagonist + Letrozole for obesity</title>
    <id>https://staging.whatcameofit.com/gnrh-antagonist-letrozole--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gnrh-antagonist-letrozole--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GnRHa + Letrozole for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/gnrha-letrozole--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gnrha-letrozole--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Goflikicept for pericarditis</title>
    <id>https://staging.whatcameofit.com/goflikicept--pericarditis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/goflikicept--pericarditis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Golimumab for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/golimumab--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/golimumab--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/granulocyte-colony-stimulating-factor-g-csf-mgta-456-infusion-busulfan-fludarabine-melphalan-mycophenolate-mofetil-hydrochloride--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/granulocyte-colony-stimulating-factor-g-csf-mgta-456-infusion-busulfan-fludarabine-melphalan-mycophenolate-mofetil-hydrochloride--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/granulocyte-colony-stimulating-factor-g-csf-mgta-456-infusion-total-body-irradiation-tbi-cyclophosphamide-fludarabine-mycophenolate-mofetil-hydrochloride-tacrolimus--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/granulocyte-colony-stimulating-factor-g-csf-mgta-456-infusion-total-body-irradiation-tbi-cyclophosphamide-fludarabine-mycophenolate-mofetil-hydrochloride-tacrolimus--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Green coffee + beta-glucan for insulin resistance</title>
    <id>https://staging.whatcameofit.com/green-coffee-beta-glucan--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/green-coffee-beta-glucan--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Green coffee + beta-glucan for obesity</title>
    <id>https://staging.whatcameofit.com/green-coffee-beta-glucan--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/green-coffee-beta-glucan--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Green coffee extract for insulin resistance</title>
    <id>https://staging.whatcameofit.com/green-coffee-extract--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/green-coffee-extract--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Green coffee extract for obesity</title>
    <id>https://staging.whatcameofit.com/green-coffee-extract--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/green-coffee-extract--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Green light for migraine disorders</title>
    <id>https://staging.whatcameofit.com/green-light--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/green-light--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Green tea leaf for leiomyoma</title>
    <id>https://staging.whatcameofit.com/green-tea-leaf--leiomyoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/green-tea-leaf--leiomyoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/group-therapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/group-therapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + naltrexone and bupropion (combination) for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + naltrexone and bupropion (combination) for obesity</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + naltrexone and bupropion (combination) for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-naltrexone-and-bupropion-combination--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Phentermine-Topiramate for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Phentermine-Topiramate for obesity</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Phentermine-Topiramate for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-phentermine-topiramate--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Semaglutide for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-semaglutide--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-semaglutide--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Semaglutide for obesity</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-semaglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-semaglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program + Semaglutide for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/group-therapy-program-semaglutide--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program-semaglutide--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/group-therapy-program--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program for obesity</title>
    <id>https://staging.whatcameofit.com/group-therapy-program--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Group Therapy Program for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/group-therapy-program--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/group-therapy-program--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GSK malaria vaccine 257049 Vaccine for malaria</title>
    <id>https://staging.whatcameofit.com/gsk-malaria-vaccine-257049-vaccine--malaria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gsk-malaria-vaccine-257049-vaccine--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GSK3862995B for bronchiectasis</title>
    <id>https://staging.whatcameofit.com/gsk3862995b--bronchiectasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gsk3862995b--bronchiectasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>GSK5471713 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/gsk5471713--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gsk5471713--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GSK5784283 for nasal polyps</title>
    <id>https://staging.whatcameofit.com/gsk5784283--nasal-polyps#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/gsk5784283--nasal-polyps"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GSK5784283 for paranasal sinus diseases</title>
    <id>https://staging.whatcameofit.com/gsk5784283--paranasal-sinus-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/gsk5784283--paranasal-sinus-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/gt101-human-interleukin-2--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gt101-human-interleukin-2--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Guselkumab for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/guselkumab--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/guselkumab--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Guselkumab for crohn disease</title>
    <id>https://staging.whatcameofit.com/guselkumab--crohn-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/guselkumab--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>gut-brain axis (GLP-1)-activating food carbohydrate for obesity</title>
    <id>https://staging.whatcameofit.com/gut-brain-axis-glp-1-activating-food-carbohydrate--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gut-brain-axis-glp-1-activating-food-carbohydrate--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GV-971 + MEMANTINE for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/gv-971-memantine--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/gv-971-memantine--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>GV-971 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/gv-971--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/gv-971--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>GVHD prophylaxis regimen + RIC regimen for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GVHD prophylaxis regimen + RIC regimen for bone marrow failure disorders</title>
    <id>https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--bone-marrow-failure-disorders#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--bone-marrow-failure-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GVHD prophylaxis regimen + RIC regimen for immune system diseases</title>
    <id>https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--immune-system-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--immune-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GVHD prophylaxis regimen + RIC regimen for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--metabolic-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/gvhd-prophylaxis-regimen-ric-regimen--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>GXV-813 for schizophrenia</title>
    <id>https://staging.whatcameofit.com/gxv-813--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/gxv-813--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>H021 Enteric-coated Tablets High-dose Group for crohn disease</title>
    <id>https://staging.whatcameofit.com/h021-enteric-coated-tablets-high-dose-group--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/h021-enteric-coated-tablets-high-dose-group--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>H021 Enteric-coated Tablets Low-dose Group for crohn disease</title>
    <id>https://staging.whatcameofit.com/h021-enteric-coated-tablets-low-dose-group--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/h021-enteric-coated-tablets-low-dose-group--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hafnium oxide for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/hafnium-oxide--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hafnium-oxide--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/hafnium-oxide-containing-nanoparticles-nbtxr3-radiation-therapy--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hafnium-oxide-containing-nanoparticles-nbtxr3-radiation-therapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/haic-tae-tislelizumab-surufatinib--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/haic-tae-tislelizumab-surufatinib--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hand Transplantation for amputation, traumatic</title>
    <id>https://staging.whatcameofit.com/hand-transplantation--amputation-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hand-transplantation--amputation-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Haploidentical Hematopoietic Cell Transplantation for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/haploidentical-hematopoietic-cell-transplantation--metabolic-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/haploidentical-hematopoietic-cell-transplantation--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Haploidentical Hematopoietic Cell Transplantation for primary immunodeficiency diseases</title>
    <id>https://staging.whatcameofit.com/haploidentical-hematopoietic-cell-transplantation--primary-immunodeficiency-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/haploidentical-hematopoietic-cell-transplantation--primary-immunodeficiency-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Harm Reduction (E-cigarette switching) for neoplasms</title>
    <id>https://staging.whatcameofit.com/harm-reduction-e-cigarette-switching--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/harm-reduction-e-cigarette-switching--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hatha Yoga Practice Group for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/hatha-yoga-practice-group--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hatha-yoga-practice-group--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HB-1 for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/hb-1--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hb-1--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>HB0056 for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/hb0056--idiopathic-pulmonary-fibrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hb0056--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HD-6277 100mg for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/hd-6277-100mg--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hd-6277-100mg--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>HD-6277 25mg for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/hd-6277-25mg--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hd-6277-25mg--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>HD-6277 50mg for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/hd-6277-50mg--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hd-6277-50mg--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Healthy Activity Program (HAP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/healthy-activity-program-hap--depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/healthy-activity-program-hap--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Healthy donor stool for clostridium infections</title>
    <id>https://staging.whatcameofit.com/healthy-donor-stool--clostridium-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/healthy-donor-stool--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Heart to Heart Yoga for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/heart-to-heart-yoga--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/heart-to-heart-yoga--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Heart to Heart Yoga for heart failure</title>
    <id>https://staging.whatcameofit.com/heart-to-heart-yoga--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/heart-to-heart-yoga--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + FLUDARABINE + Tacrolimus for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-busulfan-fludarabine-tacrolimus--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-busulfan-fludarabine-tacrolimus--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hematopoietic Stem Cell Transplantation + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + Tacrolimus for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-tacrolimus--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-tacrolimus--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hematopoietic stem-cell transplantation for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hematopoietic-stem-cell-transplantation--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hemoperfusion for leptospirosis</title>
    <id>https://staging.whatcameofit.com/hemoperfusion--leptospirosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hemoperfusion--leptospirosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>HepaCure for hepatitis</title>
    <id>https://staging.whatcameofit.com/hepacure--hepatitis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hepacure--hepatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>HepaCure for liver failure</title>
    <id>https://staging.whatcameofit.com/hepacure--liver-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hepacure--liver-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Heparin for cystitis, interstitial</title>
    <id>https://staging.whatcameofit.com/heparin--cystitis-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/heparin--cystitis-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>HFA-152a + Norflurane for bronchial spasm</title>
    <id>https://staging.whatcameofit.com/hfa-152a-norflurane--bronchial-spasm#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hfa-152a-norflurane--bronchial-spasm"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HFNO + Dexamethasone for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/hfno-dexamethasone--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hfno-dexamethasone--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hfno for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/hfno--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hfno--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HiCM-188 therapy for heart failure</title>
    <id>https://staging.whatcameofit.com/hicm-188-therapy--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hicm-188-therapy--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High dose CABG/LVAD+iPSC-CMs for heart failure</title>
    <id>https://staging.whatcameofit.com/high-dose-cabg-lvad-ipsc-cms--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-dose-cabg-lvad-ipsc-cms--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/high-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/high-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>High dose Jia Shen Tablet for heart failure</title>
    <id>https://staging.whatcameofit.com/high-dose-jia-shen-tablet--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-dose-jia-shen-tablet--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Dose LX2006 + Low dose LX2006 + Mid Dose LX2006 for cardiomyopathies</title>
    <id>https://staging.whatcameofit.com/high-dose-lx2006-low-dose-lx2006-mid-dose-lx2006--cardiomyopathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/high-dose-lx2006-low-dose-lx2006-mid-dose-lx2006--cardiomyopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>High dose of peanuts for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/high-dose-of-peanuts--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-dose-of-peanuts--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High dose OIT for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/high-dose-oit--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-dose-oit--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/high-dose-rate-brachytherapy-intra-lesional-boost-imrt--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-dose-rate-brachytherapy-intra-lesional-boost-imrt--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/high-dose-rate-brachytherapy-intra-lesional-boost-imrt--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-dose-rate-brachytherapy-intra-lesional-boost-imrt--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritis</title>
    <id>https://staging.whatcameofit.com/high-dose-recombinant-trivalent-subunit-rotavirus-vaccine--gastroenteritis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-dose-recombinant-trivalent-subunit-rotavirus-vaccine--gastroenteritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections</title>
    <id>https://staging.whatcameofit.com/high-dose-recombinant-trivalent-subunit-rotavirus-vaccine--rotavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-dose-recombinant-trivalent-subunit-rotavirus-vaccine--rotavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High doses of Thiamine y Biotin for huntington disease</title>
    <id>https://staging.whatcameofit.com/high-doses-of-thiamine-y-biotin--huntington-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-doses-of-thiamine-y-biotin--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High intensity whole-body infrared heating for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/high-intensity-whole-body-infrared-heating--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-whole-body-infrared-heating--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Monetary Incentive (HMI) + Message-Based Psychotherapy (MBP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-mbp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-mbp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Monetary Incentive (HMI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Monetary Incentive (HMI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-monetary-incentive-hmi-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Monetary Incentive (HMI) + Video-Chat Psychotherapy (VCP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/high-monetary-incentive-hmi-video-chat-psychotherapy-vcp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-monetary-incentive-hmi-video-chat-psychotherapy-vcp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High THC Cannabis for combat disorders</title>
    <id>https://staging.whatcameofit.com/high-thc-cannabis--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-thc-cannabis--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High THC Cannabis for marijuana abuse</title>
    <id>https://staging.whatcameofit.com/high-thc-cannabis--marijuana-abuse#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-thc-cannabis--marijuana-abuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High THC Cannabis for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/high-thc-cannabis--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-thc-cannabis--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High Tibial Osteotomy for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/high-tibial-osteotomy--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-tibial-osteotomy--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-dose experimental vaccine for herpes zoster</title>
    <id>https://staging.whatcameofit.com/high-dose-experimental-vaccine--herpes-zoster#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/high-dose-experimental-vaccine--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>High-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/high-dose-lc-z300-01-twice-daily-in-blinding--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-dose-lc-z300-01-twice-daily-in-blinding--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-Intensity Aerobic Exercise (AE) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/high-intensity-aerobic-exercise-ae--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-aerobic-exercise-ae--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-intensity inpatient MDMA-assisted psychotherapy for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/high-intensity-inpatient-mdma-assisted-psychotherapy--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/high-intensity-inpatient-mdma-assisted-psychotherapy--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>High-intensity Mediterranean diet intervention for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-intensity Mediterranean diet intervention for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--hyperlipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-intensity Mediterranean diet intervention for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-intensity Mediterranean diet intervention for obesity</title>
    <id>https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-intensity Mediterranean diet intervention for psoriasis</title>
    <id>https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--psoriasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-intensity-mediterranean-diet-intervention--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>High-resistance inspiratory muscle strength training for hypertension</title>
    <id>https://staging.whatcameofit.com/high-resistance-inspiratory-muscle-strength-training--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/high-resistance-inspiratory-muscle-strength-training--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>hiPSC-CM therapy for cardiomyopathy, dilated</title>
    <id>https://staging.whatcameofit.com/hipsc-cm-therapy--cardiomyopathy-dilated#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hipsc-cm-therapy--cardiomyopathy-dilated"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>hiPSC-CM therapy for heart failure</title>
    <id>https://staging.whatcameofit.com/hipsc-cm-therapy--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hipsc-cm-therapy--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Histotripsy for abdominal neoplasms</title>
    <id>https://staging.whatcameofit.com/histotripsy--abdominal-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/histotripsy--abdominal-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HMB-002 (Part A) for von willebrand disease, type 3</title>
    <id>https://staging.whatcameofit.com/hmb-002-part-a--von-willebrand-disease-type-3#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hmb-002-part-a--von-willebrand-disease-type-3"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>HMB-002 (Part B) for von willebrand disease, type 3</title>
    <id>https://staging.whatcameofit.com/hmb-002-part-b--von-willebrand-disease-type-3#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hmb-002-part-b--von-willebrand-disease-type-3"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) for von willebrand disease, type 3</title>
    <id>https://staging.whatcameofit.com/hmb-002-with-concomitant-factor-concentrate-part-c-not-applicable-in-us--von-willebrand-disease-type-3#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hmb-002-with-concomitant-factor-concentrate-part-c-not-applicable-in-us--von-willebrand-disease-type-3"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Home Based Physical Exercise + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/home-based-physical-exercise-sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/home-based-physical-exercise-sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/home-health-encounter-patient-monitoring-questionnaire-administration-nivolumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/home-health-encounter-patient-monitoring-questionnaire-administration-nivolumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/home-health-encounter-patient-monitoring-questionnaire-administration-nivolumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/home-health-encounter-patient-monitoring-questionnaire-administration-nivolumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Homeoblock for malocclusion</title>
    <id>https://staging.whatcameofit.com/homeoblock--malocclusion#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/homeoblock--malocclusion"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>HRS-1167 tablets + Prednisone Acetate tablets + ABIRATERONE ACETATE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/hrs-1167-tablets-prednisone-acetate-tablets-abiraterone-acetate--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hrs-1167-tablets-prednisone-acetate-tablets-abiraterone-acetate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>HRS-1780 tablets for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/hrs-1780-tablets--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hrs-1780-tablets--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HRS9531 for obesity</title>
    <id>https://staging.whatcameofit.com/hrs9531--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hrs9531--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HRS9531 Injection for obesity</title>
    <id>https://staging.whatcameofit.com/hrs9531-injection--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hrs9531-injection--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HRS9531 injection；Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/hrs9531-injection-placebo--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hrs9531-injection-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>HS-10380 for schizophrenia</title>
    <id>https://staging.whatcameofit.com/hs-10380--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hs-10380--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HS-20093 for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/hs-20093--osteosarcoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hs-20093--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HS-20094 Injection for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/hs-20094-injection--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hs-20094-injection--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HSK31679 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/hsk31679--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hsk31679--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>HSK44459 for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/hsk44459--idiopathic-pulmonary-fibrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hsk44459--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>HU6 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/hu6--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hu6--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>hUC-MSC-Exos Nasal Spray for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/huc-msc-exos-nasal-spray--autism-spectrum-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/huc-msc-exos-nasal-spray--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/human-embryonic-stem-cell-derived-retinal-pigment-epithelium-rpe--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/human-embryonic-stem-cell-derived-retinal-pigment-epithelium-rpe--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>human Mesenchymal Stem Cells for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/human-mesenchymal-stem-cells--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/human-mesenchymal-stem-cells--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>human Mesenchymal Stem Cells for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/human-mesenchymal-stem-cells--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/human-mesenchymal-stem-cells--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion for vitiligo</title>
    <id>https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-huc-msc-exos-intravenous-infusion--vitiligo#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-huc-msc-exos-intravenous-infusion--vitiligo"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Local Injection for vitiligo</title>
    <id>https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-huc-msc-exos-local-injection--vitiligo#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-huc-msc-exos-local-injection--vitiligo"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for alopecia</title>
    <id>https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes--alopecia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/human-umbilical-cord-mesenchymal-stem-cell-derived-exosomes--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hybrid Palliative Radiation Therapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/hybrid-palliative-radiation-therapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hybrid-palliative-radiation-therapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydrocortisone for pancreatitis</title>
    <id>https://staging.whatcameofit.com/hydrocortisone--pancreatitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydrocortisone--pancreatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxycarbamide for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/hydroxycarbamide--anemia-sickle-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/hydroxycarbamide--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine + azithromycin + / - tocilizumab for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-azithromycin-tocilizumab--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-azithromycin-tocilizumab--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>hydroxychloroquine + azithromycin for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-azithromycin--coronavirus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-azithromycin--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine--coronavirus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine for neoplasms</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine--respiratory-distress-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine Pill + Azithromycin Pill for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-pill-azithromycin-pill--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-pill-azithromycin-pill--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine Sulfate + Azythromycin for lung diseases</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-sulfate-azythromycin--lung-diseases#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-sulfate-azythromycin--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine sulfate for arthralgia</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-sulfate--arthralgia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-sulfate--arthralgia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hydroxychloroquine sulfate for lung diseases</title>
    <id>https://staging.whatcameofit.com/hydroxychloroquine-sulfate--lung-diseases#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/hydroxychloroquine-sulfate--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Hydroxyzine Hydrochloride + Lidocaine for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/hydroxyzine-hydrochloride-lidocaine--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hydroxyzine-hydrochloride-lidocaine--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hydroxyzine Hydrochloride for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/hydroxyzine-hydrochloride--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hydroxyzine-hydrochloride--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Hyperbaric Oxygen Therapy for combat disorders</title>
    <id>https://staging.whatcameofit.com/hyperbaric-oxygen-therapy--combat-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hyperbaric-oxygen-therapy--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hyperpolarized 13C-pyruvate for heart failure</title>
    <id>https://staging.whatcameofit.com/hyperpolarized-13c-pyruvate--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hyperpolarized-13c-pyruvate--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hyperpolarized 13C-pyruvate for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/hyperpolarized-13c-pyruvate--metabolic-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/hyperpolarized-13c-pyruvate--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastoma</title>
    <id>https://staging.whatcameofit.com/hypofractionated-re-irradiation-mannitol-cetuximab--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/hypofractionated-re-irradiation-mannitol-cetuximab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IA Carboplatin + IA Caelyx for glioblastoma</title>
    <id>https://staging.whatcameofit.com/ia-carboplatin-ia-caelyx--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ia-carboplatin-ia-caelyx--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IA Carboplatin + IA Etoposide Phosphate for glioblastoma</title>
    <id>https://staging.whatcameofit.com/ia-carboplatin-ia-etoposide-phosphate--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ia-carboplatin-ia-etoposide-phosphate--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IBI3016 for hypertension</title>
    <id>https://staging.whatcameofit.com/ibi3016--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ibi3016--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/ibi310-sintilimab-surufatinib--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ibi310-sintilimab-surufatinib--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ibogaine hydrochloride for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/ibogaine-hydrochloride--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ibogaine-hydrochloride--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ibuprofen for ductus arteriosus, patent</title>
    <id>https://staging.whatcameofit.com/ibuprofen--ductus-arteriosus-patent#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ibuprofen--ductus-arteriosus-patent"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ibuprofen for premature birth</title>
    <id>https://staging.whatcameofit.com/ibuprofen--premature-birth#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ibuprofen--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ibuprofen for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/ibuprofen--respiratory-distress-syndrome#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ibuprofen--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Icatibant for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/icatibant--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/icatibant--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Icatibant for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/icatibant--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/icatibant--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Iclepertin for schizophrenia</title>
    <id>https://staging.whatcameofit.com/iclepertin--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/iclepertin--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>iCM012 solution 2 mg/mL for reperfusion injury</title>
    <id>https://staging.whatcameofit.com/icm012-solution-2-mg-ml--reperfusion-injury#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/icm012-solution-2-mg-ml--reperfusion-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>icovamenib 100 mg for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/icovamenib-100-mg--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/icovamenib-100-mg--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>icovamenib 100mg for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/icovamenib-100mg--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/icovamenib-100mg--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>IDH1 peptide vaccine for glioma</title>
    <id>https://staging.whatcameofit.com/idh1-peptide-vaccine--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/idh1-peptide-vaccine--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>IDH1-vac for glioblastoma</title>
    <id>https://staging.whatcameofit.com/idh1-vac--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/idh1-vac--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IDH1R132H peptide vaccine + AVELUMAB for glioma</title>
    <id>https://staging.whatcameofit.com/idh1r132h-peptide-vaccine-avelumab--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/idh1r132h-peptide-vaccine-avelumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>IDH1R132H peptide vaccine for glioma</title>
    <id>https://staging.whatcameofit.com/idh1r132h-peptide-vaccine--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/idh1r132h-peptide-vaccine--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Idroxioleate Sodium for glioblastoma</title>
    <id>https://staging.whatcameofit.com/idroxioleate-sodium--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/idroxioleate-sodium--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ifinatamab deruxtecan for neoplasms</title>
    <id>https://staging.whatcameofit.com/ifinatamab-deruxtecan--neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ifinatamab-deruxtecan--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>IFN-γ positive selected T-cells for adenoviridae infections</title>
    <id>https://staging.whatcameofit.com/ifn-γ-positive-selected-t-cells--adenoviridae-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ifn-γ-positive-selected-t-cells--adenoviridae-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IFN-γ positive selected T-cells for cytomegalovirus infections</title>
    <id>https://staging.whatcameofit.com/ifn-γ-positive-selected-t-cells--cytomegalovirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ifn-γ-positive-selected-t-cells--cytomegalovirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IGT-303 for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/igt-303--renal-insufficiency-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/igt-303--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Iloprost for vaso-occlusive crises</title>
    <id>https://staging.whatcameofit.com/iloprost--vaso-occlusive-crises#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/iloprost--vaso-occlusive-crises"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Iluzanebart for leukoencephalopathies</title>
    <id>https://staging.whatcameofit.com/iluzanebart--leukoencephalopathies#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/iluzanebart--leukoencephalopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>IM ketamine in dose finding and then continuation for phantom limb</title>
    <id>https://staging.whatcameofit.com/im-ketamine-in-dose-finding-and-then-continuation--phantom-limb#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/im-ketamine-in-dose-finding-and-then-continuation--phantom-limb"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Imatinib Mesylate for hypereosinophilic syndrome</title>
    <id>https://staging.whatcameofit.com/imatinib-mesylate--hypereosinophilic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/imatinib-mesylate--hypereosinophilic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Imatinib Mesylate for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/imatinib-mesylate--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/imatinib-mesylate--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Imatinib Mesylate for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/imatinib-mesylate--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/imatinib-mesylate--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ime for hypertension</title>
    <id>https://staging.whatcameofit.com/ime--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ime--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ime for prehypertension</title>
    <id>https://staging.whatcameofit.com/ime--prehypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ime--prehypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Imifoplatin for peripheral nervous system diseases</title>
    <id>https://staging.whatcameofit.com/imifoplatin--peripheral-nervous-system-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/imifoplatin--peripheral-nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Immediate HSCT Group for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/immediate-hsct-group--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/immediate-hsct-group--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Immulina for virus diseases</title>
    <id>https://staging.whatcameofit.com/immulina--virus-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/immulina--virus-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Immunosuppressive Agents + Caesarean Section + Deceased Donor Allograft Excision + In-vitro fertilisation + Oocyte retrieval and freezing + Uterine Transplantation for infertility</title>
    <id>https://staging.whatcameofit.com/immunosuppressive-agents-caesarean-section-deceased-donor-allograft-excision-in-vitro-fertilisation-oocyte-retrieval-and-freezing-uterine-transplantation--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/immunosuppressive-agents-caesarean-section-deceased-donor-allograft-excision-in-vitro-fertilisation-oocyte-retrieval-and-freezing-uterine-transplantation--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/imnn-001-il-12-plasmid-formulated-with-peg-pei-cholesterol-lipopolymer--fallopian-tube-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/imnn-001-il-12-plasmid-formulated-with-peg-pei-cholesterol-lipopolymer--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>IMNN-001 for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/imnn-001--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/imnn-001--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Impella 5.5 for shock, cardiogenic</title>
    <id>https://staging.whatcameofit.com/impella-5-5--shock-cardiogenic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/impella-5-5--shock-cardiogenic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>in vitro matuartion of oocytes for infertility</title>
    <id>https://staging.whatcameofit.com/in-vitro-matuartion-of-oocytes--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/in-vitro-matuartion-of-oocytes--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>in vitro maturation + Polar Body Biopsy with preimplantation genetic screening for infertility</title>
    <id>https://staging.whatcameofit.com/in-vitro-maturation-polar-body-biopsy-with-preimplantation-genetic-screening--infertility#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/in-vitro-maturation-polar-body-biopsy-with-preimplantation-genetic-screening--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>In vitro maturation and in vitro fertilization for infertility</title>
    <id>https://staging.whatcameofit.com/in-vitro-maturation-and-in-vitro-fertilization--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/in-vitro-maturation-and-in-vitro-fertilization--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>In vitro maturation for infertility</title>
    <id>https://staging.whatcameofit.com/in-vitro-maturation--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/in-vitro-maturation--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>In Vitro Maturation Procedure for infertility, female</title>
    <id>https://staging.whatcameofit.com/in-vitro-maturation-procedure--infertility-female#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/in-vitro-maturation-procedure--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IN-B00009 for obesity</title>
    <id>https://staging.whatcameofit.com/in-b00009--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/in-b00009--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>INCA33890 for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/inca33890--neoplasm-residual#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inca33890--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Inclisiran for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/inclisiran--acute-coronary-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/inclisiran--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Inclisiran for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/inclisiran--hyperlipidemias#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/inclisiran--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Inclisiran for non-st elevated myocardial infarction</title>
    <id>https://staging.whatcameofit.com/inclisiran--non-st-elevated-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/inclisiran--non-st-elevated-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Inclisiran for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/inclisiran--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/inclisiran--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Increasing control over stimulant use and physical health through incentivized rehabilitation for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/increasing-control-over-stimulant-use-and-physical-health-through-incentivized-rehabilitation--substance-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/increasing-control-over-stimulant-use-and-physical-health-through-incentivized-rehabilitation--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Individualized rTMS (transcranial magnetic stimulation) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/individualized-rtms-transcranial-magnetic-stimulation--depressive-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/individualized-rtms-transcranial-magnetic-stimulation--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Indocyanine Green for biliary atresia</title>
    <id>https://staging.whatcameofit.com/indocyanine-green--biliary-atresia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/indocyanine-green--biliary-atresia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>infliximab (IFX) infusion; azathioprine (AZA) caps for crohn disease</title>
    <id>https://staging.whatcameofit.com/infliximab-ifx-infusion-azathioprine-aza-caps--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/infliximab-ifx-infusion-azathioprine-aza-caps--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>infliximab (IFX) placebo infusion; azathioprine (AZA) caps for crohn disease</title>
    <id>https://staging.whatcameofit.com/infliximab-ifx-placebo-infusion-azathioprine-aza-caps--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/infliximab-ifx-placebo-infusion-azathioprine-aza-caps--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Infliximab for aneurysm</title>
    <id>https://staging.whatcameofit.com/infliximab--aneurysm#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/infliximab--aneurysm"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Infliximab for colitis</title>
    <id>https://staging.whatcameofit.com/infliximab--colitis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/infliximab--colitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Infliximab for vasculitis</title>
    <id>https://staging.whatcameofit.com/infliximab--vasculitis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/infliximab--vasculitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Inmazeb for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/inmazeb--hemorrhagic-fever-ebola#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inmazeb--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Innoventric Unica™ System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/innoventric-unica-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/innoventric-unica-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>INP20 for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/inp20--peanut-hypersensitivity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/inp20--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>INR101 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/inr101--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inr101--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Inspiratory muscle strength training for hypertension</title>
    <id>https://staging.whatcameofit.com/inspiratory-muscle-strength-training--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inspiratory-muscle-strength-training--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Inspiratory muscle strength training for prehypertension</title>
    <id>https://staging.whatcameofit.com/inspiratory-muscle-strength-training--prehypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inspiratory-muscle-strength-training--prehypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Inspiratory muscle training (IMT) for hypertension</title>
    <id>https://staging.whatcameofit.com/inspiratory-muscle-training-imt--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inspiratory-muscle-training-imt--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Insulin efsitora alfa for insulin resistance</title>
    <id>https://staging.whatcameofit.com/insulin-efsitora-alfa--insulin-resistance#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/insulin-efsitora-alfa--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>INT-210 Capsule for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/int-210-capsule--colitis-ulcerative#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/int-210-capsule--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Integration Therapy for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/integration-therapy--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/integration-therapy--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Integration Therapy for dissociative disorders</title>
    <id>https://staging.whatcameofit.com/integration-therapy--dissociative-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/integration-therapy--dissociative-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intensified medical follow-up and glucose-lowering drugs for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intensified medical follow-up and glucose-lowering drugs for kidney diseases</title>
    <id>https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--kidney-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--kidney-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intensified medical follow-up and glucose-lowering drugs for prediabetic state</title>
    <id>https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--prediabetic-state#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intensified medical follow-up and glucose-lowering drugs for retinal diseases</title>
    <id>https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--retinal-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intensified-medical-follow-up-and-glucose-lowering-drugs--retinal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intensity-modulated radiation therapy (IMRT) for sarcoma</title>
    <id>https://staging.whatcameofit.com/intensity-modulated-radiation-therapy-imrt--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/intensity-modulated-radiation-therapy-imrt--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Intensive lifestyle Intervention + Meal replacement system for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/intensive-lifestyle-intervention-meal-replacement-system--diabetes-mellitus-type-2#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/intensive-lifestyle-intervention-meal-replacement-system--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Intensive lifestyle Intervention + Meal replacement system for obesity</title>
    <id>https://staging.whatcameofit.com/intensive-lifestyle-intervention-meal-replacement-system--obesity#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/intensive-lifestyle-intervention-meal-replacement-system--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Intensive lifestyle Intervention for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/intensive-lifestyle-intervention--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intensive-lifestyle-intervention--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intermittent energy restriction (IER) for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/intermittent-energy-restriction-ier--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-energy-restriction-ier--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intermittent fasting 5:2 + Low-carbohydrate diet + Total diet replacement for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/intermittent-fasting-5-2-low-carbohydrate-diet-total-diet-replacement--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-fasting-5-2-low-carbohydrate-diet-total-diet-replacement--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intermittent prone positioning instructions for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/intermittent-prone-positioning-instructions--respiratory-insufficiency#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/intermittent-prone-positioning-instructions--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Intermittent Reduced Calorie Diet (IRCD) for crohn disease</title>
    <id>https://staging.whatcameofit.com/intermittent-reduced-calorie-diet-ircd--crohn-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-reduced-calorie-diet-ircd--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs-methylphenidate-hydrochloride--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs-methylphenidate-hydrochloride--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for lethargy</title>
    <id>https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs-methylphenidate-hydrochloride--lethargy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs-methylphenidate-hydrochloride--lethargy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>intermittent theta burst stimulation (iTBS) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>intermittent theta burst stimulation (iTBS) for lethargy</title>
    <id>https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs--lethargy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intermittent-theta-burst-stimulation-itbs--lethargy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/internet-based-intervention-quality-of-life-assessment-questionnaire-administration--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/internet-based-intervention-quality-of-life-assessment-questionnaire-administration--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for trismus</title>
    <id>https://staging.whatcameofit.com/internet-based-intervention-quality-of-life-assessment-questionnaire-administration--trismus#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/internet-based-intervention-quality-of-life-assessment-questionnaire-administration--trismus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>intra-rectal botulinum toxin injections for fecal incontinence</title>
    <id>https://staging.whatcameofit.com/intra-rectal-botulinum-toxin-injections--fecal-incontinence#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/intra-rectal-botulinum-toxin-injections--fecal-incontinence"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>intra-striatal rAAV5-miHTT for huntington disease</title>
    <id>https://staging.whatcameofit.com/intra-striatal-raav5-mihtt--huntington-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/intra-striatal-raav5-mihtt--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>intracavernous platelet rich plasma therapy for erectile dysfunction</title>
    <id>https://staging.whatcameofit.com/intracavernous-platelet-rich-plasma-therapy--erectile-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/intracavernous-platelet-rich-plasma-therapy--erectile-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Intralesional Steroid Injection for oral submucous fibrosis</title>
    <id>https://staging.whatcameofit.com/intralesional-steroid-injection--oral-submucous-fibrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intralesional-steroid-injection--oral-submucous-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intraoral Negative Pressure Therapy + Oral Appliances + Positional Therapy + Surgery + Tongue Muscle Strength Training for obesity</title>
    <id>https://staging.whatcameofit.com/intraoral-negative-pressure-therapy-oral-appliances-positional-therapy-surgery-tongue-muscle-strength-training--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intraoral-negative-pressure-therapy-oral-appliances-positional-therapy-surgery-tongue-muscle-strength-training--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Intravaginal gel for asthenozoospermia</title>
    <id>https://staging.whatcameofit.com/intravaginal-gel--asthenozoospermia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/intravaginal-gel--asthenozoospermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Intrepid™ TTVR System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/intrepid-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/intrepid-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Inulin for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/inulin--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/inulin--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Iodine I-124 Evuzamitide for spinal stenosis</title>
    <id>https://staging.whatcameofit.com/iodine-i-124-evuzamitide--spinal-stenosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iodine-i-124-evuzamitide--spinal-stenosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ION337 for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/ion337--epilepsies-myoclonic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ion337--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Iparomlimab and Tuvonralimab (QL1706) for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/iparomlimab-and-tuvonralimab-ql1706--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/iparomlimab-and-tuvonralimab-ql1706--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ipatasertib + atezolizumab for glioblastoma</title>
    <id>https://staging.whatcameofit.com/ipatasertib-atezolizumab--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ipatasertib-atezolizumab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerations</title>
    <id>https://staging.whatcameofit.com/ipilimumab-sintilimab-cetuximab-dabrafenib--spinocerebellar-degenerations#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ipilimumab-sintilimab-cetuximab-dabrafenib--spinocerebellar-degenerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ipilimumab for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/ipilimumab--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ipilimumab--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Iptacopan for proteinuria</title>
    <id>https://staging.whatcameofit.com/iptacopan--proteinuria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/iptacopan--proteinuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + ELRAGLUSIB for glioma</title>
    <id>https://staging.whatcameofit.com/irinotecan-elraglusib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-elraglusib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/irinotecan-elraglusib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-elraglusib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + ELRAGLUSIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/irinotecan-elraglusib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-elraglusib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + ELRAGLUSIB for sarcoma</title>
    <id>https://staging.whatcameofit.com/irinotecan-elraglusib--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-elraglusib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + Temozolomide for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/irinotecan-temozolomide--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-temozolomide--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan + Temozolomide for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/irinotecan-temozolomide--sarcoma-ewing#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irinotecan-temozolomide--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>IRINOTECAN HYDROCHLORIDE + BEVACIZUMAB + LEUCOVORIN + Fluorouracil for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/irinotecan-hydrochloride-bevacizumab-leucovorin-fluorouracil--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/irinotecan-hydrochloride-bevacizumab-leucovorin-fluorouracil--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan hydrochloride + bevacizumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/irinotecan-hydrochloride-bevacizumab--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/irinotecan-hydrochloride-bevacizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma for sarcoma</title>
    <id>https://staging.whatcameofit.com/irinotecan-hydrochloride-liposome-injection-ii-combined-with-temozolomide-and-bevacizuma--sarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/irinotecan-hydrochloride-liposome-injection-ii-combined-with-temozolomide-and-bevacizuma--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/irinotecan-liposomes-adebrelimab-lenvatinib-leucovorin-calcium-fluorouracil--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/irinotecan-liposomes-adebrelimab-lenvatinib-leucovorin-calcium-fluorouracil--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/irinotecan-liposomes-adebrelimab-leucovorin-calcium-fluorouracil--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/irinotecan-liposomes-adebrelimab-leucovorin-calcium-fluorouracil--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Iron sucrose for anemia</title>
    <id>https://staging.whatcameofit.com/iron-sucrose--anemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iron-sucrose--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/irradiation-surgical-resection-pegfilgrastim-vincristine-etoposide-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/irradiation-surgical-resection-pegfilgrastim-vincristine-etoposide-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Isatuximab for anemia, aplastic</title>
    <id>https://staging.whatcameofit.com/isatuximab--anemia-aplastic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/isatuximab--anemia-aplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Iscador*P for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/iscador-p--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iscador-p--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Iscador*P for sarcoma</title>
    <id>https://staging.whatcameofit.com/iscador-p--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iscador-p--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Isoniazid + RIFAPENTINE for latent tuberculosis</title>
    <id>https://staging.whatcameofit.com/isoniazid-rifapentine--latent-tuberculosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/isoniazid-rifapentine--latent-tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ITI-1284 10 mg for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/iti-1284-10-mg--generalized-anxiety-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iti-1284-10-mg--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ITI-1284 20 mg for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/iti-1284-20-mg--generalized-anxiety-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/iti-1284-20-mg--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ITP Stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/itp-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/itp-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ivermectin + Losartan for neoplasms</title>
    <id>https://staging.whatcameofit.com/ivermectin-losartan--neoplasms#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ivermectin-losartan--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ivermectin for asymptomatic infections</title>
    <id>https://staging.whatcameofit.com/ivermectin--asymptomatic-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ivermectin--asymptomatic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ivermectin for communicable diseases</title>
    <id>https://staging.whatcameofit.com/ivermectin--communicable-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ivermectin--communicable-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ivermectin for olfaction disorders</title>
    <id>https://staging.whatcameofit.com/ivermectin--olfaction-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ivermectin--olfaction-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ivm for infertility, female</title>
    <id>https://staging.whatcameofit.com/ivm--infertility-female#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ivm--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ivm for ovarian hyperstimulation syndrome</title>
    <id>https://staging.whatcameofit.com/ivm--ovarian-hyperstimulation-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ivm--ovarian-hyperstimulation-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>IVM media + FOLLICLE STIMULATING HORMONE (PORCINE) for infertility</title>
    <id>https://staging.whatcameofit.com/ivm-media-follicle-stimulating-hormone-porcine--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ivm-media-follicle-stimulating-hormone-porcine--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ivonescimab for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/ivonescimab--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ivonescimab--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ivonescimab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/ivonescimab--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ivonescimab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/ivosidenib-capecitabine-zanidatamab-capecitabine-futibatinib--cholangiocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ivosidenib-capecitabine-zanidatamab-capecitabine-futibatinib--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ivosidenib for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/ivosidenib--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ivosidenib--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for glioma</title>
    <id>https://staging.whatcameofit.com/ivoximab-20-mg-kg-ivgtt-q4w-temozolomide--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ivoximab-20-mg-kg-ivgtt-q4w-temozolomide--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Izalontamab Brengitecan for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/izalontamab-brengitecan--carcinoma-transitional-cell#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/izalontamab-brengitecan--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>JADE101 for proteinuria</title>
    <id>https://staging.whatcameofit.com/jade101--proteinuria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jade101--proteinuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>JBI-778 for glioblastoma</title>
    <id>https://staging.whatcameofit.com/jbi-778--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/jbi-778--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>JK-1201I + Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/jk-1201i-temozolomide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jk-1201i-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>JNJ-101556143 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/jnj-101556143--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jnj-101556143--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>JNJ-64042056 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/jnj-64042056--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jnj-64042056--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>JNJ-78934804 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/jnj-78934804--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jnj-78934804--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>JP-1366 + placebo for non-erosive reflux disease</title>
    <id>https://staging.whatcameofit.com/jp-1366-placebo--non-erosive-reflux-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/jp-1366-placebo--non-erosive-reflux-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/jskn033-bevacizumab-platinum--uterine-cervical-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/jskn033-bevacizumab-platinum--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>JZP926 capsule for myoclonic epilepsy, juvenile</title>
    <id>https://staging.whatcameofit.com/jzp926-capsule--myoclonic-epilepsy-juvenile#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/jzp926-capsule--myoclonic-epilepsy-juvenile"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>K-757 120 mg BID and K-833 100 mg BID for obesity</title>
    <id>https://staging.whatcameofit.com/k-757-120-mg-bid-and-k-833-100-mg-bid--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/k-757-120-mg-bid-and-k-833-100-mg-bid--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>K-757 120 mg BID and matching placebo to K-833 for obesity</title>
    <id>https://staging.whatcameofit.com/k-757-120-mg-bid-and-matching-placebo-to-k-833--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/k-757-120-mg-bid-and-matching-placebo-to-k-833--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>K-757 and K-833 BID + K-757 and K-833 QD for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/k-757-and-k-833-bid-k-757-and-k-833-qd--diabetes-mellitus-type-2#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/k-757-and-k-833-bid-k-757-and-k-833-qd--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>K-757 and K-833 BID + K-757 and K-833 QD for obesity</title>
    <id>https://staging.whatcameofit.com/k-757-and-k-833-bid-k-757-and-k-833-qd--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/k-757-and-k-833-bid-k-757-and-k-833-qd--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>K-757 and K-833 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/k-757-and-k-833--diabetes-mellitus-type-2#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/k-757-and-k-833--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>K-757 and K-833 for obesity</title>
    <id>https://staging.whatcameofit.com/k-757-and-k-833--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/k-757-and-k-833--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>KarX-EC + KarXT for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/karx-ec-karxt--autism-spectrum-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/karx-ec-karxt--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>KarX-EC + KarXT for autistic disorder</title>
    <id>https://staging.whatcameofit.com/karx-ec-karxt--autistic-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/karx-ec-karxt--autistic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>KarX-EC + KarXT for schizophrenia</title>
    <id>https://staging.whatcameofit.com/karx-ec-karxt--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/karx-ec-karxt--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>KarXT for autistic disorder</title>
    <id>https://staging.whatcameofit.com/karxt--autistic-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/karxt--autistic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>KarXT for schizophrenia</title>
    <id>https://staging.whatcameofit.com/karxt--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/karxt--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Kenetik for ketosis</title>
    <id>https://staging.whatcameofit.com/kenetik--ketosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/kenetik--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for alcoholism</title>
    <id>https://staging.whatcameofit.com/ketamine--alcoholism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ketamine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for cocaine-related disorders</title>
    <id>https://staging.whatcameofit.com/ketamine--cocaine-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine--cocaine-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/ketamine--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/ketamine--head-and-neck-neoplasms#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ketamine--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ketamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ketamine--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for parkinson disease</title>
    <id>https://staging.whatcameofit.com/ketamine--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/ketamine--stress-disorders-post-traumatic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ketamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine Hydrochloride for alcoholism</title>
    <id>https://staging.whatcameofit.com/ketamine-hydrochloride--alcoholism#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ketamine-hydrochloride--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine Hydrochloride for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/ketamine-hydrochloride--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine-hydrochloride--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine Hydrochloride for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ketamine-hydrochloride--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketamine-hydrochloride--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketamine Hydrochloride for neoplasms</title>
    <id>https://staging.whatcameofit.com/ketamine-hydrochloride--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketamine-hydrochloride--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine Hydrochloride for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/ketamine-hydrochloride--stress-disorders-post-traumatic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ketamine-hydrochloride--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ketamine-Assisted Psychotherapy (KAP) for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/ketamine-assisted-psychotherapy-kap--anxiety-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ketamine-assisted-psychotherapy-kap--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ketamine-Assisted Psychotherapy (KAP) for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/ketamine-assisted-psychotherapy-kap--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ketamine-assisted-psychotherapy-kap--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet + Non-ketogenic Diet for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet-non-ketogenic-diet--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet-non-ketogenic-diet--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for insulin resistance</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for ketosis</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--ketosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--psychotic-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Diet for schizophrenia</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic diet intervention for ketosis</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet-intervention--ketosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet-intervention--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic diet intervention for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet-intervention--psychotic-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet-intervention--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic diet intervention for schizophrenia</title>
    <id>https://staging.whatcameofit.com/ketogenic-diet-intervention--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-diet-intervention--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic foodstuffs for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/ketogenic-foodstuffs--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-foodstuffs--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketogenic Therapy for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/ketogenic-therapy--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ketogenic-therapy--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ketoprofen for agnosia</title>
    <id>https://staging.whatcameofit.com/ketoprofen--agnosia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketoprofen--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketoprofen for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/ketoprofen--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketoprofen--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketoprofen for lymphedema</title>
    <id>https://staging.whatcameofit.com/ketoprofen--lymphedema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketoprofen--lymphedema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ketoprofen for pneumothorax</title>
    <id>https://staging.whatcameofit.com/ketoprofen--pneumothorax#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ketoprofen--pneumothorax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Kinezodianone R hydrochloride for glaucoma</title>
    <id>https://staging.whatcameofit.com/kinezodianone-r-hydrochloride--glaucoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/kinezodianone-r-hydrochloride--glaucoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>KJ101 for burns</title>
    <id>https://staging.whatcameofit.com/kj101--burns#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/kj101--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>KLH-2109+ Leurprorelin acetate Placebo for leiomyoma</title>
    <id>https://staging.whatcameofit.com/klh-2109-leurprorelin-acetate-placebo--leiomyoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/klh-2109-leurprorelin-acetate-placebo--leiomyoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>kudzu extract, puerarin for alcoholism</title>
    <id>https://staging.whatcameofit.com/kudzu-extract-puerarin--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/kudzu-extract-puerarin--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>L-PSGB first for tachycardia, ventricular</title>
    <id>https://staging.whatcameofit.com/l-psgb-first--tachycardia-ventricular#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/l-psgb-first--tachycardia-ventricular"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>L-PSGB first for ventricular fibrillation</title>
    <id>https://staging.whatcameofit.com/l-psgb-first--ventricular-fibrillation#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/l-psgb-first--ventricular-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndrome</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--down-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--down-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--myelodysplastic-syndromes#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disorders</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--myeloproliferative-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-asparaginase-erwinia-chrysanthemi-asparaginase-mitoxantrone-hydrochloride--myeloproliferative-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for down syndrome</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--down-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--down-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--myelodysplastic-syndromes#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disorders</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--myeloproliferative-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-cytarabine-etoposide-thioguanine-daunorubicin-hydrochloride--myeloproliferative-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-enzalutamide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-enzalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinous</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-pharmacological-study-bevacizumab-atezolizumab--adenocarcinoma-mucinous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-pharmacological-study-bevacizumab-atezolizumab--adenocarcinoma-mucinous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-pharmacological-study-eribulin-mesylate--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-pharmacological-study-eribulin-mesylate--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-alveolar#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-alveolar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-embryonal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-embryonal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-alveolar#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-alveolar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-embryonal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-cyclophosphamide-vincristine-sulfate--rhabdomyosarcoma-embryonal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolar</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-temsirolimus-cyclophosphamide-vinorelbine-vincristine-sulfate--rhabdomyosarcoma-alveolar#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-temsirolimus-cyclophosphamide-vinorelbine-vincristine-sulfate--rhabdomyosarcoma-alveolar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonal</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-temsirolimus-cyclophosphamide-vinorelbine-vincristine-sulfate--rhabdomyosarcoma-embryonal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-questionnaire-administration-radiation-therapy-irinotecan-hydrochloride-dactinomycin-temsirolimus-cyclophosphamide-vinorelbine-vincristine-sulfate--rhabdomyosarcoma-embryonal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND&apos;S ADJUVANT + Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-sargramostim-svn53-67-m57-klh-peptide-vaccine-incomplete-freund-s-adjuvant-temozolomide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-sargramostim-svn53-67-m57-klh-peptide-vaccine-incomplete-freund-s-adjuvant-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND&apos;S ADJUVANT + Temozolomide for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/laboratory-biomarker-analysis-sargramostim-svn53-67-m57-klh-peptide-vaccine-incomplete-freund-s-adjuvant-temozolomide--gliosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/laboratory-biomarker-analysis-sargramostim-svn53-67-m57-klh-peptide-vaccine-incomplete-freund-s-adjuvant-temozolomide--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lacosamide for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/lacosamide--bipolar-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lacosamide--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lactiplantibacillus plantarum for psoriasis</title>
    <id>https://staging.whatcameofit.com/lactiplantibacillus-plantarum--psoriasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lactiplantibacillus-plantarum--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Landiolol for shock, septic</title>
    <id>https://staging.whatcameofit.com/landiolol--shock-septic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/landiolol--shock-septic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Language Treatment for premature birth</title>
    <id>https://staging.whatcameofit.com/language-treatment--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/language-treatment--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Laplace TTVR System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/laplace-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/laplace-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Laroprovstat for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/laroprovstat--dyslipidemias#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/laroprovstat--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Larotrectinib for neoplasms</title>
    <id>https://staging.whatcameofit.com/larotrectinib--neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/larotrectinib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Lb-dtk-mv for cytomegalovirus infections</title>
    <id>https://staging.whatcameofit.com/lb-dtk-mv--cytomegalovirus-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lb-dtk-mv--cytomegalovirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Lb-dtk-mv for epstein-barr virus infections</title>
    <id>https://staging.whatcameofit.com/lb-dtk-mv--epstein-barr-virus-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lb-dtk-mv--epstein-barr-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LBP-EC01 0.01x IV Dose for escherichia coli infections</title>
    <id>https://staging.whatcameofit.com/lbp-ec01-0-01x-iv-dose--escherichia-coli-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lbp-ec01-0-01x-iv-dose--escherichia-coli-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LBP-EC01 0.1 x IV dose for escherichia coli infections</title>
    <id>https://staging.whatcameofit.com/lbp-ec01-0-1-x-iv-dose--escherichia-coli-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lbp-ec01-0-1-x-iv-dose--escherichia-coli-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LBP-EC01 for escherichia coli infections</title>
    <id>https://staging.whatcameofit.com/lbp-ec01--escherichia-coli-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lbp-ec01--escherichia-coli-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LBP-EC01 IV Infusion Dose for escherichia coli infections</title>
    <id>https://staging.whatcameofit.com/lbp-ec01-iv-infusion-dose--escherichia-coli-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lbp-ec01-iv-infusion-dose--escherichia-coli-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LCB84 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/lcb84--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lcb84--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LCB84 for glioblastoma</title>
    <id>https://staging.whatcameofit.com/lcb84--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lcb84--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LCB84 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/lcb84--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lcb84--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LCB84 for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/lcb84--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lcb84--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LCHF Ketogenic Diet for ketosis</title>
    <id>https://staging.whatcameofit.com/lchf-ketogenic-diet--ketosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lchf-ketogenic-diet--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LCHF Ketogenic Diet for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/lchf-ketogenic-diet--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lchf-ketogenic-diet--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LEAF-4L6715 for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/leaf-4l6715--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/leaf-4l6715--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lebrikizumab for dermatitis</title>
    <id>https://staging.whatcameofit.com/lebrikizumab--dermatitis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lebrikizumab--dermatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lebrikizumab for eczema</title>
    <id>https://staging.whatcameofit.com/lebrikizumab--eczema#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lebrikizumab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>LECANEMAB + Etalanetug for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/lecanemab-etalanetug--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lecanemab-etalanetug--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lecanemab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/lecanemab--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lecanemab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lecanemab for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/lecanemab--cognitive-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lecanemab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Left DLPFC tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/left-dlpfc-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/left-dlpfc-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Left main stenting with intravascular lithotripsy for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/left-main-stenting-with-intravascular-lithotripsy--atherosclerosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/left-main-stenting-with-intravascular-lithotripsy--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Left main stenting with intravascular lithotripsy for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/left-main-stenting-with-intravascular-lithotripsy--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/left-main-stenting-with-intravascular-lithotripsy--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Leia Sensory Prosthesis for peripheral nervous system diseases</title>
    <id>https://staging.whatcameofit.com/leia-sensory-prosthesis--peripheral-nervous-system-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/leia-sensory-prosthesis--peripheral-nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/lenalidomide-acalabrutinib-obinutuzumab--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lenalidomide-acalabrutinib-obinutuzumab--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lenalidomide for erdheim-chester disease</title>
    <id>https://staging.whatcameofit.com/lenalidomide--erdheim-chester-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lenalidomide--erdheim-chester-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lenalidomide for lupus erythematosus, cutaneous</title>
    <id>https://staging.whatcameofit.com/lenalidomide--lupus-erythematosus-cutaneous#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lenalidomide--lupus-erythematosus-cutaneous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>lentiviral gene therapy for drug resistant epilepsy</title>
    <id>https://staging.whatcameofit.com/lentiviral-gene-therapy--drug-resistant-epilepsy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lentiviral-gene-therapy--drug-resistant-epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lenvatinib + farletuzumab ecteribulin for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/lenvatinib-farletuzumab-ecteribulin--adenocarcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lenvatinib-farletuzumab-ecteribulin--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Lenvatinib + farletuzumab ecteribulin for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/lenvatinib-farletuzumab-ecteribulin--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lenvatinib-farletuzumab-ecteribulin--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Lenvatinib for glioblastoma</title>
    <id>https://staging.whatcameofit.com/lenvatinib--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lenvatinib--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lepodisiran for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/lepodisiran--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lepodisiran--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lepodisiran Sodium for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/lepodisiran-sodium--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lepodisiran-sodium--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoid</title>
    <id>https://staging.whatcameofit.com/letetresgene-autoleucel-lete-cel-gsk3377794-cyclophosphamide-fludarabine--liposarcoma-myxoid#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/letetresgene-autoleucel-lete-cel-gsk3377794-cyclophosphamide-fludarabine--liposarcoma-myxoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/letetresgene-autoleucel-lete-cel-gsk3377794-cyclophosphamide-fludarabine--sarcoma-synovial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/letetresgene-autoleucel-lete-cel-gsk3377794-cyclophosphamide-fludarabine--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Leucovorin for asperger syndrome</title>
    <id>https://staging.whatcameofit.com/leucovorin--asperger-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/leucovorin--asperger-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Leucovorin for autistic disorder</title>
    <id>https://staging.whatcameofit.com/leucovorin--autistic-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/leucovorin--autistic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Leucovorin for language disorders</title>
    <id>https://staging.whatcameofit.com/leucovorin--language-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/leucovorin--language-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Leucovorin for neoplasms</title>
    <id>https://staging.whatcameofit.com/leucovorin--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/leucovorin--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Levetiracetam for seizures</title>
    <id>https://staging.whatcameofit.com/levetiracetam--seizures#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/levetiracetam--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Levoleucovorin calcium for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/levoleucovorin-calcium--autism-spectrum-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/levoleucovorin-calcium--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Levoleucovorin calcium for language disorders</title>
    <id>https://staging.whatcameofit.com/levoleucovorin-calcium--language-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/levoleucovorin-calcium--language-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>libitum diet and waiting list control group for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/libitum-diet-and-waiting-list-control-group--metabolic-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/libitum-diet-and-waiting-list-control-group--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Licaminlimab for dry eye syndromes</title>
    <id>https://staging.whatcameofit.com/licaminlimab--dry-eye-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/licaminlimab--dry-eye-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lidocaine for cystitis, interstitial</title>
    <id>https://staging.whatcameofit.com/lidocaine--cystitis-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lidocaine--cystitis-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lidocaine for migraine disorders</title>
    <id>https://staging.whatcameofit.com/lidocaine--migraine-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lidocaine--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lifileucel for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/lifileucel--histiocytoma-malignant-fibrous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lifileucel--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lifileucel for liposarcoma</title>
    <id>https://staging.whatcameofit.com/lifileucel--liposarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lifileucel--liposarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lifus for dystonia</title>
    <id>https://staging.whatcameofit.com/lifus--dystonia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lifus--dystonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lifus for epilepsy</title>
    <id>https://staging.whatcameofit.com/lifus--epilepsy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lifus--epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lifus for essential tremor</title>
    <id>https://staging.whatcameofit.com/lifus--essential-tremor#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lifus--essential-tremor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lifus for parkinson disease</title>
    <id>https://staging.whatcameofit.com/lifus--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lifus--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lifus for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/lifus--substance-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lifus--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>light box + Wake Therapy + LITHIUM for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/light-box-wake-therapy-lithium--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/light-box-wake-therapy-lithium--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>light box + Wake Therapy + LITHIUM for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/light-box-wake-therapy-lithium--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/light-box-wake-therapy-lithium--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LinkCor Bioengineered Corneal Implant for keratoconus</title>
    <id>https://staging.whatcameofit.com/linkcor-bioengineered-corneal-implant--keratoconus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/linkcor-bioengineered-corneal-implant--keratoconus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Liposomal Amphotericin B (LAmB) for mycoses</title>
    <id>https://staging.whatcameofit.com/liposomal-amphotericin-b-lamb--mycoses#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/liposomal-amphotericin-b-lamb--mycoses"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Liraglutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/liraglutide--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/liraglutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Liraglutide for obesity</title>
    <id>https://staging.whatcameofit.com/liraglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/liraglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lithium carbonate + perospirone hydrochloride for depressive disorder</title>
    <id>https://staging.whatcameofit.com/lithium-carbonate-perospirone-hydrochloride--depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lithium-carbonate-perospirone-hydrochloride--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lithium for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/lithium--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lithium--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lithium for mania</title>
    <id>https://staging.whatcameofit.com/lithium--mania#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lithium--mania"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lithium sulphate prolonged-release 660 mg for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/lithium-sulphate-prolonged-release-660-mg--bipolar-disorder#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/lithium-sulphate-prolonged-release-660-mg--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Lithium sulphate prolonged-release 660 mg for tremor</title>
    <id>https://staging.whatcameofit.com/lithium-sulphate-prolonged-release-660-mg--tremor#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/lithium-sulphate-prolonged-release-660-mg--tremor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Live donor uterus transplantation + Tacrolimus for infertility, female</title>
    <id>https://staging.whatcameofit.com/live-donor-uterus-transplantation-tacrolimus--infertility-female#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/live-donor-uterus-transplantation-tacrolimus--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Liver-expressed antimicrobial peptide 2 for obesity</title>
    <id>https://staging.whatcameofit.com/liver-expressed-antimicrobial-peptide-2--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/liver-expressed-antimicrobial-peptide-2--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lixisenatide for parkinson disease</title>
    <id>https://staging.whatcameofit.com/lixisenatide--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lixisenatide--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lns for infant nutrition disorders</title>
    <id>https://staging.whatcameofit.com/lns--infant-nutrition-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lns--infant-nutrition-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lns for malnutrition</title>
    <id>https://staging.whatcameofit.com/lns--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lns--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LNZ101 (Aceclidine /Brimonidine) ophthalmic solution for presbyopia</title>
    <id>https://staging.whatcameofit.com/lnz101-aceclidine-brimonidine-ophthalmic-solution--presbyopia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/lnz101-aceclidine-brimonidine-ophthalmic-solution--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>local co-administration of autologous ADIpose for crohn disease</title>
    <id>https://staging.whatcameofit.com/local-co-administration-of-autologous-adipose--crohn-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/local-co-administration-of-autologous-adipose--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/local-consolidation-therapy-quality-of-life-assessment-radiation-therapy-therapeutic-conventional-surgery-nivolumab-ipilimumab--adenocarcinoma-of-lung#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/local-consolidation-therapy-quality-of-life-assessment-radiation-therapy-therapeutic-conventional-surgery-nivolumab-ipilimumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Local Therapy + Standard Therapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/local-therapy-standard-therapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/local-therapy-standard-therapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Loco-regional radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/loco-regional-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/loco-regional-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Loco-regional radiotherapy for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/loco-regional-radiotherapy--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/loco-regional-radiotherapy--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lomustine + ELRAGLUSIB for glioma</title>
    <id>https://staging.whatcameofit.com/lomustine-elraglusib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lomustine-elraglusib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/lomustine-elraglusib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lomustine-elraglusib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lomustine + ELRAGLUSIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/lomustine-elraglusib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lomustine-elraglusib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lomustine + ELRAGLUSIB for sarcoma</title>
    <id>https://staging.whatcameofit.com/lomustine-elraglusib--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lomustine-elraglusib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lorigerlimab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/lorigerlimab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lorigerlimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for albuminuria</title>
    <id>https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--albuminuria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--albuminuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for hypertension</title>
    <id>https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt2i-qd--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Lorundrostat for hypertension</title>
    <id>https://staging.whatcameofit.com/lorundrostat--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lorundrostat--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Losartan + Paclitaxel for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/losartan-paclitaxel--fallopian-tube-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/losartan-paclitaxel--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>low calorie diet + Phentermine/topiramate for obesity</title>
    <id>https://staging.whatcameofit.com/low-calorie-diet-phentermine-topiramate--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/low-calorie-diet-phentermine-topiramate--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>low dose CABG+iPSC-CMs for heart failure</title>
    <id>https://staging.whatcameofit.com/low-dose-cabg-ipsc-cms--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-dose-cabg-ipsc-cms--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/low-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/low-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Low Dose FMT Capsule DE for clostridium infections</title>
    <id>https://staging.whatcameofit.com/low-dose-fmt-capsule-de--clostridium-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/low-dose-fmt-capsule-de--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Low dose Jia Shen Tablet for heart failure</title>
    <id>https://staging.whatcameofit.com/low-dose-jia-shen-tablet--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-dose-jia-shen-tablet--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>low intensity focused ultrasound (LIFU) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/low-intensity-focused-ultrasound-lifu--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-intensity-focused-ultrasound-lifu--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy (MBP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-mbp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-mbp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low Monetary and Alternative Incentive (LMAI) + Video-Chat Psychotherapy (VCP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-video-chat-psychotherapy-vcp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-monetary-and-alternative-incentive-lmai-video-chat-psychotherapy-vcp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low-calorie MIND-HK diet for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/low-calorie-mind-hk-diet--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-calorie-mind-hk-diet--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low-dose experimental vaccine for herpes zoster</title>
    <id>https://staging.whatcameofit.com/low-dose-experimental-vaccine--herpes-zoster#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/low-dose-experimental-vaccine--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Low-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/low-dose-lc-z300-01-twice-daily-in-blinding--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-dose-lc-z300-01-twice-daily-in-blinding--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low-Dose Radiation Therapy (LDRT) for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/low-dose-radiation-therapy-ldrt--neoplasm-residual#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-dose-radiation-therapy-ldrt--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low-dose Radiotherapy + SINTILIMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/low-dose-radiotherapy-sintilimab--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/low-dose-radiotherapy-sintilimab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/low-intensity-focused-ultrasound-low-intensity-focused-ultrasound-sham--anxiety-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/low-intensity-focused-ultrasound-low-intensity-focused-ultrasound-sham--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/low-intensity-focused-ultrasound-low-intensity-focused-ultrasound-sham--opioid-related-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/low-intensity-focused-ultrasound-low-intensity-focused-ultrasound-sham--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Low-intensity focused ultrasound for cocaine-related disorders</title>
    <id>https://staging.whatcameofit.com/low-intensity-focused-ultrasound--cocaine-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-intensity-focused-ultrasound--cocaine-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Low-intensity focused ultrasound for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/low-intensity-focused-ultrasound--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/low-intensity-focused-ultrasound--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LP-005 Injection for periodontitis</title>
    <id>https://staging.whatcameofit.com/lp-005-injection--periodontitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lp-005-injection--periodontitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lurasidone for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/lurasidone--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lurasidone--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Lurbinectedin for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/lurbinectedin--leiomyosarcoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/lurbinectedin--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lurbinectedin for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/lurbinectedin--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lurbinectedin--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Luspatercept for anemia</title>
    <id>https://staging.whatcameofit.com/luspatercept--anemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/luspatercept--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Luspatercept for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/luspatercept--myelodysplastic-syndromes#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/luspatercept--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Luspatercept for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/luspatercept--primary-myelofibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/luspatercept--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lusutrombopag combined with recombinant human thrombopoietin for thrombocytopenia</title>
    <id>https://staging.whatcameofit.com/lusutrombopag-combined-with-recombinant-human-thrombopoietin--thrombocytopenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lusutrombopag-combined-with-recombinant-human-thrombopoietin--thrombocytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN + GALLIUM GA-68 GOZETOTIDE for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan-gallium-ga-68-gozetotide--renal-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan-gallium-ga-68-gozetotide--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/lutetium-oxodotreotide-lu-177--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lutetium-oxodotreotide-lu-177--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LuxValve PLlus for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/luxvalve-pllus--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/luxvalve-pllus--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LY-2599666 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ly-2599666--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ly-2599666--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LY-2599666 for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/ly-2599666--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ly-2599666--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>LY3002813 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ly3002813--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ly3002813--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LY3002813-IV for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ly3002813-iv--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ly3002813-iv--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LY3002813-SC for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/ly3002813-sc--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ly3002813-sc--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>LY3537021 for neoplasms</title>
    <id>https://staging.whatcameofit.com/ly3537021--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ly3537021--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LY3884961 + Sirolimus + Methylprednisolone for parkinson disease</title>
    <id>https://staging.whatcameofit.com/ly3884961-sirolimus-methylprednisolone--parkinson-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ly3884961-sirolimus-methylprednisolone--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Lysergide d-tartrate for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/lysergide-d-tartrate--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/lysergide-d-tartrate--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M032 + PEMBROLIZUMAB for glioblastoma</title>
    <id>https://staging.whatcameofit.com/m032-pembrolizumab--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/m032-pembrolizumab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>M032 + PEMBROLIZUMAB for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/m032-pembrolizumab--gliosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/m032-pembrolizumab--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>M5717 200 mg + PYRONARIDINE for asymptomatic infections</title>
    <id>https://staging.whatcameofit.com/m5717-200-mg-pyronaridine--asymptomatic-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-200-mg-pyronaridine--asymptomatic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 200 mg + PYRONARIDINE for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/m5717-200-mg-pyronaridine--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-200-mg-pyronaridine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 330 mg + PYRONARIDINE for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/m5717-330-mg-pyronaridine--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-330-mg-pyronaridine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 500 mg + M5717 660 mg + PYRONARIDINE for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/m5717-500-mg-m5717-660-mg-pyronaridine--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-500-mg-m5717-660-mg-pyronaridine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 60 mg + PYRONARIDINE for asymptomatic infections</title>
    <id>https://staging.whatcameofit.com/m5717-60-mg-pyronaridine--asymptomatic-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-60-mg-pyronaridine--asymptomatic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 60 mg + PYRONARIDINE for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/m5717-60-mg-pyronaridine--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-60-mg-pyronaridine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 660mg + PYRONARIDINE for asymptomatic infections</title>
    <id>https://staging.whatcameofit.com/m5717-660mg-pyronaridine--asymptomatic-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-660mg-pyronaridine--asymptomatic-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M5717 660mg + PYRONARIDINE for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/m5717-660mg-pyronaridine--malaria-falciparum#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/m5717-660mg-pyronaridine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine for tuberculosis</title>
    <id>https://staging.whatcameofit.com/m72-as01e-4-mycobacterium-tuberculosis-investigational-vaccine--tuberculosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/m72-as01e-4-mycobacterium-tuberculosis-investigational-vaccine--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Macupatide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/macupatide--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/macupatide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Macupatide for obesity</title>
    <id>https://staging.whatcameofit.com/macupatide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/macupatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mad for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/mad--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mad--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Magnesium for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/magnesium--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/magnesium--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-mri-with-or-without-gadolinium-contrast-agents-neuronavigation-guided-single-element-focused-ultrasound-transducer-positron-emission-tomography-pet-florbetapir-f-18-perflutren--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-mri-with-or-without-gadolinium-contrast-agents-neuronavigation-guided-single-element-focused-ultrasound-transducer-positron-emission-tomography-pet-florbetapir-f-18-perflutren--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Hypofractionated Radiation Therapy + Positron Emission Tomography + Survey Administration for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-antiandrogen-therapy-biospecimen-collection-hypofractionated-radiation-therapy-positron-emission-tomography-survey-administration--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-antiandrogen-therapy-biospecimen-collection-hypofractionated-radiation-therapy-positron-emission-tomography-survey-administration--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Antiandrogen Therapy + Biospecimen Collection + Positron Emission Tomography + Stereotactic Body Radiation Therapy + Survey Administration for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-antiandrogen-therapy-biospecimen-collection-positron-emission-tomography-stereotactic-body-radiation-therapy-survey-administration--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-antiandrogen-therapy-biospecimen-collection-positron-emission-tomography-stereotactic-body-radiation-therapy-survey-administration--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-afatinib-afatinib-dimaleate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-sunitinib-malate--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-echocardiography-test-laboratory-biomarker-analysis-radionuclide-imaging-vismodegib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-erdafitinib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-cytology-specimen-collection-procedure-laboratory-biomarker-analysis-larotrectinib-larotrectinib-sulfate--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Bone Marrow Aspiration + Bone Marrow Biopsy + Clinical Observation + Computed Tomography + Ultrasound + ETOPOSIDE + Doxorubicin hydrochloride + Cyclophosphamide + Carboplatin for ganglioneuroblastoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-bone-marrow-aspiration-bone-marrow-biopsy-clinical-observation-computed-tomography-ultrasound-etoposide-doxorubicin-hydrochloride-cyclophosphamide-carboplatin--ganglioneuroblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-bone-marrow-aspiration-bone-marrow-biopsy-clinical-observation-computed-tomography-ultrasound-etoposide-doxorubicin-hydrochloride-cyclophosphamide-carboplatin--ganglioneuroblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biopsy-procedure-computed-tomography-cytology-specimen-collection-procedure-copanlisib-hydrochloride-copanlisib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolar</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--adenocarcinoma-bronchiolo-alveolar#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--adenocarcinoma-bronchiolo-alveolar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-acinar-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-acinar-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-adenoid-cystic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-giant-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-giant-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinosarcoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--carcinosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for chordoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--chordoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--chordoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinous</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cystadenocarcinoma-mucinous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cystadenocarcinoma-mucinous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serous</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cystadenocarcinoma-serous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--cystadenocarcinoma-serous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for desmoid tumors</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--desmoid-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--desmoid-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--hemangiosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammary</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--paget-disease-extramammary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--paget-disease-extramammary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for perivascular epithelioid cell neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--perivascular-epithelioid-cell-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--perivascular-epithelioid-cell-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--pheochromocytoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--pheochromocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritonei</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--pseudomyxoma-peritonei#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--pseudomyxoma-peritonei"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for seminoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--seminoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--seminoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for vulvar neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--vulvar-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab-ipilimumab--vulvar-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolar</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--adenocarcinoma-bronchiolo-alveolar#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--adenocarcinoma-bronchiolo-alveolar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-acinar-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-acinar-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-adenoid-cystic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-giant-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-giant-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinosarcoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--carcinosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for chordoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--chordoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--chordoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinous</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cystadenocarcinoma-mucinous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cystadenocarcinoma-mucinous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serous</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cystadenocarcinoma-serous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--cystadenocarcinoma-serous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for desmoid tumors</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--desmoid-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--desmoid-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--hemangiosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammary</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--paget-disease-extramammary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--paget-disease-extramammary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for perivascular epithelioid cell neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--perivascular-epithelioid-cell-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--perivascular-epithelioid-cell-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--pheochromocytoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--pheochromocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritonei</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--pseudomyxoma-peritonei#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--pseudomyxoma-peritonei"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for seminoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--seminoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--seminoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for vulvar neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--vulvar-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-echocardiography-test-nivolumab--vulvar-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-positron-emission-tomography-psma-pet-scan-pemetrexed-disodium-pembrolizumab--carcinoma-adenoid-cystic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-positron-emission-tomography-psma-pet-scan-pemetrexed-disodium-pembrolizumab--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine + Carboplatin for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-pumvc3-higfbp-2-multi-epitope-plasmid-dna-vaccine-carboplatin--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-computed-tomography-pumvc3-higfbp-2-multi-epitope-plasmid-dna-vaccine-carboplatin--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-lumbar-puncture-radiation-therapy-dabrafenib-mesylate-trametinib-dimethyl-sulfoxide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-biospecimen-collection-lumbar-puncture-radiation-therapy-dabrafenib-mesylate-trametinib-dimethyl-sulfoxide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Clinical Observation + Computed Tomography + Ultrasound for ganglioneuroblastoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-clinical-observation-computed-tomography-ultrasound--ganglioneuroblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-clinical-observation-computed-tomography-ultrasound--ganglioneuroblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-laboratory-biomarker-analysis-radiation-therapy-vincristine-lomustine-cyclophosphamide-cisplatin-vincristine-sulfate--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-laboratory-biomarker-analysis-radiation-therapy-vincristine-lomustine-cyclophosphamide-cisplatin-vincristine-sulfate--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Magnetic Resonance Imaging + Multiparametric Magnetic Resonance Imaging + Positron Emission Tomography + Transrectal Ultrasonography Guided Biopsy + Flotufolastat F-18 Gallium for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/magnetic-resonance-imaging-multiparametric-magnetic-resonance-imaging-positron-emission-tomography-transrectal-ultrasonography-guided-biopsy-flotufolastat-f-18-gallium--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/magnetic-resonance-imaging-multiparametric-magnetic-resonance-imaging-positron-emission-tomography-transrectal-ultrasonography-guided-biopsy-flotufolastat-f-18-gallium--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) for lethargy</title>
    <id>https://staging.whatcameofit.com/magventure-magpro-transcranial-magnetic-stimulation-tms-system-active--lethargy#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/magventure-magpro-transcranial-magnetic-stimulation-tms-system-active--lethargy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Malaria Vaccine 257049 + Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria</title>
    <id>https://staging.whatcameofit.com/malaria-vaccine-257049-polio-sabin-oral-polio-vaccine-gsk-tritanrixhepb-hib--malaria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/malaria-vaccine-257049-polio-sabin-oral-polio-vaccine-gsk-tritanrixhepb-hib--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Malaria Vaccine 257049 for malaria</title>
    <id>https://staging.whatcameofit.com/malaria-vaccine-257049--malaria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/malaria-vaccine-257049--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mandibular advancement Device for essential hypertension</title>
    <id>https://staging.whatcameofit.com/mandibular-advancement-device--essential-hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mandibular-advancement-device--essential-hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mandibular advancement Device for gastroesophageal reflux</title>
    <id>https://staging.whatcameofit.com/mandibular-advancement-device--gastroesophageal-reflux#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mandibular-advancement-device--gastroesophageal-reflux"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mandibular advancement Device for heart failure</title>
    <id>https://staging.whatcameofit.com/mandibular-advancement-device--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mandibular-advancement-device--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mandibular advancement Device for hypertension</title>
    <id>https://staging.whatcameofit.com/mandibular-advancement-device--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mandibular-advancement-device--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Manualized therapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/manualized-therapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/manualized-therapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Manualized therapy + Midomafetamine HCl for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/manualized-therapy-midomafetamine-hcl--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/manualized-therapy-midomafetamine-hcl--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MAR001 for hypertriglyceridemia</title>
    <id>https://staging.whatcameofit.com/mar001--hypertriglyceridemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mar001--hypertriglyceridemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Maridebart Cafraglutide for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/maridebart-cafraglutide--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/maridebart-cafraglutide--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Maridebart Cafraglutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/maridebart-cafraglutide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/maridebart-cafraglutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Maridebart Cafraglutide for obesity</title>
    <id>https://staging.whatcameofit.com/maridebart-cafraglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/maridebart-cafraglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Maridebart Cafraglutide for overweight</title>
    <id>https://staging.whatcameofit.com/maridebart-cafraglutide--overweight#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/maridebart-cafraglutide--overweight"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Marstacimab for hemophilia a</title>
    <id>https://staging.whatcameofit.com/marstacimab--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/marstacimab--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Marstacimab for hemophilia b</title>
    <id>https://staging.whatcameofit.com/marstacimab--hemophilia-b#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/marstacimab--hemophilia-b"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Matched Placebo (oral gummy) + Δ9-Tetrahydrocannabivarin (oral gummy) for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/matched-placebo-oral-gummy-δ9-tetrahydrocannabivarin-oral-gummy--tobacco-use-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/matched-placebo-oral-gummy-δ9-tetrahydrocannabivarin-oral-gummy--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Matching Intramuscular Placebo + IBOGAINE HYDROCHLORIDE for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/matching-intramuscular-placebo-ibogaine-hydrochloride--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/matching-intramuscular-placebo-ibogaine-hydrochloride--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Matching Placebo (E2814) + LECANEMAB for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/matching-placebo-e2814-lecanemab--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-e2814-lecanemab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Matching placebo to K-757 and matching placebo to K-833 for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-to-k-757-and-matching-placebo-to-k-833--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-to-k-757-and-matching-placebo-to-k-833--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-garetosmab-matching-placebo-trevogrumab-semaglutide-trevogrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-garetosmab-matching-placebo-trevogrumab-semaglutide-trevogrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-garetosmab-matching-placebo-trevogrumab-semaglutide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-garetosmab-matching-placebo-trevogrumab-semaglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Garetosmab + Semaglutide + TREVOGRUMAB for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-garetosmab-semaglutide-trevogrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-garetosmab-semaglutide-trevogrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide-trevogrumab-garetosmab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide-trevogrumab-garetosmab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide-trevogrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide-trevogrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matching Placebo-Trevogrumab + Semaglutide for obesity</title>
    <id>https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/matching-placebo-trevogrumab-semaglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/matrix-m-with-rh5-2-vlp-and-or-r21--malaria-falciparum#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/matrix-m-with-rh5-2-vlp-and-or-r21--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastoma</title>
    <id>https://staging.whatcameofit.com/maximal-surgical-resection-radical-radiotherapy-stupp-regimen-oral-temozolomide-thiotepa--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/maximal-surgical-resection-radical-radiotherapy-stupp-regimen-oral-temozolomide-thiotepa--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mazdutide for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/mazdutide--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mazdutide--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mazdutide for obesity</title>
    <id>https://staging.whatcameofit.com/mazdutide--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mazdutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MBK-01 for clostridium infections</title>
    <id>https://staging.whatcameofit.com/mbk-01--clostridium-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mbk-01--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>MDCF-2 shelf-stable foil pouch prototype with green banana powder for malnutrition</title>
    <id>https://staging.whatcameofit.com/mdcf-2-shelf-stable-foil-pouch-prototype-with-green-banana-powder--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mdcf-2-shelf-stable-foil-pouch-prototype-with-green-banana-powder--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MDCF-2 shelf-stable foil pouch prototype with sweet potato for malnutrition</title>
    <id>https://staging.whatcameofit.com/mdcf-2-shelf-stable-foil-pouch-prototype-with-sweet-potato--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mdcf-2-shelf-stable-foil-pouch-prototype-with-sweet-potato--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MDMA Assisted Therapy for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/mdma-assisted-therapy--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mdma-assisted-therapy--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MDMA Assisted Therapy for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/mdma-assisted-therapy--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mdma-assisted-therapy--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/mdma-assisted-cognitive-processing-therapy-mdma-acpt-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mdma-assisted-cognitive-processing-therapy-mdma-acpt-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mdma-at for combat disorders</title>
    <id>https://staging.whatcameofit.com/mdma-at--combat-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mdma-at--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mdma-at for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/mdma-at--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mdma-at--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Meal Replacement Therapy for obesity</title>
    <id>https://staging.whatcameofit.com/meal-replacement-therapy--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/meal-replacement-therapy--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mechanical ventilation with the automated BVM compressor for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/mechanical-ventilation-with-the-automated-bvm-compressor--respiratory-insufficiency#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/mechanical-ventilation-with-the-automated-bvm-compressor--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/medical-or-interventional-therapy-for-rhythm-control-in-atrial-fibrillation-antiarrhythmic-drugs-ablation-electric-cardio-version--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/medical-or-interventional-therapy-for-rhythm-control-in-atrial-fibrillation-antiarrhythmic-drugs-ablation-electric-cardio-version--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/medium-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/medium-dose-dcsz11-standard-treatment--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Medtronic Activa PC+S System for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/medtronic-activa-pc-s-system--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-activa-pc-s-system--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic Activa SC DBS, Lead Model 3387 for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/medtronic-activa-sc-dbs-lead-model-3387--depressive-disorder-treatment-resistant#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/medtronic-activa-sc-dbs-lead-model-3387--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/medtronic-intrepid-transcatheter-tricuspid-valve-replacement-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-intrepid-transcatheter-tricuspid-valve-replacement-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic Percept PC DBS system for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/medtronic-percept-pc-dbs-system--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-percept-pc-dbs-system--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic Percept PC DBS system for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/medtronic-percept-pc-dbs-system--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-percept-pc-dbs-system--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic SenSight Directional DBS lead for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/medtronic-sensight-directional-dbs-lead--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-sensight-directional-dbs-lead--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic Summit RC+S DBS system for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/medtronic-summit-rc-s-dbs-system--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-summit-rc-s-dbs-system--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Medtronic Summit RC+S DBS system for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/medtronic-summit-rc-s-dbs-system--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/medtronic-summit-rc-s-dbs-system--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mefloquine + azithromycin + / - tocilizumab for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/mefloquine-azithromycin-tocilizumab--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mefloquine-azithromycin-tocilizumab--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mefloquine for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/mefloquine--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mefloquine--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Megestrol acetate/Medroxyprogesterone acetate + TAMOXIFEN + Letrozole for neoplasms</title>
    <id>https://staging.whatcameofit.com/megestrol-acetate-medroxyprogesterone-acetate-tamoxifen-letrozole--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/megestrol-acetate-medroxyprogesterone-acetate-tamoxifen-letrozole--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Meglumine sodium succinate for diabetic ketoacidosis</title>
    <id>https://staging.whatcameofit.com/meglumine-sodium-succinate--diabetic-ketoacidosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/meglumine-sodium-succinate--diabetic-ketoacidosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Melatonin for ureteral calculi</title>
    <id>https://staging.whatcameofit.com/melatonin--ureteral-calculi#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/melatonin--ureteral-calculi"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Memantine for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/memantine--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/memantine--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Meningococcal Group B Vaccine for gonorrhea</title>
    <id>https://staging.whatcameofit.com/meningococcal-group-b-vaccine--gonorrhea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/meningococcal-group-b-vaccine--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>MEOPA (Nitrous Oxide/Oxygen Premix) for combat disorders</title>
    <id>https://staging.whatcameofit.com/meopa-nitrous-oxide-oxygen-premix--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/meopa-nitrous-oxide-oxygen-premix--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>mesenchymal stem cell-derived exosomes for stomatitis</title>
    <id>https://staging.whatcameofit.com/mesenchymal-stem-cell-derived-exosomes--stomatitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mesenchymal-stem-cell-derived-exosomes--stomatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mesenchymal Stem Cells for alopecia</title>
    <id>https://staging.whatcameofit.com/mesenchymal-stem-cells--alopecia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mesenchymal-stem-cells--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Mesna + Paclitaxel + Ifosfamide for neoplasms, germ cell and embryonal</title>
    <id>https://staging.whatcameofit.com/mesna-paclitaxel-ifosfamide--neoplasms-germ-cell-and-embryonal#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mesna-paclitaxel-ifosfamide--neoplasms-germ-cell-and-embryonal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-mbp-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-mbp-message-based-psychotherapy-with-monthly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-mbp-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-mbp-message-based-psychotherapy-with-weekly-video-chat-psychotherapy--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-based psychotherapy (MBP) for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-mbp--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-mbp--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-based psychotherapy (MBP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-mbp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-mbp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-with-monthly-video-chat-psychotherapy-video-chat-psychotherapy-vcp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-with-monthly-video-chat-psychotherapy-video-chat-psychotherapy-vcp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/message-based-psychotherapy-with-weekly-video-chat-psychotherapy-video-chat-psychotherapy-vcp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/message-based-psychotherapy-with-weekly-video-chat-psychotherapy-video-chat-psychotherapy-vcp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MET097 for obesity</title>
    <id>https://staging.whatcameofit.com/met097--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/met097--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/metarem-is-a-master-protocol-that-encompasses-multiple-therapeutic-sub-protocols-each-involving-distinct-interventions-accordingly-the-description-of-the-intervention-will-be-specified-within-each--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/metarem-is-a-master-protocol-that-encompasses-multiple-therapeutic-sub-protocols-each-involving-distinct-interventions-accordingly-the-description-of-the-intervention-will-be-specified-within-each--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Metformin ER for intermittent claudication</title>
    <id>https://staging.whatcameofit.com/metformin-er--intermittent-claudication#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-er--intermittent-claudication"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/metformin--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/metformin--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Metformin for melanosis</title>
    <id>https://staging.whatcameofit.com/metformin--melanosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/metformin--melanosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Metformin for parkinson disease</title>
    <id>https://staging.whatcameofit.com/metformin--parkinson-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin for tuberculosis</title>
    <id>https://staging.whatcameofit.com/metformin--tuberculosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/metformin--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--cognitive-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for heart failure</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for hellp syndrome</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--hellp-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--hellp-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--medulloblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for pre-eclampsia</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--pre-eclampsia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--pre-eclampsia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Metformin hydrochloride for premature birth</title>
    <id>https://staging.whatcameofit.com/metformin-hydrochloride--premature-birth#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/metformin-hydrochloride--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Methadone for leiomyoma</title>
    <id>https://staging.whatcameofit.com/methadone--leiomyoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/methadone--leiomyoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Methylcobalamin for peripheral nervous system diseases</title>
    <id>https://staging.whatcameofit.com/methylcobalamin--peripheral-nervous-system-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/methylcobalamin--peripheral-nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Methylenblue for malaria</title>
    <id>https://staging.whatcameofit.com/methylenblue--malaria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/methylenblue--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Methylphenidate hydrochloride for combat disorders</title>
    <id>https://staging.whatcameofit.com/methylphenidate-hydrochloride--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/methylphenidate-hydrochloride--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Methylphenidate hydrochloride for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/methylphenidate-hydrochloride--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/methylphenidate-hydrochloride--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Metreleptin for insulin resistance</title>
    <id>https://staging.whatcameofit.com/metreleptin--insulin-resistance#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/metreleptin--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>METRONIDAZOLE + Vancomycin + Loperamide + FECAL MICROBIOTA for clostridium infections</title>
    <id>https://staging.whatcameofit.com/metronidazole-vancomycin-loperamide-fecal-microbiota--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/metronidazole-vancomycin-loperamide-fecal-microbiota--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MF-300 for sarcopenia</title>
    <id>https://staging.whatcameofit.com/mf-300--sarcopenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mf-300--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>mFOLFOXIRI for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/mfolfoxiri--neoplasm-residual#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mfolfoxiri--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritis</title>
    <id>https://staging.whatcameofit.com/mid-dose-recombinant-trivalent-subunit-rotavirus-vaccine--gastroenteritis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mid-dose-recombinant-trivalent-subunit-rotavirus-vaccine--gastroenteritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections</title>
    <id>https://staging.whatcameofit.com/mid-dose-recombinant-trivalent-subunit-rotavirus-vaccine--rotavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mid-dose-recombinant-trivalent-subunit-rotavirus-vaccine--rotavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midazolam Placebo Solution + Esketamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/midazolam-placebo-solution-esketamine--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midazolam-placebo-solution-esketamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midodrine for hypotension</title>
    <id>https://staging.whatcameofit.com/midodrine--hypotension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midodrine--hypotension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midodrine for sepsis</title>
    <id>https://staging.whatcameofit.com/midodrine--sepsis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midodrine--sepsis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine for adjustment disorders</title>
    <id>https://staging.whatcameofit.com/midomafetamine--adjustment-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/midomafetamine--adjustment-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Midomafetamine for alcoholism</title>
    <id>https://staging.whatcameofit.com/midomafetamine--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midomafetamine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine for combat disorders</title>
    <id>https://staging.whatcameofit.com/midomafetamine--combat-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midomafetamine--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/midomafetamine--substance-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midomafetamine--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine HCl for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/midomafetamine-hcl--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/midomafetamine-hcl--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Midomafetamine Hydrochloride for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/midomafetamine-hydrochloride--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/midomafetamine-hydrochloride--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Migoprotafib + Divarasib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/migoprotafib-divarasib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/migoprotafib-divarasib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Mindfulness-Based Stress Reduction for agoraphobia</title>
    <id>https://staging.whatcameofit.com/mindfulness-based-stress-reduction--agoraphobia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mindfulness-based-stress-reduction--agoraphobia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mindfulness-Based Stress Reduction for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/mindfulness-based-stress-reduction--generalized-anxiety-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mindfulness-based-stress-reduction--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mindfulness-Based Stress Reduction for panic disorder</title>
    <id>https://staging.whatcameofit.com/mindfulness-based-stress-reduction--panic-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mindfulness-based-stress-reduction--panic-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mindfulness-Based Stress Reduction for phobia, social</title>
    <id>https://staging.whatcameofit.com/mindfulness-based-stress-reduction--phobia-social#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mindfulness-based-stress-reduction--phobia-social"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mindfulness-centered psilocybin-assisted therapy + Music-centered psilocybin-assisted therapy + Psilocybin for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/mindfulness-centered-psilocybin-assisted-therapy-music-centered-psilocybin-assisted-therapy-psilocybin--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mindfulness-centered-psilocybin-assisted-therapy-music-centered-psilocybin-assisted-therapy-psilocybin--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mindset for alcohol-related disorders</title>
    <id>https://staging.whatcameofit.com/mindset--alcohol-related-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mindset--alcohol-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Minimally invasive fetoscopic repair of MMC for meningomyelocele</title>
    <id>https://staging.whatcameofit.com/minimally-invasive-fetoscopic-repair-of-mmc--meningomyelocele#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/minimally-invasive-fetoscopic-repair-of-mmc--meningomyelocele"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Minimally invasive fetoscopic repair of MMC for spinal dysraphism</title>
    <id>https://staging.whatcameofit.com/minimally-invasive-fetoscopic-repair-of-mmc--spinal-dysraphism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/minimally-invasive-fetoscopic-repair-of-mmc--spinal-dysraphism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MiniMed 670G system for hypoglycemia</title>
    <id>https://staging.whatcameofit.com/minimed-670g-system--hypoglycemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/minimed-670g-system--hypoglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Minoxidil for alopecia</title>
    <id>https://staging.whatcameofit.com/minoxidil--alopecia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/minoxidil--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>MiraBurst for dysgeusia</title>
    <id>https://staging.whatcameofit.com/miraburst--dysgeusia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/miraburst--dysgeusia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mirikizumab for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/mirikizumab--colitis-ulcerative#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mirikizumab--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>miRNA Biomarker-Guided Immunosuppression Minimization for liver diseases</title>
    <id>https://staging.whatcameofit.com/mirna-biomarker-guided-immunosuppression-minimization--liver-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mirna-biomarker-guided-immunosuppression-minimization--liver-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mirvetuximab Soravtansine for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/mirvetuximab-soravtansine--fallopian-tube-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mirvetuximab-soravtansine--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mirvetuximab Soravtansine for neoplasms</title>
    <id>https://staging.whatcameofit.com/mirvetuximab-soravtansine--neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mirvetuximab-soravtansine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Misoprostol for postpartum hemorrhage</title>
    <id>https://staging.whatcameofit.com/misoprostol--postpartum-hemorrhage#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/misoprostol--postpartum-hemorrhage"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mitapivat for anemia</title>
    <id>https://staging.whatcameofit.com/mitapivat--anemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mitapivat--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Mitomycin for pseudomyxoma peritonei</title>
    <id>https://staging.whatcameofit.com/mitomycin--pseudomyxoma-peritonei#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mitomycin--pseudomyxoma-peritonei"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MitraClip System for heart failure</title>
    <id>https://staging.whatcameofit.com/mitraclip-system--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mitraclip-system--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MitraClip System for mitral valve insufficiency</title>
    <id>https://staging.whatcameofit.com/mitraclip-system--mitral-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mitraclip-system--mitral-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MK-1167 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/mk-1167--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mk-1167--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>MK-3120 for neoplasms</title>
    <id>https://staging.whatcameofit.com/mk-3120--neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mk-3120--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>MKP10241 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/mkp10241--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mkp10241--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MKP10241 for obesity</title>
    <id>https://staging.whatcameofit.com/mkp10241--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mkp10241--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ML-007C-MA for brain diseases</title>
    <id>https://staging.whatcameofit.com/ml-007c-ma--brain-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ml-007c-ma--brain-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ML-007C-MA for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/ml-007c-ma--psychotic-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ml-007c-ma--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ML-007C-MA for schizophrenia</title>
    <id>https://staging.whatcameofit.com/ml-007c-ma--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ml-007c-ma--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ML-016 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/ml-016--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ml-016--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/mobilized-cd34-selected-peripheral-blood-stem-cell-graft--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mobilized-cd34-selected-peripheral-blood-stem-cell-graft--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mobinitinib for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/mobinitinib--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mobinitinib--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Moderate doses of Thiamine y Biotin for huntington disease</title>
    <id>https://staging.whatcameofit.com/moderate-doses-of-thiamine-y-biotin--huntington-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/moderate-doses-of-thiamine-y-biotin--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/modified-deep-cervical-lymphatic-venous-anastomosis--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/modified-deep-cervical-lymphatic-venous-anastomosis--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Modified deep cervical Lymphatic-Venous Anastomosis for parkinson disease</title>
    <id>https://staging.whatcameofit.com/modified-deep-cervical-lymphatic-venous-anastomosis--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/modified-deep-cervical-lymphatic-venous-anastomosis--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Modified delineation for radiation injuries</title>
    <id>https://staging.whatcameofit.com/modified-delineation--radiation-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/modified-delineation--radiation-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Modified delineation for thyroid diseases</title>
    <id>https://staging.whatcameofit.com/modified-delineation--thyroid-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/modified-delineation--thyroid-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Molecularly matched therapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/molecularly-matched-therapy--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/molecularly-matched-therapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Momelotinib for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/momelotinib--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/momelotinib--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Monobloc for bruxism</title>
    <id>https://staging.whatcameofit.com/monobloc--bruxism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/monobloc--bruxism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Monoclonal Antibody (Humanized Anti-CD52) + Penile Allotransplantation + Tacrolimus for amputation, traumatic</title>
    <id>https://staging.whatcameofit.com/monoclonal-antibody-humanized-anti-cd52-penile-allotransplantation-tacrolimus--amputation-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/monoclonal-antibody-humanized-anti-cd52-penile-allotransplantation-tacrolimus--amputation-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Monotherapy, Dose-reduced (75%) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/monotherapy-dose-reduced-75--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/monotherapy-dose-reduced-75--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Moringa Oleifera for dental plaque</title>
    <id>https://staging.whatcameofit.com/moringa-oleifera--dental-plaque#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/moringa-oleifera--dental-plaque"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Mosquirixs for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/mosquirixs--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mosquirixs--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Moxifloxacin + rifapentine for tuberculosis, lymph node</title>
    <id>https://staging.whatcameofit.com/moxifloxacin-rifapentine--tuberculosis-lymph-node#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/moxifloxacin-rifapentine--tuberculosis-lymph-node"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>MR guided low intensity focused ultrasound for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/mr-guided-low-intensity-focused-ultrasound--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mr-guided-low-intensity-focused-ultrasound--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MR-Guided Transurethral US Ablation of Prostate Tissue for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/mr-guided-transurethral-us-ablation-of-prostate-tissue--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mr-guided-transurethral-us-ablation-of-prostate-tissue--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MRI + Psilocybin + Risperidone for anhedonia</title>
    <id>https://staging.whatcameofit.com/mri-psilocybin-risperidone--anhedonia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mri-psilocybin-risperidone--anhedonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/mri-guided-intensity-modulated-radiotherapy-imrt-planning--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mri-guided-intensity-modulated-radiotherapy-imrt-planning--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MRI-Guided Transurethral Ultrasound Ablation for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/mri-guided-transurethral-ultrasound-ablation--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mri-guided-transurethral-ultrasound-ablation--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>mRNA-1018-H5 for influenza in birds</title>
    <id>https://staging.whatcameofit.com/mrna-1018-h5--influenza-in-birds#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mrna-1018-h5--influenza-in-birds"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>mRNA-3927 for acidosis</title>
    <id>https://staging.whatcameofit.com/mrna-3927--acidosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mrna-3927--acidosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>mRNA-3927 for propionic acidemia</title>
    <id>https://staging.whatcameofit.com/mrna-3927--propionic-acidemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/mrna-3927--propionic-acidemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>MSCs for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/mscs--renal-insufficiency-chronic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mscs--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>MT1013 for hyperparathyroidism, secondary</title>
    <id>https://staging.whatcameofit.com/mt1013--hyperparathyroidism-secondary#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mt1013--hyperparathyroidism-secondary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>MT1013 for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/mt1013--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/mt1013--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mtbvac for tuberculosis</title>
    <id>https://staging.whatcameofit.com/mtbvac--tuberculosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mtbvac--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>MTX-474 for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/mtx-474--scleroderma-diffuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/mtx-474--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/multi-allergen-oral-immunotherapy-omalizumab--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/multi-allergen-oral-immunotherapy-omalizumab--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Multiprofen-CC™ plus standard treatment for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/multiprofen-cc-plus-standard-treatment--osteoarthritis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/multiprofen-cc-plus-standard-treatment--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mupirocin Ointment [Treatment] for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/mupirocin-ointment-treatment--head-and-neck-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mupirocin-ointment-treatment--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Music &amp; Auditory Beat Stimulation for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/music-auditory-beat-stimulation--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/music-auditory-beat-stimulation--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Music and Theta Auditory Beat Stimulation for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/music-and-theta-auditory-beat-stimulation--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/music-and-theta-auditory-beat-stimulation--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Music Therapy for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/music-therapy--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/music-therapy--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Music Therapy for psoriasis</title>
    <id>https://staging.whatcameofit.com/music-therapy--psoriasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/music-therapy--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Muvalaplin for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/muvalaplin--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/muvalaplin--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>myTAP oral appliance plus mouth shield for mouth breathing</title>
    <id>https://staging.whatcameofit.com/mytap-oral-appliance-plus-mouth-shield--mouth-breathing#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/mytap-oral-appliance-plus-mouth-shield--mouth-breathing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>N-Acetylcysteine (NAC) Treatment for tuberculosis</title>
    <id>https://staging.whatcameofit.com/n-acetylcysteine-nac-treatment--tuberculosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/n-acetylcysteine-nac-treatment--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/n-dodecyl-b-d-maltoside-cretostimogene-grenadenorepvec--carcinoma-transitional-cell#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/n-dodecyl-b-d-maltoside-cretostimogene-grenadenorepvec--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>N1 Implant + R1 Robot for dysarthria</title>
    <id>https://staging.whatcameofit.com/n1-implant-r1-robot--dysarthria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/n1-implant-r1-robot--dysarthria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>N1 Implant + R1 Robot for quadriplegia</title>
    <id>https://staging.whatcameofit.com/n1-implant-r1-robot--quadriplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/n1-implant-r1-robot--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>N17350 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/n17350--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/n17350--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>N17350 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/n17350--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/n17350--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nab-paclitaxel + Gemcitabine + VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/nab-paclitaxel-gemcitabine-vcn-01-oncolytic-adenovirus-zabilugene-almadenorepvec--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nab-paclitaxel-gemcitabine-vcn-01-oncolytic-adenovirus-zabilugene-almadenorepvec--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nab-paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/nab-paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nab-paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nalbuphine for chronic cough</title>
    <id>https://staging.whatcameofit.com/nalbuphine--chronic-cough#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nalbuphine--chronic-cough"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NanoKnife System for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/nanoknife-system--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nanoknife-system--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>NanoLithium® NP03 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/nanolithium-np03--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nanolithium-np03--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Napazimone for mitochondrial diseases</title>
    <id>https://staging.whatcameofit.com/napazimone--mitochondrial-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/napazimone--mitochondrial-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Narrative Intervention for Chronic Illness-Heart Failure for heart failure</title>
    <id>https://staging.whatcameofit.com/narrative-intervention-for-chronic-illness-heart-failure--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/narrative-intervention-for-chronic-illness-heart-failure--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Narsoplimab for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/narsoplimab--respiratory-distress-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/narsoplimab--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Narsoplimab for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/narsoplimab--respiratory-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/narsoplimab--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Navepegritide for achondroplasia</title>
    <id>https://staging.whatcameofit.com/navepegritide--achondroplasia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/navepegritide--achondroplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Navigate for affective disorders, psychotic</title>
    <id>https://staging.whatcameofit.com/navigate--affective-disorders-psychotic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/navigate--affective-disorders-psychotic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Navigate for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/navigate--psychotic-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/navigate--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Navigate for schizophrenia</title>
    <id>https://staging.whatcameofit.com/navigate--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/navigate--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Navigate for schizophrenia, childhood</title>
    <id>https://staging.whatcameofit.com/navigate--schizophrenia-childhood#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/navigate--schizophrenia-childhood"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NAVIO/CORI Surgical System for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/navio-cori-surgical-system--osteoarthritis#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/navio-cori-surgical-system--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Navitoclax for neoplasms</title>
    <id>https://staging.whatcameofit.com/navitoclax--neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/navitoclax--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Navitoclax for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/navitoclax--primary-myelofibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/navitoclax--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Navlimetostat for mesothelioma</title>
    <id>https://staging.whatcameofit.com/navlimetostat--mesothelioma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/navlimetostat--mesothelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Naxitamab for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/naxitamab--sarcoma-ewing#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/naxitamab--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NBI-1117570 for schizophrenia</title>
    <id>https://staging.whatcameofit.com/nbi-1117570--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nbi-1117570--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/near-infrared-fluorescence-imaging-indocyanine-green--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/near-infrared-fluorescence-imaging-indocyanine-green--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Neoadjuvant chemotherapy instead of upfront surgery for neoplastic cells, circulating</title>
    <id>https://staging.whatcameofit.com/neoadjuvant-chemotherapy-instead-of-upfront-surgery--neoplastic-cells-circulating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/neoadjuvant-chemotherapy-instead-of-upfront-surgery--neoplastic-cells-circulating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Neoadjuvant Radiation + Surgery + TALIMOGENE LAHERPAREPVEC for sarcoma</title>
    <id>https://staging.whatcameofit.com/neoadjuvant-radiation-surgery-talimogene-laherparepvec--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/neoadjuvant-radiation-surgery-talimogene-laherparepvec--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Neolizumab for epidermolysis bullosa dystrophica</title>
    <id>https://staging.whatcameofit.com/neolizumab--epidermolysis-bullosa-dystrophica#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/neolizumab--epidermolysis-bullosa-dystrophica"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Neolizumab for pruritus</title>
    <id>https://staging.whatcameofit.com/neolizumab--pruritus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/neolizumab--pruritus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Neovasc Reducer for angina pectoris</title>
    <id>https://staging.whatcameofit.com/neovasc-reducer--angina-pectoris#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/neovasc-reducer--angina-pectoris"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Neovasculgen® for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/neovasculgen--diabetes-mellitus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/neovasculgen--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Neovasculgen® for foot ulcer</title>
    <id>https://staging.whatcameofit.com/neovasculgen--foot-ulcer#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/neovasculgen--foot-ulcer"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Neridronic acid for reflex sympathetic dystrophy</title>
    <id>https://staging.whatcameofit.com/neridronic-acid--reflex-sympathetic-dystrophy#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/neridronic-acid--reflex-sympathetic-dystrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Neural Prosthetic System 2 (NPS2) for quadriplegia</title>
    <id>https://staging.whatcameofit.com/neural-prosthetic-system-2-nps2--quadriplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/neural-prosthetic-system-2-nps2--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NeuroSAFE procedure for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/neurosafe-procedure--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/neurosafe-procedure--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nevibolol for microvascular angina</title>
    <id>https://staging.whatcameofit.com/nevibolol--microvascular-angina#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nevibolol--microvascular-angina"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Next Generation Dome Helmet (NGDH) for substance-related disorders</title>
    <id>https://staging.whatcameofit.com/next-generation-dome-helmet-ngdh--substance-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/next-generation-dome-helmet-ngdh--substance-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NI + No ENDS for obesity</title>
    <id>https://staging.whatcameofit.com/ni-no-ends--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ni-no-ends--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Niacinamide for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/niacinamide--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/niacinamide--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nicotinamide Riboside (NR) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/nicotinamide-riboside-nr--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nicotinamide-riboside-nr--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nicotinamide Riboside (NR) for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/nicotinamide-riboside-nr--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nicotinamide-riboside-nr--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nicotinamide riboside for glaucoma</title>
    <id>https://staging.whatcameofit.com/nicotinamide-riboside--glaucoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nicotinamide-riboside--glaucoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nicotinamide riboside for peripheral nervous system diseases</title>
    <id>https://staging.whatcameofit.com/nicotinamide-riboside--peripheral-nervous-system-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nicotinamide-riboside--peripheral-nervous-system-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nicotine replacement therapy (NRT) for obesity</title>
    <id>https://staging.whatcameofit.com/nicotine-replacement-therapy-nrt--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nicotine-replacement-therapy-nrt--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nicotine-Free Electronic Cigarette and behavioural change support. for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/nicotine-free-electronic-cigarette-and-behavioural-change-support--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nicotine-free-electronic-cigarette-and-behavioural-change-support--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nifurtimox for chagas disease</title>
    <id>https://staging.whatcameofit.com/nifurtimox--chagas-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nifurtimox--chagas-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nightmare Deconstruction and Reprocessing for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/nightmare-deconstruction-and-reprocessing--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nightmare-deconstruction-and-reprocessing--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NightWare for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/nightware--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NightWare for primary dysautonomias</title>
    <id>https://staging.whatcameofit.com/nightware--primary-dysautonomias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware--primary-dysautonomias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NightWare for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/nightware--renal-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NightWare for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/nightware--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nightware--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns. for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/nightware-smartwatch-configured-to-detect-physiological-signs-of-sympathetic-activation-during-sleep-such-as-heart-rate-spikes-and-movement-patterns--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware-smartwatch-configured-to-detect-physiological-signs-of-sympathetic-activation-during-sleep-such-as-heart-rate-spikes-and-movement-patterns--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NightWare Therapeutic System for combat disorders</title>
    <id>https://staging.whatcameofit.com/nightware-therapeutic-system--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware-therapeutic-system--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NightWare Therapeutic System for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/nightware-therapeutic-system--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nightware-therapeutic-system--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nile Tilapia Fish Skin for burns</title>
    <id>https://staging.whatcameofit.com/nile-tilapia-fish-skin--burns#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nile-tilapia-fish-skin--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Nilotinib and Paclitaxel for neoplasms</title>
    <id>https://staging.whatcameofit.com/nilotinib-and-paclitaxel--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nilotinib-and-paclitaxel--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NIMOTUZUMAB + Ivonescimab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/nimotuzumab-ivonescimab--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nimotuzumab-ivonescimab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/nimotuzumab-benmelstobart--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nimotuzumab-benmelstobart--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nintedanib for epistaxis</title>
    <id>https://staging.whatcameofit.com/nintedanib--epistaxis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nintedanib--epistaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nintedanib for telangiectasia, hereditary hemorrhagic</title>
    <id>https://staging.whatcameofit.com/nintedanib--telangiectasia-hereditary-hemorrhagic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nintedanib--telangiectasia-hereditary-hemorrhagic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Niraparib for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/niraparib--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/niraparib--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Niraparib for glioblastoma</title>
    <id>https://staging.whatcameofit.com/niraparib--glioblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/niraparib--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Niraparib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/niraparib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/niraparib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nirsevimab for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/nirsevimab--respiratory-syncytial-virus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nirsevimab--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Nitrous Oxide for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/nitrous-oxide--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nitrous-oxide--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Nitrous Oxide for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/nitrous-oxide--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nitrous-oxide--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Nivegacetor for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/nivegacetor--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivegacetor--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab &amp; Ipilimumab + Zirdafulven for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/nivolumab-ipilimumab-zirdafulven--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nivolumab-ipilimumab-zirdafulven--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>NIVOLUMAB + Catequentinib for sarcoma</title>
    <id>https://staging.whatcameofit.com/nivolumab-catequentinib--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nivolumab-catequentinib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + daratumumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-daratumumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-daratumumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + ipilimumab + trabectedin for sarcoma</title>
    <id>https://staging.whatcameofit.com/nivolumab-ipilimumab-trabectedin--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nivolumab-ipilimumab-trabectedin--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + ipilimumab for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-ipilimumab--head-and-neck-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nivolumab-ipilimumab--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + ipilimumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-ipilimumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-ipilimumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + ipilimumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/nivolumab-ipilimumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-ipilimumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + Relatlimab + CAPECITABINE for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-relatlimab-capecitabine--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-relatlimab-capecitabine--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + relatlimab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/nivolumab-relatlimab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-relatlimab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab + rucaparib for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-rucaparib--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-rucaparib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NIVOLUMAB + Temozolomide for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-temozolomide--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-temozolomide--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NIVOLUMAB + Trametinib + IPILIMUMAB for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab-trametinib-ipilimumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-trametinib-ipilimumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab and Ipilimumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/nivolumab-and-ipilimumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab-and-ipilimumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/nivolumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/nivolumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nivolumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab for sarcoma</title>
    <id>https://staging.whatcameofit.com/nivolumab--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nivolumab--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nivolumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/nivolumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/nivolumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>NK cell perfusion group for abortion, missed</title>
    <id>https://staging.whatcameofit.com/nk-cell-perfusion-group--abortion-missed#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nk-cell-perfusion-group--abortion-missed"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nk-dli for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/nk-dli--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nk-dli--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nmdae for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/nmdae--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nmdae--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Nmdae for schizophrenia</title>
    <id>https://staging.whatcameofit.com/nmdae--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nmdae--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NMDAE plus AIFA for schizophrenia</title>
    <id>https://staging.whatcameofit.com/nmdae-plus-aifa--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nmdae-plus-aifa--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NMS-01 for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/nms-01--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nms-01--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NNC0487-0111 for obesity</title>
    <id>https://staging.whatcameofit.com/nnc0487-0111--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nnc0487-0111--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>No intervention + Tranexamic acid for postpartum hemorrhage</title>
    <id>https://staging.whatcameofit.com/no-intervention-tranexamic-acid--postpartum-hemorrhage#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/no-intervention-tranexamic-acid--postpartum-hemorrhage"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Non-Specific Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations</title>
    <id>https://staging.whatcameofit.com/non-specific-cognitive-training-tdcs-sham-stimulation--neurobehavioral-manifestations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/non-specific-cognitive-training-tdcs-sham-stimulation--neurobehavioral-manifestations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Norucholic acid for cholangitis, sclerosing</title>
    <id>https://staging.whatcameofit.com/norucholic-acid--cholangitis-sclerosing#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/norucholic-acid--cholangitis-sclerosing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NSAI + CDK4/6i + Capivasertib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/nsai-cdk4-6i-capivasertib--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nsai-cdk4-6i-capivasertib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>NT-101 ophthalmic solution for macular degeneration</title>
    <id>https://staging.whatcameofit.com/nt-101-ophthalmic-solution--macular-degeneration#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nt-101-ophthalmic-solution--macular-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NTLA-2001 for cardiomyopathies</title>
    <id>https://staging.whatcameofit.com/ntla-2001--cardiomyopathies#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ntla-2001--cardiomyopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>NTLA-2001 for polyneuropathies</title>
    <id>https://staging.whatcameofit.com/ntla-2001--polyneuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ntla-2001--polyneuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Nut oral desensitization for nut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/nut-oral-desensitization--nut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/nut-oral-desensitization--nut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/nutritional-assessment-short-term-fasting-metformin-hydrochloride--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/nutritional-assessment-short-term-fasting-metformin-hydrochloride--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>NVDX3 for wrist fractures</title>
    <id>https://staging.whatcameofit.com/nvdx3--wrist-fractures#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/nvdx3--wrist-fractures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OAV101 for bulbo-spinal atrophy, x-linked</title>
    <id>https://staging.whatcameofit.com/oav101--bulbo-spinal-atrophy-x-linked#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/oav101--bulbo-spinal-atrophy-x-linked"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>OAV101 for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/oav101--muscular-atrophy#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/oav101--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Obefazimod for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/obefazimod--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/obefazimod--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Obeticholic acid for fatty liver</title>
    <id>https://staging.whatcameofit.com/obeticholic-acid--fatty-liver#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/obeticholic-acid--fatty-liver"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/obicetrapib-10-mg-ezetimibe-10-mg-fdc-daily--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/obicetrapib-10-mg-ezetimibe-10-mg-fdc-daily--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/obicetrapib-10-mg-ezetimibe-10-mg-fdc-daily--hyperlipidemias#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/obicetrapib-10-mg-ezetimibe-10-mg-fdc-daily--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Obicetrapib 10 mg for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/obicetrapib-10-mg--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/obicetrapib-10-mg--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Observation for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/observation--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/observation--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>OCU400 High Dose + OCU400 Med Dose for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/ocu400-high-dose-ocu400-med-dose--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-high-dose-ocu400-med-dose--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/ocu400-high-dose-ocu400-med-dose--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-high-dose-ocu400-med-dose--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 High Dose for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/ocu400-high-dose--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-high-dose--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 High Dose for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/ocu400-high-dose--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-high-dose--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Low Dose for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/ocu400-low-dose--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-low-dose--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Low Dose for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/ocu400-low-dose--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-low-dose--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Med Dose for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/ocu400-med-dose--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-med-dose--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Med Dose for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/ocu400-med-dose--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-med-dose--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Second Eye Dosing for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/ocu400-second-eye-dosing--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-second-eye-dosing--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU400 Second Eye Dosing for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/ocu400-second-eye-dosing--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu400-second-eye-dosing--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>OCU410 for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/ocu410--geographic-atrophy#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ocu410--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Oculus VR headset for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/oculus-vr-headset--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/oculus-vr-headset--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents for neoplasms</title>
    <id>https://staging.whatcameofit.com/off-label-ici-s-with-other-agents-that-are-not-targeted-including-but-not-limited-to-chemotherapy-hormonal-therapy-immunotherapy-other-than-icis-with-or-without-targeted-agents--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/off-label-ici-s-with-other-agents-that-are-not-targeted-including-but-not-limited-to-chemotherapy-hormonal-therapy-immunotherapy-other-than-icis-with-or-without-targeted-agents--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Off-label ICI(s) with targeted therapy for neoplasms</title>
    <id>https://staging.whatcameofit.com/off-label-ici-s-with-targeted-therapy--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/off-label-ici-s-with-targeted-therapy--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>OK-432 for carcinoma in situ</title>
    <id>https://staging.whatcameofit.com/ok-432--carcinoma-in-situ#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ok-432--carcinoma-in-situ"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Olanzapine and Fluoxetine combination (OFC) for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/olanzapine-and-fluoxetine-combination-ofc--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/olanzapine-and-fluoxetine-combination-ofc--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Olanzapine for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/olanzapine--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/olanzapine--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Olaparib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/olaparib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/olaparib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Olaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/olaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/olaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oleclumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/oleclumab--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/oleclumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Olezarsen for hyperlipoproteinemia type i</title>
    <id>https://staging.whatcameofit.com/olezarsen--hyperlipoproteinemia-type-i#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/olezarsen--hyperlipoproteinemia-type-i"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>OLN324 for macular degeneration</title>
    <id>https://staging.whatcameofit.com/oln324--macular-degeneration#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oln324--macular-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Olomorasib + PEMBROLIZUMAB + Cetuximab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/olomorasib-pembrolizumab-cetuximab--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/olomorasib-pembrolizumab-cetuximab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Olomorasib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/olomorasib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/olomorasib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Olz/sam for schizophrenia</title>
    <id>https://staging.whatcameofit.com/olz-sam--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/olz-sam--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Omalizumab for anaphylaxis</title>
    <id>https://staging.whatcameofit.com/omalizumab--anaphylaxis#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/omalizumab--anaphylaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Omalizumab for food hypersensitivity</title>
    <id>https://staging.whatcameofit.com/omalizumab--food-hypersensitivity#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/omalizumab--food-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Omalizumab for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/omalizumab--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/omalizumab--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>omega-3 for antisocial personality disorder</title>
    <id>https://staging.whatcameofit.com/omega-3--antisocial-personality-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/omega-3--antisocial-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Omega-3 supplemented drink for antisocial personality disorder</title>
    <id>https://staging.whatcameofit.com/omega-3-supplemented-drink--antisocial-personality-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/omega-3-supplemented-drink--antisocial-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistant</title>
    <id>https://staging.whatcameofit.com/omeprazole-80-mg-twice-daily--prostatic-neoplasms-castration-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/omeprazole-80-mg-twice-daily--prostatic-neoplasms-castration-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/ommaya-vps-surgical-resection-pegfilgrastim-vincristine-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ommaya-vps-surgical-resection-pegfilgrastim-vincristine-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Onabotulinumtoxin-A for migraine disorders</title>
    <id>https://staging.whatcameofit.com/onabotulinumtoxin-a--migraine-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/onabotulinumtoxin-a--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linked</title>
    <id>https://staging.whatcameofit.com/onasemnogene-abeparvovec--bulbo-spinal-atrophy-x-linked#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/onasemnogene-abeparvovec--bulbo-spinal-atrophy-x-linked"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Onasemnogene abeparvovec for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/onasemnogene-abeparvovec--muscular-atrophy#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/onasemnogene-abeparvovec--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Onasemnogene abeparvovec for muscular atrophy, spinal</title>
    <id>https://staging.whatcameofit.com/onasemnogene-abeparvovec--muscular-atrophy-spinal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/onasemnogene-abeparvovec--muscular-atrophy-spinal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Onasemnogene abeparvovec for spinal muscular atrophies of childhood</title>
    <id>https://staging.whatcameofit.com/onasemnogene-abeparvovec--spinal-muscular-atrophies-of-childhood#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/onasemnogene-abeparvovec--spinal-muscular-atrophies-of-childhood"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/oncosignature-prexasertib-gemcitabine--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oncosignature-prexasertib-gemcitabine--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>OncoSignature + Prexasertib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/oncosignature-prexasertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oncosignature-prexasertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>one night of sleep deprivation and two FDG PET scans for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/one-night-of-sleep-deprivation-and-two-fdg-pet-scans--bipolar-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/one-night-of-sleep-deprivation-and-two-fdg-pet-scans--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>one night of sleep deprivation and two FDG PET scans for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/one-night-of-sleep-deprivation-and-two-fdg-pet-scans--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/one-night-of-sleep-deprivation-and-two-fdg-pet-scans--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>One or more off-label ICIs alone or with other on-label ICI(s) for neoplasms</title>
    <id>https://staging.whatcameofit.com/one-or-more-off-label-icis-alone-or-with-other-on-label-ici-s--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/one-or-more-off-label-icis-alone-or-with-other-on-label-ici-s--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Onfekafusp alfa for glioblastoma</title>
    <id>https://staging.whatcameofit.com/onfekafusp-alfa--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/onfekafusp-alfa--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Onfekafusp alfa for sarcoma</title>
    <id>https://staging.whatcameofit.com/onfekafusp-alfa--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/onfekafusp-alfa--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Opakalim for drug resistant epilepsy</title>
    <id>https://staging.whatcameofit.com/opakalim--drug-resistant-epilepsy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/opakalim--drug-resistant-epilepsy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Opakalim for epilepsies, partial</title>
    <id>https://staging.whatcameofit.com/opakalim--epilepsies-partial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/opakalim--epilepsies-partial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Opakalim for seizures</title>
    <id>https://staging.whatcameofit.com/opakalim--seizures#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/opakalim--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Opiate Sparing for anterior cruciate ligament injuries</title>
    <id>https://staging.whatcameofit.com/opiate-sparing--anterior-cruciate-ligament-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/opiate-sparing--anterior-cruciate-ligament-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>OpRegen for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/opregen--geographic-atrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/opregen--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>OpRegen for macular degeneration</title>
    <id>https://staging.whatcameofit.com/opregen--macular-degeneration#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/opregen--macular-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Optical Coherence Tomography + Reflectance confocal microscopy + DUPILUMAB for eczema</title>
    <id>https://staging.whatcameofit.com/optical-coherence-tomography-reflectance-confocal-microscopy-dupilumab--eczema#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/optical-coherence-tomography-reflectance-confocal-microscopy-dupilumab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Optune System + PEMBROLIZUMAB + Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/optune-system-pembrolizumab-temozolomide--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/optune-system-pembrolizumab-temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>OR502 + CEMIPLIMAB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/or502-cemiplimab--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/or502-cemiplimab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Oral appliance for pre-eclampsia</title>
    <id>https://staging.whatcameofit.com/oral-appliance--pre-eclampsia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-appliance--pre-eclampsia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oral appliance therapy for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/oral-appliance-therapy--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-appliance-therapy--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oral Appliances for mouth breathing</title>
    <id>https://staging.whatcameofit.com/oral-appliances--mouth-breathing#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-appliances--mouth-breathing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oral BGE-102 for obesity</title>
    <id>https://staging.whatcameofit.com/oral-bge-102--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oral-bge-102--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oral immunotheraphy (OIT) for nut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/oral-immunotheraphy-oit--nut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-immunotheraphy-oit--nut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oral immunotheraphy (OIT) for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/oral-immunotheraphy-oit--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-immunotheraphy-oit--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oral immunotherapy with peanut for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/oral-immunotherapy-with-peanut--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oral-immunotherapy-with-peanut--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Orforglipron for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/orforglipron--cardiovascular-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Orforglipron for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/orforglipron--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Orforglipron for hypertension</title>
    <id>https://staging.whatcameofit.com/orforglipron--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Orforglipron for obesity</title>
    <id>https://staging.whatcameofit.com/orforglipron--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Orforglipron for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/orforglipron--osteoarthritis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Orforglipron for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/orforglipron--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/orforglipron--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>ORG-34517 for combat disorders</title>
    <id>https://staging.whatcameofit.com/org-34517--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/org-34517--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>ORG-34517 for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/org-34517--wounds-and-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/org-34517--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Osilodrostat for acth syndrome, ectopic</title>
    <id>https://staging.whatcameofit.com/osilodrostat--acth-syndrome-ectopic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/osilodrostat--acth-syndrome-ectopic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Osilodrostat for adrenal hyperplasia, congenital</title>
    <id>https://staging.whatcameofit.com/osilodrostat--adrenal-hyperplasia-congenital#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/osilodrostat--adrenal-hyperplasia-congenital"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Osilodrostat for cushing syndrome</title>
    <id>https://staging.whatcameofit.com/osilodrostat--cushing-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/osilodrostat--cushing-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/osimertinib-patritumab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/osimertinib-patritumab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Osimertinib + Savolitinib for carcinoma</title>
    <id>https://staging.whatcameofit.com/osimertinib-savolitinib--carcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/osimertinib-savolitinib--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Osimertinib + Savolitinib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/osimertinib-savolitinib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/osimertinib-savolitinib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Osimertinib for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/osimertinib--neoplasm-residual#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/osimertinib--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>OT-led Exercise Group for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/ot-led-exercise-group--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ot-led-exercise-group--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>OXALIPLATIN + LEUCOVORIN + Fluorouracil for neoplasms</title>
    <id>https://staging.whatcameofit.com/oxaliplatin-leucovorin-fluorouracil--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxaliplatin-leucovorin-fluorouracil--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxcarbazepine for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/oxcarbazepine--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oxcarbazepine--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oxford + Unicompartment knee arthroplasty for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/oxford-unicompartment-knee-arthroplasty--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oxford-unicompartment-knee-arthroplasty--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oxford unicompartmental knee arthroplasty for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/oxford-unicompartmental-knee-arthroplasty--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oxford-unicompartmental-knee-arthroplasty--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/oxygen-ozone-therapy-probiotic-supplementation-and-standard-of-care-sivomixx-200-billion--coronavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxygen-ozone-therapy-probiotic-supplementation-and-standard-of-care-sivomixx-200-billion--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxymetazoline for nasal obstruction</title>
    <id>https://staging.whatcameofit.com/oxymetazoline--nasal-obstruction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxymetazoline--nasal-obstruction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxytocin for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/oxytocin--autism-spectrum-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxytocin--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxytocin for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/oxytocin--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/oxytocin--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Oxytocin for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/oxytocin--pediatric-obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxytocin--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxytocin for sarcopenia</title>
    <id>https://staging.whatcameofit.com/oxytocin--sarcopenia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/oxytocin--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Paclitaxcel Q3W for adenocarcinoma, mucinous</title>
    <id>https://staging.whatcameofit.com/paclitaxcel-q3w--adenocarcinoma-mucinous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paclitaxcel-q3w--adenocarcinoma-mucinous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>paclitaxel combined with platinum for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/paclitaxel-combined-with-platinum--uterine-cervical-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/paclitaxel-combined-with-platinum--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Paclitaxel for adenocarcinoma, mucinous</title>
    <id>https://staging.whatcameofit.com/paclitaxel--adenocarcinoma-mucinous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paclitaxel--adenocarcinoma-mucinous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paclitaxel for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/paclitaxel--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paclitaxel--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib for sarcoma</title>
    <id>https://staging.whatcameofit.com/paclitaxel-polymer-micelles-gemcitabine-anlotinib--sarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/paclitaxel-polymer-micelles-gemcitabine-anlotinib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib for sarcoma</title>
    <id>https://staging.whatcameofit.com/paclitaxel-polymer-micelles-gemcitabine-lenvatinib--sarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/paclitaxel-polymer-micelles-gemcitabine-lenvatinib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Padeliporfin for carcinoma</title>
    <id>https://staging.whatcameofit.com/padeliporfin--carcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/padeliporfin--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Padeliporfin for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/padeliporfin--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/padeliporfin--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Paired Vagus Nerve Stimulation for paresis</title>
    <id>https://staging.whatcameofit.com/paired-vagus-nerve-stimulation--paresis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/paired-vagus-nerve-stimulation--paresis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Datopotamab Deruxtecan for astrocytoma</title>
    <id>https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Datopotamab Deruxtecan for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Datopotamab Deruxtecan for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-datopotamab-deruxtecan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Temozolomide for astrocytoma</title>
    <id>https://staging.whatcameofit.com/palacaparib-temozolomide--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-temozolomide--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Temozolomide for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib-temozolomide--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-temozolomide--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib + Temozolomide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib-temozolomide--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib-temozolomide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib for astrocytoma</title>
    <id>https://staging.whatcameofit.com/palacaparib--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Palacaparib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/palacaparib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/palacaparib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PALI-2108 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/pali-2108--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pali-2108--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pancreatic enzyme capsules for exocrine pancreatic insufficiency</title>
    <id>https://staging.whatcameofit.com/pancreatic-enzyme-capsules--exocrine-pancreatic-insufficiency#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pancreatic-enzyme-capsules--exocrine-pancreatic-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pancreatic enzyme capsules for pancreatitis, acute necrotizing</title>
    <id>https://staging.whatcameofit.com/pancreatic-enzyme-capsules--pancreatitis-acute-necrotizing#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pancreatic-enzyme-capsules--pancreatitis-acute-necrotizing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Panitumumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/panitumumab--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/panitumumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Parathyroid Allotransplant for hypoparathyroidism</title>
    <id>https://staging.whatcameofit.com/parathyroid-allotransplant--hypoparathyroidism#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/parathyroid-allotransplant--hypoparathyroidism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Partial or total penectomy with inguinal and/or pelvic lymph node dissection + PEMBROLIZUMAB + PYRUVATE CARBOXYLASE, MITOCHONDRIAL for penile neoplasms</title>
    <id>https://staging.whatcameofit.com/partial-or-total-penectomy-with-inguinal-and-or-pelvic-lymph-node-dissection-pembrolizumab-pyruvate-carboxylase-mitochondrial--penile-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/partial-or-total-penectomy-with-inguinal-and-or-pelvic-lymph-node-dissection-pembrolizumab-pyruvate-carboxylase-mitochondrial--penile-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/participants-will-receive-tongmai-jiangtang-capsule-tjc-in-addition-to-standard-treatment--metabolic-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/participants-will-receive-tongmai-jiangtang-capsule-tjc-in-addition-to-standard-treatment--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Patiromer for hyperkalemia</title>
    <id>https://staging.whatcameofit.com/patiromer--hyperkalemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/patiromer--hyperkalemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Patritumab Deruxtecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/patritumab-deruxtecan--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/patritumab-deruxtecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Patritumab Deruxtecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/patritumab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/patritumab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Patritumab Deruxtecan for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/patritumab-deruxtecan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/patritumab-deruxtecan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Patritumab Deruxtecan for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/patritumab-deruxtecan--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/patritumab-deruxtecan--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paxalisib for focal cortical dysplasia</title>
    <id>https://staging.whatcameofit.com/paxalisib--focal-cortical-dysplasia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/paxalisib--focal-cortical-dysplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/paxlovid-10-days-remdesivir--immunologic-deficiency-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paxlovid-10-days-remdesivir--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paxlovid 10 days for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/paxlovid-10-days--immunologic-deficiency-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paxlovid-10-days--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paxlovid 5 days + REMDESIVIR for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/paxlovid-5-days-remdesivir--immunologic-deficiency-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paxlovid-5-days-remdesivir--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paxlovid 5 days for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/paxlovid-5-days--immunologic-deficiency-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/paxlovid-5-days--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Paxlovid for uremia</title>
    <id>https://staging.whatcameofit.com/paxlovid--uremia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/paxlovid--uremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/pbi-11-1-dose-placebo-2-doses--papillomavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pbi-11-1-dose-placebo-2-doses--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>pBI-11 (3 doses) for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/pbi-11-3-doses--papillomavirus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pbi-11-3-doses--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PBT-434 for multiple system atrophy</title>
    <id>https://staging.whatcameofit.com/pbt-434--multiple-system-atrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pbt-434--multiple-system-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pci for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/pci--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pci--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PD-1 Inhibitors + Mitoxantrone Hydrochloride for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pd-1-inhibitors-mitoxantrone-hydrochloride--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pd-1-inhibitors-mitoxantrone-hydrochloride--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PD-1antibody plus GEMOX for klatskin tumor</title>
    <id>https://staging.whatcameofit.com/pd-1antibody-plus-gemox--klatskin-tumor#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pd-1antibody-plus-gemox--klatskin-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pd1-tils-numarzu-001-product-infusion--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/pd1-tils-numarzu-001-product-infusion--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peanut for anaphylaxis</title>
    <id>https://staging.whatcameofit.com/peanut--anaphylaxis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peanut--anaphylaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peanut for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/peanut--peanut-hypersensitivity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peanut--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peanut in common foods or supermarket-sourced cow&apos;s milk (CM) for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/peanut-in-common-foods-or-supermarket-sourced-cow-s-milk-cm--peanut-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/peanut-in-common-foods-or-supermarket-sourced-cow-s-milk-cm--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Peanut oral immunotherapy for anaphylaxis</title>
    <id>https://staging.whatcameofit.com/peanut-oral-immunotherapy--anaphylaxis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/peanut-oral-immunotherapy--anaphylaxis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Peanut oral immunotherapy for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/peanut-oral-immunotherapy--peanut-hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/peanut-oral-immunotherapy--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>peanut powder for food hypersensitivity</title>
    <id>https://staging.whatcameofit.com/peanut-powder--food-hypersensitivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/peanut-powder--food-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PEDIACEL® and Prevenar® for diphtheria</title>
    <id>https://staging.whatcameofit.com/pediacel-and-prevenar--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pediacel-and-prevenar--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PEDIACEL® and Prevenar® for haemophilus infections</title>
    <id>https://staging.whatcameofit.com/pediacel-and-prevenar--haemophilus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pediacel-and-prevenar--haemophilus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PEDIACEL® and Prevenar® for pneumococcal infections</title>
    <id>https://staging.whatcameofit.com/pediacel-and-prevenar--pneumococcal-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pediacel-and-prevenar--pneumococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PEDIACEL® and Prevenar® for tetanus</title>
    <id>https://staging.whatcameofit.com/pediacel-and-prevenar--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pediacel-and-prevenar--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Pegargiminase for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/pegargiminase--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pegargiminase--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Peginterferon α-2b injection for thrombocythemia, essential</title>
    <id>https://staging.whatcameofit.com/peginterferon-α-2b-injection--thrombocythemia-essential#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/peginterferon-α-2b-injection--thrombocythemia-essential"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pegylated liposomal doxorubicin + TOPOTECAN + Paclitaxel for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/pegylated-liposomal-doxorubicin-topotecan-paclitaxel--fallopian-tube-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pegylated-liposomal-doxorubicin-topotecan-paclitaxel--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pelabresib for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/pelabresib--primary-myelofibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pelabresib--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab + lenvatinib for lung diseases</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-lenvatinib--lung-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-lenvatinib--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab + lenvatinib for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-lenvatinib--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-lenvatinib--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PEMBROLIZUMAB + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab + nesuparib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-nesuparib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-nesuparib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PEMBROLIZUMAB + Paclitaxel for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-paclitaxel--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-paclitaxel--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PEMBROLIZUMAB + Porustobart for spinocerebellar degenerations</title>
    <id>https://staging.whatcameofit.com/pembrolizumab-porustobart--spinocerebellar-degenerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab-porustobart--spinocerebellar-degenerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for carcinosarcoma</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--carcinosarcoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--carcinosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for leukoplakia</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--leukoplakia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--leukoplakia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pembrolizumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/pembrolizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pembrolizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed + AVELUMAB for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/pemetrexed-avelumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pemetrexed-avelumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/pemetrexed-carboplatin-olomorasib-pembrolizumab-cetuximab-cisplatin--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/pemetrexed-carboplatin-olomorasib-pembrolizumab-cetuximab-cisplatin--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/pemetrexed-carboplatin-pembrolizumab-cisplatin--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pemetrexed-carboplatin-pembrolizumab-cisplatin--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed for neoplasms</title>
    <id>https://staging.whatcameofit.com/pemetrexed--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pemetrexed--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinoma</title>
    <id>https://staging.whatcameofit.com/pemetrexed-carboplatin-pemetrexed-cisplatin--carcinoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pemetrexed-carboplatin-pemetrexed-cisplatin--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pemetrexed-carboplatin-pemetrexed-cisplatin--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pemetrexed-carboplatin-pemetrexed-cisplatin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pemvidutide for alcoholism</title>
    <id>https://staging.whatcameofit.com/pemvidutide--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pemvidutide--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pemvidutide for obesity</title>
    <id>https://staging.whatcameofit.com/pemvidutide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pemvidutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Penn Microbiome Therapy - 001 + Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections</title>
    <id>https://staging.whatcameofit.com/penn-microbiome-therapy-001-penn-microbiome-therapy-002-penn-microbiome-therapy-003--clostridium-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/penn-microbiome-therapy-001-penn-microbiome-therapy-002-penn-microbiome-therapy-003--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Penn Microbiome Therapy - 001 for clostridium infections</title>
    <id>https://staging.whatcameofit.com/penn-microbiome-therapy-001--clostridium-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/penn-microbiome-therapy-001--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Penn Microbiome Therapy - 002 + Penn Microbiome Therapy - 003 for clostridium infections</title>
    <id>https://staging.whatcameofit.com/penn-microbiome-therapy-002-penn-microbiome-therapy-003--clostridium-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/penn-microbiome-therapy-002-penn-microbiome-therapy-003--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Pentacel®: DTaP-IPV/Hib combined for diphtheria</title>
    <id>https://staging.whatcameofit.com/pentacel-dtap-ipv-hib-combined--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pentacel-dtap-ipv-hib-combined--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Pentacel®: DTaP-IPV/Hib combined for tetanus</title>
    <id>https://staging.whatcameofit.com/pentacel-dtap-ipv-hib-combined--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pentacel-dtap-ipv-hib-combined--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Peptide vaccine IPX for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/peptide-vaccine-ipx--rhabdomyosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peptide-vaccine-ipx--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peptide vaccine IPX for sarcoma, ewing</title>
    <id>https://staging.whatcameofit.com/peptide-vaccine-ipx--sarcoma-ewing#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peptide-vaccine-ipx--sarcoma-ewing"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peptide vaccine IPX for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/peptide-vaccine-ipx--sarcoma-synovial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peptide-vaccine-ipx--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/percept-pc-and-percept-rc-with-adaptive-dbs-adbs--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/percept-pc-and-percept-rc-with-adaptive-dbs-adbs--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Percutaneous epidural electrical spinal stimulation for paraplegia</title>
    <id>https://staging.whatcameofit.com/percutaneous-epidural-electrical-spinal-stimulation--paraplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/percutaneous-epidural-electrical-spinal-stimulation--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Percutaneous epidural electrical spinal stimulation for quadriplegia</title>
    <id>https://staging.whatcameofit.com/percutaneous-epidural-electrical-spinal-stimulation--quadriplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/percutaneous-epidural-electrical-spinal-stimulation--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Perillyl alcohol for glioblastoma</title>
    <id>https://staging.whatcameofit.com/perillyl-alcohol--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/perillyl-alcohol--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--graft-vs-host-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--primary-myelofibrosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/peripheral-blood-hematopoietic-cell-transplantation-hct-total-body-irradiation-tbi-cyclophosphamide-busulfan-fludarabine-filgrastim-mycophenolate-mofetil-hydrochloride-sirolimus--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/peripheral-blood-stem-cell-transplantation-hematopoietic-cell-transplantation-laboratory-biomarker-analysis-quality-of-life-assessment-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/peripheral-blood-stem-cell-transplantation-hematopoietic-cell-transplantation-laboratory-biomarker-analysis-quality-of-life-assessment-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Peripheral Blood Stem Cell Transplantation + Hematopoietic Cell Transplantation + Laboratory Biomarker Analysis + Quality-of-Life Assessment + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/peripheral-blood-stem-cell-transplantation-hematopoietic-cell-transplantation-laboratory-biomarker-analysis-quality-of-life-assessment-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/peripheral-blood-stem-cell-transplantation-hematopoietic-cell-transplantation-laboratory-biomarker-analysis-quality-of-life-assessment-fludarabine-phosphate-cyclophosphamide-mycophenolate-mofetil-busulfan-tacrolimus--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Permethrin-treated lesu for malaria</title>
    <id>https://staging.whatcameofit.com/permethrin-treated-lesu--malaria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/permethrin-treated-lesu--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Permethrin-treated lesu for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/permethrin-treated-lesu--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/permethrin-treated-lesu--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Perospirone hydrochloride tablets for depressive disorder</title>
    <id>https://staging.whatcameofit.com/perospirone-hydrochloride-tablets--depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/perospirone-hydrochloride-tablets--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Persona Partial Knee (PPK) for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/persona-partial-knee-ppk--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/persona-partial-knee-ppk--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/personalized-neuroprotective-strategies-vitamin-b12-folinic-acid-omega-3-nac--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/personalized-neuroprotective-strategies-vitamin-b12-folinic-acid-omega-3-nac--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PET/CT + FLUDEOXYGLUCOSE F-18 + [18F]-FAPI-74 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/pet-ct-fludeoxyglucose-f-18-18f-fapi-74--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pet-ct-fludeoxyglucose-f-18-18f-fapi-74--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Petosemtamab for laryngeal diseases</title>
    <id>https://staging.whatcameofit.com/petosemtamab--laryngeal-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/petosemtamab--laryngeal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Petosemtamab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/petosemtamab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/petosemtamab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Petrelintide for obesity</title>
    <id>https://staging.whatcameofit.com/petrelintide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/petrelintide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PF-06649751 high dose (15 mg QD) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/pf-06649751-high-dose-15-mg-qd--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/pf-06649751-high-dose-15-mg-qd--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>PF-06649751 low dose (1 mg QD) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/pf-06649751-low-dose-1-mg-qd--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/pf-06649751-low-dose-1-mg-qd--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>PF-06649751 middle dose 1 (3 mg QD) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/pf-06649751-middle-dose-1-3-mg-qd--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/pf-06649751-middle-dose-1-3-mg-qd--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>PF-06649751 middle dose 2 (7 mg QD) for parkinson disease</title>
    <id>https://staging.whatcameofit.com/pf-06649751-middle-dose-2-7-mg-qd--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/pf-06649751-middle-dose-2-7-mg-qd--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>PF-06882961 (Cohort 3) for obesity</title>
    <id>https://staging.whatcameofit.com/pf-06882961-cohort-3--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pf-06882961-cohort-3--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PF-06882961 (Cohorts 1 and 2) for obesity</title>
    <id>https://staging.whatcameofit.com/pf-06882961-cohorts-1-and-2--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pf-06882961-cohorts-1-and-2--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/pf-08634404-enfortumab-vedotin--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/pf-08634404-enfortumab-vedotin--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PF-08634404 for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/pf-08634404--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/pf-08634404--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PF-08653944 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/pf-08653944--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pf-08653944--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PF-08653944 for obesity</title>
    <id>https://staging.whatcameofit.com/pf-08653944--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pf-08653944--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PG-102 for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/pg-102--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pg-102--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PG4 for pneumococcal infections</title>
    <id>https://staging.whatcameofit.com/pg4--pneumococcal-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pg4--pneumococcal-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>pharmacogenetic algorithm for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/pharmacogenetic-algorithm--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pharmacogenetic-algorithm--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for congenital bone marrow failure syndromes</title>
    <id>https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--congenital-bone-marrow-failure-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--congenital-bone-marrow-failure-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathies</title>
    <id>https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--hemoglobinopathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--hemoglobinopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--immunologic-deficiency-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errors</title>
    <id>https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--metabolism-inborn-errors#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-1-dose-level-1-phase-1-dose-level-2-phase-1-dose-level-3--metabolism-inborn-errors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromes</title>
    <id>https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--congenital-bone-marrow-failure-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--congenital-bone-marrow-failure-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathies</title>
    <id>https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--hemoglobinopathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--hemoglobinopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--immunologic-deficiency-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errors</title>
    <id>https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--metabolism-inborn-errors#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-established-dose-from-prior-study-nct03810196--metabolism-inborn-errors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Maximum Tolerated Dose determined in Phase 1 for congenital bone marrow failure syndromes</title>
    <id>https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--congenital-bone-marrow-failure-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--congenital-bone-marrow-failure-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathies</title>
    <id>https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--hemoglobinopathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--hemoglobinopathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Maximum Tolerated Dose determined in Phase 1 for immunologic deficiency syndromes</title>
    <id>https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--immunologic-deficiency-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--immunologic-deficiency-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errors</title>
    <id>https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--metabolism-inborn-errors#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/phase-2-maximum-tolerated-dose-determined-in-phase-1--metabolism-inborn-errors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PHEN/TPM ER (Qsymia®) for binge-eating disorder</title>
    <id>https://staging.whatcameofit.com/phen-tpm-er-qsymia--binge-eating-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/phen-tpm-er-qsymia--binge-eating-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for craniopharyngioma</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate-extended-release-oral-capsule-qsymia--craniopharyngioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate-extended-release-oral-capsule-qsymia--craniopharyngioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for sexual infantilism</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate-extended-release-oral-capsule-qsymia--sexual-infantilism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate-extended-release-oral-capsule-qsymia--sexual-infantilism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine / Topiramate Oral Product for glucose intolerance</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate-oral-product--glucose-intolerance#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate-oral-product--glucose-intolerance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine / Topiramate Oral Product for obesity</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate-oral-product--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate-oral-product--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/phentermine--pediatric-obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine-Topiramate ER for obesity</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate-er--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate-er--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Phentermine-Topiramate for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Phentermine-Topiramate for obesity</title>
    <id>https://staging.whatcameofit.com/phentermine-topiramate--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/phentermine-topiramate--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Photobiomodulation for obesity, morbid</title>
    <id>https://staging.whatcameofit.com/photobiomodulation--obesity-morbid#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/photobiomodulation--obesity-morbid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PIFLUFOLASTAT F-18 + GOZETOTIDE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/piflufolastat-f-18-gozetotide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/piflufolastat-f-18-gozetotide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PIFLUFOLASTAT F-18 for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/piflufolastat-f-18--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/piflufolastat-f-18--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pirfenidoneone for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/pirfenidoneone--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pirfenidoneone--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pirfenidoneone for lymphedema</title>
    <id>https://staging.whatcameofit.com/pirfenidoneone--lymphedema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pirfenidoneone--lymphedema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PJ009 for short bowel syndrome</title>
    <id>https://staging.whatcameofit.com/pj009--short-bowel-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pj009--short-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo - 100 mg + Ritlecitinib 50 mg for alopecia areata</title>
    <id>https://staging.whatcameofit.com/placebo-100-mg-ritlecitinib-50-mg--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-100-mg-ritlecitinib-50-mg--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo - 50 mg + Ritlecitinib 100 mg for alopecia areata</title>
    <id>https://staging.whatcameofit.com/placebo-50-mg-ritlecitinib-100-mg--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-50-mg-ritlecitinib-100-mg--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo (for Syntocinon) + Oxytocin for craniopharyngioma</title>
    <id>https://staging.whatcameofit.com/placebo-for-syntocinon-oxytocin--craniopharyngioma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-for-syntocinon-oxytocin--craniopharyngioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo (for Syntocinon) + Oxytocin for sexual infantilism</title>
    <id>https://staging.whatcameofit.com/placebo-for-syntocinon-oxytocin--sexual-infantilism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-for-syntocinon-oxytocin--sexual-infantilism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo (matched to semaglutide) + Zenagamtide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-matched-to-semaglutide-zenagamtide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-matched-to-semaglutide-zenagamtide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + ADUCANUMAB for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/placebo-aducanumab--alzheimer-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-aducanumab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + ADUCANUMAB for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/placebo-aducanumab--cognitive-dysfunction#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/placebo-aducanumab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Placebo + Donanemab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/placebo-donanemab--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-donanemab--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + DUPILUMAB for eczema</title>
    <id>https://staging.whatcameofit.com/placebo-dupilumab--eczema#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-dupilumab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo + Eloralintide + Macupatide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-eloralintide-macupatide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-eloralintide-macupatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Eloralintide + Tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-eloralintide-tirzepatide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-eloralintide-tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Eloralintide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-eloralintide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-eloralintide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Empagliflozin for heart failure</title>
    <id>https://staging.whatcameofit.com/placebo-empagliflozin--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-empagliflozin--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Escitalopram + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/placebo-escitalopram-venlafaxine-duloxetine-sertraline--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-escitalopram-venlafaxine-duloxetine-sertraline--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + LEBRIKIZUMAB for eczema</title>
    <id>https://staging.whatcameofit.com/placebo-lebrikizumab--eczema#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-lebrikizumab--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Lorundrostat for hypertension</title>
    <id>https://staging.whatcameofit.com/placebo-lorundrostat--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-lorundrostat--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + MAZDUTIDE for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-mazdutide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-mazdutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Metformin for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/placebo-metformin--medulloblastoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-metformin--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Naperiglipron for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-naperiglipron--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-naperiglipron--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Nimodipine for alcoholism</title>
    <id>https://staging.whatcameofit.com/placebo-nimodipine--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-nimodipine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo + Orforglipron for hypertension</title>
    <id>https://staging.whatcameofit.com/placebo-orforglipron--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-orforglipron--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Oxytocin for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-oxytocin--obesity#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/placebo-oxytocin--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Placebo + Psilocybin + Propofol for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/placebo-psilocybin-propofol--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-psilocybin-propofol--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo + Psilocybin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/placebo-psilocybin--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-psilocybin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Psilocybin for migraine disorders</title>
    <id>https://staging.whatcameofit.com/placebo-psilocybin--migraine-disorders#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-psilocybin--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Reduced-calorie diet + Tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-reduced-calorie-diet-tirzepatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-reduced-calorie-diet-tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + SOTAGLIFLOZIN for albuminuria</title>
    <id>https://staging.whatcameofit.com/placebo-sotagliflozin--albuminuria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-sotagliflozin--albuminuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo + SRP-1005 for huntington disease</title>
    <id>https://staging.whatcameofit.com/placebo-srp-1005--huntington-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-srp-1005--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + Standardized diet and physical activity counseling throughout the study. + Retatrutide for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-standardized-diet-and-physical-activity-counseling-throughout-the-study-retatrutide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-standardized-diet-and-physical-activity-counseling-throughout-the-study-retatrutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson disease</title>
    <id>https://staging.whatcameofit.com/placebo-tavapadon-trimethobenzamide-hydrochloride--parkinson-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-tavapadon-trimethobenzamide-hydrochloride--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo + Upadacitinib for alopecia areata</title>
    <id>https://staging.whatcameofit.com/placebo-upadacitinib--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-upadacitinib--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>placebo 2 tablets qhs for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/placebo-2-tablets-qhs--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo-2-tablets-qhs--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo for alopecia areata</title>
    <id>https://staging.whatcameofit.com/placebo--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/placebo--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for crohn disease</title>
    <id>https://staging.whatcameofit.com/placebo--crohn-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/placebo--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for eczema</title>
    <id>https://staging.whatcameofit.com/placebo--eczema#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--eczema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for glomerulosclerosis, focal segmental</title>
    <id>https://staging.whatcameofit.com/placebo--glomerulosclerosis-focal-segmental#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--glomerulosclerosis-focal-segmental"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for herpes genitalis</title>
    <id>https://staging.whatcameofit.com/placebo--herpes-genitalis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo--herpes-genitalis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo for migraine disorders</title>
    <id>https://staging.whatcameofit.com/placebo--migraine-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for Multi-Allergen Oral Immunotherapy + Omalizumab for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/placebo-for-multi-allergen-oral-immunotherapy-omalizumab--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-for-multi-allergen-oral-immunotherapy-omalizumab--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for myositis ossificans</title>
    <id>https://staging.whatcameofit.com/placebo--myositis-ossificans#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--myositis-ossificans"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/placebo--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for Oral Azacitidine for anemia</title>
    <id>https://staging.whatcameofit.com/placebo-for-oral-azacitidine--anemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-for-oral-azacitidine--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for Oral Azacitidine for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/placebo-for-oral-azacitidine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-for-oral-azacitidine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for Oral Azacitidine for thrombocytopenia</title>
    <id>https://staging.whatcameofit.com/placebo-for-oral-azacitidine--thrombocytopenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-for-oral-azacitidine--thrombocytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for parkinson disease</title>
    <id>https://staging.whatcameofit.com/placebo--parkinson-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for pruritus</title>
    <id>https://staging.whatcameofit.com/placebo--pruritus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo--pruritus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo for schizophrenia</title>
    <id>https://staging.whatcameofit.com/placebo--schizophrenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/placebo--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/placebo--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Placebo for tuberculosis</title>
    <id>https://staging.whatcameofit.com/placebo--tuberculosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo--tuberculosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo IV + SAD IV Dose 1 - 150mg ABS201 IV Single Dose for alopecia</title>
    <id>https://staging.whatcameofit.com/placebo-iv-sad-iv-dose-1-150mg-abs201-iv-single-dose--alopecia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-iv-sad-iv-dose-1-150mg-abs201-iv-single-dose--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo Nasal Spray - Placebo Nasal Spray for phobia, social</title>
    <id>https://staging.whatcameofit.com/placebo-nasal-spray-placebo-nasal-spray--phobia-social#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-nasal-spray-placebo-nasal-spray--phobia-social"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo Nasal Spray for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-nasal-spray--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-nasal-spray--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo Nasal Spray for phobia, social</title>
    <id>https://staging.whatcameofit.com/placebo-nasal-spray--phobia-social#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/placebo-nasal-spray--phobia-social"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Placebo Nasal Spray for sarcopenia</title>
    <id>https://staging.whatcameofit.com/placebo-nasal-spray--sarcopenia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-nasal-spray--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo of trazodone + Psilocybin for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/placebo-of-trazodone-psilocybin--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-of-trazodone-psilocybin--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for albuminuria</title>
    <id>https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--albuminuria#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--albuminuria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for hypertension</title>
    <id>https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-qd-sglt2i-qd-washout-lorundrostat-25mg-sglt2i-qd--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>placebo with matching dosage + ECNOGLUTIDE for obesity</title>
    <id>https://staging.whatcameofit.com/placebo-with-matching-dosage-ecnoglutide--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/placebo-with-matching-dosage-ecnoglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Placebo-to-match emvistegrast + Emvistegrast for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/placebo-to-match-emvistegrast-emvistegrast--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/placebo-to-match-emvistegrast-emvistegrast--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Platelet rich plasma for infertility, female</title>
    <id>https://staging.whatcameofit.com/platelet-rich-plasma--infertility-female#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/platelet-rich-plasma--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Platelet-Rich Plasma-Fibrin Glue for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/platelet-rich-plasma-fibrin-glue--wounds-and-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/platelet-rich-plasma-fibrin-glue--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria</title>
    <id>https://staging.whatcameofit.com/polio-sabin-oral-polio-vaccine-gsk-tritanrixhepb-hib--malaria#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/polio-sabin-oral-polio-vaccine-gsk-tritanrixhepb-hib--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Polycap for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/polycap--atherosclerosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/polycap--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PolyCore (Polydextrin, L-Carnitine, D-xylitol) for heart failure</title>
    <id>https://staging.whatcameofit.com/polycore-polydextrin-l-carnitine-d-xylitol--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/polycore-polydextrin-l-carnitine-d-xylitol--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PolyPill for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/polypill--cardiovascular-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/polypill--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PolyPill for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/polypill--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/polypill--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PolyPill for heart diseases</title>
    <id>https://staging.whatcameofit.com/polypill--heart-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/polypill--heart-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PolyPill for hyperlipidemias</title>
    <id>https://staging.whatcameofit.com/polypill--hyperlipidemias#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/polypill--hyperlipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PolyPill for hypertension</title>
    <id>https://staging.whatcameofit.com/polypill--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/polypill--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PolyPill for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/polypill--non-alcoholic-fatty-liver-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/polypill--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PolyPill for non-st elevated myocardial infarction</title>
    <id>https://staging.whatcameofit.com/polypill--non-st-elevated-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/polypill--non-st-elevated-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PolyPill for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/polypill--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/polypill--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Polypill: Red Heart Pill for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/polypill-red-heart-pill--cardiovascular-diseases#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/polypill-red-heart-pill--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ponsegromab for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/ponsegromab--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ponsegromab--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Posaconazole for chagas disease</title>
    <id>https://staging.whatcameofit.com/posaconazole--chagas-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/posaconazole--chagas-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Povidone-iodine for surgical wound infection</title>
    <id>https://staging.whatcameofit.com/povidone-iodine--surgical-wound-infection#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/povidone-iodine--surgical-wound-infection"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pozelimab + cemdisiran for hemoglobinuria, paroxysmal</title>
    <id>https://staging.whatcameofit.com/pozelimab-cemdisiran--hemoglobinuria-paroxysmal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/pozelimab-cemdisiran--hemoglobinuria-paroxysmal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PP405 0.05% Topical Gel for alopecia</title>
    <id>https://staging.whatcameofit.com/pp405-0-05-topical-gel--alopecia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pp405-0-05-topical-gel--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prasugrel for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/prasugrel--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prasugrel--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prasugrel or Ticagrelor for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/prasugrel-or-ticagrelor--acute-coronary-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/prasugrel-or-ticagrelor--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Prasugrel or Ticagrelor for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/prasugrel-or-ticagrelor--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/prasugrel-or-ticagrelor--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pravastatin (drug) for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/pravastatin-drug--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pravastatin-drug--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pravastatin (drug) for lymphedema</title>
    <id>https://staging.whatcameofit.com/pravastatin-drug--lymphedema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pravastatin-drug--lymphedema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pravastatin 40 mg for fetal growth retardation</title>
    <id>https://staging.whatcameofit.com/pravastatin-40-mg--fetal-growth-retardation#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pravastatin-40-mg--fetal-growth-retardation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pravastatin 40 mg for placental insufficiency</title>
    <id>https://staging.whatcameofit.com/pravastatin-40-mg--placental-insufficiency#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pravastatin-40-mg--placental-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Pravastatin 40 mg for pre-eclampsia</title>
    <id>https://staging.whatcameofit.com/pravastatin-40-mg--pre-eclampsia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pravastatin-40-mg--pre-eclampsia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prednisolone for abortion, habitual</title>
    <id>https://staging.whatcameofit.com/prednisolone--abortion-habitual#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/prednisolone--abortion-habitual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Prexasertib + Gemcitabine for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/prexasertib-gemcitabine--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prexasertib-gemcitabine--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prexasertib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/prexasertib--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prexasertib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>prifetrastat in combination with fulvestrant for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/prifetrastat-in-combination-with-fulvestrant--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prifetrastat-in-combination-with-fulvestrant--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>prifetrastat monotherapy for 15 days then combination with fulvestrant for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/prifetrastat-monotherapy-for-15-days-then-combination-with-fulvestrant--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prifetrastat-monotherapy-for-15-days-then-combination-with-fulvestrant--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PRIMA Bionic Vision System for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/prima-bionic-vision-system--geographic-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prima-bionic-vision-system--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prima for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/prima--geographic-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prima--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PRIMA Products for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/prima-products--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prima-products--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PRIMA Products for stargardt disease</title>
    <id>https://staging.whatcameofit.com/prima-products--stargardt-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prima-products--stargardt-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Primaquine for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/primaquine--malaria-vivax#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/primaquine--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PRL3-zumab for neoplasms</title>
    <id>https://staging.whatcameofit.com/prl3-zumab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prl3-zumab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Probiotic for hypersensitivity</title>
    <id>https://staging.whatcameofit.com/probiotic--hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/probiotic--hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Procellera for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/procellera--wounds-and-injuries#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/procellera--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Procellera® for burns</title>
    <id>https://staging.whatcameofit.com/procellera--burns#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/procellera--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prolonged Exposure + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/prolonged-exposure-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/prolonged-exposure-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Prolonged exposure therapy + MIDOMAFETAMINE for alcoholism</title>
    <id>https://staging.whatcameofit.com/prolonged-exposure-therapy-midomafetamine--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prolonged-exposure-therapy-midomafetamine--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prolonged exposure therapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/prolonged-exposure-therapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prolonged-exposure-therapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prolonged Proned Positioning for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/prolonged-proned-positioning--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prolonged-proned-positioning--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone decubitus for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/prone-decubitus--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-decubitus--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Position for acute lung injury</title>
    <id>https://staging.whatcameofit.com/prone-position--acute-lung-injury#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-position--acute-lung-injury"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Position for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/prone-position--coronavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-position--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Position for respiratory aspiration</title>
    <id>https://staging.whatcameofit.com/prone-position--respiratory-aspiration#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-position--respiratory-aspiration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Position for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/prone-position--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-position--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Positioning (PP) for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/prone-positioning-pp--coronavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-positioning-pp--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Positioning (PP) for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/prone-positioning-pp--respiratory-distress-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-positioning-pp--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prone Positioning (PP) for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/prone-positioning-pp--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-positioning-pp--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>prone positioning for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/prone-positioning--coronavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prone-positioning--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>prone positioning for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/prone-positioning--respiratory-distress-syndrome#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/prone-positioning--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Proning for respiratory insufficiency</title>
    <id>https://staging.whatcameofit.com/proning--respiratory-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/proning--respiratory-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prophylactic External Beam Radiotherapy for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/prophylactic-external-beam-radiotherapy--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prophylactic-external-beam-radiotherapy--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prophylactic for dental caries</title>
    <id>https://staging.whatcameofit.com/prophylactic--dental-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prophylactic--dental-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/prophylactic-intervention-for-relapse-prevention-post-allogeneic-transplantation--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prophylactic-intervention-for-relapse-prevention-post-allogeneic-transplantation--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Propranolol for combat disorders</title>
    <id>https://staging.whatcameofit.com/propranolol--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/propranolol--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Propranolol for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/propranolol--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/propranolol--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prostate Radiotherapy + Radical Prostatectomy for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/prostate-radiotherapy-radical-prostatectomy--adenocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prostate-radiotherapy-radical-prostatectomy--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Prostate Radiotherapy + Radical Prostatectomy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/prostate-radiotherapy-radical-prostatectomy--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/prostate-radiotherapy-radical-prostatectomy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide--rhabdomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-or-external-beam-radiation-or-brachytherapy-surgical-resection-dactinomycin-vincristine-cyclophosphamide--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--dermatofibrosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--dermatofibrosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex development</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--disorders-of-sex-development#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--disorders-of-sex-development"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--glomus-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--glomus-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--granular-cell-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--granular-cell-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--hemangioendothelioma-epithelioid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--hemangioendothelioma-epithelioid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--hemangiosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--histiocytoma-malignant-fibrous#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--leiomyosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--liposarcoma-myxoid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--liposarcoma-myxoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for myoepithelioma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--myoepithelioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--myoepithelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--osteosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--sarcoma-clear-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--sarcoma-clear-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--sarcoma-synovial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-pazopanib-doxorubicin-ifosfamide--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for dermatofibrosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--dermatofibrosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--dermatofibrosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex development</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--disorders-of-sex-development#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--disorders-of-sex-development"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for glomus tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--glomus-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--glomus-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for granular cell tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--granular-cell-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--granular-cell-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangioendothelioma, epithelioid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--hemangioendothelioma-epithelioid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--hemangioendothelioma-epithelioid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--hemangiosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--histiocytoma-malignant-fibrous#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--leiomyosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for liposarcoma, myxoid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--liposarcoma-myxoid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--liposarcoma-myxoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for myoepithelioma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--myoepithelioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--myoepithelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--osteosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, clear cell</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--sarcoma-clear-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--sarcoma-clear-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--sarcoma-synovial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection-selinexor-pazopanib-doxorubicin-ifosfamide--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for dermatofibrosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--dermatofibrosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--dermatofibrosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for disorders of sex development</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--disorders-of-sex-development#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--disorders-of-sex-development"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for glomus tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--glomus-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--glomus-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for granular cell tumor</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--granular-cell-tumor#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--granular-cell-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for hemangioendothelioma, epithelioid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--hemangioendothelioma-epithelioid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--hemangioendothelioma-epithelioid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--hemangiosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--histiocytoma-malignant-fibrous#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--leiomyosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for liposarcoma, myxoid</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--liposarcoma-myxoid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--liposarcoma-myxoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for myoepithelioma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--myoepithelioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--myoepithelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--osteosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for sarcoma, clear cell</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--sarcoma-clear-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--sarcoma-clear-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton beam radiation therapy + Surgical resection for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--sarcoma-synovial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-beam-radiation-therapy-surgical-resection--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Proton Total Marrow Irradiation for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/proton-total-marrow-irradiation--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/proton-total-marrow-irradiation--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>PRT-064040 nasal spray for migraine disorders</title>
    <id>https://staging.whatcameofit.com/prt-064040-nasal-spray--migraine-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/prt-064040-nasal-spray--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psa for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psa--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psa--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + MBCT therapy for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/psilocybin-mbct-therapy--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin-mbct-therapy--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin + Modafinil for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-modafinil--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-modafinil--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + PIMAVANSERIN + Modafinil for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-pimavanserin-modafinil--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-pimavanserin-modafinil--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + PIMAVANSERIN for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-pimavanserin--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-pimavanserin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + PIMAVANSERIN for parkinson disease</title>
    <id>https://staging.whatcameofit.com/psilocybin-pimavanserin--parkinson-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin-pimavanserin--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin + Placebo for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-placebo--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin-placebo--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin + ZOLPIDEM + Modafinil for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-zolpidem-modafinil--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-zolpidem-modafinil--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + ZOLPIDEM + PIMAVANSERIN + Modafinil for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-zolpidem-pimavanserin-modafinil--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-zolpidem-pimavanserin-modafinil--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + ZOLPIDEM + PIMAVANSERIN for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-zolpidem-pimavanserin--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-zolpidem-pimavanserin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin + ZOLPIDEM for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin-zolpidem--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin-zolpidem--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin for agnosia</title>
    <id>https://staging.whatcameofit.com/psilocybin--agnosia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for alcoholism</title>
    <id>https://staging.whatcameofit.com/psilocybin--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for anhedonia</title>
    <id>https://staging.whatcameofit.com/psilocybin--anhedonia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--anhedonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/psilocybin--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin--bipolar-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for borderline personality disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin--borderline-personality-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--borderline-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for cocaine-related disorders</title>
    <id>https://staging.whatcameofit.com/psilocybin--cocaine-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psilocybin--cocaine-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psilocybin for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/psilocybin--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin--generalized-anxiety-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/psilocybin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for migraine disorders</title>
    <id>https://staging.whatcameofit.com/psilocybin--migraine-disorders#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/psilocybin--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for neoplasms</title>
    <id>https://staging.whatcameofit.com/psilocybin--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for neuralgia</title>
    <id>https://staging.whatcameofit.com/psilocybin--neuralgia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--neuralgia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for paraplegia</title>
    <id>https://staging.whatcameofit.com/psilocybin--paraplegia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/psilocybin--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for quadriplegia</title>
    <id>https://staging.whatcameofit.com/psilocybin--quadriplegia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/psilocybin--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/psilocybin--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/psilocybin--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/psilocybin--wounds-and-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/psilocybin--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PSMA-guided Salvage Radiation for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/psma-guided-salvage-radiation--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psma-guided-salvage-radiation--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>PST-611 for geographic atrophy</title>
    <id>https://staging.whatcameofit.com/pst-611--geographic-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pst-611--geographic-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psychopharmacological treatment for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/psychopharmacological-treatment--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psychopharmacological-treatment--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + Medication for opioid use disorder for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/psychotherapy-medication-for-opioid-use-disorder--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-medication-for-opioid-use-disorder--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + MIDOMAFETAMINE for combat disorders</title>
    <id>https://staging.whatcameofit.com/psychotherapy-midomafetamine--combat-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-midomafetamine--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/psychotherapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + Survey Administration + Psilocybin for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/psychotherapy-survey-administration-psilocybin--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-survey-administration-psilocybin--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + Survey Administration + Psilocybin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/psychotherapy-survey-administration-psilocybin--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-survey-administration-psilocybin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psychotherapy + TRYP-0082 for irritable bowel syndrome</title>
    <id>https://staging.whatcameofit.com/psychotherapy-tryp-0082--irritable-bowel-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/psychotherapy-tryp-0082--irritable-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Psychotherapy for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/psychotherapy--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/psychotherapy--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>PTX-022 for pachyonychia congenita</title>
    <id>https://staging.whatcameofit.com/ptx-022--pachyonychia-congenita#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ptx-022--pachyonychia-congenita"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>PUCOTENLIMAB + Becotatug Vedotin for penile neoplasms</title>
    <id>https://staging.whatcameofit.com/pucotenlimab-becotatug-vedotin--penile-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/pucotenlimab-becotatug-vedotin--penile-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Puliretgene Parvec for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/puliretgene-parvec--retinitis-pigmentosa#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/puliretgene-parvec--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Pulmonary segmentectomy for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/pulmonary-segmentectomy--adenocarcinoma-of-lung#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pulmonary-segmentectomy--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/pulsed-adaptive-radiotherapy-combined-with-pembrolizumab-with-or-without-chemotherapy--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pulsed-adaptive-radiotherapy-combined-with-pembrolizumab-with-or-without-chemotherapy--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Purified peanut protein extract + peanut for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/purified-peanut-protein-extract-peanut--peanut-hypersensitivity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/purified-peanut-protein-extract-peanut--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Purified peanut protein extract for peanut hypersensitivity</title>
    <id>https://staging.whatcameofit.com/purified-peanut-protein-extract--peanut-hypersensitivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/purified-peanut-protein-extract--peanut-hypersensitivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Puxitatug Samrotecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/puxitatug-samrotecan--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/puxitatug-samrotecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Puxitatug Samrotecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/puxitatug-samrotecan--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/puxitatug-samrotecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Pvs230D1-EPA/Matrix-M for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/pvs230d1-epa-matrix-m--malaria-vivax#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pvs230d1-epa-matrix-m--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Pvs230D1-EPA/Matrix-M for parasitemia</title>
    <id>https://staging.whatcameofit.com/pvs230d1-epa-matrix-m--parasitemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/pvs230d1-epa-matrix-m--parasitemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>QEL-005 for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/qel-005--scleroderma-diffuse#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/qel-005--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Qidan Xiaoke Granules + Standard Medical Therapy for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/qidan-xiaoke-granules-standard-medical-therapy--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/qidan-xiaoke-granules-standard-medical-therapy--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>QLH12016 + Enzalutamide + ABIRATERONE ACETATE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/qlh12016-enzalutamide-abiraterone-acetate--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/qlh12016-enzalutamide-abiraterone-acetate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Qsymia 11.25Mg-69Mg Extended Release Capsule + Qsymia 15Mg-92Mg Extended Release Capsule + Qsymia 3.75Mg-23Mg Extended Release Capsule + Qsymia 7.5Mg-46Mg Extended Release Capsule for obesity</title>
    <id>https://staging.whatcameofit.com/qsymia-11-25mg-69mg-extended-release-capsule-qsymia-15mg-92mg-extended-release-capsule-qsymia-3-75mg-23mg-extended-release-capsule-qsymia-7-5mg-46mg-extended-release-capsule--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/qsymia-11-25mg-69mg-extended-release-capsule-qsymia-15mg-92mg-extended-release-capsule-qsymia-3-75mg-23mg-extended-release-capsule-qsymia-7-5mg-46mg-extended-release-capsule--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Qsymia and lifestyle management therapy for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/qsymia-and-lifestyle-management-therapy--pediatric-obesity#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/qsymia-and-lifestyle-management-therapy--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Qsymia for obesity</title>
    <id>https://staging.whatcameofit.com/qsymia--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/qsymia--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Quabodepistat for tuberculosis, multidrug-resistant</title>
    <id>https://staging.whatcameofit.com/quabodepistat--tuberculosis-multidrug-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/quabodepistat--tuberculosis-multidrug-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Quality of Life + Functional outcome + preoperative for dermatofibrosarcoma</title>
    <id>https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--dermatofibrosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--dermatofibrosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Quality of Life + Functional outcome + preoperative for histiocytoma, malignant fibrous</title>
    <id>https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--histiocytoma-malignant-fibrous#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--histiocytoma-malignant-fibrous"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Quality of Life + Functional outcome + preoperative for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Quality of Life + Functional outcome + preoperative for liposarcoma</title>
    <id>https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--liposarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--liposarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Quality of Life + Functional outcome + preoperative for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--sarcoma-synovial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-functional-outcome-preoperative--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/quality-of-life-assessment-nivolumab-ipilimumab--adenocarcinoma-of-lung#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-assessment-nivolumab-ipilimumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/quality-of-life-assessment-questionnaire-administration-recombinant-human-egf-rp64k-montanide-isa-51-vaccine--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/quality-of-life-assessment-questionnaire-administration-recombinant-human-egf-rp64k-montanide-isa-51-vaccine--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Questionnaire Administration + Dordaviprone + Paclitaxel for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/questionnaire-administration-dordaviprone-paclitaxel--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/questionnaire-administration-dordaviprone-paclitaxel--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Questionnaires + Waitlist Control for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/questionnaires-waitlist-control--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/questionnaires-waitlist-control--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Questionnaires for alcoholism</title>
    <id>https://staging.whatcameofit.com/questionnaires--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/questionnaires--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Questionnaires for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/questionnaires--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/questionnaires--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Quetiapine for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/quetiapine--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/quetiapine--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>R21 in Matrix- M adjuvant vaccine for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/r21-in-matrix-m-adjuvant-vaccine--malaria-falciparum#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/r21-in-matrix-m-adjuvant-vaccine--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>R21/Matrix-M - single vial formulation for malaria</title>
    <id>https://staging.whatcameofit.com/r21-matrix-m-single-vial-formulation--malaria#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/r21-matrix-m-single-vial-formulation--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>R21/Matrix-M - two vial formulation for malaria</title>
    <id>https://staging.whatcameofit.com/r21-matrix-m-two-vial-formulation--malaria#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/r21-matrix-m-two-vial-formulation--malaria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>rAAV2.REP1 for choroideremia</title>
    <id>https://staging.whatcameofit.com/raav2-rep1--choroideremia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/raav2-rep1--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>rAAV2.REP1 for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/raav2-rep1--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/raav2-rep1--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>rAAV2.REP1 vector for choroideremia</title>
    <id>https://staging.whatcameofit.com/raav2-rep1-vector--choroideremia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/raav2-rep1-vector--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Rabeprazole sodium for gastroesophageal reflux</title>
    <id>https://staging.whatcameofit.com/rabeprazole-sodium--gastroesophageal-reflux#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rabeprazole-sodium--gastroesophageal-reflux"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>rabies vaccine for rabies</title>
    <id>https://staging.whatcameofit.com/rabies-vaccine--rabies#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rabies-vaccine--rabies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/radiation-therapy-oxaliplatin-docetaxel-levoleucovorin-pembrolizumab-fluorouracil--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radiation-therapy-oxaliplatin-docetaxel-levoleucovorin-pembrolizumab-fluorouracil--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Radiation Therapy + Radical Prostatectomy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radiation-therapy-radical-prostatectomy--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/radiation-therapy-radical-prostatectomy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Radiation Therapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radiation-therapy--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radiation-therapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Radiation Therapy for sarcoma</title>
    <id>https://staging.whatcameofit.com/radiation-therapy--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/radiation-therapy--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/radical-surgery-camrelizumab-paclitaxel-cisplatin--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radical-surgery-camrelizumab-paclitaxel-cisplatin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastoma</title>
    <id>https://staging.whatcameofit.com/radiodynamic-therapy-aminolevulinic-acid-hydrochloride--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/radiodynamic-therapy-aminolevulinic-acid-hydrochloride--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/radiotherapy-cisplatin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radiotherapy-cisplatin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Radiotherapy + TRABECTEDIN for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/radiotherapy-trabectedin--leiomyosarcoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/radiotherapy-trabectedin--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Radiotherapy + TRABECTEDIN for liposarcoma, myxoid</title>
    <id>https://staging.whatcameofit.com/radiotherapy-trabectedin--liposarcoma-myxoid#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/radiotherapy-trabectedin--liposarcoma-myxoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Radiotherapy for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radiotherapy--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/radiotherapy--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Radiotherapy in painting dose on histoscannographic mapping for neoplasms</title>
    <id>https://staging.whatcameofit.com/radiotherapy-in-painting-dose-on-histoscannographic-mapping--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radiotherapy-in-painting-dose-on-histoscannographic-mapping--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>radium Ra 223 dichloride + Laboratory Biomarker Analysis + Enzalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radium-ra-223-dichloride-laboratory-biomarker-analysis-enzalutamide--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/radium-ra-223-dichloride-laboratory-biomarker-analysis-enzalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Olaparib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radium-ra-223-dichloride-magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-quality-of-life-assessment-olaparib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/radium-ra-223-dichloride-magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-quality-of-life-assessment-olaparib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>radium Ra 223 dichloride + Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Quality-of-Life Assessment for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/radium-ra-223-dichloride-magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-quality-of-life-assessment--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/radium-ra-223-dichloride-magnetic-resonance-imaging-biopsy-procedure-biospecimen-collection-computed-tomography-laboratory-biomarker-analysis-quality-of-life-assessment--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Randomized, staggered withdrawal phase for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/randomized-staggered-withdrawal-phase--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/randomized-staggered-withdrawal-phase--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Randomized, staggered withdrawal phase for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/randomized-staggered-withdrawal-phase--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/randomized-staggered-withdrawal-phase--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ranolazine for heart failure</title>
    <id>https://staging.whatcameofit.com/ranolazine--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ranolazine--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ranolazine for ventricular dysfunction, right</title>
    <id>https://staging.whatcameofit.com/ranolazine--ventricular-dysfunction-right#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ranolazine--ventricular-dysfunction-right"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RAP-219 for epilepsies, partial</title>
    <id>https://staging.whatcameofit.com/rap-219--epilepsies-partial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rap-219--epilepsies-partial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RAP-219 for seizures</title>
    <id>https://staging.whatcameofit.com/rap-219--seizures#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rap-219--seizures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rapid sedation for status epilepticus</title>
    <id>https://staging.whatcameofit.com/rapid-sedation--status-epilepticus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rapid-sedation--status-epilepticus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>RAY1225 for obesity</title>
    <id>https://staging.whatcameofit.com/ray1225--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ray1225--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RBX2660 (microbiota suspension) for clostridium infections</title>
    <id>https://staging.whatcameofit.com/rbx2660-microbiota-suspension--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rbx2660-microbiota-suspension--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>RBX2660 for clostridium infections</title>
    <id>https://staging.whatcameofit.com/rbx2660--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rbx2660--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>RBX2660 for communicable diseases</title>
    <id>https://staging.whatcameofit.com/rbx2660--communicable-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rbx2660--communicable-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ready-to-use supplementary food (RUSF) arm for malnutrition</title>
    <id>https://staging.whatcameofit.com/ready-to-use-supplementary-food-rusf-arm--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ready-to-use-supplementary-food-rusf-arm--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>real-time fMRI neurofeedback training + Ketamine for cocaine-related disorders</title>
    <id>https://staging.whatcameofit.com/real-time-fmri-neurofeedback-training-ketamine--cocaine-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/real-time-fmri-neurofeedback-training-ketamine--cocaine-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>real-time fMRI neurofeedback training for cocaine-related disorders</title>
    <id>https://staging.whatcameofit.com/real-time-fmri-neurofeedback-training--cocaine-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/real-time-fmri-neurofeedback-training--cocaine-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Receive tDCS+CR for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/receive-tdcs-cr--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/receive-tdcs-cr--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Receive tDCS+CR for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/receive-tdcs-cr--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/receive-tdcs-cr--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Receive tDCS+CR for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/receive-tdcs-cr--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/receive-tdcs-cr--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>RECLAIM System for locked-in syndrome</title>
    <id>https://staging.whatcameofit.com/reclaim-system--locked-in-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/reclaim-system--locked-in-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recombinant G-CSF for abortion, habitual</title>
    <id>https://staging.whatcameofit.com/recombinant-g-csf--abortion-habitual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/recombinant-g-csf--abortion-habitual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Recombinant Human Thymosin Beta 4 Injection (NL005) for anterior wall myocardial infarction</title>
    <id>https://staging.whatcameofit.com/recombinant-human-thymosin-beta-4-injection-nl005--anterior-wall-myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recombinant-human-thymosin-beta-4-injection-nl005--anterior-wall-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recombinant Human Thymosin Beta 4 Injection (NL005) for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/recombinant-human-thymosin-beta-4-injection-nl005--st-elevation-myocardial-infarction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recombinant-human-thymosin-beta-4-injection-nl005--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Recombinant varicella zoster virus glycoprotein e antigen for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recombinant varicella zoster virus glycoprotein e antigen for dementia</title>
    <id>https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--dementia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--dementia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster</title>
    <id>https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--herpes-zoster#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--herpes-zoster"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Recombinant varicella zoster virus glycoprotein e antigen for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/recombinant-varicella-zoster-virus-glycoprotein-e-antigen--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/recombinant-zaire-ebolavirus-kikwit-95-envelope-glycoprotein-modified-vesicular-stomatitis-virus--hemorrhagic-fever-ebola#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/recombinant-zaire-ebolavirus-kikwit-95-envelope-glycoprotein-modified-vesicular-stomatitis-virus--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Recorded Maternal Voice for premature birth</title>
    <id>https://staging.whatcameofit.com/recorded-maternal-voice--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recorded-maternal-voice--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for alcoholism</title>
    <id>https://staging.whatcameofit.com/recovery-management-checkups-rmc-delivered-by-community-based-agencies-rmc-adopters--alcoholism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recovery-management-checkups-rmc-delivered-by-community-based-agencies-rmc-adopters--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/recovery-management-checkups-rmc-delivered-by-community-based-agencies-rmc-adopters--opioid-related-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/recovery-management-checkups-rmc-delivered-by-community-based-agencies-rmc-adopters--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Red Heart Pill 2b (Polypill) for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/red-heart-pill-2b-polypill--cardiovascular-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/red-heart-pill-2b-polypill--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplastic</title>
    <id>https://staging.whatcameofit.com/reduced-dose-conditioning-regimen-containing-tbi-in-hematopoietic-stem-cell-transplantation-treating-elderly-patients-with-aplastic-anemia--anemia-aplastic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/reduced-dose-conditioning-regimen-containing-tbi-in-hematopoietic-stem-cell-transplantation-treating-elderly-patients-with-aplastic-anemia--anemia-aplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>reduced-dose PTCy for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/reduced-dose-ptcy--graft-vs-host-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/reduced-dose-ptcy--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Regadenoson for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/regadenoson--coronary-artery-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/regadenoson--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Regorafenib for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/regorafenib--osteosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/regorafenib--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Regorafinib for neoplasms</title>
    <id>https://staging.whatcameofit.com/regorafinib--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/regorafinib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Relacorilant + nab-paclitaxel for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/relacorilant-nab-paclitaxel--fallopian-tube-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/relacorilant-nab-paclitaxel--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Relacorilant for cushing syndrome</title>
    <id>https://staging.whatcameofit.com/relacorilant--cushing-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/relacorilant--cushing-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Relacorilant for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/relacorilant--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/relacorilant--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Relacorilant for insulin resistance</title>
    <id>https://staging.whatcameofit.com/relacorilant--insulin-resistance#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/relacorilant--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Relapse prevention cognitive behavioral therapy (CBT) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/relapse-prevention-cognitive-behavioral-therapy-cbt--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/relapse-prevention-cognitive-behavioral-therapy-cbt--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Relugolix for leiomyoma</title>
    <id>https://staging.whatcameofit.com/relugolix--leiomyoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/relugolix--leiomyoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Relugolix for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/relugolix--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/relugolix--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Relutrigine for spasms, infantile</title>
    <id>https://staging.whatcameofit.com/relutrigine--spasms-infantile#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/relutrigine--spasms-infantile"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Remestemcel-l for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/remestemcel-l--graft-vs-host-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/remestemcel-l--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rentosertib for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/rentosertib--idiopathic-pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rentosertib--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>REPAIR Sleep for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/repair-sleep--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/repair-sleep--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>REPAIR Sleep for cognition disorders</title>
    <id>https://staging.whatcameofit.com/repair-sleep--cognition-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/repair-sleep--cognition-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Repairing Gel and Platelet-Rich Plasma-Fibrin Glue for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/repairing-gel-and-platelet-rich-plasma-fibrin-glue--wounds-and-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/repairing-gel-and-platelet-rich-plasma-fibrin-glue--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Repairing Gel for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/repairing-gel--wounds-and-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/repairing-gel--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Reproductive organ sparing radical cystectomy for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/reproductive-organ-sparing-radical-cystectomy--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/reproductive-organ-sparing-radical-cystectomy--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rescue in vitro maturation with iPSC-derived ovarian support cell co-culture for infertility</title>
    <id>https://staging.whatcameofit.com/rescue-in-vitro-maturation-with-ipsc-derived-ovarian-support-cell-co-culture--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rescue-in-vitro-maturation-with-ipsc-derived-ovarian-support-cell-co-culture--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rescue medications + Sacituzumab tirumotecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/rescue-medications-sacituzumab-tirumotecan--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rescue-medications-sacituzumab-tirumotecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Resistant Potato Starch for persian gulf syndrome</title>
    <id>https://staging.whatcameofit.com/resistant-potato-starch--persian-gulf-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/resistant-potato-starch--persian-gulf-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>responsive neurostimulation for obesity, morbid</title>
    <id>https://staging.whatcameofit.com/responsive-neurostimulation--obesity-morbid#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/responsive-neurostimulation--obesity-morbid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>resveratrol mouthwash for gingival hemorrhage</title>
    <id>https://staging.whatcameofit.com/resveratrol-mouthwash--gingival-hemorrhage#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/resveratrol-mouthwash--gingival-hemorrhage"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for cardiovascular diseases</title>
    <id>https://staging.whatcameofit.com/retatrutide--cardiovascular-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--cardiovascular-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/retatrutide--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/retatrutide--diabetes-mellitus#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/retatrutide--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/retatrutide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for insulin resistance</title>
    <id>https://staging.whatcameofit.com/retatrutide--insulin-resistance#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/retatrutide--insulin-resistance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/retatrutide--kidney-failure-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/retatrutide--metabolic-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/retatrutide--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for obesity</title>
    <id>https://staging.whatcameofit.com/retatrutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/retatrutide--osteoarthritis-knee#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for peripheral arterial disease</title>
    <id>https://staging.whatcameofit.com/retatrutide--peripheral-arterial-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--peripheral-arterial-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Retatrutide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/retatrutide--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/retatrutide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Rexlemestrocel-L + HA mixture for intervertebral disc degeneration</title>
    <id>https://staging.whatcameofit.com/rexlemestrocel-l-ha-mixture--intervertebral-disc-degeneration#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rexlemestrocel-l-ha-mixture--intervertebral-disc-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Rexlemestrocel-l for intervertebral disc degeneration</title>
    <id>https://staging.whatcameofit.com/rexlemestrocel-l--intervertebral-disc-degeneration#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rexlemestrocel-l--intervertebral-disc-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>RGH-202 for phobia, social</title>
    <id>https://staging.whatcameofit.com/rgh-202--phobia-social#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rgh-202--phobia-social"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ribupatide for obesity</title>
    <id>https://staging.whatcameofit.com/ribupatide--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ribupatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Right DLPFC tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/right-dlpfc-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/right-dlpfc-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rilzabrutinib for glomerulosclerosis, focal segmental</title>
    <id>https://staging.whatcameofit.com/rilzabrutinib--glomerulosclerosis-focal-segmental#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rilzabrutinib--glomerulosclerosis-focal-segmental"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rilzabrutinib for nephrosis, lipoid</title>
    <id>https://staging.whatcameofit.com/rilzabrutinib--nephrosis-lipoid#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rilzabrutinib--nephrosis-lipoid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rimegepant for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/rimegepant--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rimegepant--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Risankizumab for crohn disease</title>
    <id>https://staging.whatcameofit.com/risankizumab--crohn-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risankizumab--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Risankizumab for psoriasis</title>
    <id>https://staging.whatcameofit.com/risankizumab--psoriasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risankizumab--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Risdiplam for muscular atrophy, spinal</title>
    <id>https://staging.whatcameofit.com/risdiplam--muscular-atrophy-spinal#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risdiplam--muscular-atrophy-spinal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Risperidone for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/risperidone--psychotic-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risperidone--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Risperidone for schizophrenia</title>
    <id>https://staging.whatcameofit.com/risperidone--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risperidone--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Risvutatug rezetecan (Ris-Rez) for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/risvutatug-rezetecan-ris-rez--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/risvutatug-rezetecan-ris-rez--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ritlecitinib 100 mg for alopecia areata</title>
    <id>https://staging.whatcameofit.com/ritlecitinib-100-mg--alopecia-areata#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ritlecitinib-100-mg--alopecia-areata"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Rituximab + belimumab for scleroderma, systemic</title>
    <id>https://staging.whatcameofit.com/rituximab-belimumab--scleroderma-systemic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rituximab-belimumab--scleroderma-systemic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RITUXIMAB + Cyclophosphamide + MP + Busulfan + FLUDARABINE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/rituximab-cyclophosphamide-mp-busulfan-fludarabine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rituximab-cyclophosphamide-mp-busulfan-fludarabine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/rituximab-lenalidomide-acalabrutinib--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rituximab-lenalidomide-acalabrutinib--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rituximab for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/rituximab--psychotic-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rituximab--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rivaroxaban for venous thromboembolism</title>
    <id>https://staging.whatcameofit.com/rivaroxaban--venous-thromboembolism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rivaroxaban--venous-thromboembolism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rivogenlecleucel + rimiducid for anemia, aplastic</title>
    <id>https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--anemia-aplastic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--anemia-aplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rivogenlecleucel + rimiducid for cytopenia</title>
    <id>https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--cytopenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--cytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rivogenlecleucel + rimiducid for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rivogenlecleucel + rimiducid for osteopetrosis</title>
    <id>https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--osteopetrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--osteopetrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rivogenlecleucel + rimiducid for primary immunodeficiency diseases</title>
    <id>https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--primary-immunodeficiency-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rivogenlecleucel-rimiducid--primary-immunodeficiency-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Robot-assisted partial knee arthroplasty for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/robot-assisted-partial-knee-arthroplasty--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/robot-assisted-partial-knee-arthroplasty--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Robot-Assisted Radical Prostatectomy + ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/robot-assisted-radical-prostatectomy-allogeneic-human-amnion-chorion-membrane--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/robot-assisted-radical-prostatectomy-allogeneic-human-amnion-chorion-membrane--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ROC-101 for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/roc-101--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/roc-101--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ROC-101 for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/roc-101--lung-diseases-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/roc-101--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ROC-101 for pulmonary arterial hypertension</title>
    <id>https://staging.whatcameofit.com/roc-101--pulmonary-arterial-hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/roc-101--pulmonary-arterial-hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rocuronium 1.5mg/kg/hr for muscle hypotonia</title>
    <id>https://staging.whatcameofit.com/rocuronium-1-5mg-kg-hr--muscle-hypotonia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rocuronium-1-5mg-kg-hr--muscle-hypotonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rocuronium 1.5mg/kg/hr for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/rocuronium-1-5mg-kg-hr--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rocuronium-1-5mg-kg-hr--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Roflumilast for dermatitis, seborrheic</title>
    <id>https://staging.whatcameofit.com/roflumilast--dermatitis-seborrheic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/roflumilast--dermatitis-seborrheic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Roflumilast for psoriasis</title>
    <id>https://staging.whatcameofit.com/roflumilast--psoriasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/roflumilast--psoriasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Romiplostim for anemia, aplastic</title>
    <id>https://staging.whatcameofit.com/romiplostim--anemia-aplastic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/romiplostim--anemia-aplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Romiplostim for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/romiplostim--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/romiplostim--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>ROPEGINTERFERON ALFA-2B for thrombocythemia, essential</title>
    <id>https://staging.whatcameofit.com/ropeginterferon-alfa-2b--thrombocythemia-essential#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ropeginterferon-alfa-2b--thrombocythemia-essential"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Rosuvastatin for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/rosuvastatin--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rosuvastatin--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rovadicitinib for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/rovadicitinib--graft-vs-host-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rovadicitinib--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>RP-A501 for cardiomyopathy, hypertrophic</title>
    <id>https://staging.whatcameofit.com/rp-a501--cardiomyopathy-hypertrophic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rp-a501--cardiomyopathy-hypertrophic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RP-A501 for hypertrophy, left ventricular</title>
    <id>https://staging.whatcameofit.com/rp-a501--hypertrophy-left-ventricular#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rp-a501--hypertrophy-left-ventricular"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RP-A501 for lysosomal storage diseases</title>
    <id>https://staging.whatcameofit.com/rp-a501--lysosomal-storage-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rp-a501--lysosomal-storage-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RP902 for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/rp902--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rp902--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/rsvpref3-oa-investigational-vaccine--respiratory-syncytial-virus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rsvpref3-oa-investigational-vaccine--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>rTMS treatment + Ketamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/rtms-treatment-ketamine--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rtms-treatment-ketamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>RTx-015 for retinitis pigmentosa</title>
    <id>https://staging.whatcameofit.com/rtx-015--retinitis-pigmentosa#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/rtx-015--retinitis-pigmentosa"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Rucaparib for neoplasms</title>
    <id>https://staging.whatcameofit.com/rucaparib--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/rucaparib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Rugonersen for angelman syndrome</title>
    <id>https://staging.whatcameofit.com/rugonersen--angelman-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/rugonersen--angelman-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib + NAVITOCLAX for neoplasms</title>
    <id>https://staging.whatcameofit.com/ruxolitinib-navitoclax--neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib-navitoclax--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib + NAVITOCLAX for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/ruxolitinib-navitoclax--primary-myelofibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib-navitoclax--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/ruxolitinib--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib for lichen sclerosus et atrophicus</title>
    <id>https://staging.whatcameofit.com/ruxolitinib--lichen-sclerosus-et-atrophicus#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib--lichen-sclerosus-et-atrophicus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/ruxolitinib--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ruxolitinib for vitiligo</title>
    <id>https://staging.whatcameofit.com/ruxolitinib--vitiligo#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ruxolitinib--vitiligo"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ruxoprubart for hemoglobinuria, paroxysmal</title>
    <id>https://staging.whatcameofit.com/ruxoprubart--hemoglobinuria-paroxysmal#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ruxoprubart--hemoglobinuria-paroxysmal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>S-1 + Irinotecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/s-1-irinotecan--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/s-1-irinotecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>S-337395 for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/s-337395--respiratory-syncytial-virus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/s-337395--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>S1B-408 for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/s1b-408--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/s1b-408--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>S241656 + PEMBROLIZUMAB for histiocytosis</title>
    <id>https://staging.whatcameofit.com/s241656-pembrolizumab--histiocytosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/s241656-pembrolizumab--histiocytosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>S241656 + Trametinib for histiocytosis</title>
    <id>https://staging.whatcameofit.com/s241656-trametinib--histiocytosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/s241656-trametinib--histiocytosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>S241656 for histiocytosis</title>
    <id>https://staging.whatcameofit.com/s241656--histiocytosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/s241656--histiocytosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Saccharomyces cerevisiae for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/saccharomyces-cerevisiae--autism-spectrum-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/saccharomyces-cerevisiae--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Saccharomyces cerevisiae for ichthyosis bullosa of siemens</title>
    <id>https://staging.whatcameofit.com/saccharomyces-cerevisiae--ichthyosis-bullosa-of-siemens#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/saccharomyces-cerevisiae--ichthyosis-bullosa-of-siemens"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Saccharomyces cerevisiae for irritable bowel syndrome</title>
    <id>https://staging.whatcameofit.com/saccharomyces-cerevisiae--irritable-bowel-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/saccharomyces-cerevisiae--irritable-bowel-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab + cisplatin for uterine neoplasms</title>
    <id>https://staging.whatcameofit.com/sacituzumab-cisplatin--uterine-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-cisplatin--uterine-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab govitecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/sacituzumab-govitecan--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-govitecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab govitecan for glioblastoma</title>
    <id>https://staging.whatcameofit.com/sacituzumab-govitecan--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-govitecan--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab govitecan for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/sacituzumab-govitecan--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-govitecan--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab tirumotecan for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/sacituzumab-tirumotecan--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-tirumotecan--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab tirumotecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/sacituzumab-tirumotecan--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-tirumotecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab tirumotecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/sacituzumab-tirumotecan--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-tirumotecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sacituzumab tirumotecan for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sacituzumab-tirumotecan--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-tirumotecan--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacituzumab tirumotecan for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/sacituzumab-tirumotecan--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacituzumab-tirumotecan--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sacubitril-valsartan for heart failure</title>
    <id>https://staging.whatcameofit.com/sacubitril-valsartan--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sacubitril-valsartan--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SakuraBead Resorbable Microspheres for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/sakurabead-resorbable-microspheres--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sakurabead-resorbable-microspheres--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SAL0140 for hypertension</title>
    <id>https://staging.whatcameofit.com/sal0140--hypertension#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sal0140--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Satralizumab for myelin oligodendrocyte glycoprotein antibody-associated disease</title>
    <id>https://staging.whatcameofit.com/satralizumab--myelin-oligodendrocyte-glycoprotein-antibody-associated-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/satralizumab--myelin-oligodendrocyte-glycoprotein-antibody-associated-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Savolitinib + Placebo for carcinoma</title>
    <id>https://staging.whatcameofit.com/savolitinib-placebo--carcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/savolitinib-placebo--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Savolitinib + Placebo for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/savolitinib-placebo--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/savolitinib-placebo--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SB-007 for stargardt disease</title>
    <id>https://staging.whatcameofit.com/sb-007--stargardt-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sb-007--stargardt-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SB-01 For Injection for intervertebral disc degeneration</title>
    <id>https://staging.whatcameofit.com/sb-01-for-injection--intervertebral-disc-degeneration#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sb-01-for-injection--intervertebral-disc-degeneration"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sbrt for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/sbrt--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sbrt--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sbrt for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/sbrt--neuroendocrine-tumors#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sbrt--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>scaffold-free SHED-derived pellet for dental pulp necrosis</title>
    <id>https://staging.whatcameofit.com/scaffold-free-shed-derived-pellet--dental-pulp-necrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/scaffold-free-shed-derived-pellet--dental-pulp-necrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Scar gel for keloid</title>
    <id>https://staging.whatcameofit.com/scar-gel--keloid#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/scar-gel--keloid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sea-it for combat disorders</title>
    <id>https://staging.whatcameofit.com/sea-it--combat-disorders#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sea-it--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sea-it for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/sea-it--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sea-it--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Segmentectomy for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/segmentectomy--adenocarcinoma-of-lung#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/segmentectomy--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Selective coverage radiotherapy for thyroid carcinoma, anaplastic</title>
    <id>https://staging.whatcameofit.com/selective-coverage-radiotherapy--thyroid-carcinoma-anaplastic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/selective-coverage-radiotherapy--thyroid-carcinoma-anaplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Selinexor for glioblastoma</title>
    <id>https://staging.whatcameofit.com/selinexor--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/selinexor--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Selinexor for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/selinexor--primary-myelofibrosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/selinexor--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Selinexor for rhabdoid tumor</title>
    <id>https://staging.whatcameofit.com/selinexor--rhabdoid-tumor#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/selinexor--rhabdoid-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cell</title>
    <id>https://staging.whatcameofit.com/selinexor-anti-pd-1-antibody-plus-golidocitinib--lymphoma-extranodal-nk-t-cell#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/selinexor-anti-pd-1-antibody-plus-golidocitinib--lymphoma-extranodal-nk-t-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Selnoflast for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/selnoflast--atherosclerosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/selnoflast--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Selpercatinib for carcinoma, medullary</title>
    <id>https://staging.whatcameofit.com/selpercatinib--carcinoma-medullary#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/selpercatinib--carcinoma-medullary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semagludtide for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/semagludtide--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semagludtide--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + BIMAGRUMAB for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide-bimagrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide-bimagrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + Cagrilintide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/semaglutide-cagrilintide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide-cagrilintide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + Cagrilintide for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide-cagrilintide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide-cagrilintide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + Cagrilintide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/semaglutide-cagrilintide--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide-cagrilintide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide-trevogrumab-garetosmab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide-trevogrumab-garetosmab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide + TREVOGRUMAB for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide-trevogrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide-trevogrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/semaglutide--atherosclerosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for atrial fibrillation</title>
    <id>https://staging.whatcameofit.com/semaglutide--atrial-fibrillation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--atrial-fibrillation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/semaglutide--diabetes-mellitus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/semaglutide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for glucose intolerance</title>
    <id>https://staging.whatcameofit.com/semaglutide--glucose-intolerance#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide--glucose-intolerance"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/semaglutide--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide--pediatric-obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/semaglutide--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for prediabetic state</title>
    <id>https://staging.whatcameofit.com/semaglutide--prediabetic-state#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/semaglutide--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/semaglutide--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/semaglutide--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG for obesity</title>
    <id>https://staging.whatcameofit.com/semaglutide-1-34-mg-ml-and-metformin-hydrochloride-500-mg--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide-1-34-mg-ml-and-metformin-hydrochloride-500-mg--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sense4Safety for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/sense4safety--cognitive-dysfunction#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sense4safety--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sequential cytoreductive intervention for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/sequential-cytoreductive-intervention--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sequential-cytoreductive-intervention--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>sequential IVM system for infertility</title>
    <id>https://staging.whatcameofit.com/sequential-ivm-system--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sequential-ivm-system--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sernova Cell Pouch for hypoglycemia</title>
    <id>https://staging.whatcameofit.com/sernova-cell-pouch--hypoglycemia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sernova-cell-pouch--hypoglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Serplulimab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/serplulimab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/serplulimab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sertraline for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/sertraline--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sertraline--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>sertraline, lithium for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/sertraline-lithium--bipolar-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sertraline-lithium--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>sertraline, lithium for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/sertraline-lithium--major-depressive-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sertraline-lithium--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Service-only Fitting for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/service-only-fitting--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/service-only-fitting--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Service-only Fitting for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/service-only-fitting--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/service-only-fitting--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>sex therapy + Flibanserin for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/sex-therapy-flibanserin--sexual-dysfunctions-psychological#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/sex-therapy-flibanserin--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>SGB - Combined Solution of Bupivacaine + Ketamine Adjuvant for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/sgb-combined-solution-of-bupivacaine-ketamine-adjuvant--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sgb-combined-solution-of-bupivacaine-ketamine-adjuvant--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>sham acupuncture + SSRIs for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/sham-acupuncture-ssris--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sham-acupuncture-ssris--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sham neurofeedback for borderline personality disorder</title>
    <id>https://staging.whatcameofit.com/sham-neurofeedback--borderline-personality-disorder#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sham-neurofeedback--borderline-personality-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SHJ002 for myopia, degenerative</title>
    <id>https://staging.whatcameofit.com/shj002--myopia-degenerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/shj002--myopia-degenerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SHR-1918 for homozygous familial hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/shr-1918--homozygous-familial-hypercholesterolemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/shr-1918--homozygous-familial-hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SHR-A1811 Injection for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/shr-a1811-injection--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/shr-a1811-injection--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Shuganjieyu capsule for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/shuganjieyu-capsule--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/shuganjieyu-capsule--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/si-b003-izalontamab-brengitecan--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/si-b003-izalontamab-brengitecan--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SI-B003 + Izalontamab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/si-b003-izalontamab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/si-b003-izalontamab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sigma hp partial knee for chondrocalcinosis</title>
    <id>https://staging.whatcameofit.com/sigma-hp-partial-knee--chondrocalcinosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sigma-hp-partial-knee--chondrocalcinosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sigma hp partial knee for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/sigma-hp-partial-knee--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sigma-hp-partial-knee--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sigvotatug Vedotin for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sigvotatug-vedotin--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sigvotatug Vedotin for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/sigvotatug-vedotin--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sigvotatug-vedotin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sildenafil Citrate for dyspnea</title>
    <id>https://staging.whatcameofit.com/sildenafil-citrate--dyspnea#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sildenafil-citrate--dyspnea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sildenafil Citrate for fetal growth retardation</title>
    <id>https://staging.whatcameofit.com/sildenafil-citrate--fetal-growth-retardation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sildenafil-citrate--fetal-growth-retardation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sildenafil Citrate for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/sildenafil-citrate--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sildenafil-citrate--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sildenafil for fetal growth retardation</title>
    <id>https://staging.whatcameofit.com/sildenafil--fetal-growth-retardation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sildenafil--fetal-growth-retardation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Silkworm pupa tablets for malnutrition</title>
    <id>https://staging.whatcameofit.com/silkworm-pupa-tablets--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/silkworm-pupa-tablets--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Silkworm pupa tablets for sarcopenia</title>
    <id>https://staging.whatcameofit.com/silkworm-pupa-tablets--sarcopenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/silkworm-pupa-tablets--sarcopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Silver Diamine Fluoride (SDF) for dental caries</title>
    <id>https://staging.whatcameofit.com/silver-diamine-fluoride-sdf--dental-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/silver-diamine-fluoride-sdf--dental-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Silver diammine fluoride for heart arrest</title>
    <id>https://staging.whatcameofit.com/silver-diammine-fluoride--heart-arrest#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/silver-diammine-fluoride--heart-arrest"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Silver diammine fluoride for root caries</title>
    <id>https://staging.whatcameofit.com/silver-diammine-fluoride--root-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/silver-diammine-fluoride--root-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Simple cognitive task for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/simple-cognitive-task--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/simple-cognitive-task--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Simufilam for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/simufilam--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/simufilam--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for laryngeal diseases</title>
    <id>https://staging.whatcameofit.com/simultaneous-integrated-boost-intensity-modulated-radiation-therapy-volume-modulated-arc-therapy-nivolumab-ipilimumab--laryngeal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/simultaneous-integrated-boost-intensity-modulated-radiation-therapy-volume-modulated-arc-therapy-nivolumab-ipilimumab--laryngeal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/simultaneous-integrated-boost-intensity-modulated-radiation-therapy-volume-modulated-arc-therapy-nivolumab-ipilimumab--lung-diseases-interstitial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/simultaneous-integrated-boost-intensity-modulated-radiation-therapy-volume-modulated-arc-therapy-nivolumab-ipilimumab--lung-diseases-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>single FMT for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/single-fmt--colitis-ulcerative#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/single-fmt--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Single high dose of liposomal amphotericin B for histoplasmosis</title>
    <id>https://staging.whatcameofit.com/single-high-dose-of-liposomal-amphotericin-b--histoplasmosis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/single-high-dose-of-liposomal-amphotericin-b--histoplasmosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Single Photon Emission Computed Tomography + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/single-photon-emission-computed-tomography-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/single-photon-emission-computed-tomography-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SINTILIMAB + Megestrol + MEDROXYPROGESTERONE for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/sintilimab-megestrol-medroxyprogesterone--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sintilimab-megestrol-medroxyprogesterone--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sintilimab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/sintilimab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sintilimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Siremadlin + PAZOPANIB for sarcoma</title>
    <id>https://staging.whatcameofit.com/siremadlin-pazopanib--sarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/siremadlin-pazopanib--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sirolimus for arteriovenous malformations</title>
    <id>https://staging.whatcameofit.com/sirolimus--arteriovenous-malformations#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sirolimus--arteriovenous-malformations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sirolimus for corneal dystrophies, hereditary</title>
    <id>https://staging.whatcameofit.com/sirolimus--corneal-dystrophies-hereditary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sirolimus--corneal-dystrophies-hereditary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sirolimus for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/sirolimus--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sirolimus--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SKG0201 Injection for spinal muscular atrophies of childhood</title>
    <id>https://staging.whatcameofit.com/skg0201-injection--spinal-muscular-atrophies-of-childhood#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/skg0201-injection--spinal-muscular-atrophies-of-childhood"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Skin of Nile tilapia for burns</title>
    <id>https://staging.whatcameofit.com/skin-of-nile-tilapia--burns#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/skin-of-nile-tilapia--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Skin Xenotransplant for burns</title>
    <id>https://staging.whatcameofit.com/skin-xenotransplant--burns#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/skin-xenotransplant--burns"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Small interfering RNA (siRNA) Microneedle Patches for keloid</title>
    <id>https://staging.whatcameofit.com/small-interfering-rna-sirna-microneedle-patches--keloid#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/small-interfering-rna-sirna-microneedle-patches--keloid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SmartSleep EEG recording headband + Ketamine for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/smartsleep-eeg-recording-headband-ketamine--stress-disorders-post-traumatic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/smartsleep-eeg-recording-headband-ketamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>SNP-610 for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/snp-610--non-alcoholic-fatty-liver-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/snp-610--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Soaked lesu for malaria, falciparum</title>
    <id>https://staging.whatcameofit.com/soaked-lesu--malaria-falciparum#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/soaked-lesu--malaria-falciparum"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/soc-plus-trastuzumab-and-pembrolizumab--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/soc-plus-trastuzumab-and-pembrolizumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sodium lactate for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/sodium-lactate--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sodium-lactate--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sodium oligo-mannurarate 600mg for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/sodium-oligo-mannurarate-600mg--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sodium-oligo-mannurarate-600mg--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sodium oligo-mannurarate 600mg for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/sodium-oligo-mannurarate-600mg--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sodium-oligo-mannurarate-600mg--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sodium oligo-mannurarate 900mg for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/sodium-oligo-mannurarate-900mg--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sodium-oligo-mannurarate-900mg--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sodium oligo-mannurarate 900mg for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/sodium-oligo-mannurarate-900mg--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sodium-oligo-mannurarate-900mg--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sodium Oligomannate Capsules for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/sodium-oligomannate-capsules--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sodium-oligomannate-capsules--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sodium zirconium cyclosilicate for heart failure</title>
    <id>https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sodium zirconium cyclosilicate for hyperkalemia</title>
    <id>https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--hyperkalemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--hyperkalemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sodium zirconium cyclosilicate for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sodium-zirconium-cyclosilicate--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Solanezumab for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/solanezumab--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/solanezumab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>solifenacin combined with gabapentin for urinary bladder, overactive</title>
    <id>https://staging.whatcameofit.com/solifenacin-combined-with-gabapentin--urinary-bladder-overactive#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/solifenacin-combined-with-gabapentin--urinary-bladder-overactive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Solizmestrocel for bronchopulmonary dysplasia</title>
    <id>https://staging.whatcameofit.com/solizmestrocel--bronchopulmonary-dysplasia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/solizmestrocel--bronchopulmonary-dysplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Solizmestrocel for erectile dysfunction</title>
    <id>https://staging.whatcameofit.com/solizmestrocel--erectile-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/solizmestrocel--erectile-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Solizmestrocel for premature birth</title>
    <id>https://staging.whatcameofit.com/solizmestrocel--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/solizmestrocel--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Solizmestrocel for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/solizmestrocel--respiratory-distress-syndrome#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/solizmestrocel--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Solriamfetol for binge-eating disorder</title>
    <id>https://staging.whatcameofit.com/solriamfetol--binge-eating-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/solriamfetol--binge-eating-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sonesitatug Vedotin + Rilvegostomig for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/sonesitatug-vedotin-rilvegostomig--adenocarcinoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sonesitatug-vedotin-rilvegostomig--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sonesitatug Vedotin for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/sonesitatug-vedotin--adenocarcinoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/sonesitatug-vedotin--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastoma</title>
    <id>https://staging.whatcameofit.com/sonication-for-opening-of-blood-brain-barrier-carboplatin-nab-paclitaxel--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonication-for-opening-of-blood-brain-barrier-carboplatin-nab-paclitaxel--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcoma</title>
    <id>https://staging.whatcameofit.com/sonication-for-opening-of-blood-brain-barrier-carboplatin-nab-paclitaxel--gliosarcoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonication-for-opening-of-blood-brain-barrier-carboplatin-nab-paclitaxel--gliosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SonoCloud-4 (SC4) device for neuroinflammatory diseases</title>
    <id>https://staging.whatcameofit.com/sonocloud-4-sc4-device--neuroinflammatory-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonocloud-4-sc4-device--neuroinflammatory-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax + Azacitidine for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/sonrotoclax-azacitidine--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax-azacitidine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax + Azacitidine for myelodysplastic-myeloproliferative diseases</title>
    <id>https://staging.whatcameofit.com/sonrotoclax-azacitidine--myelodysplastic-myeloproliferative-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax-azacitidine--myelodysplastic-myeloproliferative-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/sonrotoclax-posaconazole-azacitidine--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax-posaconazole-azacitidine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax + Posaconazole + Azacitidine for myelodysplastic-myeloproliferative diseases</title>
    <id>https://staging.whatcameofit.com/sonrotoclax-posaconazole-azacitidine--myelodysplastic-myeloproliferative-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax-posaconazole-azacitidine--myelodysplastic-myeloproliferative-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/sonrotoclax--myelodysplastic-syndromes#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sonrotoclax for myelodysplastic-myeloproliferative diseases</title>
    <id>https://staging.whatcameofit.com/sonrotoclax--myelodysplastic-myeloproliferative-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sonrotoclax--myelodysplastic-myeloproliferative-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Sotorasib for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/sotorasib--adenocarcinoma-of-lung#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sotorasib--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Soy-tomato juice product + Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed for pancreatitis, chronic</title>
    <id>https://staging.whatcameofit.com/soy-tomato-juice-product-will-include-a-soy-tomato-juice-product-to-be-consumed-during-the-4-week-intervention-phase-a-total-of-about-12-ounces-administered-in-two-small-cans-of-the-juice-will-be-consumed--pancreatitis-chronic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/soy-tomato-juice-product-will-include-a-soy-tomato-juice-product-to-be-consumed-during-the-4-week-intervention-phase-a-total-of-about-12-ounces-administered-in-two-small-cans-of-the-juice-will-be-consumed--pancreatitis-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/spartalizumab--adenocarcinoma-of-lung#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/spartalizumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/spartalizumab--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for mesothelioma</title>
    <id>https://staging.whatcameofit.com/spartalizumab--mesothelioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--mesothelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for neoplasms, unknown primary</title>
    <id>https://staging.whatcameofit.com/spartalizumab--neoplasms-unknown-primary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--neoplasms-unknown-primary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for sarcoma</title>
    <id>https://staging.whatcameofit.com/spartalizumab--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/spartalizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spartalizumab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/spartalizumab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spartalizumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab for neoplasms</title>
    <id>https://staging.whatcameofit.com/spatially-fractionated-radiation-therapy-followed-by-sequential-hypofractionated-or-conventional-fractionated-radiotherapy-combined-with-iparomlimab-and-tuvonralimab--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spatially-fractionated-radiation-therapy-followed-by-sequential-hypofractionated-or-conventional-fractionated-radiotherapy-combined-with-iparomlimab-and-tuvonralimab--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhood</title>
    <id>https://staging.whatcameofit.com/spinal-cord-stimulator-octopolar-medtronic-vectris-leads--spinal-muscular-atrophies-of-childhood#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/spinal-cord-stimulator-octopolar-medtronic-vectris-leads--spinal-muscular-atrophies-of-childhood"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SPK-8011QQ for hemophilia a</title>
    <id>https://staging.whatcameofit.com/spk-8011qq--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/spk-8011qq--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SPT-300 for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/spt-300--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spt-300--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPT-300 for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/spt-300--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spt-300--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY001 + SPY002 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy001-spy002--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy001-spy002--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY001 + SPY003 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy001-spy003--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy001-spy003--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY001 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy001--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy001--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY002 + SPY003 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy002-spy003--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy002-spy003--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY002 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy002--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy002--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY002-072 for axial spondyloarthritis</title>
    <id>https://staging.whatcameofit.com/spy002-072--axial-spondyloarthritis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy002-072--axial-spondyloarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY002-072 for collagen diseases</title>
    <id>https://staging.whatcameofit.com/spy002-072--collagen-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy002-072--collagen-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SPY003 for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/spy003--colitis-ulcerative#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/spy003--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SR604 for factor vii deficiency</title>
    <id>https://staging.whatcameofit.com/sr604--factor-vii-deficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sr604--factor-vii-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SR604 for hemophilia a</title>
    <id>https://staging.whatcameofit.com/sr604--hemophilia-a#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sr604--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SR604 for hemophilia b</title>
    <id>https://staging.whatcameofit.com/sr604--hemophilia-b#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/sr604--hemophilia-b"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SR604 for von willebrand diseases</title>
    <id>https://staging.whatcameofit.com/sr604--von-willebrand-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sr604--von-willebrand-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Srs + retifanlimab + ragifilimab for glioblastoma</title>
    <id>https://staging.whatcameofit.com/srs-retifanlimab-ragifilimab--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/srs-retifanlimab-ragifilimab--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SSRI/SNRI + Esketamine for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/ssri-snri-esketamine--depressive-disorder-treatment-resistant#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ssri-snri-esketamine--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>SSRI/SNRI + Esketamine for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/ssri-snri-esketamine--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ssri-snri-esketamine--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>STAM 1100mAh CE4 eGo Clearomizer for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/stam-1100mah-ce4-ego-clearomizer--tobacco-use-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stam-1100mah-ce4-ego-clearomizer--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>standard care + rotigotine at 4 mg/24h for 24 months. for kidney diseases</title>
    <id>https://staging.whatcameofit.com/standard-care-rotigotine-at-4-mg-24h-for-24-months--kidney-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-care-rotigotine-at-4-mg-24h-for-24-months--kidney-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard cytotherapy + Bemarituzumab for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/standard-cytotherapy-bemarituzumab--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-cytotherapy-bemarituzumab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard cytotherapy + DEPATUXIZUMAB for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/standard-cytotherapy-depatuxizumab--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-cytotherapy-depatuxizumab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard cytotherapy + NIVOLUMAB for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/standard-cytotherapy-nivolumab--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-cytotherapy-nivolumab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard cytotherapy + RAMUCIRUMAB for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/standard-cytotherapy-ramucirumab--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-cytotherapy-ramucirumab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard cytotherapy + TRASTUZUMAB for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/standard-cytotherapy-trastuzumab--adenocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-cytotherapy-trastuzumab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard of Care (SOC) for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/standard-of-care-soc--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-soc--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard of Care (SOC) for lymphedema</title>
    <id>https://staging.whatcameofit.com/standard-of-care-soc--lymphedema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-soc--lymphedema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard of Care SBRT and ADT + ABIRATERONE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/standard-of-care-sbrt-and-adt-abiraterone--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-sbrt-and-adt-abiraterone--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard of Care SBRT and ADT + Atorvastatin + ABIRATERONE for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/standard-of-care-sbrt-and-adt-atorvastatin-abiraterone--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-sbrt-and-adt-atorvastatin-abiraterone--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standard of Care Surgery + NIVOLUMAB + IPILIMUMAB for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/standard-of-care-surgery-nivolumab-ipilimumab--head-and-neck-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-surgery-nivolumab-ipilimumab--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Standard of Care Surgery + NIVOLUMAB for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/standard-of-care-surgery-nivolumab--head-and-neck-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/standard-of-care-surgery-nivolumab--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Standard Soy Milk for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/standard-soy-milk--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standard-soy-milk--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for malnutrition</title>
    <id>https://staging.whatcameofit.com/standardized-exercize-program-standardized-nutritional-program-whey-protein-supplement-with-added-leucine-and-β-hydroxy-β-methylbutyrate-hmb--malnutrition#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/standardized-exercize-program-standardized-nutritional-program-whey-protein-supplement-with-added-leucine-and-β-hydroxy-β-methylbutyrate-hmb--malnutrition"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for neoplasms</title>
    <id>https://staging.whatcameofit.com/standardized-exercize-program-standardized-nutritional-program-whey-protein-supplement-with-added-leucine-and-β-hydroxy-β-methylbutyrate-hmb--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/standardized-exercize-program-standardized-nutritional-program-whey-protein-supplement-with-added-leucine-and-β-hydroxy-β-methylbutyrate-hmb--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Standardized kudzu for alcoholism</title>
    <id>https://staging.whatcameofit.com/standardized-kudzu--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standardized-kudzu--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Standardized kudzu for sexually transmitted diseases</title>
    <id>https://staging.whatcameofit.com/standardized-kudzu--sexually-transmitted-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/standardized-kudzu--sexually-transmitted-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/stanford-accelerated-intelligent-neuromodulation-therapy-saint-with-the-magnus-neuromodulation-system--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stanford-accelerated-intelligent-neuromodulation-therapy-saint-with-the-magnus-neuromodulation-system--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for memory disorders</title>
    <id>https://staging.whatcameofit.com/stanford-accelerated-intelligent-neuromodulation-therapy-saint-with-the-magnus-neuromodulation-system--memory-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stanford-accelerated-intelligent-neuromodulation-therapy-saint-with-the-magnus-neuromodulation-system--memory-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stem Cell Infusion + Total Body Irradiation + Cyclophosphamide + Mycophenolate Mofetil + TREOSULFAN + FLUDARABINE + Tacrolimus for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/stem-cell-infusion-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-treosulfan-fludarabine-tacrolimus--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/stem-cell-infusion-total-body-irradiation-cyclophosphamide-mycophenolate-mofetil-treosulfan-fludarabine-tacrolimus--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Stent Implantation for pseudotumor cerebri</title>
    <id>https://staging.whatcameofit.com/stent-implantation--pseudotumor-cerebri#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/stent-implantation--pseudotumor-cerebri"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Step count goal for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/step-count-goal--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/step-count-goal--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Step count goal for chronobiology disorders</title>
    <id>https://staging.whatcameofit.com/step-count-goal--chronobiology-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/step-count-goal--chronobiology-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Step count goal for pregnancy complications</title>
    <id>https://staging.whatcameofit.com/step-count-goal--pregnancy-complications#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/step-count-goal--pregnancy-complications"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/stereotactic-ablative-radiotherapy-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/stereotactic-ablative-radiotherapy-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/stereotactic-ablative-radiotherapy-testosterone-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/stereotactic-ablative-radiotherapy-testosterone-lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/stereotactic-body-radiation-therapy-5-days-surgical-resection-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/stereotactic-body-radiation-therapy-5-days-surgical-resection-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>stimulation device for akinetic mutism</title>
    <id>https://staging.whatcameofit.com/stimulation-device--akinetic-mutism#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-device--akinetic-mutism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>stimulation device for persistent vegetative state</title>
    <id>https://staging.whatcameofit.com/stimulation-device--persistent-vegetative-state#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-device--persistent-vegetative-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stimulation for blood pressure with stand for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/stimulation-for-blood-pressure-with-stand--neurogenic-bowel#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-for-blood-pressure-with-stand--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stimulation for blood pressure without stand for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/stimulation-for-blood-pressure-without-stand--neurogenic-bowel#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-for-blood-pressure-without-stand--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stimulation for trunk and core without stand for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/stimulation-for-trunk-and-core-without-stand--neurogenic-bowel#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-for-trunk-and-core-without-stand--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stimulation for trunk or core with stand for neurogenic bowel</title>
    <id>https://staging.whatcameofit.com/stimulation-for-trunk-or-core-with-stand--neurogenic-bowel#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-for-trunk-or-core-with-stand--neurogenic-bowel"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Stimulation-ON for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/stimulation-on--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/stimulation-on--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>STK-001 - Single Ascending Doses for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/stk-001-single-ascending-doses--epilepsies-myoclonic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/stk-001-single-ascending-doses--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) + Psilocybin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) + Psilocybin for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) + Psilocybin for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--wounds-and-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt-psilocybin--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--major-depressive-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--stress-disorders-post-traumatic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured Integrated Reframing Therapy (SIRT) for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--wounds-and-injuries#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/structured-integrated-reframing-therapy-sirt--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Structured weight-loss program for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/structured-weight-loss-program--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/structured-weight-loss-program--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Structured weight-loss program for obesity</title>
    <id>https://staging.whatcameofit.com/structured-weight-loss-program--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/structured-weight-loss-program--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for dry eye syndromes</title>
    <id>https://staging.whatcameofit.com/subconjuntival-injection-of-expanded-allogenic-adult-adipose-tissue-derived-mesenchymal-stem-cells-asc--dry-eye-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/subconjuntival-injection-of-expanded-allogenic-adult-adipose-tissue-derived-mesenchymal-stem-cells-asc--dry-eye-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/subconjuntival-injection-of-expanded-allogenic-adult-adipose-tissue-derived-mesenchymal-stem-cells-asc--graft-vs-host-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/subconjuntival-injection-of-expanded-allogenic-adult-adipose-tissue-derived-mesenchymal-stem-cells-asc--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>subcutaneous Enoxaparin for fetal growth retardation</title>
    <id>https://staging.whatcameofit.com/subcutaneous-enoxaparin--fetal-growth-retardation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/subcutaneous-enoxaparin--fetal-growth-retardation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>subcutaneous Enoxaparin for pre-eclampsia</title>
    <id>https://staging.whatcameofit.com/subcutaneous-enoxaparin--pre-eclampsia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/subcutaneous-enoxaparin--pre-eclampsia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>subcutaneous Enoxaparin for premature birth</title>
    <id>https://staging.whatcameofit.com/subcutaneous-enoxaparin--premature-birth#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/subcutaneous-enoxaparin--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Submucosal Cryotherapy + Dexamethasone Sodium Phosphate for pulpitis</title>
    <id>https://staging.whatcameofit.com/submucosal-cryotherapy-dexamethasone-sodium-phosphate--pulpitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/submucosal-cryotherapy-dexamethasone-sodium-phosphate--pulpitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Submucosal Cryotherapy + Diclofenac Sodium for pulpitis</title>
    <id>https://staging.whatcameofit.com/submucosal-cryotherapy-diclofenac-sodium--pulpitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/submucosal-cryotherapy-diclofenac-sodium--pulpitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Submucosal Cryotherapy for pulpitis</title>
    <id>https://staging.whatcameofit.com/submucosal-cryotherapy--pulpitis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/submucosal-cryotherapy--pulpitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Subventricular Zone radiation for glioblastoma</title>
    <id>https://staging.whatcameofit.com/subventricular-zone-radiation--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/subventricular-zone-radiation--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sucrose for surgical wound infection</title>
    <id>https://staging.whatcameofit.com/sucrose--surgical-wound-infection#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sucrose--surgical-wound-infection"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sugemalimab for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/sugemalimab--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sugemalimab--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sun-exposure-vitamin-d3-supplements--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SUN-627 for neuroinflammatory diseases</title>
    <id>https://staging.whatcameofit.com/sun-627--neuroinflammatory-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sun-627--neuroinflammatory-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Sunitinib for neoplasms</title>
    <id>https://staging.whatcameofit.com/sunitinib--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sunitinib--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Super Floss + Silver diammine fluoride for dental caries</title>
    <id>https://staging.whatcameofit.com/super-floss-silver-diammine-fluoride--dental-caries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/super-floss-silver-diammine-fluoride--dental-caries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/supermicrosurgical-lymphaticovenular-anastomosis-lva--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/supermicrosurgical-lymphaticovenular-anastomosis-lva--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Supportive psychotherapy + Psilocybin + MICROCRYSTALLINE CELLULOSE for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/supportive-psychotherapy-psilocybin-microcrystalline-cellulose--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/supportive-psychotherapy-psilocybin-microcrystalline-cellulose--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Supportive psychotherapy + Psilocybin for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/supportive-psychotherapy-psilocybin--major-depressive-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/supportive-psychotherapy-psilocybin--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma</title>
    <id>https://staging.whatcameofit.com/surgical-resection-pegfilgrastim-vincristine-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/surgical-resection-pegfilgrastim-vincristine-topotecan-cyclophosphamide-carboplatin-filgrastim-cisplatin-methotrexate--medulloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/surufatinib-combined-with-temozolomide-and-s-1--neuroendocrine-tumors#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/surufatinib-combined-with-temozolomide-and-s-1--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Survodutide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/survodutide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/survodutide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Survodutide for liver diseases</title>
    <id>https://staging.whatcameofit.com/survodutide--liver-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/survodutide--liver-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Survodutide for non-alcoholic fatty liver disease</title>
    <id>https://staging.whatcameofit.com/survodutide--non-alcoholic-fatty-liver-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/survodutide--non-alcoholic-fatty-liver-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for agnosia</title>
    <id>https://staging.whatcameofit.com/suzetrigine--agnosia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for breast diseases</title>
    <id>https://staging.whatcameofit.com/suzetrigine--breast-diseases#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--breast-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for hip fractures</title>
    <id>https://staging.whatcameofit.com/suzetrigine--hip-fractures#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--hip-fractures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for nail diseases</title>
    <id>https://staging.whatcameofit.com/suzetrigine--nail-diseases#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--nail-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/suzetrigine--osteoarthritis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/suzetrigine--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for rib fractures</title>
    <id>https://staging.whatcameofit.com/suzetrigine--rib-fractures#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--rib-fractures"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Suzetrigine for urinary incontinence, stress</title>
    <id>https://staging.whatcameofit.com/suzetrigine--urinary-incontinence-stress#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/suzetrigine--urinary-incontinence-stress"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SXRN Injection for neoplasms</title>
    <id>https://staging.whatcameofit.com/sxrn-injection--neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sxrn-injection--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Synsepalum dulcificum fruit for dysgeusia</title>
    <id>https://staging.whatcameofit.com/synsepalum-dulcificum-fruit--dysgeusia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/synsepalum-dulcificum-fruit--dysgeusia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sys6002-becotatug-enlonstobart--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sys6002-becotatug-enlonstobart--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SYS6002 + Enlonstobart for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sys6002-enlonstobart--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sys6002-enlonstobart--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SYS6002 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sys6002--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/sys6002--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sys6010-injection-enlonstobart--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sys6010-injection-enlonstobart--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/sys6010-injection-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/sys6010-injection-pembrolizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>tACS combined with 40 Hz sound stimulation for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/tacs-combined-with-40-hz-sound-stimulation--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tacs-combined-with-40-hz-sound-stimulation--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tactile-kinesthetic stimulation for premature birth</title>
    <id>https://staging.whatcameofit.com/tactile-kinesthetic-stimulation--premature-birth#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tactile-kinesthetic-stimulation--premature-birth"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tafenoquine + chloroquine for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/tafenoquine-chloroquine--malaria-vivax#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tafenoquine-chloroquine--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tafenoquine succinate for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/tafenoquine-succinate--malaria-vivax#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tafenoquine-succinate--malaria-vivax"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/tagraxofusp-azacitidine-venetoclax--neoplasm-residual#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tagraxofusp-azacitidine-venetoclax--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tai Chi (CHI) for hypertension</title>
    <id>https://staging.whatcameofit.com/tai-chi-chi--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tai-chi-chi--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tai Chi (CHI) for prehypertension</title>
    <id>https://staging.whatcameofit.com/tai-chi-chi--prehypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tai-chi-chi--prehypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Taladegib for idiopathic pulmonary fibrosis</title>
    <id>https://staging.whatcameofit.com/taladegib--idiopathic-pulmonary-fibrosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/taladegib--idiopathic-pulmonary-fibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Talazoparib + avelumab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/talazoparib-avelumab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/talazoparib-avelumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>talazoparib plus enzalutamide for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/talazoparib-plus-enzalutamide--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/talazoparib-plus-enzalutamide--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/talimogene-laherparepvec-t-vec--carcinoma-squamous-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/talimogene-laherparepvec-t-vec--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Talimogene laherparepvec + nivolumab + trabectedin for sarcoma</title>
    <id>https://staging.whatcameofit.com/talimogene-laherparepvec-nivolumab-trabectedin--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/talimogene-laherparepvec-nivolumab-trabectedin--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tamoxifen-fulvestrant-anastrozole-abemaciclib-letrozole-imlunestrant-tersolisib-palbociclib-exemestane-ribociclib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tamoxifen for carcinoma, intraductal, noninfiltrating</title>
    <id>https://staging.whatcameofit.com/tamoxifen--carcinoma-intraductal-noninfiltrating#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tamoxifen--carcinoma-intraductal-noninfiltrating"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tamoxifen for neoplasm recurrence, local</title>
    <id>https://staging.whatcameofit.com/tamoxifen--neoplasm-recurrence-local#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tamoxifen--neoplasm-recurrence-local"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tapinarof for keratoderma, palmoplantar</title>
    <id>https://staging.whatcameofit.com/tapinarof--keratoderma-palmoplantar#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tapinarof--keratoderma-palmoplantar"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TAR-0520 gel for hand-foot syndrome</title>
    <id>https://staging.whatcameofit.com/tar-0520-gel--hand-foot-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tar-0520-gel--hand-foot-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Targeted Epidural Spinal Stimulation for autonomic dysreflexia</title>
    <id>https://staging.whatcameofit.com/targeted-epidural-spinal-stimulation--autonomic-dysreflexia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/targeted-epidural-spinal-stimulation--autonomic-dysreflexia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tarlatamab + Temozolomide for glioma</title>
    <id>https://staging.whatcameofit.com/tarlatamab-temozolomide--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tarlatamab-temozolomide--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tarlatamab for carcinoma, neuroendocrine</title>
    <id>https://staging.whatcameofit.com/tarlatamab--carcinoma-neuroendocrine#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tarlatamab--carcinoma-neuroendocrine"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Task-oriented resistance exercise for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/task-oriented-resistance-exercise--cognitive-dysfunction#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/task-oriented-resistance-exercise--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TASQUINIMOD + Ruxolitinib for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/tasquinimod-ruxolitinib--primary-myelofibrosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tasquinimod-ruxolitinib--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tasquinimod for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/tasquinimod--primary-myelofibrosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tasquinimod--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TAU+CBT for pts+Family Intervention+CM. for affective disorders, psychotic</title>
    <id>https://staging.whatcameofit.com/tau-cbt-for-pts-family-intervention-cm--affective-disorders-psychotic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tau-cbt-for-pts-family-intervention-cm--affective-disorders-psychotic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TAU+CBT for pts+Family Intervention+CM. for psychotic disorders</title>
    <id>https://staging.whatcameofit.com/tau-cbt-for-pts-family-intervention-cm--psychotic-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tau-cbt-for-pts-family-intervention-cm--psychotic-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Taurine for cataract</title>
    <id>https://staging.whatcameofit.com/taurine--cataract#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/taurine--cataract"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Taurine for stomatitis</title>
    <id>https://staging.whatcameofit.com/taurine--stomatitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/taurine--stomatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/tcrα-β-and-cd19-depleted-haploidentical-stem-cell-transplantation--anemia-sickle-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tcrα-β-and-cd19-depleted-haploidentical-stem-cell-transplantation--anemia-sickle-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for diphtheria</title>
    <id>https://staging.whatcameofit.com/tdap-tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis--diphtheria#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdap-tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis--diphtheria"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) for tetanus</title>
    <id>https://staging.whatcameofit.com/tdap-tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis--tetanus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdap-tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis--tetanus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TDCS - transcranial direct current stimulation for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/tdcs-transcranial-direct-current-stimulation--anxiety-disorders#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/tdcs-transcranial-direct-current-stimulation--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>tDCS (Eldith DC-Stimulator (CE certified)) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/tdcs-eldith-dc-stimulator-ce-certified--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdcs-eldith-dc-stimulator-ce-certified--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>tDCS for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/tdcs--depressive-disorder-treatment-resistant#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdcs--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>tDCS for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>tDCS over DLPFC for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/tdcs-over-dlpfc--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdcs-over-dlpfc--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>tDCS over DLPFC for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/tdcs-over-dlpfc--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tdcs-over-dlpfc--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Telacebec + Rifampicine for leprosy, multibacillary</title>
    <id>https://staging.whatcameofit.com/telacebec-rifampicine--leprosy-multibacillary#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/telacebec-rifampicine--leprosy-multibacillary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Telacebec 300 mg for leprosy, multibacillary</title>
    <id>https://staging.whatcameofit.com/telacebec-300-mg--leprosy-multibacillary#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/telacebec-300-mg--leprosy-multibacillary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Telacebec 600 mg for leprosy, multibacillary</title>
    <id>https://staging.whatcameofit.com/telacebec-600-mg--leprosy-multibacillary#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/telacebec-600-mg--leprosy-multibacillary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Telesurgery utilizing Microport Medbot Robotic Platform for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/telesurgery-utilizing-microport-medbot-robotic-platform--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/telesurgery-utilizing-microport-medbot-robotic-platform--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Telisotuzumab vedotin for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/telisotuzumab-vedotin--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/telisotuzumab-vedotin--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Telitacicept for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/telitacicept--scleroderma-diffuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/telitacicept--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Telpegfilgrastim for neoplasms</title>
    <id>https://staging.whatcameofit.com/telpegfilgrastim--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/telpegfilgrastim--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) for gonorrhea</title>
    <id>https://staging.whatcameofit.com/temocillin-negaban-2-g-intramuscular-single-dose-with-lidocaine-3ml--gonorrhea#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/temocillin-negaban-2-g-intramuscular-single-dose-with-lidocaine-3ml--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml) for gonorrhea</title>
    <id>https://staging.whatcameofit.com/temocillin-negaban-2-g-intravenous-with-lidocaine-3ml--gonorrhea#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/temocillin-negaban-2-g-intravenous-with-lidocaine-3ml--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Temozolomide for glioblastoma</title>
    <id>https://staging.whatcameofit.com/temozolomide--glioblastoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/temozolomide--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Temozolomide for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/temozolomide--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/temozolomide--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tenecteplase for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/tenecteplase--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tenecteplase--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tenofovir Alafenamide Citrate for renal insufficiency</title>
    <id>https://staging.whatcameofit.com/tenofovir-alafenamide-citrate--renal-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tenofovir-alafenamide-citrate--renal-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Terbium 161- PSMA I&amp;T for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/terbium-161-psma-i-t--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/terbium-161-psma-i-t--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tersolisib for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/tersolisib--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tersolisib--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tersolisib for hereditary sensory and autonomic neuropathies</title>
    <id>https://staging.whatcameofit.com/tersolisib--hereditary-sensory-and-autonomic-neuropathies#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tersolisib--hereditary-sensory-and-autonomic-neuropathies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tersolisib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/tersolisib--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tersolisib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tersolisib for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/tersolisib--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tersolisib--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tersolisib for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/tersolisib--uterine-cervical-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tersolisib--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tertinat for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/tertinat--atherosclerosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tertinat--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tertinat for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/tertinat--coronary-artery-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tertinat--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Test group for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/test-group--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/test-group--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Test group for hypertension</title>
    <id>https://staging.whatcameofit.com/test-group--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/test-group--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Testosterone enanthate for eunuchism</title>
    <id>https://staging.whatcameofit.com/testosterone-enanthate--eunuchism#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/testosterone-enanthate--eunuchism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Testosterone for eunuchism</title>
    <id>https://staging.whatcameofit.com/testosterone--eunuchism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/testosterone--eunuchism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Testosterone for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/testosterone--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/testosterone--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Testosterone for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/testosterone--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/testosterone--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Testosterone undecanoate for sexual dysfunctions, psychological</title>
    <id>https://staging.whatcameofit.com/testosterone-undecanoate--sexual-dysfunctions-psychological#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/testosterone-undecanoate--sexual-dysfunctions-psychological"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tetanus-Diphtheria booster for papillomavirus infections</title>
    <id>https://staging.whatcameofit.com/tetanus-diphtheria-booster--papillomavirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tetanus-diphtheria-booster--papillomavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TEV-56286 for multiple system atrophy</title>
    <id>https://staging.whatcameofit.com/tev-56286--multiple-system-atrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tev-56286--multiple-system-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion &lt;50%, wish to retain their ovaries a BSO may be omitted for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/th-bso-with-snb-note-if-participants-45yo-grade-1-endometrial-adenocarcinoma-with-myometrial-invasion-50-wish-to-retain-their-ovaries-a-bso-may-be-omitted--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/th-bso-with-snb-note-if-participants-45yo-grade-1-endometrial-adenocarcinoma-with-myometrial-invasion-50-wish-to-retain-their-ovaries-a-bso-may-be-omitted--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>The LFP Beta aDBS System for parkinson disease</title>
    <id>https://staging.whatcameofit.com/the-lfp-beta-adbs-system--parkinson-disease#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/the-lfp-beta-adbs-system--parkinson-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band. for asthenopia</title>
    <id>https://staging.whatcameofit.com/the-new-type-of-filtering-glasses-can-efficiently-filter-out-the-high-energy-blue-and-green-light-within-a-narrow-wavelength-band--asthenopia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/the-new-type-of-filtering-glasses-can-efficiently-filter-out-the-high-energy-blue-and-green-light-within-a-narrow-wavelength-band--asthenopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>the Terumo Hydropearl® microspheres device for agnosia</title>
    <id>https://staging.whatcameofit.com/the-terumo-hydropearl-microspheres-device--agnosia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/the-terumo-hydropearl-microspheres-device--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>the Terumo Hydropearl® microspheres device for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/the-terumo-hydropearl-microspheres-device--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/the-terumo-hydropearl-microspheres-device--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Therabot for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/therabot--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/therabot--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Therabot for feeding and eating disorders</title>
    <id>https://staging.whatcameofit.com/therabot--feeding-and-eating-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/therabot--feeding-and-eating-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Therapeutic Intervention for neoplasms</title>
    <id>https://staging.whatcameofit.com/therapeutic-intervention--neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/therapeutic-intervention--neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/therapy-midomafetamine--stress-disorders-post-traumatic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/therapy-midomafetamine--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Thiamine Mononitrate 300 mg for heart failure</title>
    <id>https://staging.whatcameofit.com/thiamine-mononitrate-300-mg--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/thiamine-mononitrate-300-mg--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplastic</title>
    <id>https://staging.whatcameofit.com/thrombopoietin-receptor-agonist-tpo-ra-cyclosporine-romiplostim--anemia-aplastic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/thrombopoietin-receptor-agonist-tpo-ra-cyclosporine-romiplostim--anemia-aplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ticagrelor + Aspirin for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/ticagrelor-aspirin--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ticagrelor-aspirin--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ticagrelor + placebo for non-st elevated myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ticagrelor-placebo--non-st-elevated-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor-placebo--non-st-elevated-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor + placebo for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ticagrelor-placebo--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor-placebo--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for angina, stable</title>
    <id>https://staging.whatcameofit.com/ticagrelor--angina-stable#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--angina-stable"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for angina, unstable</title>
    <id>https://staging.whatcameofit.com/ticagrelor--angina-unstable#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--angina-unstable"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/ticagrelor--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ticagrelor--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for non-st elevated myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ticagrelor--non-st-elevated-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--non-st-elevated-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/ticagrelor--renal-insufficiency-chronic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for st elevation myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ticagrelor--st-elevation-myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--st-elevation-myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tifeglipron for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/tifeglipron--diabetes-mellitus-type-2#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tifeglipron--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Time Restricted Eating (TRE) for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/time-restricted-eating-tre--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/time-restricted-eating-tre--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Time Restricted Eating As Treatment (TREAT) for Diabetes. for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/time-restricted-eating-as-treatment-treat-for-diabetes--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/time-restricted-eating-as-treatment-treat-for-diabetes--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Time restricted feeding for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/time-restricted-feeding--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/time-restricted-feeding--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Time-restricted eating for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/time-restricted-eating--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/time-restricted-eating--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Time-restricted eating for overweight</title>
    <id>https://staging.whatcameofit.com/time-restricted-eating--overweight#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/time-restricted-eating--overweight"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Timrepigene emparvovec for choroideremia</title>
    <id>https://staging.whatcameofit.com/timrepigene-emparvovec--choroideremia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/timrepigene-emparvovec--choroideremia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tinzaparin for fetal growth retardation</title>
    <id>https://staging.whatcameofit.com/tinzaparin--fetal-growth-retardation#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tinzaparin--fetal-growth-retardation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tiragolumab and atezolizumab for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/tiragolumab-and-atezolizumab--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tiragolumab-and-atezolizumab--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/tirellizumab-combined-with-carboplatin-and-albumin-paclitaxel-neoadjuvant-therapy-surgery--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tirellizumab-combined-with-carboplatin-and-albumin-paclitaxel-neoadjuvant-therapy-surgery--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for alcoholism</title>
    <id>https://staging.whatcameofit.com/tirzepatide--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/tirzepatide--diabetes-mellitus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/tirzepatide--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for dyslipidemias</title>
    <id>https://staging.whatcameofit.com/tirzepatide--dyslipidemias#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--dyslipidemias"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for heart failure, systolic</title>
    <id>https://staging.whatcameofit.com/tirzepatide--heart-failure-systolic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--heart-failure-systolic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for hypertension</title>
    <id>https://staging.whatcameofit.com/tirzepatide--hypertension#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for metabolic diseases</title>
    <id>https://staging.whatcameofit.com/tirzepatide--metabolic-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--metabolic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for metabolic syndrome</title>
    <id>https://staging.whatcameofit.com/tirzepatide--metabolic-syndrome#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--metabolic-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for obesity</title>
    <id>https://staging.whatcameofit.com/tirzepatide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for prediabetic state</title>
    <id>https://staging.whatcameofit.com/tirzepatide--prediabetic-state#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--prediabetic-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tirzepatide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/tirzepatide--renal-insufficiency-chronic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tirzepatide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tisagenlecleucel for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/tisagenlecleucel--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tisagenlecleucel--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for adenocarcinoma of lung</title>
    <id>https://staging.whatcameofit.com/tislelizumab--adenocarcinoma-of-lung#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--adenocarcinoma-of-lung"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/tislelizumab--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for cholangiocarcinoma</title>
    <id>https://staging.whatcameofit.com/tislelizumab--cholangiocarcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--cholangiocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for mesothelioma</title>
    <id>https://staging.whatcameofit.com/tislelizumab--mesothelioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--mesothelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for neoplasms, unknown primary</title>
    <id>https://staging.whatcameofit.com/tislelizumab--neoplasms-unknown-primary#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--neoplasms-unknown-primary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for sarcoma</title>
    <id>https://staging.whatcameofit.com/tislelizumab--sarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--sarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/tislelizumab--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/tislelizumab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumor</title>
    <id>https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--desmoplastic-small-round-cell-tumor#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--desmoplastic-small-round-cell-tumor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcoma</title>
    <id>https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--hemangiosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--hemangiosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcoma</title>
    <id>https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--leiomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--leiomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcoma</title>
    <id>https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--liposarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tislelizumab-liposomal-doxorubicin-ifosfamide--liposarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tissue Engineered Product for lacerations</title>
    <id>https://staging.whatcameofit.com/tissue-engineered-product--lacerations#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tissue-engineered-product--lacerations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TissueGene-C for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/tissuegene-c--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tissuegene-c--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Titrated weaning of vasopressin. for shock, septic</title>
    <id>https://staging.whatcameofit.com/titrated-weaning-of-vasopressin--shock-septic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/titrated-weaning-of-vasopressin--shock-septic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tki + blinatumomab for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/tki-blinatumomab--neoplasm-residual#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tki-blinatumomab--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TNX-103 for heart failure</title>
    <id>https://staging.whatcameofit.com/tnx-103--heart-failure#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tnx-103--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>TOCOPHEROL + Pentoxifylline for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/tocopherol-pentoxifylline--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tocopherol-pentoxifylline--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TOCOPHEROL + Pentoxifylline for lymphedema</title>
    <id>https://staging.whatcameofit.com/tocopherol-pentoxifylline--lymphedema#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tocopherol-pentoxifylline--lymphedema"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tolvaptan for oligohydramnios</title>
    <id>https://staging.whatcameofit.com/tolvaptan--oligohydramnios#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tolvaptan--oligohydramnios"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tolvaptan for polycystic kidney, autosomal recessive</title>
    <id>https://staging.whatcameofit.com/tolvaptan--polycystic-kidney-autosomal-recessive#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tolvaptan--polycystic-kidney-autosomal-recessive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tominersen for chorea</title>
    <id>https://staging.whatcameofit.com/tominersen--chorea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tominersen--chorea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tominersen for huntington disease</title>
    <id>https://staging.whatcameofit.com/tominersen--huntington-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tominersen--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Topaz TTVR System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/topaz-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/topaz-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Topical application of Periplaneta americana-derived Meilian Fuxin Solution for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/topical-application-of-periplaneta-americana-derived-meilian-fuxin-solution--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/topical-application-of-periplaneta-americana-derived-meilian-fuxin-solution--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Topical ceftazidime and vancomycin for surgical wound infection</title>
    <id>https://staging.whatcameofit.com/topical-ceftazidime-and-vancomycin--surgical-wound-infection#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/topical-ceftazidime-and-vancomycin--surgical-wound-infection"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Topical emollient (moisturizer) + DUPILUMAB for pruritus</title>
    <id>https://staging.whatcameofit.com/topical-emollient-moisturizer-dupilumab--pruritus#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/topical-emollient-moisturizer-dupilumab--pruritus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Topical Simvastatin 2% Cream for xanthomatosis</title>
    <id>https://staging.whatcameofit.com/topical-simvastatin-2-cream--xanthomatosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/topical-simvastatin-2-cream--xanthomatosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Topotecan + toripalimab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/topotecan-toripalimab--endometrial-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/topotecan-toripalimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total Body Irradiation 12 Gy + Total Body Irradiation 8 Gy for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/total-body-irradiation-12-gy-total-body-irradiation-8-gy--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/total-body-irradiation-12-gy-total-body-irradiation-8-gy--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Total Diet Replacement (800kcal/day) for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/total-diet-replacement-800kcal-day--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-diet-replacement-800kcal-day--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total Diet Replacement (TDR) Program for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/total-diet-replacement-tdr-program--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-diet-replacement-tdr-program--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total Diet Replacement (TDR) Program for obesity</title>
    <id>https://staging.whatcameofit.com/total-diet-replacement-tdr-program--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-diet-replacement-tdr-program--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total Diet Replacement for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/total-diet-replacement--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-diet-replacement--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total Diet Replacement for obesity</title>
    <id>https://staging.whatcameofit.com/total-diet-replacement--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-diet-replacement--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total knee replacement for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/total-knee-replacement--muscular-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-knee-replacement--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total knee replacement for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/total-knee-replacement--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/total-knee-replacement--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/total-body-irradiation-umbilical-cord-blood-transplantation-cyclophosphamide-dilanubicel-fludarabine--anemia-refractory-with-excess-of-blasts#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/total-body-irradiation-umbilical-cord-blood-transplantation-cyclophosphamide-dilanubicel-fludarabine--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/total-body-irradiation-umbilical-cord-blood-transplantation-cyclophosphamide-thiotepa-dilanubicel-fludarabine--anemia-refractory-with-excess-of-blasts#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/total-body-irradiation-umbilical-cord-blood-transplantation-cyclophosphamide-thiotepa-dilanubicel-fludarabine--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Tovecimig for glioblastoma</title>
    <id>https://staging.whatcameofit.com/tovecimig--glioblastoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tovecimig--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tozinameran for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/tozinameran--renal-insufficiency-chronic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/tozinameran--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>TPX-100 200mg, Once weekly for 4 weeks for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/tpx-100-200mg-once-weekly-for-4-weeks--osteoarthritis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tpx-100-200mg-once-weekly-for-4-weeks--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TQC2731 injection for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/tqc2731-injection--pulmonary-disease-chronic-obstructive#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tqc2731-injection--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tradipitant for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/tradipitant--coronavirus-infections#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tradipitant--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + DABRAFENIB for ameloblastoma</title>
    <id>https://staging.whatcameofit.com/trametinib-dabrafenib--ameloblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-dabrafenib--ameloblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + DABRAFENIB for erdheim-chester disease</title>
    <id>https://staging.whatcameofit.com/trametinib-dabrafenib--erdheim-chester-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-dabrafenib--erdheim-chester-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + DABRAFENIB for glioma</title>
    <id>https://staging.whatcameofit.com/trametinib-dabrafenib--glioma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-dabrafenib--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + DABRAFENIB for pancreatic diseases</title>
    <id>https://staging.whatcameofit.com/trametinib-dabrafenib--pancreatic-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-dabrafenib--pancreatic-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + DABRAFENIB for thyroid carcinoma, anaplastic</title>
    <id>https://staging.whatcameofit.com/trametinib-dabrafenib--thyroid-carcinoma-anaplastic#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-dabrafenib--thyroid-carcinoma-anaplastic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/trametinib-doxorubicin-cisplatin-gefitinib-disulfiram-sunitinib-methotrexate--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-doxorubicin-cisplatin-gefitinib-disulfiram-sunitinib-methotrexate--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/trametinib-doxorubicin-cisplatin-gefitinib-disulfiram-sunitinib-methotrexate--osteosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-doxorubicin-cisplatin-gefitinib-disulfiram-sunitinib-methotrexate--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/trametinib-gefitinib-disulfiram-ifosfamide-sunitinib--neoplasm-metastasis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-gefitinib-disulfiram-ifosfamide-sunitinib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for osteosarcoma</title>
    <id>https://staging.whatcameofit.com/trametinib-gefitinib-disulfiram-ifosfamide-sunitinib--osteosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trametinib-gefitinib-disulfiram-ifosfamide-sunitinib--osteosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trametinib and Nivolumab for glioma</title>
    <id>https://staging.whatcameofit.com/trametinib-and-nivolumab--glioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/trametinib-and-nivolumab--glioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for anemia</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--anemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--anemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for anterior cruciate ligament injuries</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--anterior-cruciate-ligament-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--anterior-cruciate-ligament-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for hemarthrosis</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--hemarthrosis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--hemarthrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for hyperpigmentation</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--hyperpigmentation#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--hyperpigmentation"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for iron deficiencies</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--iron-deficiencies#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--iron-deficiencies"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tranexamic acid for sepsis</title>
    <id>https://staging.whatcameofit.com/tranexamic-acid--sepsis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/tranexamic-acid--sepsis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Transarterial geniculate artery embolization for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/transarterial-geniculate-artery-embolization--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transarterial-geniculate-artery-embolization--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumors</title>
    <id>https://staging.whatcameofit.com/transarterial-radioembolization-capecitabine-temozolomide--neuroendocrine-tumors#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/transarterial-radioembolization-capecitabine-temozolomide--neuroendocrine-tumors"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Transcatheter PDA Coil for ductus arteriosus, patent</title>
    <id>https://staging.whatcameofit.com/transcatheter-pda-coil--ductus-arteriosus-patent#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-pda-coil--ductus-arteriosus-patent"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter tricuspid valve edge-to-edge repair for heart failure</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-edge-to-edge-repair--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-edge-to-edge-repair--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter tricuspid valve edge-to-edge repair for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-edge-to-edge-repair--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-edge-to-edge-repair--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter Tricuspid Valve Intervention for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-intervention--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-intervention--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement-ttvr-with-laplace-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement-ttvr-with-laplace-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement-ttvr-with-vdyne-trinova-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement-ttvr-with-vdyne-trinova-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter tricuspid valve replacement for gastroesophageal reflux</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement--gastroesophageal-reflux#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement--gastroesophageal-reflux"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter tricuspid valve replacement for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valve-replacement--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcatheter Tricuspid Valved Stent Graft for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transcatheter-tricuspid-valved-stent-graft--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcatheter-tricuspid-valved-stent-graft--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial alternating current stimulation for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/transcranial-alternating-current-stimulation--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-alternating-current-stimulation--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>transcranial direct current stimulation (tDCS) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial direct current stimulation (tDCS) on the Left DLPFC for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs-on-the-left-dlpfc--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs-on-the-left-dlpfc--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial direct current stimulation (tDCS) on the right VLPFC for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs-on-the-right-vlpfc--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation-tdcs-on-the-right-vlpfc--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial Direct Current Stimulation + SERTRALINE for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation-sertraline--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation-sertraline--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial Direct Current Stimulation for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial Direct Current Stimulation for migraine disorders</title>
    <id>https://staging.whatcameofit.com/transcranial-direct-current-stimulation--migraine-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-direct-current-stimulation--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcranial focused ultrasound stimulation for essential tremor</title>
    <id>https://staging.whatcameofit.com/transcranial-focused-ultrasound-stimulation--essential-tremor#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-focused-ultrasound-stimulation--essential-tremor"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/transcranial-magnetic-resonance-guided-focused-ultrasound-bbb-disruption--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcranial-magnetic-resonance-guided-focused-ultrasound-bbb-disruption--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcutaneous electrical spinal stimulation for paraplegia</title>
    <id>https://staging.whatcameofit.com/transcutaneous-electrical-spinal-stimulation--paraplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcutaneous-electrical-spinal-stimulation--paraplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcutaneous electrical spinal stimulation for quadriplegia</title>
    <id>https://staging.whatcameofit.com/transcutaneous-electrical-spinal-stimulation--quadriplegia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcutaneous-electrical-spinal-stimulation--quadriplegia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transcutaneous vagus nerve stimulation for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/transcutaneous-vagus-nerve-stimulation--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transcutaneous-vagus-nerve-stimulation--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transdermal estrogen for rotator cuff injuries</title>
    <id>https://staging.whatcameofit.com/transdermal-estrogen--rotator-cuff-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transdermal-estrogen--rotator-cuff-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Transporter Cocktail + ZIPALERTINIB for carcinoma</title>
    <id>https://staging.whatcameofit.com/transporter-cocktail-zipalertinib--carcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/transporter-cocktail-zipalertinib--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Transporter Cocktail + ZIPALERTINIB for lung diseases</title>
    <id>https://staging.whatcameofit.com/transporter-cocktail-zipalertinib--lung-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/transporter-cocktail-zipalertinib--lung-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Transvenous Tricuspid Valve System implantation + OMT for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/transvenous-tricuspid-valve-system-implantation-omt--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/transvenous-tricuspid-valve-system-implantation-omt--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytoma</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--astrocytoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--astrocytoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TRASTUZUMAB DERUXTECAN + Palacaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TRASTUZUMAB DERUXTECAN + Palacaparib for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--prostatic-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan-palacaparib--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TRASTUZUMAB DERUXTECAN + Rilvegostomig for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan-rilvegostomig--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan-rilvegostomig--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Trastuzumab deruxtecan for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan--endometrial-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Trastuzumab deruxtecan for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/trastuzumab-deruxtecan--neoplasm-metastasis#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/trastuzumab-deruxtecan--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Trazodone 5mg + Psilocybin for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/trazodone-5mg-psilocybin--depressive-disorder-treatment-resistant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trazodone-5mg-psilocybin--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TREATMENT ARM: Full dose for combat disorders</title>
    <id>https://staging.whatcameofit.com/treatment-arm-full-dose--combat-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/treatment-arm-full-dose--combat-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TREATMENT ARM: Full dose for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/treatment-arm-full-dose--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/treatment-arm-full-dose--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TREATMENT ARM: Full dose for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/treatment-arm-full-dose--wounds-and-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/treatment-arm-full-dose--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>treatment with focal HIFU for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/treatment-with-focal-hifu--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/treatment-with-focal-hifu--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Treatment with Ketone Supplement for ketosis</title>
    <id>https://staging.whatcameofit.com/treatment-with-ketone-supplement--ketosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/treatment-with-ketone-supplement--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Treatment with Ketone Supplement for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/treatment-with-ketone-supplement--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/treatment-with-ketone-supplement--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Treatment with Placebo for ketosis</title>
    <id>https://staging.whatcameofit.com/treatment-with-placebo--ketosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/treatment-with-placebo--ketosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Treatment with Placebo for opioid-related disorders</title>
    <id>https://staging.whatcameofit.com/treatment-with-placebo--opioid-related-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/treatment-with-placebo--opioid-related-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TREMELIMUMAB + Olaparib for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/tremelimumab-olaparib--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tremelimumab-olaparib--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Tremelimumab for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/tremelimumab--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tremelimumab--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Treosulfan for nijmegen breakage syndrome</title>
    <id>https://staging.whatcameofit.com/treosulfan--nijmegen-breakage-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/treosulfan--nijmegen-breakage-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Treprostinil for pulmonary arterial hypertension</title>
    <id>https://staging.whatcameofit.com/treprostinil--pulmonary-arterial-hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/treprostinil--pulmonary-arterial-hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Treprostinil for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/treprostinil--pulmonary-disease-chronic-obstructive#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/treprostinil--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Treprostinil palmitil for pulmonary arterial hypertension</title>
    <id>https://staging.whatcameofit.com/treprostinil-palmitil--pulmonary-arterial-hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/treprostinil-palmitil--pulmonary-arterial-hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tretinoin for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/tretinoin--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tretinoin--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tretinoin for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/tretinoin--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tretinoin--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tretinoin for thrombocytopenia</title>
    <id>https://staging.whatcameofit.com/tretinoin--thrombocytopenia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tretinoin--thrombocytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tretinoin for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/tretinoin--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tretinoin--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trevogrumab for obesity</title>
    <id>https://staging.whatcameofit.com/trevogrumab--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/trevogrumab--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>tributyrin for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/tributyrin--alzheimer-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tributyrin--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>tributyrin for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/tributyrin--cognitive-dysfunction#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tributyrin--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TRiCares Topaz TTVR System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/tricares-topaz-ttvr-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tricares-topaz-ttvr-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tricuspid Valve Replacement System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/tricuspid-valve-replacement-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tricuspid-valve-replacement-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tricuspid Valve Replacement System via jugular vein for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/tricuspid-valve-replacement-system-via-jugular-vein--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tricuspid-valve-replacement-system-via-jugular-vein--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TricValve System for heart failure</title>
    <id>https://staging.whatcameofit.com/tricvalve-system--heart-failure#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tricvalve-system--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>trigagrelor for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/trigagrelor--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/trigagrelor--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Triple oral lipid lowering treatment for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/triple-oral-lipid-lowering-treatment--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/triple-oral-lipid-lowering-treatment--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Triptorelin pamoate for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/triptorelin-pamoate--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/triptorelin-pamoate--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Troculeucel for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/troculeucel--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/troculeucel--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Trontinemab for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/trontinemab--cognitive-dysfunction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/trontinemab--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>TruGamma System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/trugamma-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/trugamma-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tsa for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/tsa--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tsa--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TTP-ICG fluorescent probe for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/ttp-icg-fluorescent-probe--carcinoma-transitional-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ttp-icg-fluorescent-probe--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TTYP01 Tablets (12mg or 18mg) for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/ttyp01-tablets-12mg-or-18mg--autism-spectrum-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ttyp01-tablets-12mg-or-18mg--autism-spectrum-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Tulisokibart for scleroderma, diffuse</title>
    <id>https://staging.whatcameofit.com/tulisokibart--scleroderma-diffuse#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/tulisokibart--scleroderma-diffuse"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>TULSA Procedure for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/tulsa-procedure--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tulsa-procedure--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Tulsa-pro for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/tulsa-pro--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/tulsa-pro--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>TYRA-300 for carcinoma, transitional cell</title>
    <id>https://staging.whatcameofit.com/tyra-300--carcinoma-transitional-cell#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tyra-300--carcinoma-transitional-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>TYRA-300 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/tyra-300--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/tyra-300--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>UB-621 high-dose for herpes genitalis</title>
    <id>https://staging.whatcameofit.com/ub-621-high-dose--herpes-genitalis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ub-621-high-dose--herpes-genitalis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>UB-621 low-dose for herpes genitalis</title>
    <id>https://staging.whatcameofit.com/ub-621-low-dose--herpes-genitalis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ub-621-low-dose--herpes-genitalis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>UBAMATAMAB + Ubletamig + SARILUMAB for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/ubamatamab-ubletamig-sarilumab--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ubamatamab-ubletamig-sarilumab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>UBAMATAMAB + Ubletamig + SARILUMAB for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/ubamatamab-ubletamig-sarilumab--fallopian-tube-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ubamatamab-ubletamig-sarilumab--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ubrogepant + ERENUMAB for migraine disorders</title>
    <id>https://staging.whatcameofit.com/ubrogepant-erenumab--migraine-disorders#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ubrogepant-erenumab--migraine-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ubt251--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 2.0 mg and UBT251 Injection Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-2-0-mg-and-ubt251-injection-placebo--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-2-0-mg-and-ubt251-injection-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-4-0-mg-id-0-5-mg-and-ubt251-injection-placebo--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-4-0-mg-id-0-5-mg-and-ubt251-injection-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-4-0-mg-id-1-0-mg-and-ubt251-injection-placebo--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-4-0-mg-id-1-0-mg-and-ubt251-injection-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 4.0 mg for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-4-0-mg--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-4-0-mg--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 6.0 mg and UBT251 Injection Placebo for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-6-0-mg-and-ubt251-injection-placebo--obesity#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-6-0-mg-and-ubt251-injection-placebo--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>UBT251 Injection 6.0 mg for obesity</title>
    <id>https://staging.whatcameofit.com/ubt251-injection-6-0-mg--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ubt251-injection-6-0-mg--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>UC-MSC and Secretome for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/uc-msc-and-secretome--respiratory-distress-syndrome#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/uc-msc-and-secretome--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>UKidney for kidney failure, chronic</title>
    <id>https://staging.whatcameofit.com/ukidney--kidney-failure-chronic#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/ukidney--kidney-failure-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>ULIXERTINIB + Ruxolitinib for primary myelofibrosis</title>
    <id>https://staging.whatcameofit.com/ulixertinib-ruxolitinib--primary-myelofibrosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/ulixertinib-ruxolitinib--primary-myelofibrosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Ulotaront for schizophrenia</title>
    <id>https://staging.whatcameofit.com/ulotaront--schizophrenia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ulotaront--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ultra-fractionated radiation therapy for radiation injuries</title>
    <id>https://staging.whatcameofit.com/ultra-fractionated-radiation-therapy--radiation-injuries#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ultra-fractionated-radiation-therapy--radiation-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ultrasound lipolysis for obesity, abdominal</title>
    <id>https://staging.whatcameofit.com/ultrasound-lipolysis--obesity-abdominal#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ultrasound-lipolysis--obesity-abdominal"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ultrasound-guided Adductor Canal Block (ACB) + Ultrasound-guided iPACK block for anterior cruciate ligament injuries</title>
    <id>https://staging.whatcameofit.com/ultrasound-guided-adductor-canal-block-acb-ultrasound-guided-ipack-block--anterior-cruciate-ligament-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ultrasound-guided-adductor-canal-block-acb-ultrasound-guided-ipack-block--anterior-cruciate-ligament-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes for erectile dysfunction</title>
    <id>https://staging.whatcameofit.com/umblical-cord-derived-mesenchymal-stem-cell-derived-exosomes--erectile-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/umblical-cord-derived-mesenchymal-stem-cell-derived-exosomes--erectile-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Unicompartmental Knee Arthroplasty (UKA) for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/unicompartmental-knee-arthroplasty-uka--osteoarthritis-knee#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/unicompartmental-knee-arthroplasty-uka--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Unicompartmental knee replacement for muscular atrophy</title>
    <id>https://staging.whatcameofit.com/unicompartmental-knee-replacement--muscular-atrophy#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/unicompartmental-knee-replacement--muscular-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Unicompartmental knee replacement for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/unicompartmental-knee-replacement--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/unicompartmental-knee-replacement--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Unicondylar Knee Arthroplasty for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/unicondylar-knee-arthroplasty--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/unicondylar-knee-arthroplasty--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Unicondylar Knee Replacement for osteoarthritis, knee</title>
    <id>https://staging.whatcameofit.com/unicondylar-knee-replacement--osteoarthritis-knee#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/unicondylar-knee-replacement--osteoarthritis-knee"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blasts</title>
    <id>https://staging.whatcameofit.com/unmanipulated-bone-marrow-graft-with-cyclophosphamide-cyclophosphamide--anemia-refractory-with-excess-of-blasts#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/unmanipulated-bone-marrow-graft-with-cyclophosphamide-cyclophosphamide--anemia-refractory-with-excess-of-blasts"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Upacicalcet for hyperparathyroidism, secondary</title>
    <id>https://staging.whatcameofit.com/upacicalcet--hyperparathyroidism-secondary#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/upacicalcet--hyperparathyroidism-secondary"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Upacicalcet for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/upacicalcet--renal-insufficiency-chronic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/upacicalcet--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Upifitimab rilsodotin for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/upifitimab-rilsodotin--fallopian-tube-neoplasms#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/upifitimab-rilsodotin--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Ustekinumab for alopecia</title>
    <id>https://staging.whatcameofit.com/ustekinumab--alopecia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ustekinumab--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Uterine Transplant for infertility</title>
    <id>https://staging.whatcameofit.com/uterine-transplant--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterine-transplant--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Uterine Transplant for infertility, female</title>
    <id>https://staging.whatcameofit.com/uterine-transplant--infertility-female#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/uterine-transplant--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Uterine transplantation for infertility</title>
    <id>https://staging.whatcameofit.com/uterine-transplantation--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterine-transplantation--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Uterus Transplant for infertility</title>
    <id>https://staging.whatcameofit.com/uterus-transplant--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterus-transplant--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>uterus transplantation for infertility</title>
    <id>https://staging.whatcameofit.com/uterus-transplantation--infertility#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterus-transplantation--infertility"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>uterus transplantation for infertility, female</title>
    <id>https://staging.whatcameofit.com/uterus-transplantation--infertility-female#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterus-transplantation--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>uterus transplantation surgery and IVF for infertility, female</title>
    <id>https://staging.whatcameofit.com/uterus-transplantation-surgery-and-ivf--infertility-female#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/uterus-transplantation-surgery-and-ivf--infertility-female"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Utidelone capsule 35mg/m2/d BID for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/utidelone-capsule-35mg-m2-d-bid--fallopian-tube-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/utidelone-capsule-35mg-m2-d-bid--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Utidelone capsule 40mg/m2/d BID for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/utidelone-capsule-40mg-m2-d-bid--fallopian-tube-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/utidelone-capsule-40mg-m2-d-bid--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Utidelone capsule 50mg/m2/d BID for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/utidelone-capsule-50mg-m2-d-bid--fallopian-tube-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/utidelone-capsule-50mg-m2-d-bid--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Utidelone capsule 75mg/m2/d QD for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/utidelone-capsule-75mg-m2-d-qd--fallopian-tube-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/utidelone-capsule-75mg-m2-d-qd--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vagus nerve stimulation; for persistent vegetative state</title>
    <id>https://staging.whatcameofit.com/vagus-nerve-stimulation--persistent-vegetative-state#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/vagus-nerve-stimulation--persistent-vegetative-state"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Valacyclovir for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/valacyclovir--alzheimer-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/valacyclovir--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Valacyclovir for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/valacyclovir--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/valacyclovir--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Valacyclovir for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/valacyclovir--head-and-neck-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/valacyclovir--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Valacyclovir for stomatitis</title>
    <id>https://staging.whatcameofit.com/valacyclovir--stomatitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/valacyclovir--stomatitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Valganciclovir for cytomegalovirus infections</title>
    <id>https://staging.whatcameofit.com/valganciclovir--cytomegalovirus-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/valganciclovir--cytomegalovirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Valiltramiprosate for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/valiltramiprosate--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/valiltramiprosate--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Valproic acid for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/valproic-acid--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/valproic-acid--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Valproic acid for mania</title>
    <id>https://staging.whatcameofit.com/valproic-acid--mania#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/valproic-acid--mania"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Valsartan for heart failure</title>
    <id>https://staging.whatcameofit.com/valsartan--heart-failure#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/valsartan--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/vancomycin-nitazoxanide--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vancomycin-nitazoxanide--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vancomycin for clostridium infections</title>
    <id>https://staging.whatcameofit.com/vancomycin--clostridium-infections#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vancomycin--clostridium-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vanguard M fixed-bearing or Oxford mobile-bearing prostheses for osteoarthritis</title>
    <id>https://staging.whatcameofit.com/vanguard-m-fixed-bearing-or-oxford-mobile-bearing-prostheses--osteoarthritis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vanguard-m-fixed-bearing-or-oxford-mobile-bearing-prostheses--osteoarthritis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Varenicline for marijuana use</title>
    <id>https://staging.whatcameofit.com/varenicline--marijuana-use#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/varenicline--marijuana-use"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Varenicline for tobacco use disorder</title>
    <id>https://staging.whatcameofit.com/varenicline--tobacco-use-disorder#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/varenicline--tobacco-use-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Varespladib methyl + varespladib for snake bites</title>
    <id>https://staging.whatcameofit.com/varespladib-methyl-varespladib--snake-bites#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/varespladib-methyl-varespladib--snake-bites"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vasopressin for agnosia</title>
    <id>https://staging.whatcameofit.com/vasopressin--agnosia#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vasopressin--agnosia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Vasopressin for shock, septic</title>
    <id>https://staging.whatcameofit.com/vasopressin--shock-septic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vasopressin--shock-septic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VCA-894A for charcot-marie-tooth disease</title>
    <id>https://staging.whatcameofit.com/vca-894a--charcot-marie-tooth-disease#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vca-894a--charcot-marie-tooth-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VDPHL01 BID for alopecia</title>
    <id>https://staging.whatcameofit.com/vdphl01-bid--alopecia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vdphl01-bid--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VDPHL01 for alopecia</title>
    <id>https://staging.whatcameofit.com/vdphl01--alopecia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vdphl01--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VDPHL01 QD for alopecia</title>
    <id>https://staging.whatcameofit.com/vdphl01-qd--alopecia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vdphl01-qd--alopecia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VDyne Transcatheter Tricuspid Valve Replacement System for tricuspid valve insufficiency</title>
    <id>https://staging.whatcameofit.com/vdyne-transcatheter-tricuspid-valve-replacement-system--tricuspid-valve-insufficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vdyne-transcatheter-tricuspid-valve-replacement-system--tricuspid-valve-insufficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vebreltinib for glioblastoma</title>
    <id>https://staging.whatcameofit.com/vebreltinib--glioblastoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vebreltinib--glioblastoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vedolizumab for colitis</title>
    <id>https://staging.whatcameofit.com/vedolizumab--colitis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vedolizumab--colitis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vedolizumab for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/vedolizumab--colitis-ulcerative#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vedolizumab--colitis-ulcerative"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vedolizumab for crohn disease</title>
    <id>https://staging.whatcameofit.com/vedolizumab--crohn-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vedolizumab--crohn-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vehicle for myopia</title>
    <id>https://staging.whatcameofit.com/vehicle--myopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vehicle--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vehicle for presbyopia</title>
    <id>https://staging.whatcameofit.com/vehicle--presbyopia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vehicle--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vehicle proprietary ophthalmic solution for myopia</title>
    <id>https://staging.whatcameofit.com/vehicle-proprietary-ophthalmic-solution--myopia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vehicle-proprietary-ophthalmic-solution--myopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vehicle proprietary ophthalmic solution for presbyopia</title>
    <id>https://staging.whatcameofit.com/vehicle-proprietary-ophthalmic-solution--presbyopia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vehicle-proprietary-ophthalmic-solution--presbyopia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Venetoclax + AB-8939 for gata2 deficiency</title>
    <id>https://staging.whatcameofit.com/venetoclax-ab-8939--gata2-deficiency#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/venetoclax-ab-8939--gata2-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Venetoclax + FLUDARABINE for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/venetoclax-fludarabine--myelodysplastic-syndromes#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/venetoclax-fludarabine--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Venlafaxine for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/venlafaxine--generalized-anxiety-disorder#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/venlafaxine--generalized-anxiety-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Venous Excess Ultrasound (VEXUS)-Guided Management for hyperemia</title>
    <id>https://staging.whatcameofit.com/venous-excess-ultrasound-vexus-guided-management--hyperemia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/venous-excess-ultrasound-vexus-guided-management--hyperemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Venous Excess Ultrasound (VEXUS)-Guided Management for shock, septic</title>
    <id>https://staging.whatcameofit.com/venous-excess-ultrasound-vexus-guided-management--shock-septic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/venous-excess-ultrasound-vexus-guided-management--shock-septic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VER-01 for neuralgia</title>
    <id>https://staging.whatcameofit.com/ver-01--neuralgia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ver-01--neuralgia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vericiguat for cognitive dysfunction</title>
    <id>https://staging.whatcameofit.com/vericiguat--cognitive-dysfunction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vericiguat--cognitive-dysfunction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vericiguat for heart failure</title>
    <id>https://staging.whatcameofit.com/vericiguat--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vericiguat--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VERVE-102 for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/verve-102--atherosclerosis#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/verve-102--atherosclerosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VERVE-102 for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/verve-102--coronary-artery-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/verve-102--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VERVE-102 for hypercholesterolemia</title>
    <id>https://staging.whatcameofit.com/verve-102--hypercholesterolemia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/verve-102--hypercholesterolemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VERVE-102 for hyperlipoproteinemia type ii</title>
    <id>https://staging.whatcameofit.com/verve-102--hyperlipoproteinemia-type-ii#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/verve-102--hyperlipoproteinemia-type-ii"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VERVE-102 for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/verve-102--myocardial-infarction#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/verve-102--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Very Low-calorie MIND-HK diet for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/very-low-calorie-mind-hk-diet--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/very-low-calorie-mind-hk-diet--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Very-low calorie diet for fatty liver</title>
    <id>https://staging.whatcameofit.com/very-low-calorie-diet--fatty-liver#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/very-low-calorie-diet--fatty-liver"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Very-short DAPT less than 1 month after PCI for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/very-short-dapt-less-than-1-month-after-pci--acute-coronary-syndrome#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/very-short-dapt-less-than-1-month-after-pci--acute-coronary-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Very-short DAPT less than 1 month after PCI for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/very-short-dapt-less-than-1-month-after-pci--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/very-short-dapt-less-than-1-month-after-pci--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VI-0521 for obesity</title>
    <id>https://staging.whatcameofit.com/vi-0521--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vi-0521--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VI-0521 for obesity, morbid</title>
    <id>https://staging.whatcameofit.com/vi-0521--obesity-morbid#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vi-0521--obesity-morbid"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VI-0521 Mid Dose for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/vi-0521-mid-dose--pediatric-obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vi-0521-mid-dose--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VI-0521 oral capsule for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/vi-0521-oral-capsule--pediatric-obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vi-0521-oral-capsule--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VI-0521 Top Dose for pediatric obesity</title>
    <id>https://staging.whatcameofit.com/vi-0521-top-dose--pediatric-obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vi-0521-top-dose--pediatric-obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vi-Typhoid Conjugate Vaccine (Vi-TCV) for typhoid fever</title>
    <id>https://staging.whatcameofit.com/vi-typhoid-conjugate-vaccine-vi-tcv--typhoid-fever#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vi-typhoid-conjugate-vaccine-vi-tcv--typhoid-fever"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>vicadrostat / empagliflozin combination 1 for heart failure</title>
    <id>https://staging.whatcameofit.com/vicadrostat-empagliflozin-combination-1--heart-failure#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vicadrostat-empagliflozin-combination-1--heart-failure"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vicadrostat for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/vicadrostat--diabetes-mellitus-type-2#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vicadrostat--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vicadrostat for hypertension</title>
    <id>https://staging.whatcameofit.com/vicadrostat--hypertension#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vicadrostat--hypertension"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Video-chat Psychotherapy (VCP) for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/video-chat-psychotherapy-vcp--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/video-chat-psychotherapy-vcp--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Video-chat Psychotherapy (VCP) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/video-chat-psychotherapy-vcp--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/video-chat-psychotherapy-vcp--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Viloxazine hydrochloride for attention deficit disorder with hyperactivity</title>
    <id>https://staging.whatcameofit.com/viloxazine-hydrochloride--attention-deficit-disorder-with-hyperactivity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/viloxazine-hydrochloride--attention-deficit-disorder-with-hyperactivity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Vinorelbine for rhabdomyosarcoma</title>
    <id>https://staging.whatcameofit.com/vinorelbine--rhabdomyosarcoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vinorelbine--rhabdomyosarcoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VIR-5500 for prostatic neoplasms, castration-resistant</title>
    <id>https://staging.whatcameofit.com/vir-5500--prostatic-neoplasms-castration-resistant#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vir-5500--prostatic-neoplasms-castration-resistant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Viral Specific T-cells (VSTs) for virus diseases</title>
    <id>https://staging.whatcameofit.com/viral-specific-t-cells-vsts--virus-diseases#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/viral-specific-t-cells-vsts--virus-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Virtual Weight Management Coaching + Semaglutide for obesity</title>
    <id>https://staging.whatcameofit.com/virtual-weight-management-coaching-semaglutide--obesity#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/virtual-weight-management-coaching-semaglutide--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Virtual Weight Management Coaching + Semaglutide for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/virtual-weight-management-coaching-semaglutide--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/virtual-weight-management-coaching-semaglutide--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Visuospatial interference for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/visuospatial-interference--wounds-and-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/visuospatial-interference--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Visuospatial Task (VST) for stress disorders, post-traumatic</title>
    <id>https://staging.whatcameofit.com/visuospatial-task-vst--stress-disorders-post-traumatic#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/visuospatial-task-vst--stress-disorders-post-traumatic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Visuospatial Task (VST) for wounds and injuries</title>
    <id>https://staging.whatcameofit.com/visuospatial-task-vst--wounds-and-injuries#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/visuospatial-task-vst--wounds-and-injuries"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin C (ascorbic acid) for cytopenia</title>
    <id>https://staging.whatcameofit.com/vitamin-c-ascorbic-acid--cytopenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-c-ascorbic-acid--cytopenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin C (ascorbic acid) for myelodysplastic syndromes</title>
    <id>https://staging.whatcameofit.com/vitamin-c-ascorbic-acid--myelodysplastic-syndromes#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-c-ascorbic-acid--myelodysplastic-syndromes"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin D 100 micrograms for depressive disorder</title>
    <id>https://staging.whatcameofit.com/vitamin-d-100-micrograms--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d-100-micrograms--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>vitamin D 25(OH)D for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/vitamin-d-25-oh-d--adenocarcinoma#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d-25-oh-d--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>vitamin D 25(OH)D for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/vitamin-d-25-oh-d--prostatic-neoplasms#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d-25-oh-d--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin d for seasonal affective disorder</title>
    <id>https://staging.whatcameofit.com/vitamin-d--seasonal-affective-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d--seasonal-affective-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin d for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/vitamin-d--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin D supplementation for diabetes mellitus</title>
    <id>https://staging.whatcameofit.com/vitamin-d-supplementation--diabetes-mellitus#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d-supplementation--diabetes-mellitus"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vitamin D supplementation for vitamin d deficiency</title>
    <id>https://staging.whatcameofit.com/vitamin-d-supplementation--vitamin-d-deficiency#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vitamin-d-supplementation--vitamin-d-deficiency"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VLA15 for lyme disease</title>
    <id>https://staging.whatcameofit.com/vla15--lyme-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vla15--lyme-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VLS-1488 for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/vls-1488--endometrial-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vls-1488--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VLS-1488 for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/vls-1488--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vls-1488--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--carcinoma-adenoid-cystic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for laryngeal diseases</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--laryngeal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--laryngeal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for mesothelioma</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--mesothelioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--mesothelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 100 mg Tablet for tracheal diseases</title>
    <id>https://staging.whatcameofit.com/vmd-928-100-mg-tablet--tracheal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-100-mg-tablet--tracheal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cystic</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--carcinoma-adenoid-cystic#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--carcinoma-adenoid-cystic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for laryngeal diseases</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--laryngeal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--laryngeal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for mesothelioma</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--mesothelioma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--mesothelioma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VMD-928 Tablet and Pembrolizumab (200 mg) for tracheal diseases</title>
    <id>https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--tracheal-diseases#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vmd-928-tablet-and-pembrolizumab-200-mg--tracheal-diseases"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VNX001 for cystitis, interstitial</title>
    <id>https://staging.whatcameofit.com/vnx001--cystitis-interstitial#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vnx001--cystitis-interstitial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>voretigene neparvovec-rzyl for leber congenital amaurosis</title>
    <id>https://staging.whatcameofit.com/voretigene-neparvovec-rzyl--leber-congenital-amaurosis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/voretigene-neparvovec-rzyl--leber-congenital-amaurosis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Vosoritide for achondroplasia</title>
    <id>https://staging.whatcameofit.com/vosoritide--achondroplasia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vosoritide--achondroplasia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Votoplam (blinded) for huntington disease</title>
    <id>https://staging.whatcameofit.com/votoplam-blinded--huntington-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/votoplam-blinded--huntington-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VR social musical exergame for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/vr-social-musical-exergame--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vr-social-musical-exergame--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>VR solo musical exergame for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/vr-solo-musical-exergame--anxiety-disorders#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/vr-solo-musical-exergame--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Vudalimab for adenocarcinoma, clear cell</title>
    <id>https://staging.whatcameofit.com/vudalimab--adenocarcinoma-clear-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vudalimab--adenocarcinoma-clear-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vudalimab for endometrial neoplasms</title>
    <id>https://staging.whatcameofit.com/vudalimab--endometrial-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vudalimab--endometrial-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vudalimab for fallopian tube neoplasms</title>
    <id>https://staging.whatcameofit.com/vudalimab--fallopian-tube-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vudalimab--fallopian-tube-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vudalimab for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/vudalimab--prostatic-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vudalimab--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vudalimab for uterine cervical neoplasms</title>
    <id>https://staging.whatcameofit.com/vudalimab--uterine-cervical-neoplasms#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vudalimab--uterine-cervical-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Vusolimogene Oderparepvec for carcinoma, squamous cell</title>
    <id>https://staging.whatcameofit.com/vusolimogene-oderparepvec--carcinoma-squamous-cell#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vusolimogene-oderparepvec--carcinoma-squamous-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VX-017 for hypoglycemia</title>
    <id>https://staging.whatcameofit.com/vx-017--hypoglycemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/vx-017--hypoglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>VX-407 for polycystic kidney, autosomal dominant</title>
    <id>https://staging.whatcameofit.com/vx-407--polycystic-kidney-autosomal-dominant#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vx-407--polycystic-kidney-autosomal-dominant"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VX-670 for myotonia</title>
    <id>https://staging.whatcameofit.com/vx-670--myotonia#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/vx-670--myotonia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections</title>
    <id>https://staging.whatcameofit.com/vxa-g1-1-nn-vxa-g2-4-ns--caliciviridae-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vxa-g1-1-nn-vxa-g2-4-ns--caliciviridae-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VXA-G1.1-NN for caliciviridae infections</title>
    <id>https://staging.whatcameofit.com/vxa-g1-1-nn--caliciviridae-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vxa-g1-1-nn--caliciviridae-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>VXA-G2.4-NS for caliciviridae infections</title>
    <id>https://staging.whatcameofit.com/vxa-g2-4-ns--caliciviridae-infections#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/vxa-g2-4-ns--caliciviridae-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Walk-and-talk therapy for anxiety disorders</title>
    <id>https://staging.whatcameofit.com/walk-and-talk-therapy--anxiety-disorders#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/walk-and-talk-therapy--anxiety-disorders"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Wbh for hyperthermia</title>
    <id>https://staging.whatcameofit.com/wbh--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/wbh--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Wbh for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/wbh--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/wbh--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Wharton&apos;s jelly derived Mesenchymal stem cells. for coronavirus infections</title>
    <id>https://staging.whatcameofit.com/wharton-s-jelly-derived-mesenchymal-stem-cells--coronavirus-infections#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/wharton-s-jelly-derived-mesenchymal-stem-cells--coronavirus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Wharton&apos;s jelly derived Mesenchymal stem cells. for respiratory distress syndrome</title>
    <id>https://staging.whatcameofit.com/wharton-s-jelly-derived-mesenchymal-stem-cells--respiratory-distress-syndrome#status-2026-11-19-terminated</id>
    <link href="https://staging.whatcameofit.com/wharton-s-jelly-derived-mesenchymal-stem-cells--respiratory-distress-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trials ended early.</summary>
  </entry>
  <entry>
    <title>Whole-body hyperthermia + standard medical care for depressive disorder</title>
    <id>https://staging.whatcameofit.com/whole-body-hyperthermia-standard-medical-care--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/whole-body-hyperthermia-standard-medical-care--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Whole-body hyperthermia + standard medical care for hyperthermia</title>
    <id>https://staging.whatcameofit.com/whole-body-hyperthermia-standard-medical-care--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/whole-body-hyperthermia-standard-medical-care--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Whole-Body Hyperthermia for depressive disorder</title>
    <id>https://staging.whatcameofit.com/whole-body-hyperthermia--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/whole-body-hyperthermia--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Whole-Body Hyperthermia for hyperthermia</title>
    <id>https://staging.whatcameofit.com/whole-body-hyperthermia--hyperthermia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/whole-body-hyperthermia--hyperthermia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Whole-Body Hyperthermia for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/whole-body-hyperthermia--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/whole-body-hyperthermia--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Wolbachia-infected Aedes aegypti for chikungunya fever</title>
    <id>https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--chikungunya-fever#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--chikungunya-fever"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Wolbachia-infected Aedes aegypti for dengue</title>
    <id>https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--dengue#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--dengue"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Wolbachia-infected Aedes aegypti for zika virus infection</title>
    <id>https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--zika-virus-infection#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/wolbachia-infected-aedes-aegypti--zika-virus-infection"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>WS016 for hyperkalemia</title>
    <id>https://staging.whatcameofit.com/ws016--hyperkalemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ws016--hyperkalemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Wujia Yizhi granules for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/wujia-yizhi-granules--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/wujia-yizhi-granules--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>WVE-007 for obesity</title>
    <id>https://staging.whatcameofit.com/wve-007--obesity#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/wve-007--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Wysa Digital Chatbot Program for [obsolete] disordered eating behavior</title>
    <id>https://staging.whatcameofit.com/wysa-digital-chatbot-program--obsolete-disordered-eating-behavior#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/wysa-digital-chatbot-program--obsolete-disordered-eating-behavior"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Xaluritamig for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/xaluritamig--prostatic-neoplasms#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/xaluritamig--prostatic-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/xanomeline-enteric-capsule-xanomeline-trospium-chloride-capsule--alzheimer-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/xanomeline-enteric-capsule-xanomeline-trospium-chloride-capsule--alzheimer-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Xiaochaihu Granules (Low Dose) for depressive disorder</title>
    <id>https://staging.whatcameofit.com/xiaochaihu-granules-low-dose--depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/xiaochaihu-granules-low-dose--depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Xiaochaihu Granules (Low Dose) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/xiaochaihu-granules-low-dose--neoplasm-metastasis#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/xiaochaihu-granules-low-dose--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Xingqi Daozhi Decoction for schizophrenia</title>
    <id>https://staging.whatcameofit.com/xingqi-daozhi-decoction--schizophrenia#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/xingqi-daozhi-decoction--schizophrenia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>XON7 for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/xon7--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/xon7--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>XPO1 inhibitor for lymphoma, extranodal nk-t-cell</title>
    <id>https://staging.whatcameofit.com/xpo1-inhibitor--lymphoma-extranodal-nk-t-cell#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/xpo1-inhibitor--lymphoma-extranodal-nk-t-cell"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>YA-101 for multiple system atrophy</title>
    <id>https://staging.whatcameofit.com/ya-101--multiple-system-atrophy#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ya-101--multiple-system-atrophy"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Yband(YDT-201N) for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/yband-ydt-201n--major-depressive-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/yband-ydt-201n--major-depressive-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>YMI024 for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/ymi024--coronary-artery-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/ymi024--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>YOLT-203 for kidney calculi</title>
    <id>https://staging.whatcameofit.com/yolt-203--kidney-calculi#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/yolt-203--kidney-calculi"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zabdeno® booster for hemorrhagic fever, ebola</title>
    <id>https://staging.whatcameofit.com/zabdeno-booster--hemorrhagic-fever-ebola#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zabdeno-booster--hemorrhagic-fever-ebola"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zanzalintinib for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/zanzalintinib--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zanzalintinib--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zelicapavir for respiratory syncytial virus infections</title>
    <id>https://staging.whatcameofit.com/zelicapavir--respiratory-syncytial-virus-infections#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zelicapavir--respiratory-syncytial-virus-infections"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zeltiq CoolSculpting device for obesity</title>
    <id>https://staging.whatcameofit.com/zeltiq-coolsculpting-device--obesity#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/zeltiq-coolsculpting-device--obesity"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Zemocimig for hemophilia a</title>
    <id>https://staging.whatcameofit.com/zemocimig--hemophilia-a#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zemocimig--hemophilia-a"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zenagamtide for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/zenagamtide--diabetes-mellitus-type-2#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/zenagamtide--diabetes-mellitus-type-2"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>zevor-cel for carcinoma</title>
    <id>https://staging.whatcameofit.com/zevor-cel--carcinoma#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zevor-cel--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for head and neck neoplasms</title>
    <id>https://staging.whatcameofit.com/zi-ma4-1-tcr-nk-cells-cyclophosphamide-fludarabine--head-and-neck-neoplasms#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zi-ma4-1-tcr-nk-cells-cyclophosphamide-fludarabine--head-and-neck-neoplasms"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>ZI-MA4-1 (TCR-NK cells) + Cyclophosphamide + FLUDARABINE for sarcoma, synovial</title>
    <id>https://staging.whatcameofit.com/zi-ma4-1-tcr-nk-cells-cyclophosphamide-fludarabine--sarcoma-synovial#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zi-ma4-1-tcr-nk-cells-cyclophosphamide-fludarabine--sarcoma-synovial"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Zidesamtinib (NVL-520) for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/zidesamtinib-nvl-520--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zidesamtinib-nvl-520--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Zigakibart for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/zigakibart--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zigakibart--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ziltivekimab for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/ziltivekimab--coronary-artery-disease#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ziltivekimab--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ziltivekimab for myocardial infarction</title>
    <id>https://staging.whatcameofit.com/ziltivekimab--myocardial-infarction#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ziltivekimab--myocardial-infarction"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ziltivekimab for renal insufficiency, chronic</title>
    <id>https://staging.whatcameofit.com/ziltivekimab--renal-insufficiency-chronic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/ziltivekimab--renal-insufficiency-chronic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zimislecel for hypoglycemia</title>
    <id>https://staging.whatcameofit.com/zimislecel--hypoglycemia#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zimislecel--hypoglycemia"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zipalertinib for carcinoma</title>
    <id>https://staging.whatcameofit.com/zipalertinib--carcinoma#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zipalertinib--carcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ziprasidone for bipolar disorder</title>
    <id>https://staging.whatcameofit.com/ziprasidone--bipolar-disorder#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ziprasidone--bipolar-disorder"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Zirdafulven + Olaparib for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/zirdafulven-olaparib--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zirdafulven-olaparib--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Zirdafulven for neoplasm metastasis</title>
    <id>https://staging.whatcameofit.com/zirdafulven--neoplasm-metastasis#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zirdafulven--neoplasm-metastasis"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Zolbetuximab for adenocarcinoma</title>
    <id>https://staging.whatcameofit.com/zolbetuximab--adenocarcinoma#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zolbetuximab--adenocarcinoma"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zoliflodacin for gonorrhea</title>
    <id>https://staging.whatcameofit.com/zoliflodacin--gonorrhea#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zoliflodacin--gonorrhea"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zonisamide for alcoholism</title>
    <id>https://staging.whatcameofit.com/zonisamide--alcoholism#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zonisamide--alcoholism"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zorevunersen for epilepsies, myoclonic</title>
    <id>https://staging.whatcameofit.com/zorevunersen--epilepsies-myoclonic#status-2026-11-19-phase_3</id>
    <link href="https://staging.whatcameofit.com/zorevunersen--epilepsies-myoclonic"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zotarolimus-eluting stent (Endeavor Resolute) for coronary artery disease</title>
    <id>https://staging.whatcameofit.com/zotarolimus-eluting-stent-endeavor-resolute--coronary-artery-disease#status-2026-11-19-trial_registered</id>
    <link href="https://staging.whatcameofit.com/zotarolimus-eluting-stent-endeavor-resolute--coronary-artery-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Zovegalisib for klippel-trenaunay-weber syndrome</title>
    <id>https://staging.whatcameofit.com/zovegalisib--klippel-trenaunay-weber-syndrome#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zovegalisib--klippel-trenaunay-weber-syndrome"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zovegalisib for lymphatic abnormalities</title>
    <id>https://staging.whatcameofit.com/zovegalisib--lymphatic-abnormalities#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zovegalisib--lymphatic-abnormalities"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zovegalisib for vascular malformations</title>
    <id>https://staging.whatcameofit.com/zovegalisib--vascular-malformations#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/zovegalisib--vascular-malformations"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Zymosan + α-lactalbumin vaccine for neoplasm, residual</title>
    <id>https://staging.whatcameofit.com/zymosan-α-lactalbumin-vaccine--neoplasm-residual#status-2026-11-19-phase_1</id>
    <link href="https://staging.whatcameofit.com/zymosan-α-lactalbumin-vaccine--neoplasm-residual"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>αβ T-cells depletion + Cyclophosphamide for graft vs host disease</title>
    <id>https://staging.whatcameofit.com/αβ-t-cells-depletion-cyclophosphamide--graft-vs-host-disease#status-2026-11-19-phase_2</id>
    <link href="https://staging.whatcameofit.com/αβ-t-cells-depletion-cyclophosphamide--graft-vs-host-disease"/>
    <updated>2026-11-19T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Ambroxol for dementia</title>
    <id>https://staging.whatcameofit.com/ambroxol--dementia#status-2026-11-16-trial_registered</id>
    <link href="https://staging.whatcameofit.com/ambroxol--dementia"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Apitegromab for obesity</title>
    <id>https://staging.whatcameofit.com/apitegromab--obesity#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/apitegromab--obesity"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Aticaprant for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/aticaprant--major-depressive-disorder#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/aticaprant--major-depressive-disorder"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Azetukalner for major depressive disorder</title>
    <id>https://staging.whatcameofit.com/azetukalner--major-depressive-disorder#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/azetukalner--major-depressive-disorder"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Baxdrostat for hyperaldosteronism</title>
    <id>https://staging.whatcameofit.com/baxdrostat--hyperaldosteronism#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/baxdrostat--hyperaldosteronism"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Baxdrostat for hypertension</title>
    <id>https://staging.whatcameofit.com/baxdrostat--hypertension#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/baxdrostat--hypertension"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Buntanetap for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/buntanetap--alzheimer-disease#status-2026-11-16-phase_1</id>
    <link href="https://staging.whatcameofit.com/buntanetap--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Cannabidiol for epilepsy</title>
    <id>https://staging.whatcameofit.com/cannabidiol--epilepsy#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/cannabidiol--epilepsy"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Deep Brain Stimulation for depressive disorder, treatment-resistant</title>
    <id>https://staging.whatcameofit.com/deep-brain-stimulation--depressive-disorder-treatment-resistant#status-2026-11-16-trial_registered</id>
    <link href="https://staging.whatcameofit.com/deep-brain-stimulation--depressive-disorder-treatment-resistant"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Eloralintide for obesity</title>
    <id>https://staging.whatcameofit.com/eloralintide--obesity#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/eloralintide--obesity"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Empagliflozin for heart failure</title>
    <id>https://staging.whatcameofit.com/empagliflozin--heart-failure#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/empagliflozin--heart-failure"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Emvistegrast for colitis, ulcerative</title>
    <id>https://staging.whatcameofit.com/emvistegrast--colitis-ulcerative#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/emvistegrast--colitis-ulcerative"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Evorpacept for squamous cell carcinoma of head and neck</title>
    <id>https://staging.whatcameofit.com/evorpacept--squamous-cell-carcinoma-of-head-and-neck#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/evorpacept--squamous-cell-carcinoma-of-head-and-neck"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Exagamglogene autotemcel for anemia, sickle cell</title>
    <id>https://staging.whatcameofit.com/exagamglogene-autotemcel--anemia-sickle-cell#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/exagamglogene-autotemcel--anemia-sickle-cell"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Fasudil for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/fasudil--alzheimer-disease#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/fasudil--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Fidanacogene Elaparvovec for hemophilia b</title>
    <id>https://staging.whatcameofit.com/fidanacogene-elaparvovec--hemophilia-b#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/fidanacogene-elaparvovec--hemophilia-b"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Gantenerumab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/gantenerumab--alzheimer-disease#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/gantenerumab--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Infliximab for crohn disease</title>
    <id>https://staging.whatcameofit.com/infliximab--crohn-disease#status-2026-11-16-trial_registered</id>
    <link href="https://staging.whatcameofit.com/infliximab--crohn-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Insulin efsitora alfa for diabetes mellitus, type 2</title>
    <id>https://staging.whatcameofit.com/insulin-efsitora-alfa--diabetes-mellitus-type-2#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/insulin-efsitora-alfa--diabetes-mellitus-type-2"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ivermectin for malaria</title>
    <id>https://staging.whatcameofit.com/ivermectin--malaria#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/ivermectin--malaria"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Leucovorin for autism spectrum disorder</title>
    <id>https://staging.whatcameofit.com/leucovorin--autism-spectrum-disorder#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/leucovorin--autism-spectrum-disorder"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms</title>
    <id>https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/lutetium-lu-177-vipivotide-tetraxetan--prostatic-neoplasms"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Lysergide d-tartrate for generalized anxiety disorder</title>
    <id>https://staging.whatcameofit.com/lysergide-d-tartrate--generalized-anxiety-disorder#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/lysergide-d-tartrate--generalized-anxiety-disorder"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Mevidalen for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/mevidalen--alzheimer-disease#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/mevidalen--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Niraparib for mesothelioma</title>
    <id>https://staging.whatcameofit.com/niraparib--mesothelioma#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/niraparib--mesothelioma"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Oxytocin for obesity</title>
    <id>https://staging.whatcameofit.com/oxytocin--obesity#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/oxytocin--obesity"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Prasinezumab for parkinson disease</title>
    <id>https://staging.whatcameofit.com/prasinezumab--parkinson-disease#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/prasinezumab--parkinson-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for obsessive-compulsive disorder</title>
    <id>https://staging.whatcameofit.com/psilocybin--obsessive-compulsive-disorder#status-2026-11-16-phase_1</id>
    <link href="https://staging.whatcameofit.com/psilocybin--obsessive-compulsive-disorder"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 1 trial.</summary>
  </entry>
  <entry>
    <title>Psilocybin for parkinson disease</title>
    <id>https://staging.whatcameofit.com/psilocybin--parkinson-disease#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/psilocybin--parkinson-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Semaglutide for alcoholism</title>
    <id>https://staging.whatcameofit.com/semaglutide--alcoholism#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/semaglutide--alcoholism"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Silver diammine fluoride for dental caries</title>
    <id>https://staging.whatcameofit.com/silver-diammine-fluoride--dental-caries#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/silver-diammine-fluoride--dental-caries"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Solanezumab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/solanezumab--alzheimer-disease#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/solanezumab--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Survodutide for obesity</title>
    <id>https://staging.whatcameofit.com/survodutide--obesity#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/survodutide--obesity"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tafenoquine for malaria, vivax</title>
    <id>https://staging.whatcameofit.com/tafenoquine--malaria-vivax#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/tafenoquine--malaria-vivax"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tavapadon for parkinson disease</title>
    <id>https://staging.whatcameofit.com/tavapadon--parkinson-disease#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/tavapadon--parkinson-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Ticagrelor for acute coronary syndrome</title>
    <id>https://staging.whatcameofit.com/ticagrelor--acute-coronary-syndrome#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/ticagrelor--acute-coronary-syndrome"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tozorakimab for pulmonary disease, chronic obstructive</title>
    <id>https://staging.whatcameofit.com/tozorakimab--pulmonary-disease-chronic-obstructive#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/tozorakimab--pulmonary-disease-chronic-obstructive"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Trontinemab for alzheimer disease</title>
    <id>https://staging.whatcameofit.com/trontinemab--alzheimer-disease#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/trontinemab--alzheimer-disease"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Tulisokibart for lung diseases, interstitial</title>
    <id>https://staging.whatcameofit.com/tulisokibart--lung-diseases-interstitial#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/tulisokibart--lung-diseases-interstitial"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
  <entry>
    <title>Upadacitinib for alopecia areata</title>
    <id>https://staging.whatcameofit.com/upadacitinib--alopecia-areata#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/upadacitinib--alopecia-areata"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zasocitinib for psoriasis</title>
    <id>https://staging.whatcameofit.com/zasocitinib--psoriasis#status-2026-11-16-trial_registered</id>
    <link href="https://staging.whatcameofit.com/zasocitinib--psoriasis"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Trial registered.</summary>
  </entry>
  <entry>
    <title>Ziltivekimab for atherosclerosis</title>
    <id>https://staging.whatcameofit.com/ziltivekimab--atherosclerosis#status-2026-11-16-phase_3</id>
    <link href="https://staging.whatcameofit.com/ziltivekimab--atherosclerosis"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 3 trial.</summary>
  </entry>
  <entry>
    <title>Zipalertinib for lung diseases</title>
    <id>https://staging.whatcameofit.com/zipalertinib--lung-diseases#status-2026-11-16-phase_2</id>
    <link href="https://staging.whatcameofit.com/zipalertinib--lung-diseases"/>
    <updated>2026-11-16T00:00:00Z</updated>
    <summary>First status: Phase 2 trial.</summary>
  </entry>
</feed>
